46th Annual Meeting
June 4–8, 2010
Chicago, Illinois

ANNUAL MEETING PROGRAM

Upcoming Meetings

Breast Cancer Symposium
October 1–3, 2010
Suburban Washington, D.C.

EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer
October 18–20, 2010
Hollywood, Florida

Gastrointestinal Cancers Symposium
January 20–22, 2011
San Francisco, California

Genitourinary Cancers Symposium
February 17–19, 2011
Orlando, Florida

47th ASCO Annual Meeting
June 3–7, 2011
Chicago, Illinois

Copyright 2010 by the American Society of Clinical Oncology. All programs presented at the 2010 Annual Meeting constitute copyrighted presentations owned by the American Society of Clinical Oncology.

Copyright of the 2010 ASCO Annual Meeting Program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings. Attendees are encouraged to check the Annual Meeting program materials for information about Annual Meeting-related publications for purchase and additional ASCO online resources at www.asco.org/chicago2010, including the ASCO Virtual Meeting.
## CONTENTS

### Sessions and Symposia
- Scientific Sessions ................................................................. 4
- Special Sessions ........................................................................ 6
- Clinical Science Symposia ......................................................... 6

### Annual Meeting Planning Committees
- ASCO Officers and Directors ................................................... 7
- The ASCO Cancer Foundation Officers and Directors ............... 7
- Cancer Communications News Planning Subcommittee ............. 7
- Cancer Education Committee .................................................... 8
- Scientific Program Committee .................................................. 10

### Continuing Medical Education Information
- Onsite Details ........................................................................... 12
- ASCO Shuttle Service .............................................................. 13
- Policies ..................................................................................... 18

### Awards
- Special Awards ......................................................................... 19
- Merit Awards ............................................................................ 20
- Advanced Clinical Research Awards ........................................ 22
- Career Development Awards .................................................... 22
- Clinical Trials Participation Awards ......................................... 23
- Community Oncology Research Grants .................................... 23
- Comparative Effectiveness Research Professorship .................. 23
- Improving Cancer Care Grants ................................................ 23
- International Development and Education Awards .................. 24
- Long-term International Fellowship ......................................... 24
- State Affiliate Grants ............................................................... 24
- Young Investigator Awards ...................................................... 24
- Past ACRA/CDA/TRP/YIA Grant Recipients ............................... 25

### Descriptions of Session Types
- Annual Meeting Supporters ..................................................... 28
- 2010 Annual Meeting Program by Track ................................ 31
- 2010 Annual Meeting Program
  - Friday .................................................................................. 55
  - Saturday .............................................................................. 80
  - Sunday ............................................................................... 190
  - Monday .............................................................................. 292
  - Tuesday .............................................................................. 416
### SCIENTIFIC SESSIONS

#### Breast Cancer
- Local-Regional and Adjuvant Therapy Oral Abstract Session ................................................................. 342
- Metastatic Oral Abstract Session ........................................................................................................... 435
- Local-Regional and Adjuvant Therapy Poster Discussion Session ...................................................... 393
- Metastatic Poster Discussion Session .................................................................................................... 115
- Local-Regional and Adjuvant Therapy General Poster Session ........................................................... 146
- Metastatic General Poster Session ........................................................................................................ 158

#### Cancer Prevention/Epidemiology
- Oral Abstract Session ............................................................................................................................. 228
- Poster Discussion Session .................................................................................................................... 396
- General Poster Session ......................................................................................................................... 87

#### Central Nervous System Tumors
- Oral Abstract Session ............................................................................................................................. 181
- Poster Discussion Session .................................................................................................................... 118
- General Poster Session ......................................................................................................................... 197

#### Developmental Therapeutics
- Clinical Pharmacology and Immunotherapy Oral Abstract Session .................................................. 437
- Experimental Therapeutics Oral Abstract Session .................................................................................. 129
- Clinical Pharmacology and Immunotherapy Poster Discussion Session ........................................ 121
- Experimental Therapeutics Poster Discussion Session ........................................................................ 247
- Clinical Pharmacology and Immunotherapy General Poster Session ............................................ 301
- Experimental Therapeutics General Poster Session ........................................................................... 308

#### Gastrointestinal Cancer
- Colorectal Cancer Oral Abstract Session ............................................................................................... 229
- Noncolorectal Cancer Oral Abstract Session ......................................................................................... 408
- Colorectal Cancer Poster Discussion Session ...................................................................................... 421
- Noncolorectal Cancer Poster Discussion Session ................................................................................. 63
- Colorectal Cancer General Poster Session .......................................................................................... 256
- Noncolorectal Cancer General Poster Session .................................................................................... 267

#### Genitourinary Cancer
- Prostate Cancer Oral Abstract Session .................................................................................................. 231
- Testes, Kidney, and Bladder Cancer Oral Abstract Session .................................................................. 438
- Prostate Cancer Poster Discussion Session .......................................................................................... 335
- Nonprostate Cancer Poster Discussion Session .................................................................................... 140
- General Poster Session ......................................................................................................................... 359

#### Gynecologic Cancer
- Oral Abstract Session ............................................................................................................................. 233
- Poster Discussion Session .................................................................................................................... 250
- General Poster Session ......................................................................................................................... 169

#### Head and Neck Cancer
- Oral Abstract Session ............................................................................................................................. 410
- Poster Discussion Session .................................................................................................................... 66
- General Poster Session .......................................................................................................................... 202

#### Health Services Research
- Oral Abstract Session ............................................................................................................................. 344
- Poster Discussion Session .................................................................................................................... 124
- General Poster Session ......................................................................................................................... 369

#### Leukemia, Myelodysplasia, and Transplantation
- Oral Abstract Session ............................................................................................................................. 345
- Poster Discussion Session .................................................................................................................... 399
- General Poster Session .......................................................................................................................... 92
<table>
<thead>
<tr>
<th>Section</th>
<th>Oral Abstract Session</th>
<th>Poster Discussion Session</th>
<th>General Poster Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung Cancer</td>
<td>Local-Regional</td>
<td>179</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and Adjuvant Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Abstract Session</td>
<td>406</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local-Regional</td>
<td>430</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and Adjuvant Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>338</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local-Regional</td>
<td>208</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and Adjuvant Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>214</td>
<td></td>
</tr>
<tr>
<td>Lymphoma and Plasma Cell Disorders</td>
<td>Lymphoma Oral Abstract</td>
<td>131</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myeloma Oral Abstract</td>
<td>234</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>Melanoma/Skin Cancers</td>
<td>Oral Abstract Session</td>
<td>133</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>299</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>223</td>
<td></td>
</tr>
<tr>
<td>Patient and Survivor Care</td>
<td>Oral Abstract Session</td>
<td>182</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>424</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>378</td>
<td></td>
</tr>
<tr>
<td>Pediatric Oncology</td>
<td>Pediatric Oncology I</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Abstract Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pediatric Oncology II</td>
<td>347</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Abstract Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>253</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>277</td>
<td></td>
</tr>
<tr>
<td>Sarcoma</td>
<td>Oral Abstract Session</td>
<td>357</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>427</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>280</td>
<td></td>
</tr>
<tr>
<td>Tumor Biology</td>
<td>Oral Abstract Session</td>
<td>412</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Discussion Session</td>
<td>143</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Poster Session</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Trials in Progress Poster Session</td>
<td></td>
<td></td>
<td>314</td>
</tr>
</tbody>
</table>
# Session and Symposia

## Special Sessions

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advancing Pain and Palliative Care Globally for Patients with Cancer</td>
<td>433</td>
</tr>
<tr>
<td>ASCO—American Cancer Society Award and Lecture</td>
<td>349</td>
</tr>
<tr>
<td>ASCO/American Society of Hematology Joint Session</td>
<td>74</td>
</tr>
<tr>
<td>ASCO/European CanCer Organisation Joint Session: Personalized Medicine in</td>
<td></td>
</tr>
<tr>
<td>Locally Advanced Non-small Cell Lung Cancer</td>
<td>387</td>
</tr>
<tr>
<td>B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology</td>
<td>287</td>
</tr>
<tr>
<td>Cancer Survivors: A Challenge to Health Care Systems Worldwide</td>
<td>293</td>
</tr>
<tr>
<td>Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications</td>
<td>86</td>
</tr>
<tr>
<td>Distinguished Achievement Award</td>
<td>79</td>
</tr>
<tr>
<td>Forum on Reimbursement</td>
<td>191</td>
</tr>
<tr>
<td>From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—</td>
<td></td>
</tr>
<tr>
<td>An ASCO/American Association for Cancer Research Joint Session</td>
<td>413</td>
</tr>
<tr>
<td>Health Care Reform: Resetting the Clock</td>
<td>176</td>
</tr>
<tr>
<td>Highlights of the Day I including Clinical Trials Participation Awards</td>
<td>190</td>
</tr>
<tr>
<td>Highlights of the Day II including Partners in Progress Award</td>
<td>292</td>
</tr>
<tr>
<td>Highlights of the Day III</td>
<td>416</td>
</tr>
<tr>
<td>Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/</td>
<td></td>
</tr>
<tr>
<td>Radiological Society of North America Joint Session</td>
<td>440</td>
</tr>
<tr>
<td>Maintenance of Certification and Lifelong Learning Workshop</td>
<td>62</td>
</tr>
<tr>
<td>Opening Session with Presidential Address, NCI Director’s Address,</td>
<td></td>
</tr>
<tr>
<td>David A. Karnofsky Memorial Award and Lecture, and The ASCO Cancer Foundation Donor</td>
<td>127</td>
</tr>
<tr>
<td>Recognition Awards</td>
<td></td>
</tr>
<tr>
<td>Pediatric Oncology Award and Lecture</td>
<td>176</td>
</tr>
<tr>
<td>Plenary Session including Science of Oncology Award and Lecture</td>
<td>246</td>
</tr>
<tr>
<td>Special Recognition Award</td>
<td>79</td>
</tr>
<tr>
<td>The Hospital/Physician Relationship: Tensions Arising</td>
<td>354</td>
</tr>
<tr>
<td>Training Program Directors’ Special Session—Addressing the Competencies:</td>
<td></td>
</tr>
<tr>
<td>Professionalism and Practice-based Learning</td>
<td>242</td>
</tr>
</tbody>
</table>

## Clinical Science Symposia

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circulating Tumor Cells in Breast Cancer: Where Are We?</td>
<td>405</td>
</tr>
<tr>
<td>Genetic and Molecular Predictors in Genitourinary Malignancies</td>
<td>84</td>
</tr>
<tr>
<td>Molecularly Targeted Trials in Lung Cancer</td>
<td>85</td>
</tr>
<tr>
<td>Novel Therapies and Approaches for Management of Gynecologic Cancers</td>
<td>352</td>
</tr>
<tr>
<td>Novel Therapies for Myeloma</td>
<td>185</td>
</tr>
<tr>
<td>Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets</td>
<td>186</td>
</tr>
<tr>
<td>Optimizing Care of the Elderly and Underserved</td>
<td>245</td>
</tr>
<tr>
<td>PARP Inhibition: DNA Repair as the Target</td>
<td>187</td>
</tr>
<tr>
<td>Paths for Clinical Development of PI3K Inhibition</td>
<td>298</td>
</tr>
<tr>
<td>Pharmacologic Treatment of Cancer-related Fatigue: Does It Make a Difference?</td>
<td>240</td>
</tr>
<tr>
<td>Predictors of Response to Preoperative Therapy: Where Are We?</td>
<td>286</td>
</tr>
<tr>
<td>Promising Targeted Therapies for Head and Neck Cancer</td>
<td>353</td>
</tr>
<tr>
<td>Signaling in Pediatric Cancer Comes to the Clinic</td>
<td>184</td>
</tr>
<tr>
<td>Smoothened/Hedgehog/Gamma Secretase</td>
<td>241</td>
</tr>
<tr>
<td>Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life</td>
<td>139</td>
</tr>
<tr>
<td>The MEK Pathway</td>
<td>196</td>
</tr>
<tr>
<td>Unraveling the Cancer Genome: Clinical Implications of Next-generation Technologies</td>
<td>392</td>
</tr>
</tbody>
</table>
ANNUAL MEETING PLANNING COMMITTEES

2009-2010 ASCO Board of Directors

ASCO Officers

President
Douglas W. Blayney, MD

President-Elect
George W. Sledge, MD

Immediate Past President
Richard L. Schilsky, MD

Treasurer
Clifford Hudis, MD

Chief Executive Officer
Allen S. Lichter, MD

Directors
Dean F. Bajorin, MD
Monica M. Burtzanolli, MD
Eduardo L. Cazap, MD, PhD
Susan L. Cohn, MD
Bruce E. Johnson, MD
Robert M. Langdon Jr., MD
Robert S. Miller, MD
Kathleen I. Pritchard, MD
Deborah Schrag, MD
Lynn M. Schuchter, MD
Sandra M. Swain, MD
Joel E. Tepper, MD
Everett E. Vokes, MD
Peter P. Yu, MD

2010 The ASCO Cancer Foundation Board of Directors

The ASCO Cancer Foundation Officers

Chair
Martin J. Murphy Jr., PhD, DMedSc

Treasurer
W. Charles Penley, MD

Secretary
Richard L. Schilsky, MD

Chief Executive Officer
Allen S. Lichter, MD, Ex-Officio

Directors
Joseph S. Bailes, MD
Lawrence H. Einhorn, MD
John H. Glick, MD
Nora A. Janjan, MD, MPSA, MBA
Thomas A. Marsland, MD
Robert J. Mayer, MD
Sandra M. Swain, MD
Nancy R. Daly, MS, MPH, Ex-Officio

Cancer Communications Committee News Planning Subcommittee

Chair
Nicholas J. Petrelli, MD

Chair-Elect
Mark G. Kris, MD

Immediate Past Chair
Eric P. Winer, MD

Julie R. Brahmer, MD
Lisa Diller, MD
Therese M. Mulvey, MD
Jennifer C. Obel, MD
Lori Pierce, MD
Sonali M. Smith, MD
Robert P. Sticca, MD
Charles R. Thomas Jr., MD
Timothy J. Whelan, BM, BCh, MSc
Nicholas J. Vogelzang, MD

Subcommittee Liaisons
Lynn M. Schuchter, MD, Board Liaison
Michelle W. Lau, MD, Career Development Subcommittee Liaison
## ANNUAL MEETING PLANNING COMMITTEES

### Cancer Education Committee (CEC)
Kim Allyson Margolin, MD, **Chair**  
Charles Blanke, MD, **Chair-Elect**  
Maha Hussain, MD, **Immediate Past Chair**  
Bruce E. Johnson, MD, **Board Liaison**

### CEC Annual Meeting and Thematic Meetings Subcommittee

#### Breast Cancer Track
Antonio C. Wolff, MD, FACP, **Track Leader**  
Jonas Bergh, MD, PhD  
Lisa A. Carey, MD  
Maura N. Dickler, MD  
Jennifer J. Griggs, MD  
Barbara Parker, MD  
Anna Storniolo, MD  
Richard Zellars, MD

#### Cancer Genetics Track
Angela R. Bradbury, MD, **Track Leader**  
Judy Garber, MD, MPH  
Steve B. Gruber, MD, PhD  
Beth Karihan, MD  
Sancy Leachman, MD, PhD

#### Cancer Prevention/Epidemiology Track
William Nelson, MD, PhD, **Track Leader**  
Marie-France Demierre, MD  
Gary E. Goodman, MD  
Joanne M. Jeter, MD  
Melanie Palomares, MD

#### Central Nervous System Tumors Track
John L. Villano, MD, PhD, **Track Leader**  
Timothy Cloughsey, MD  
Patrick Wen, MD

#### Clinical Trials Track
Julie R. Park, MD, **Track Leader**  
Steven D. Averbuch, MD  
Christopher Booth, MD  
Tim Eisen, PhD, FRCP  
Patricia LoRusso, DO  
Daniel P. Petrylak, MD  
David R. Spigel, MD

#### Developmental Therapeutics Track
Alexander Dimitrios Colevas, MD, **Track Leader**  
Merrill Egorin, MD  
Timothy Synold, PharmD  
James Andrew Zwiebel, MD, FACP

#### Ethics Track
Eileen Smith, MD, **Track Leader**  
Manish Agrawal, MD  
Rebecca D. Pentz, PhD  
Jeffrey M. Peppercorn, MD, MPH

#### Gastrointestinal (Colorectal) Cancer Track
Axel Grotthey, MD, **Track Leader**  
Bruce D. Minsky, MD  
Margaret M. Mooney, MD  
David Ryan, MD

#### Gastrointestinal (Noncolorectal) Cancer Track
Mark Krasna, MD, **Track Leader**  
Johanna C. Bendell, MD  
Cliff Connery, MD  
Peter C. Enzinger, MD

Melanie B. Thomas, MD  
Christopher Willett, MD

#### Genitourinary Cancer Track
Celestia S. Higano, MD, **Track Leader**  
Primo Lara Jr., MD  
Gary R. MacVicar, MD  
Edwin M. Posadas, MD  
Andrew Stephenson, MD  
Mary- Ellen Taplin, MD

#### Geriatric Oncology Track
Arash Naeim, MD, **Track Leader**  
Kathryn A. Bylow, MD  
Arti Hurria, MD  
Rosemary Yancik, PhD

#### Gynecologic Cancer Track
S. Diane Yamada, MD, **Track Leader**  
David Cohn, MD  
Ursula Matulonis, MD

#### Head and Neck Cancer Track
Maura Gillison, MD, PhD, **Track Leader**  
Vassiliki Papadimitrakopoulou, MD  
Gregory T. Wolf, MD

#### Health Services Research Track
Brent Hollenbeck, MD, MS, **Track Leader**  
Steven Katz, MD  
Elizabeth B. Lamont, MD, MS  
Gary H. Lyman, MD  
Rinaa S. Punglia, MD

#### Leukemia, Myelodysplasia, and Transplantation Track
Koen van Besien, MD, **Track Leader**  
Hagop Kantarjian, MD  
Moshe Talpaz, MD

#### Lung Cancer Track
Michael Kelley, MD, **Track Leader**  
Jeffrey A. Bogart, MD  
Julie R. Brahmer, MD  
Ramdaswaren Govindan, MD  
Renato Martins, MD, MPH  
Harvey I. Pass, MD

#### Lymphoma and Plasma Cell Disorders Track
Todd M. Zimmerman, MD, **Track Leader**  
Richard F. Ambinder, MD, PhD  
Myron Stefan Czuczman, MD  
Francine M. Foss, MD  
Amrita Krishman, MD

#### Melanoma/Skin Cancers Track
Julie R. Lange, MD, **Track Leader**  
Thomas Gajewski, MD, PhD  
Christopher D. Lao, MD  
Gregory K. Pennock, MD  
Hensin Tsao, MD, PhD

#### Patient and Survivor Care Track
Jennifer A. Ligibel, MD, **Track Leader**  
Wendy Demark-Wahnefried, PhD, RD
Michelle Joy Naughton, PhD  
Julia Rowland, PhD

**Pediatric Oncology Track**  
Susan Lerner Cohn, MD, *Track Leader*  
Lisa Diller, MD  
Judith Sato, MD  
Anne Warwick, MD, MPH

**Practice Management and Information Technology Track**  
John V. Cox, DO, *Track Leader*  
Patrick A. Grusenmeyer, ScD, FACHE  
Alan Keller, MD  
Therese Mulvey, MD  
Dee Anna Smith

**Professional Development Track**  
Timothy J. Moynihan, MD, *Track Leader*  
Stephen M. Hahn, MD  
Anand Karnad, MD  
Allison Kurian, MD, MSc  
Gregory Masters, MD, FACP  
Lidia Schapira, MD

**Sarcoma Track**  
Samuel Singer, MD, *Track Leader*  
Warren Chow, MD, FACP  
Rashmi Chugh, MD  
R. Lor Randall, MD, FACS

**Tumor Biology Track**  
George Coukos, MD, *Track Leader*  
Mary Y. Armanios, MD  
Kenneth J. Pienta, MD  
Josep Taberner, MD

**CEC Continuing Medical Education Subcommittee**  
Laura Fulper Hutchins, MD, *Subcommittee Chair*  
Lucille A. Leong, MD, *Subcommittee Chair-Elect*  
Charles F. von Gunten, MD, PhD, FACP, *Immediate Past Chair*  
J. Thaddeus Beck, MD  
David Danforth Jr., MD  
Thomas Fahey Jr., MD  
Norah Lynn Henry, MD, PhD  
Jeffrey Hines, MD  
Halle C. F. Moore, MD  
Paul Wissel, MD  
Judith L. Bader, MD  
Phillip C. Hoffman, MD  
Catherine E. Klein, MD  
Jed D. Wolchok, MD, PhD

**CEC Education Products Subcommittee**  
Jamie H. Von Roenn, MD, *Subcommittee Chair*  
Ronald H. Blum, MD, *Subcommittee Chair-Elect*  
Michael C. Perry, MD, *Subcommittee Chair*  
Kathleen W. Beekman, MD  
Jan Buckner, MD  
Michael Fisch, MD, MPH  
Justin D. Floyd, DO  
Martee Leigh Hensley, MD, MSc  
Tari A. King, MD  
Bhoomi Mehrotra, MD  
W. Robert Lee, MD, MS, MEd  
Charles Loprinzi, MD  
Tina M. Maluso-Bolton, MSN, NP  
Robert Gary Mennel, MD  
Jennifer E. Schwartz, MD, FRCPC  
William Small Jr., MD
Scientific Program Committee
Daniel F. Hayes, MD, Chair
Kathy Miller, MD, Chair-Elect
Everett E. Vokes, MD, Immediate Past Chair
Douglas W. Blayney, MD, Board Liaison

Biostatistics Track
Marc E. Buyse, ScD, Track Leader
Thomas Braun, PhD
Elizabeth Garrett-Mayer, PhD
Susan Michelle Geyer, PhD
Daniel Heitjan, PhD
Terry Hyslop, PhD
Alexia Iasonos, PhD
Judith Manola, MS
Andre Rogatko, PhD

Breast Cancer—Local-Regional and Adjuvant Therapy Track
Claudine Isaacs, MD, Track Leader
Kirby I. Bland, MD
Stephen K. L. Chia, MD
Reshma Jagsi, MD, PhD
Seema A. Khan, MD, FACS, MPH
Rita Nanda, MD
Lisa Yee, MD

Breast Cancer—Metastatic Track
Herve Bonnefoi, MD, Track Leader
Harold J. Burstein, MD, PhD
Suzanne D. Conzen, MD
Elizabeth Claire Dees, MD
Hope S. Rugo, MD
Anne F. Schott, MD

Cancer Prevention/Epidemiology Track
Eva Szabo, MD, Track Leader
Dean Brenner, MD
Frank Sincirope, MD
Kala Visvanathan, MD, MHS
Marie Wood, MD

Central Nervous System Tumors Track
M. Kelly Nicholas, MD, PhD, Track Leader
Eric L. Chang, MD
Louis Nabors, MD
Myrna R. Rosenfeld, MD, PhD

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy Track
Razelle Kurzrock, MD, Track Leader
Ivan Borrello, MD
Tyler J. Curiel, MD
Charles G. Drake, MD, PhD
Kenneth A. Foon, MD
Federico Innocenti, MD, PhD
Duncan Ian Jodrell, MD, MSc
Justin Paul Kline, MD

Developmental Therapeutics—Experimental Therapeutics Track
Michael L. Maitland, MD, PhD, Track Leader
Tomislav Dragovich, MD, PhD
Paula M. Fracasso, MD, PhD, FACP
Pasi A. Janne, MD, PhD
Patrick Johnston, MD, PhD
Timothy Madden, PharmD
Patrick Schöffski, MD, MPH
Lillian L. Siu, MD

Gastrointestinal (Colorectal) Cancer Track
Howard S. Hochster, MD, Track Leader
Tanios S. Bekaii-Saab, MD
Chris R. Garrett, MD
Richard M. Goldberg, MD
Michael J. Hall, MD
Richard Herrmann, MD
John S. Kauh, MD
John Marshall, MD
Wells A. Messersmith, MD
Blase N. Polite, MD, MPH
Kenneth Tanabe, MD
Robert S. Warren, MD

Gastrointestinal (Noncolorectal) Cancer Track
David Linehan, MD, Track Leader
Charles Blanke, MD
Ian Chau, MD
Theodore S. Hong, MD
Milind M. Javle, MD
Jennifer J. Knox, MD
Timothy M. Pawlik, MD, MPH
Alexandria T. Phan, MD
Gauri Varadhachary, MD
Andrea Wang-Gillam, MD, PhD
Colin D. Weekes, MD, PhD

Genitourinary Cancer Track
Michael J. Morris, MD, Track Leader
Daniel J. George, MD
James L. Mohler, MD
Joel B. Nelson, MD
George Philips, MD, MPH
Brian I. Rini, MD
Matthew R. Smith, MD
Ulka N. Vaishampayan, MD
Richard K. Valicenti, MD
David P. Wood, MD

Gynecologic Cancer Track
Amit M. Oza, MD, Track Leader
Ronald J. Buckanovich, MD, PhD
Robert L. Coleman, MD
Patricia J. Eifel, MD
Ernst Lengyel, MD, PhD
Claire F. Verschraegen, MD

Head and Neck Cancer Track
Ezra E. W. Cohen, MD, FRCPC, Track Leader
Christine H. Chung, MD
Avraham Eisbruch, MD
D. Neil Hayes, MD, MPH
Cherie-Ann Nathan, MD
Andy Trott, MD

Health Services Research Track
Sharon Hermes Giordano, MD, Track Leader
Charles L. Bennett, MD, PhD
Craig Earle, MD
Chris Friesen, RN, PhD
Sarah Hawley, PhD
Jeanne Mandelblatt, MD, MPH
Leukemia, Myelodysplasia, and Transplantation
Track
Olatoyosi Odenike, MD, Track Leader
Harry Erba, MD, PhD
Jeffrey E. Lancet, MD
Jane Liesveld, MD
Guido Marcucci, MD
Susan M. O’Brien, MD

Lung Cancer—Local-Regional and Adjuvant Therapy Track
Corey J. Langer, MD, Track Leader
David Harpole Jr., MD
Katherine Pisters, MD
Joseph B. Putnam, MD, FACS
Joseph K. Salama, MD
Antoinette J. Wozniak, MD
Stephen C. Yang, MD

Lung Cancer—Metastatic Track
Martin J. Edelman, MD, Track Leader
D. Ross Camidge, MD, PhD
Raffit Hassan, MD
Rebecca Suk Heist, MD
Gregory P. Kalemkerian, MD
Suresh S. Ramalingam, MD
Karen L. Reckamp, MD, MS
Ravi Salgia, MD, PhD

Lymphoma and Plasma Cell Disorders Track
John P. Leonard, MD, Track Leader
Nancy Bartlett, MD
Asher A. Chanan-Khan, MD
Kenneth Cohen, MD
Andrzej J. Jakubowiak, MD, PhD

Melanoma/Skin Cancers Track
F. Stephen Hodi, MD, Track Leader
David F. McDermott, MD
Antoni Ribas, MD
Michael S. Sabel, MD, FACS

Patient and Survivor Care Track
Teresa Gilewski, MD, Track Leader
Janet Lee Abraham, MD
Gretchen Genevieve Kimmick, MD
Barbara A. Murphy, MD
Thomas J. Smith, MD

Pediatric Oncology Track
John Cunningham, MD, Track Leader
Peter C. Adamson, MD
Gregory T. Armstrong, MD
Katherine K. Matthey, MD, MSCE

Sarcoma Track
Bruce Brockstein, MD, Track Leader
Suzanne George, MD
Raphael E. Pollock, MD, PhD
William D. Tap, MD

Tumor Biology Track
Charles D. Lopez, MD, PhD, Track Leader
Michael J. Ellis, PhD, MB
Phillip G. Febbo, MD
Robert A. Kratzke, MD
Sofia Merajver, MD
Anil Potti, MD
The goal of the 2010 ASCO Annual Meeting is to foster communication among oncology-related subspecialties and the exchange of a wide range of ideas related to cancer. ASCO’s objectives are to advance the education of physicians and other professionals caring for patients with cancer, to support the development of clinical cancer researchers, and to facilitate the delivery of high-quality health care to patients with cancer. The 2010 ASCO Annual Meeting is designed to serve the respective interests of the Society’s multidisciplinary membership, with education focused on medical, surgical, and radiation oncology.

Needs Statement
With emerging educational and scientific advances, oncology is a field where patient care standards can change very quickly. Due to the high volume of literature and best practices information available, it is important that oncologists and other cancer care providers synthesize and digest the latest evidence-based information applicable to their practice/research setting.

In an effort to meet educational needs based on this rapid exchange of information, ASCO is committed to disseminating the latest scientific findings in oncology and practice-changing advances in cancer prevention, diagnosis, treatment, and survivorship.

Target Audience
The Annual Meeting is designed for U.S. and international physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.

The Annual Meeting can also benefit nurses, pharmacists, physician assistants, and other health care professionals involved in clinical cancer care and cancer research.

Learning Objectives
Upon participation in this activity, attendees will be able to:

• Examine scientific advances that further enhance knowledge of cancer biology and pathogenesis
• Incorporate knowledge gained pertaining to advances in clinical cancer research into innovative management strategies and trial designs to improve patient outcomes
• Review recent and emerging data from key studies in clinical cancer research
• Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of people with cancer
• Implement clinical and scientific strategies designed to improve the quality of cancer care, as appropriate
• Effectively communicate with colleagues and with patients regarding advances in clinical oncology science
• Identify and utilize tools for cancer risk assessment and risk reduction based on the best available evidence
• Engage in networking and collaboration among domestic and international oncology specialists and scientists

Continuing Medical Accreditation Statement and Credit Designation
ASCO is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASCO designates this educational activity for a maximum of 42 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy and Nursing Continuing Education
Due to limited demand and increased accreditation requirements, ASCO will no longer be partnering with Professional Education Services Group to offer specific nursing and pharmacy continuing education credit for 2010 Annual Meeting sessions. All nonphysician attendees are welcome to submit a request for a Certificate of Participation, through the submission of the evaluation form, which may enable nonphysicians to apply their Annual Meeting participation toward re-licensure.

Any questions related to CME may be directed to ASCO Staff at cme@asco.org or 571-483-1403.

New for 2010: Submit Program Evaluation Online, Certificates Available Immediately
All attendees are encouraged to provide feedback to the planning committees to develop future Symposium sessions and document their participation, requesting either a CME Certificate (MD and DO) or a Certificate of Participation that may be used to claim credits toward re-licensure (nonphysicians).

Evaluations will be accepted until July 9, 2010. In an effort to be environmentally friendly, paper evaluations are no longer being accepted. Evaluations must be submitted online at www.asco.org/chicago2010 or www.asco.org/cme. Attendees can access the Internet onsite by using the Internet Stations available throughout the convention center or by taking advantage of the complimentary Wi-Fi access available throughout the public areas.

Proof of Attendance
An official certificate that verifies attendance at the 2010 Annual Meeting is available at www.asco.org/chicago2010.
Air Travel Assistance Desk
Attendees who made their air travel arrangements through TravelStore, Inc. can check or change their flight arrangements with a travel agent at the Air Travel Assistance Desk located in ASCO Concierge Services in the North Building, Grand Concourse Lobby.

ASCO Annual Business Meeting and Presentation of ASCO Statesman Awards
ASCO members are encouraged to attend the 2010 ASCO Annual Business Meeting, to be held on Monday, June 7 from 12:00 PM to 1:00 PM at the Hyatt McCormick Place, Regency Ballroom. The Annual Business Meeting will feature the presentation of the Statesman Awards, which honor the meritorious service of Society members for their significant volunteer efforts. Criteria for award selection include at least 20 cumulative years of volunteer service to the Society in elected or appointed positions, such as participation on committees, guideline panels, and task forces, or as an association liaison.

ASCO Headquarters Office
ASCO Headquarters office is located in the North Building, Room N427a.

ASCO on Twitter
ASCO maintains a profile page on the social networking site Twitter. Access attendee information, news, and events in real time leading up to and during the Annual Meeting. Visit ASCO on Twitter and click “Follow”.

ASCO is tweeting several times a day and using the following hashtags:
• #ASCO10—for attendee information, event reminders, and Meeting-related news and commentary
• #ASCOPress—for breaking news, media alerts, and updates

ASCO TV
The onsite Annual Meeting broadcast network, ASCO TV features important messages from ASCO leadership as well as replays of Highlights of the Day, Plenary, and other sessions of interest. ASCO TV Cafés are located in the South Building, S102 Lobby; North Building, Grand Concourse Lobby; South Building, Oncology Professionals Hall Food Court (Hall A2), and East Building, Hall E Lobby.

Baggage Check
Coat and baggage check services are available for all attendees in the following areas: South Building, Room S104 (near Gate 2); South Building, Level 1, Main Entrance (near Gate 4); North Building, Level 1, Lobby (near Gate 26); and East Building, Level 2, Room E251 (near Registration). There is a charge per item for this service.

Career Fair
The 10th Annual Career Fair offers a convenient way for Meeting attendees to explore available career options with representatives from hospitals, academic institutions, private practices, and leading firms in the field of oncology. Job seekers will learn about new job openings, meet face-to-face with recruiters, and schedule personal interviews in the employers' private interview booth. The Career Fair is located in Exhibits, in the South Building, Level 3, Halls A1-A2. The Career Fair is open Saturday through Sunday from 9:00 AM to 5:00 PM. Career Fair participants must be registered for the Meeting to gain access to the Career Fair.

Career Opportunities and Other Medical Meetings Posting Boards
The Career Opportunities and Other Medical Meetings Posting Boards, located in Exhibits, adjacent to the Career Fair, provides organizations with the opportunity to make readily available to attendees information about job openings or other medical meetings held throughout the year. ASCO staff are available on Friday, June 4 from 7:00 AM to 6:00 PM at any of the Annual Meeting Information Desks throughout McCormick Place to receive authorized postings. Once the Hall opens on Saturday, June 5, ASCO staff are available at the Career Fair registration desk from 9:00 AM to 5:00 PM to receive and approve authorized postings.

Electronic Health Records (EHR) Lab
Attendees can visit the Electronic Health Records (EHR) Lab (Booth #16087 in Exhibits) to learn about EHR technologies appropriate for their practices and gain hands-on experience with the latest EHRs. A special EHR compare challenge will highlight the capacity of the vendor products to provide oncology-specific support. The EHR Lab is open Saturday through Monday from 9:00 AM to 5:00 PM.

ePosters
ePosters allow attendees to view 2010 Annual Meeting poster presentations electronically onsite at the ePoster Station (located in the Oncology Professionals Hall) or the Virtual Meeting Replay Station (located in the North Building, Level 2.5) at anytime throughout the Meeting. New this year, ePosters offer the following benefits:
• View electronic posters before they are available on Virtual Meeting
• Get a more detailed look at the poster using “Pan & Zoom” feature
• E-mail the poster presenter with questions

Exhibitor Directory
The Exhibitor Directory is a list of Annual Meeting exhibitors distributed to all attendees at tote bag pick-up areas. It is also available online at Exhibitor Directory Stations, located at the entrance to the Oncology Professionals Hall. The online Exhibitor Directory offers Meeting attendees the opportunity to view a detailed
floor plan of Exhibits and to search the list of exhibitors by company name, keyword, category, cancer type, country, or pavilion.

**Emergency Response for Visitors**
If an alarm sounds in McCormick Place
- Please proceed to the nearest exit
- Instructions will be given over the public announcement system

**Evacuation Instructions**
- Visitors will be directed over the public announcement system to exit through the closest “Emergency Exit”
- Doors marked as “Stairs” also serve as emergency exits
- In the event of a power failure, all emergency systems will run on emergency power
- Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place

**Faculty Registration and Ready Room**
During registration hours, all faculty will check in at the Faculty Registration and Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty should report to this room to review and submit their presentations, with assistance from ASCO’s audiovisual personnel.

**First Aid**
Staffed First Aid stations are located in the South Building, Level 2.5 Lobby (near the Business Center) and East Building, Level 1 (near Arie Crown Theater). Both stations are able to accommodate nursing mothers. Check with onsite security personnel or the staff at any ASCO Information Desk for the location of the nearest First Aid station. In addition, directional signage is available throughout the facility.

**Internet Stations**
Internet Stations, which offer full Internet access, are located throughout McCormick Place. Users can view ASCO.org, print their itinerary from the online Annual Meeting Program, and access ASCO online evaluation and CME credit request forms, as well as check and send e-mail.

**Lost and Found**
ASCO Lost and Found is located in the South Building, Level 1, Room S101 and is open from 7:00 AM to 6:00 PM Friday through Monday, and from 7:00 AM to 1:00 PM Tuesday.

**Oncology Professionals Hall**
Located in the South Building, Level 3, Halls A1-A2, the Oncology Professionals Hall (formerly known as the Exhibit Hall) is comprised of Exhibits, General Posters, and a Food Court. Exhibits will highlight the most advanced treatments, products, and services in oncology and will provide attendees the opportunity to meet with representatives from the health care industry, including pharmaceutical companies, scientific publishers, and advocacy groups. Exhibits are open during the following hours:

Saturday, June 5 . . . . . . . . . . 9:00 AM – 5:00 PM
Sunday, June 6 . . . . . . . . . . . . 9:00 AM – 5:00 PM
Monday, June 7 . . . . . . . . . . 9:00 AM – 5:00 PM

General Posters are located on the far right side of the Oncology Professionals Hall and can be accessed directly from the South Building escalators, by S102. You can also enter General Posters from the Grand Concourse entrance to the Oncology Professionals Hall.

New this year to the Oncology Professionals Hall, ASCO’s Networking & Connection Hub (Booth #10163) offers topic-based discussions for interaction with your peers; demonstrations of networking tools such as mobile applications, smart phones, and e-readers; and sessions introducing ASCO on social networking platforms. The full schedule for each day is available in that day’s edition of *ASCO Daily News*, as well as posted at the booth. “Lunchtime Conversations” each day from 12:00 PM to 1:30 PM provide a unique opportunity for attendees to pick up lunch at the nearby food court and join a conversation with senior members of ASCO’s staff and volunteer leadership.

**Passport Program**
The ASCO Cancer Foundation is excited to offer the Passport Program for the second year. Passport booklets will be distributed at tote bag pick-up areas and at the Grand Concourse entrance to the Oncology Professionals Hall and in the ASCO Cancer Foundation Donor Lounge (Room S401). Attendees who have their passport stamped by all participating exhibitors will receive an ASCO Cancer Foundation hand sanitizer and the opportunity to win one of the following:
- Complimentary registration to the 2011 Annual Meeting (eight winners)
- Complimentary registration to the 2011 Annual Meeting and hotel accommodations for five nights at a downtown Chicago hotel (two winners)

Winners will be announced following the Annual Meeting.

**Podcast**
Presentations from the Meeting are also available in the form of audio and video podcasts. Subscribers to the Annual Meeting Podcast enjoy full access to all captured oral presentations and can conveniently listen to the
files on a computer, download them to a portable MP3 player, or burn them to a CD. Video podcasts are optimized for viewing on an MP4 player or iPod. Subscriptions are available to ASCO members for $80 and to nonmembers for $100. Attendees who purchased a subscription prior to or at the event can activate their accounts online. Audio and video files will be available for download within 24 hours of the session’s completion. Only those who have purchased a subscription will have access to the podcasts. Save up to 80% on Virtual Meeting and Podcast when you purchase with Annual Meeting registration.

Services Available to Meeting Attendees
The following services are available to attendees at McCormick Place:

- Air Travel Assistance Desk: North Building, Grand Concourse Lobby
- Annual Meeting Information Desks: Located throughout McCormick Place
- ASCO Store: North Building, Grand Concourse Lobby and South Building, ASCO Central (Booth #7004)
- ASCO TV: Grand Concourse Lobby; Hall E Lobby; and Oncology Professionals Hall Food Court (Hall A2)
- Baggage Checks: South Building, Room S104; South Building, Level 1, Main Entrance; North Building, Level 1, Lobby; East Building, Level 2, Room E251
- Chicago Information Desk: North Building, Grand Concourse Lobby
- Exhibitor Directory Stations: South Building, Grand Concourse Entrance to Halls A1-A2
- First Aid Stations: South Building, Level 2.5 Lobby near Business Center; East Building, Level 1 near Arie Crown Theater
- Housing Assistance Desk: North Building, Grand Concourse Lobby
- International Assistance Desk: North Building, Grand Concourse Lobby
- Internet Stations: South Building, S101 Lobby; North Building, Grand Concourse Lobby; South Building, Hall A2; East Building, Hall D2 Lobby
- Member Services Desk: North Building, Grand Concourse Lobby; South Building, ASCO Central (Booth #7004); East Building, Hall E, Registration
- Restaurant Reservations Desk: North Building, Grand Concourse Lobby
- Virtual Meeting Replay Station: North Building, Level 2.5
- Virtual Meeting and Podcast Sales and Assistance: North Building, Level 2.5

Shuttle Bus Service
ASCO provides complimentary shuttle transportation June 4-8 between all official ASCO hotels and McCormick Place (except for the Hyatt Regency McCormick Place, which is adjacent to the convention center). Please refer to page 16 for the shuttle bus schedule.

Special Assistance
All of the official ASCO hotels, as well as McCormick Place, comply with the Americans with Disabilities Act. If you require special assistance with housing for the Annual Meeting, please contact the ASCO Housing Center by phone at 888-788-1522 or 703-449-6418.

Tote Bag/Meeting Materials Pick-up
Attendees who have registered and received their badge in advance may bring their tote bag coupon to Registration in Hall E or the other satellite tote bag pick-up locations throughout McCormick Place.

Virtual Meeting
Virtual Meeting helps maximize your participation at the Annual Meeting by allowing you to view or review sessions from your hotel room, home, or office. Virtual Meeting allows viewing of video and slides of all captured educational and scientific sessions from the Annual Meeting within 24 hours of the session’s completion.

Experience the Virtual Meeting onsite by visiting the Virtual Meeting Replay Station, located in the North Building, Level 2.5 Lobby. The Virtual Meeting Replay Station provides attendees who may have missed an important presentation and opportunity to view and listen to selected sessions from the previous day(s). Access to the Virtual Meeting Replay Station is available to all Meeting attendees free of charge for the duration of the Annual Meeting.

For continued access to the Virtual Meeting after June 8, purchasing “Registration with Virtual Meeting” includes exclusive access to 2010 Annual Meeting content until June 1, 2013, when all sessions become available to the public. Those who registered without purchasing the Virtual Meeting can add the Virtual Meeting until the close of the Meeting by choosing the “Changes and Cancellations” option on the online registration page at www.asco.org/chicago2010. The fee for ASCO member attendees is $45 and the fee for nonmember attendees is $75.

Wi-Fi Access
Meeting attendees with wireless capabilities can access the Internet in selected areas of McCormick Place. Full Internet access is available to attendees with a laptop, PDA, or any Internet-capable device. Technical assistance, power supplies, and Ethernet connections to the Internet also are available in the North Building, Level 2.5 in the Wi-Fi Zone.
Complimentary shuttle service is provided between McCormick Place and the hotels listed below. Please be sure to check the ASCO Shuttle sign in your hotel upon arrival for any changes, additional information, frequency of service, and specific departure times for the designated route.

Hours of Operation

Friday, June 4
Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Saturday, June 5
Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Sunday, June 6
Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Monday, June 7
Shuttle between hotels and McCormick Place 6:45 AM - 7:00 PM*

Tuesday, June 8
Shuttle between hotels and McCormick Place 6:45 AM - 1:30 PM*

*Last shuttle departs McCormick Place at this time. Last shuttle departs hotels approximately 90 minutes prior to this time.

Shuttle service is approximately every 20 minutes. McCormick Place is the transfer point to change routes.

If you have any questions regarding the shuttle, or would like to make a reservation for a wheelchair-accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call KUSHNER & ASSOCIATES at 312-808-2000 during shuttle hours.

Route 1 - Gate 1: South Building, Level 1, near Room S105
One-way travel time is approximately 20-25 minutes.
Hard Rock Hotel
Holiday Inn Chicago Mart Plaza
Hotel 71
Hotel Monaco Chicago
Renaissance Chicago Hotel
Residence Inn Chicago Downtown River North
Springhill Suites by Marriott Chicago Downtown River North
theWit, a Doubletree Hotel
Westin Chicago River North

Route 2 - Gate 1: South Building, Level 1, near Room S105
One-way travel time is approximately 20-25 minutes.
Amalfi Hotel Chicago
Best Western River North Hotel
Comfort Inn and Suites Downtown
Courtyard Chicago Downtown River North
Dana Hotel
Embassy Suites Hotel Chicago Downtown
Hampton Inn and Suites
Hilton Garden Inn Chicago Downtown Magnificent Mile
Homewood Suites by Hilton Chicago Downtown
Hotel Felix
Hotel Palomar
Hotel Sax Chicago
Trump International Hotel & Tower

Route 3 - Gate 2: South Building, Level 1, near Room S103
One-way travel time is approximately 15-20 minutes.
Chicago Marriott Downtown Magnificent Mile
Conrad Chicago
Four Points by Sheraton Chicago Downtown
Hotel Cass, Holiday Inn Express
Hotel InterContinental Chicago
James Hotel, The
Route 8 - Gate 21: North Building, Level 1, near Room N139
One-way travel time is approximately 20-30 minutes.
Ambassador East Hotel
Hotel Indigo Chicago Gold Coast

Route 9 - Gate 21: North Building, Level 1, near Room N139
One-way travel time is approximately 20-25 minutes.
Hotel Allegro Chicago, A Kimpton Hotel
W Chicago City Center

Route 10 - Gate 26: North Building, Level 1 Escalator Lobby
One-way travel time is approximately 15-20 minutes.
Blackstone - A Renaissance Hotel, The Hilton Chicago

Route 11 - Gate 26: North Building, Level 1 Escalator Lobby
One-way travel time is approximately 20-25 minutes.
Hampton Majestic
Hotel Burnham Chicago, A Kimpton Hotel
Palmer House Hilton
Silversmith Hotel, The

Route 12 - Gate 26: North Building, Level 1 Escalator Lobby
One-way travel time is approximately 15-20 minutes.
Chicago South Loop Hotel

Route 13 - Gate 31: East Building, Level 2, near Arie Crown Theater Box Office
One-way travel time is approximately 12-15 minutes.
Fairmont Chicago
Hyatt Regency Chicago
Swisshotel Chicago

Route 14 - Gate 32: East Building, Level 2, near Arie Crown Theater Box Office
One-way travel time is approximately 20-25 minutes.
Crowne Plaza Chicago Metro
Holiday Inn Hotel & Suites - Chicago Downtown
Hotel Blake
Union League Club of Chicago

Walk to McCormick Place
No shuttle bus service is provided for the Hyatt Regency McCormick Place as it is within walking distance of McCormick Place.
Important Security and Attendee Conduct Information

For security reasons, 2010 ASCO Annual Meeting badges are required for admittance to all events. Badges should be worn and visible at all times. Lost badges should be reported to the Registration staff immediately. The following badge policies are in effect throughout the Meeting:

1) 2010 ASCO Annual Meeting badges are the sole property of ASCO.
2) Badges are nontransferable.
3) False certification of individuals as paid Annual Meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any Annual Meeting event, or any inappropriate or unauthorized conduct will be just cause for repossessing badges of any individuals involved and expelling all parties involved from the Meeting without obligation on the part of ASCO for refund of any fees.

In addition, individuals who are part of the 2010 ASCO Annual Meeting may not engage in any demonstrations or other behavior that ASCO deems to be potentially disruptive to the conduct of the Meeting. Violation of this rule is grounds for immediate dismissal from the Meeting and/or ineligibility for attendance at future Annual Meetings. Any person who is dismissed from the Meeting may request that ASCO review the matter, provided, however, that the individual understands that such dismissal will be effective immediately and will continue until and unless ASCO issues a contrary decision.

Cancellation Statement

ASCO reserves the right to cancel this activity because of unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to each registrant.

Equal Opportunity Statement

ASCO events and activities are available without regard to race, color, sex, national origin, disability, age, or veteran status as provided by law and in accordance with the Society’s respect for personal dignity.

Age Requirement for Attendees

Due to the detailed nature of the programs, no persons under the age of 18 will be admitted into any official ASCO function. This includes, but is not limited to, education and scientific sessions, as well as the Oncology Professionals Hall.

Annual Meeting Policy of Recording (Audio, Video, and Still Photography)

Copyright of the 2010 ASCO Annual Meeting program is owned by the American Society of Clinical Oncology. ASCO reserves the rights to all recordings or reproductions or presentations at this Annual Meeting and all ASCO educational and scientific meetings.

Any photography, filming, taping, recording, or reproduction in any medium, including via the use of tripod-based equipment, of any of the programs and/or posters presented at the 2010 Annual Meeting without the express written consent of the American Society of Clinical Oncology is strictly forbidden. Exception: Non-flash photography and audiotape recording using hand-held equipment, for strictly personal and noncommercial use, are permitted if not disruptive.

Smoking Prohibition

Smoking is prohibited in all 2010 ASCO Annual Meeting facilities, including public areas and the Oncology Professionals Hall. This policy will be enforced.

Unlabelled Usage Statement

The information presented is that of the contributing faculty and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.
AWARDS

ASCO 2010 SPECIAL AWARDS

David A. Karnofsky Memorial Award and Lecture
Presented during the Annual Meeting Opening Session, Saturday, June 5, 9:30 AM–12:00 PM
Daniel D. Von Hoff, MD, Translational Genomics Research Institute

Science of Oncology Award and Lecture
Presented during the Plenary Session, Sunday, June 6, 1:00 PM–4:00 PM
Frank McCormick, PhD, FRS, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

ASCO–American Cancer Society Award and Lecture
Monday, June 7, 9:45 AM–11:00 AM
Joseph V. Simone, MD, University of Florida Shands Cancer Center

Gianni Bonadonna Breast Cancer Award and Lecture
To be presented at the 2010 Breast Cancer Symposium, Suburban Washington, D.C., October 1-3, 2010
Nancy E. Davidson, MD, University of Pittsburgh Cancer Institute

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
Sunday, June 6, 4:45 PM–6:00 PM
Harvey Jay Cohen, MD, Duke University Medical Center

Pediatric Oncology Award and Lecture
Saturday, June 5, 3:00 PM–4:15 PM
Sharon B. Murphy, MD, Institute of Medicine

Distinguished Achievement Award
Presented during a private function on Friday, June 4
Eli Glatstein, MD, University of Pennsylvania School of Medicine

Partners in Progress Award
Presented during the Highlights of the Day II Session, Monday, June 7, 7:30 AM–9:00 AM
Ellen V. Sigal, PhD, Friends of Cancer Research

Special Recognition Award
Presented during a private function on Friday, June 4
Patrick J. Loehrer Sr., MD, Indiana University School of Medicine

ASCO Statesman Awards
Presented during the ASCO Annual Business Meeting on Monday, June 7, 12:00 PM–1:00 PM

Laurence H. Baker, DO
Edward P. Balaban, DO
C. D. Blanke, MD
Howard A. Burris III, MD
John V. Cox, DO
Robert Dreicer, MD
Stephen B. Edge, MD
Alexander M. Eggermont, MD, PhD
Charles M. Haskell, MD
Maha Hussain, MD
Mark G. Kris, MD
Theodore S. Lawrence, MD, PhD
Gary H. Lyman, MD
Gregory A. Masters, MD
Therese M. Mulvey, MD
Olufunmilayo I. Olopade, MBBS
Bruce A. Peterson, MD
William T. Purcell, MD
Derek Raghavan, MD, PhD
Gregory H. Reaman, MD
Mack Roach III, MD
Bruce J. Roth, MD
Mace L. Rothenberg, MD
Charles A. Schiffer, MD
Branimir I. Sikic, MD
Margaret A. Tempero, MD
Linda T. Vahdat, MD
Antonio C. Wolff, MD
2010 Merit Awards

Bradley Stuart Beller Merit Award
This special recognition is given to the fellow who submitted the overall highest-ranking abstract as determined by the Scientific Program Committee. This individual receives $2,000 and is given special recognition during the Opening Ceremony.

Kristin A. Higgins, MD, Duke University Medical Center

Brigid Leventhal Merit Award
In honor of Brigid Leventhal, a physician-pioneer in pediatric research, the Brigid Leventhal Merit Award is presented to the fellow who submitted the highest-ranking abstract in pediatrics as determined by the Program Committee’s Pediatrics Subcommittee. This individual is also recognized during the Opening Ceremony and is awarded a $1500 stipend.

Laura E. Hogan, MD, New York University Langone Medical Center

Merit Award Recipients
One hundred $1,500 Merit Awards are given annually in recognition of outstanding abstracts submitted to the Scientific Program Committee for the upcoming Annual Meeting. The Merit Award program was established to encourage more fellows to attend the Annual Meeting and to further promote clinical research in young scientists.

The First Author must meet all of the following requirements to be considered for a Merit Award:

• Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD) or be a doctoral degree candidate at the time of abstract submission
• Be enrolled in an oncology fellowship training program at the time of abstract submission
• Be working in an oncology laboratory or clinical research setting
• Be the First Author and presenter of the submitted abstract
• Provide a letter of support from his or her Training Program Director indicating eligibility for the award
• Provide a two-page curriculum vitae

Charu Aggarwal, MD, MPH, Fox Chase Cancer Center
Alain P. Algazi, MD, University of California, San Francisco
Eitan Amir, MB, ChB, Princess Margaret Hospital
Valsamo K. Anagnostou, MD, Yale University School of Medicine
Joo Em Ang, MB, BCHir, MA, MRCP, The Royal Marsden NHS Foundation Trust
Fernanda I. Arnaldez, MD, Pediatric Oncology Branch, National Cancer Institute
Mohammed Ayoubi, MD, University of Texas M. D. Anderson Cancer Center
Xavier Badoux, MB, BS, University of Texas M. D. Anderson Cancer Center
Aditya Bardia, MD, MPH, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University
Gregory L. Beatty, MD, PhD, Abramson Cancer Center, University of Pennsylvania
Yanis Bellili, MD, Duke University Medical Center
Stefan H. Boeck, MD, University of Munich
Pierre O. Bohanes, MD, University of Southern California Norris Comprehensive Cancer Center
Linda E. Coate, MD, Princess Margaret Hospital and University of Toronto
Austin J. Combest, PharmD, MBA, University of North Carolina Eshelman School of Pharmacy
Elizabeth A. Comen, MD, Memorial Sloan-Kettering Cancer Center
Sandra P. D’Angelo, MD, Memorial Sloan-Kettering Cancer Center
Jonas A. De Souza, MD, The University of Chicago Medical Center
Andrea Dean, MD, University of Texas M. D. Anderson Cancer Center
Erin R. DeRose, MD, Beth Israel Deaconess Medical Center
Vincent O. Dezentje, MD, Leiden University Medical Center
Neelsha C. Dhani, MD, FRCP, Princess Margaret Hospital
Karel Echoute, MD, Daniel den Hoed Cancer Center, Erasmus University Medical Center
David J. Gallagher, MD, Memorial Sloan-Kettering Cancer Center
Bernardo Haddock L. Gouart, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center
Minal M. Gounder, MD, Memorial Sloan-Kettering Cancer Center
Christian Grommes, MD, Memorial Sloan-Kettering Cancer Center
Philip G. Hepp, MD, University Dusseldorf
Michaela J. Higgins, MD, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University
Matthias Holdhoff, MD, Johns Hopkins University
Hui Y. Hou, Penn State Hershey Medical Center
Ilaria Iacobucci, Department of Hematology/Oncology Seràgnoli
Antoine Italien, MD, PhD, Institut Bergonie
Sekwon Jang, MD, University of Minnesota
Filip Janku, MD, PhD, University of Texas M. D. Anderson Cancer Center
Nagesh H. Jayaram, MD, Indiana University School of Medicine
Sao Jiralerspong, MD, PhD, University of Texas M. D. Anderson Cancer Center
AWARDS continued

2010 Advanced Clinical Research Award in Breast Cancer
Isabelle Bedrosian, MD, University of Texas M. D. Anderson Cancer Center

*This grant was generously supported by The Breast Cancer Research Foundation.*

2010 Advanced Clinical Research Award in Colorectal Cancer
Sanjay Goel, MD, MS, Montefiore Medical Center

*This grant was generously supported by Genentech BioOncology™.*

2010 Advanced Clinical Research Award in Sarcoma
David G. Kirsch, MD, PhD, Duke University Medical Center

*This grant was generously supported by the Sarcoma Foundation of America and the Capon Family.*

2010 Career Development Awards*
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute
Nilofer Azad, MD, The Johns Hopkins University
Rupal Satish Bhatt, MD, PhD, Beth Israel Deaconess Medical Center
Toni K. Choueiri, MD, Dana-Farber Cancer Institute
Richard D. Carvajal, MD, Memorial Sloan-Kettering Cancer Center
Michael Arywn Davies, MD, PhD, University of Texas M. D. Anderson Cancer Center
Daniel Hamstra, MD, PhD, University of Michigan
Nimish Arun Mohile, MD, University of Rochester
Kimmie Ng, MD, MPH, Dana-Farber Cancer Institute
Shannon Puhalla, MD, University of Pittsburgh
Guilherme Rabinowits, MD, University of Louisville/James Graham Brown Cancer Center
Carlos A. Ramos, MD, Baylor College of Medicine
Neil H. Segal, MD, PhD, Memorial Sloan-Kettering Cancer Center
Zsofia K. Stadler, MD, Memorial Sloan-Kettering Cancer Center

*These grants were generously supported by Amgen (2), The ASCO Cancer Foundation, The Breast Cancer Foundation, Celgene Corporation, Genentech BioOncology™ (5), Lilly USA, LLC, Novartis Oncology, sanofi-aventis U.S. (2)*

*As of April 22, 2010*
2010 Clinical Trials Participation Awards

The purpose of the Clinical Trials Participation Awards is to increase the awareness of and participation in clinical trials among physicians through the recognition of quality, community-based clinical research sites. This award is supported by the Coalition of Cancer Cooperative Groups.

Dean Hematology Oncology
Madison, Wisconsin

Gundersen Lutheran Center for Cancer and Blood Disorders
La Crosse, Wisconsin

New Hanover Radiation Oncology Center (NHROC)
Wilmington, North Carolina

Aurora Advanced Health Care
Wauwatosa, Wisconsin

Saint Francis Medical Center/Cancer Treatment Center
Grand Island, Nebraska

Sanford Hematology and Oncology
Sioux Falls, South Dakota

Sandra and Malcolm Berman Cancer Institute, Greater Baltimore Medical Center
Baltimore, Maryland

Southeastern Medical Oncology Center
Goldsboro, North Carolina

The Virginia Mason Cancer Institute
Seattle, Washington

The West Clinic
Memphis, Tennessee

2010 Community Oncology Research Grants

The Community Oncology Research Grants provide funding to quality, U.S., community-based practices to support efforts to enhance their clinical trials programs. This grant is supported by Astellas USA Foundation.

Kellogg Cancer Centers
Evanston, Illinois

Missouri Baptist Medical Center
St. Louis, Missouri

Saint Francis Medical Center/Cancer Treatment Center
Grand Island, Nebraska

2010 Comparative Effectiveness Research Professorship in Breast Cancer

Patricia A. Ganz, MD, University of California, Los Angeles

This grant was generously supported by The Breast Cancer Research Foundation.

2010 ASCO Cancer Foundation Improving Cancer Care Grants, funded by Susan G. Komen for the Cure®

Patricia Harrigan Hardenbergh, MD, Shaw Regional Cancer Center
Ann Partridge, MD, MPH, Dana-Farber Cancer Institute
2010 International Development and Education Awards

The ASCO Cancer Foundation International Development and Education Award (IDEA) provides support for early-career oncologists in developing countries to attend the ASCO Annual Meeting and spend additional time at a cancer center in the United States or Canada. Eligible recipients also receive three years of complimentary ASCO membership, which includes a subscription to the Journal of Clinical Oncology. The awards are designed to provide continuing medical education, assist in career development, and help establish strong relationships between recipients and leading ASCO members who serve as scientific mentors.

Motasem Mohammad Al-Hanaqta, MD Jordan
Clarissa Seródio da Baldotto, MD Brazil
Yanin Chávarri Guerra, MD Mexico
Ganesh Dangal, MD Nepal
Luiz Henrique de Lima Araújo, MD Brazil
Senem Demirci, MD Turkey
Song Dong, PhD China
Vuong Ngoc Duong, MD Vietnam
Mustafa S. El-Sherify, MD Kuwait
Nikhil Suress Ghadyalpatil, MD, DM India
Suthinee Ithimakin, MD Thailand
Mustapha Abubakar Jamda, MBBS, MPH, FMCPH Nigeria
Nehal Rishi Khanna, MD India
Haresh Kunhiparambath, MBBS, MD, DNB India
Iwona A. Lugowska, MD, PhD Poland
Ilya Pokataev, MD Russia
Mudasiru Adebayo Salami, MD, MRCS(Glasg.), FWACS Nigeria
Krishna Sagar Sharma, MD Nepal
Amelia Janina Szymanowska-Narloch, MD, PhD Poland
Chanida Vinayanuwattikun, MD Thailand
Xin-Rong Yang, MD, PhD China

2010 Long-term International Fellowship

Cesar Giovanni Sanchez Rojel, MD, Washington University in St. Louis

2010 State Affiliate Grants

Alabama Cancer Congress
Kansas Society of Clinical Oncology
Northern New England Clinical Oncology Society
Washington State Medical Oncology Society
West Virginia Oncology Society

2010 Young Investigator Awards*

Aditya Bardia, MD, MPH, The Johns Hopkins University
Daniel Becker, MD, Columbia University Medical Center
Trever Bivona, MD, PhD, Memorial Sloan-Kettering Cancer Center
Elizabeth Buchbinder, MD, Beth Israel Deaconess Medical Center
Monika Burness, MD, The University of Chicago
Nicole Chau, MD, Princess Margaret Hospital
Lucy Chen, MD, The University of Chicago
Anthony Conley, MD, University of Texas M. D. Anderson Cancer Center
Aimee Crago, MD, PhD, Memorial Sloan-Kettering Cancer Center
Marco Davila, MD, PhD, Memorial Sloan-Kettering Cancer Center
Farshid Davyani, MD, PhD, University of Texas M. D. Anderson Cancer Center
Christina Derleth, MD, Vanderbilt University Medical Center
Andrew Epstein, MD, Memorial Sloan-Kettering Cancer Center
Felix Feng, MD, University of Michigan
Terence Friedlander, MD, University of California, San Francisco
Ahmad Paiman Ghafoori, MD, Duke University Medical Center
Keerthi Gogineni, MD, University of Pennsylvania
Matthias Holdhoff, MD, PhD, The Johns Hopkins University
Andrew Caleb Hsieh, MD, University of California, San Francisco
Gopa Iyer, MD, Memorial Sloan-Kettering Cancer Center
Richard Joseph, MD, University of Texas M. D. Anderson Cancer Center
R. Katie Kelley, MD, University of California, San Francisco
Jenny J. Kim, MD, MSc, The Cleveland Clinic
Holbrook Edwin Kohrt, MD, MD, Stanford University
Maxwell M. Krem, MD, PhD, University of Washington/Fred Hutchinson Cancer Center
Nico M. Kuderer, MD, MS, Duke University Medical Center
Christopher Lieu, MD, University of Texas M. D. Anderson Cancer Center
Frederick L. Locke, MD, The University of Chicago
Maryam Lustberg, MD, The Ohio State University
Kami Maddocks, MD, The Ohio State University
Ana Maria Molina, MD, Memorial Sloan-Kettering Cancer Center
Janet E. Murphy, MD, Massachusetts General Hospital/Dana-Farber Cancer Institute
Geoffrey R. Oxnard, MD, Memorial Sloan-Kettering Cancer Center
Navin Pinto, MD, The University of Chicago
Ran Reshef, MD, University of Pennsylvania
Jeffrey Rothman, MD, PhD, Columbia University Medical Center
William Rule, MD, University of Texas Southwestern Medical Center at Dallas
Philip Saylor, MD, Massachusetts General Hospital
Theresa Shao, MD, Columbia University Medical Center
Rachna Shroff, MD, University of Texas M. D. Anderson Cancer Center
Grace Suh, MD, University of Texas M. D. Anderson Cancer Center
Iain Tan, MBBS, MRCP, National Cancer Centre Singapore
Neeta Kiran Venepalli, MD, Vanderbilt University Medical Center
Shaveta Vinayak, MD, MS, Stanford University
Channing Yu, MD, PhD, Dana-Farber Cancer Institute
Jingsong Zhang, MD, PhD, H. Lee Moffitt Cancer Center


*As of April 22, 2010

Past ACRA/CDA/TRP/YIA Grant Recipients
The recipients listed below submitted an abstract that includes the results of the research funded by their Advanced Clinical Research Award (ACRA), Career Development Award (CDA), Translational Research Professorship (TRP), or Young Investigator Award (YIA). Visit www.ascocancerfoundation.org for recipients’ research titles.

Presented Abstracts
These recipients submitted an abstract that was selected to be presented within designated tracks at the Meeting.

2004 CDA Shabbir M. H. Alibhai, MD, MSc Abstract #9027
2002 YIA/2006 CDA Fabrice Andre, MD Abstract #550
2007 YIA Tracy A. Balbroui, MD, MPH Abstract #9012
2006 YIA/2009 CDA Don M. Benson, MD Abstract #8139
2009 CDA Jaishri O'Neill Blakeley, MD Abstract #2012
2008 YIA Daniel Costin Danila, MD Abstract #4635
2009 TRP Merrill J. Egorin, MD Abstract #2545
2007 ACRA David H. Gorski, MD, PhD, FACS Abstract #10619
Publication Abstracts
This recipient submitted an abstract that was selected for online publication at www.asco.org. This abstract is not scheduled to be presented onsite at the Meeting.

2008 YIA Loren K. Mell, MD Abstract #e13570
The 2010 Annual Meeting, developed by the ASCO 2009-2010 Cancer Education Committee and Scientific Program Committee, is made up of the following types of sessions:

**Special Sessions**
Special Sessions include the following:
- presentation of Special Awards as well as Award Lectures—didactic lectures presented by the recipients of ASCO’s Special Awards;
- Highlights of the Day—morning sessions in which experts in the field present key findings, put abstracts into clinical context, and provide an overview of the previous day’s Oral Abstract Sessions; and
- sessions recommended by individuals and other oncology-related organizations (and developed in conjunction with ASCO), the Cancer Education Committee, the Scientific Program Committee, and the ASCO Board of Directors as being of particular interest, importance, and relevance to Meeting attendees.

**Clinical Science Symposia**
Clinical Science Symposia provide a forum for science in oncology, combining didactic lectures on a specific topic with the presentation of abstracts. Experts in the field classify studies on the basis of the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.

**Education Sessions**
Education Sessions offer multidisciplinary explorations of focused topics in clinical oncology. Particular care is taken to ensure that these sessions are integrated when appropriate regarding issues such as surgical, radiation, and geriatric oncology; symptom management; health services research; international perspectives; and pathology.

**Extended Education Sessions**
Extended Education Sessions are part of ASCO’s continuing effort to provide in-depth learning experiences on topics that address educational needs in oncology, as determined by the Cancer Education Committee and other ASCO leaders.

**Oral Abstract Sessions**
Oral Abstract Sessions include didactic presentations of the abstracts determined by the Scientific Program Committee to be of the highest scientific merit. Experts in the field serve as Discussants to place the findings into perspective. The Plenary Session includes the abstracts selected by the Scientific Program Committee as having practice-changing findings.

**Poster Discussion Sessions**
Poster Discussion Sessions highlight selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time, followed by a discussion session in which expert Discussants provide commentary on the research findings.

**General Poster Sessions**
General Poster Sessions include selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time.

**Trials in Progress Poster Session**
The Trials in Progress Poster Session is a new Annual Meeting session designed to facilitate awareness of open, ongoing clinical trials. This session encourages discussion of new clinical research and the exchange of ideas on clinical trial design. There will be no presentation of trial results.

**Ticketed Sessions**
Ticketed sessions require additional registration. Each ticketed session has a code that should be entered during the registration process. Early registration is encouraged, as attendance in these sessions is limited.

**Meet the Professor Sessions**
Meet the Professor Sessions provide open discussion between recognized experts and session attendees, with an opportunity for attendees to obtain answers to specific questions.

**Clinical Problems in Oncology Sessions**
Clinical Problems in Oncology Sessions combine the use of case-based panel discussion with interactive, keypad technology for audience participation.
THE ASCO CANCER FOUNDATION
MISSION ENDOWMENT FOUNDING DONORS
Genentech BioOncology™
GlaxoSmithKline Oncology
Novartis Oncology
sanofi-aventis

THE ASCO CANCER FOUNDATION
MISSION ENDOWMENT 2009 SUSTAINING DONORS
Millennium: The Takeda Oncology Company
sanofi-aventis

EDUCATIONAL SUPPORT
Amgen
Best of ASCO Meetings
Developmental Therapeutics—Clinical Pharmacology Track
Gastrointestinal (Colorectal) Cancer Track
Genitourinary Cancer Track
Health Services Research Track
Pediatric Oncology Track

ARIAD Pharmaceuticals, Inc.
Sarcoma Track

Boehringer Ingelheim Pharmaceuticals, Inc.
Best of ASCO Meetings
Lung Cancer Track

Bristol-Myers Squibb
Gastrointestinal (Colorectal) Cancer Track
Head and Neck Cancer Track
Leukemia, Myelodysplasia, and Transplantation Track
Lymphoma and Plasma Cell Disorders Track

Celgene Corporation
Leukemia, Myelodysplasia, and Transplantation Track
Lymphoma and Plasma Cell Disorders Track

Centocor Ortho Biotech Inc.
Gynecologic Cancer Track

Dendreon Corporation
Best of ASCO Meeting
Genitourinary Cancer Track

Eisai Inc.
Best of ASCO Meetings
Leukemia, Myelodysplasia, and Transplantation Track

EMD Serono Inc.
Breast Cancer Track
Central Nervous System Tumors Track
Lung Cancer Track

GE Healthcare
Practice Management and Information Technology Track

Genentech BioOncology™
Breast Cancer Track
Tumor Biology Track
Gastrointestinal (Colorectal) Cancer Track

Genentech BioOncology™
Breast Cancer Track
Lung Cancer Track
Professional Development Track

Kidney Cancer Association
Genitourinary Cancer Track

Lilly USA, LLC
Best of ASCO Meetings
Breast Cancer Track
Gynecologic Cancer Track
Gastrointestinal (Colorectal) Cancer Track
Head and Neck Cancer Track
Lung Cancer Track

Merck Oncology
Sarcoma Track

Millennium: The Takeda Oncology Company
Best of ASCO Meetings
Genitourinary Cancer Track
Lymphoma and Plasma Cell Disorders Track

Myriad Genetics Laboratories, Inc.
Cancer Genetics Track

Pfizer Oncology
Best of ASCO Meetings
Genitourinary Cancer Track
Leukemia, Myelodysplasia, and Transplantation Track
Lung Cancer Track
Lymphoma and Plasma Cell Disorders Track

Purdue Pharma L.P.
Patient and Survivor Care Track

sanofi-aventis U.S.
Best of ASCO Meetings
Breast Cancer Track
Educational Book
Gastrointestinal (Colorectal) Cancer Track
International Track

GENERAL SUPPORT
Abbott Oncology
The ASCO Cancer Foundation Young Investigator Award

Abraxis BioScience
The ASCO Cancer Foundation Young Investigator Award (2)

American Cancer Society
The ASCO Cancer Foundation Merit Awards
ASCO–American Cancer Society Award and Lecture

Amgen
The ASCO Cancer Foundation Career Development Award (2)
The ASCO Cancer Foundation International Development and Education Awards
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award (2)
Long-term International Fellowship (LIFe) in memory of Lina Cassol, MD
ARIAD Pharmaceuticals, Inc.
The ASCO Cancer Foundation Advanced Clinical Research Award in Sarcoma Research

ASCO and The ASCO Cancer Foundation Boards of Directors
The ASCO Cancer Foundation Young Investigator Award

ASCO Cancer Research Committee
The ASCO Cancer Foundation Young Investigator Award

ASCO Clinical Practice Committee
The ASCO Cancer Foundation Young Investigator Award

Association of Specialty Professors
B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Astellas USA Foundation
Community Oncology Research Grants

AstraZeneca
The ASCO Cancer Foundation Young Investigator Award

Bayer Healthcare Pharmaceuticals
The ASCO Cancer Foundation General Contribution

Boehringer Ingelheim Pharmaceuticals, Inc.
Abstracts on ASCO.org
Annual Meeting Smartphone Applications
The ASCO Cancer Foundation Young Investigator Award

Bradley Stuart Beller Endowed Fund
Bradley Stuart Beller Special Merit Award

The Breast Cancer Research Foundation
The ASCO Cancer Foundation Advanced Clinical Research Award in Breast Cancer
The ASCO Cancer Foundation Career Development Award in Breast Cancer
The ASCO Cancer Foundation Comparative Effectiveness Research Professorship in Breast Cancer
The ASCO Cancer Foundation Young Investigator Award in Breast Cancer
The ASCO Cancer Foundation Young Investigator Award in Breast Cancer in honor of Susan Hirschhorn and in memory of her mother

Bristol-Myers Squibb
Annual Meeting Program (Pocket Program)
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award

Celgene Corporation
The ASCO Cancer Foundation Career Development Award
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award
Patient Advocate Scholarship

Coalition of Cancer Cooperative Groups
The ASCO Cancer Foundation Clinical Trials Participation Award

Dendreon Corporation
ASCO Annual Meeting Proceedings Parts I and II (print versions)
The ASCO Cancer Foundation General Contribution Wi-Fi Zones

Don Shula Foundation, Inc.
The ASCO Cancer Foundation Young Investigator Award in Breast Cancer

Eisai Inc.
The ASCO Cancer Foundation Young Investigator Award (2)
Exhibitor Directory Stations
Patient Advocate Scholarship Program
Preliminary Annual Meeting Program
Wi-Fi Zones
The ASCO Cancer Foundation General Contribution

EMD Serono Inc.
The ASCO Cancer Foundation Young Investigator Award

EMD Serono Inc. and Merck KGaA
The ASCO Cancer Foundation International Development and Education Awards
Internet Stations

Estate of Sandra Syms
The ASCO Cancer Foundation Young Investigator Award in Kidney Cancer Research (2)

Ewa Maria Kukrika Fund for Pancreatic Cancer Research
The ASCO Cancer Foundation Young Investigator Award in Pancreatic Cancer

Genentech BioOncology™
The ASCO Cancer Foundation Advanced Clinical Research Award in Colorectal Cancer
The ASCO Cancer Foundation Advanced Clinical Research Award in Glioma
The ASCO Cancer Foundation Advanced Clinical Research Award in Hematologic Malignancies
The ASCO Cancer Foundation Career Development Award (5)
The ASCO Cancer Foundation Translational Research Professorship
The ASCO Cancer Foundation Young Investigator Award (5)
Associate and Active-Junior Lounge
Program Announcement
Registration and Housing Announcement

Genzyme
The ASCO Cancer Foundation Merit Awards

GlaxoSmithKline Oncology
The ASCO Cancer Foundation Translational Research Professorship

Journal of Clinical Oncology
The ASCO Cancer Foundation Young Investigator Award

Kidney Cancer Association
The ASCO Cancer Foundation Young Investigator Award in Renal Cell Carcinoma

29
Lilly USA, LLC
The ASCO Cancer Foundation Career Development Award
The ASCO Cancer Foundation General Contribution Award
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award
Patient Advocate Scholarship Program

Merck Oncology
The ASCO Cancer Foundation Young Investigator Award

Millennium: The Takeda Oncology Company
Annual Meeting Smartphone Applications
The ASCO Cancer Foundation International Development and Education Awards
The ASCO Cancer Foundation Young Investigator Award (2)
Internet Stations
Patient Advocate Scholarship Program
Virtual Meetings

Novartis Oncology
The ASCO Cancer Foundation Career Development Award
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award (4)

Onyx Pharmaceuticals, Inc.
The ASCO Cancer Foundation General Contribution Award

OSI Pharmaceuticals, Inc.
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award

Pfizer Oncology
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Young Investigator Award (3)
ASCO Annual Meeting Proceedings Part I (USB) and Part II (CD)

Roche
The ASCO Cancer Foundation International Development and Education Awards
The ASCO Cancer Foundation Young Investigator Award (5)

Virtual Meetings
Wi-Fi Zones

sanofi-aventis U.S.
Abstracts on ASCO.org
Annual Meeting Smartphone Applications
The ASCO Cancer Foundation Career Development Award (2)
The ASCO Cancer Foundation Merit Awards
The ASCO Cancer Foundation Oncology Trainee Travel Awards
The ASCO Cancer Foundation Young Investigator Award (3)
Virtual Meetings

Sarcoma Foundation of America
The ASCO Cancer Foundation Young Investigator Award in Sarcoma Research

Sarcoma Foundation of America and Capon Family
The ASCO Cancer Foundation Advanced Clinical Research Award in Sarcoma Research

The Susan G. Komen for the Cure®/ASCO Cancer Foundation Collaborative Commitment:
The Susan G. Komen for the Cure/ASCO Cancer Foundation Research Initiative
• The ASCO Cancer Foundation Improving Cancer Grant, funded by Susan G. Komen for the Cure
The Susan G. Komen for the Cure/ASCO Quality of Care Initiative
• The ASCO Breast Cancer Registry Pilot Program, funded by Susan G. Komen for the Cure
• The ASCO Diversity in Oncology Initiative, funded by Susan G. Komen for the Cure
• The ASCO Study of Collaborative Practice Arrangements, funded by Susan G. Komen for the Cure
• The ASCO Study of Geographic Access to Oncology Care, funded by Susan G. Komen for the Cure

WWW Foundation, Inc. (Quad W) and McHenry and Lisa Tichenor Fund of Communities Foundation of Texas
The ASCO Cancer Foundation Young Investigator Award in Sarcoma in memory of Willie Tichenor

*This list reflects commitments as of April 22, 2010.
The 2010 ASCO Annual Meeting is structured to serve the respective interests of the Society’s multidisciplinary membership, with education focused on medical, surgical, and radiation oncology. Again this year, both educational and scientific sessions have been combined to form tracks, or series of focused learning opportunities on disease-specific topics and oncology-related subjects. Because many sessions can be categorized according to more than one track, attendees are encouraged to review the sessions offered in other tracks to ensure that they find all the sessions in their preferred area of interest. Attendees can customize their meeting schedules through the online Meeting Program, available at www.asco.org/chicago2010.

Note: Sessions in which Special Awards are being presented are shaded in gray.

### BREAST CANCER

**FRIDAY, JUNE 4, 2010**

1:00 PM - 2:15 PM Education Session  
**Bone Therapy in Breast Cancer: Why, When, and What’s Next? E Hall D1**

1:00 PM - 3:15 PM Extended Education Sessions  
**Advances in Prevention of Major Malignancies E354b**  
**Sex and the Survivor E Arie Crown Theater**

4:30 PM - 5:45 PM Education Session  
**Molecular Profiling in Breast Cancer: Ten Years Later E Hall D1**

**SATURDAY, JUNE 5, 2010**

8:00 AM - 9:15 AM Education Sessions  
**Cancer Fatigue and Contributing Factors: Recognition and Treatment E354b**  
**Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation E Arie Crown Theater**

8:00 AM - 1:00 PM Poster Discussion Session  
**Breast Cancer—Metastatic E450b**

2:00 PM - 6:00 PM General Poster Sessions  
**Breast Cancer—Local-Regional and Adjuvant Therapy S Hall A2**  
**Breast Cancer—Metastatic S Hall A2**

3:00 PM - 4:15 PM Clinical Problems in Oncology  
**Central Nervous System Metastases: From Local to Systemic Therapy (C05)-TICKETED SESSION E451a**

4:45 PM - 6:00 PM Education Session  
**Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer N Hall B1**

**SUNDAY, JUNE 6, 2010**

9:45 AM - 11:00 AM Education Session  
**Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat S100a**

4:30 PM - 6:00 PM Clinical Science Symposium  
**Predictors of Response to Preoperative Therapy: Where Are We? N Hall B1**

4:45 PM - 6:00 PM Education Session  
**Physical Activity in Cancer Populations: What’s New? E354b**

**MONDAY, JUNE 7, 2010**

8:00 AM - 9:15 AM Education Session  
**Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer N Hall B1**

9:30 AM - 12:30 PM Oral Abstract Session  
**Breast Cancer—Local-Regional and Adjuvant Therapy N Hall B1**
PROGRAM BY TRACK
Breast Cancer continued

1:15 PM - 2:30 PM Education Session
Controversies in the Management of Metastatic Breast Cancer  E Hall D1

2:00 PM - 6:00 PM Poster Discussion Session
Breast Cancer—Local-Regional and Adjuvant Therapy  S403

3:00 PM - 4:30 PM Clinical Science Symposium
Circulating Tumor Cells in Breast Cancer: Where Are We?  N Hall B1

4:45 PM - 6:00 PM Education Session
Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer  S504

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Session
Building Bridges for Successful Breast Cancer Survivorship Care  E354a

9:30 AM - 12:30 PM Oral Abstract Session
Breast Cancer—Metastatic  E Hall D1

CANCER GENETICS
FRIDAY, JUNE 4, 2010
4:30 PM - 5:45 PM Education Session
Molecular Profiling in Breast Cancer: Ten Years Later  E Hall D1

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation  E Arie Crown Theater

3:00 PM - 4:15 PM Meet the Professor Session
Clinical Management of Hereditary Colorectal Cancer (M03)-TICKETED SESSION  E451b

4:45 PM - 6:00 PM Education Session
Cutaneous Cancer Syndromes  E353

SUNDAY, JUNE 6, 2010
11:30 AM - 12:45 PM Education Session
Evaluating the Evidence and Marketing of Pharmacogenomic Tests  E353

4:45 PM - 6:00 PM Education Session
The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?  E Hall D1

MONDAY, JUNE 7, 2010
4:45 PM - 6:00 PM Special Session
From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—An ASCO/American Association for Cancer Research Joint Session  S404

4:45 PM - 6:00 PM Clinical Problems in Oncology
Advances in Hereditary Pancreatic Cancer (C13)-TICKETED SESSION  E451a

CANCER PREVENTION/EPIDEMIOLOGY
FRIDAY, JUNE 4, 2010
1:00 PM - 3:15 PM Extended Education Session
Advances in Prevention of Major Malignancies  E354b
SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Micronutrient Supplementation versus Dietary Modification of Cancer Prevention: Which Is Better? S100b

8:00 AM - 12:00 PM General Poster Session
Cancer Prevention/Epidemiology S Hall A2

1:00 PM - 2:15 PM Meet the Professor Session
Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention (M02)-TICKETED SESSION E451b

1:15 PM - 2:30 PM Education Session
The Global Burden of Cancer: The Worldwide Challenge of Cancer Control S100b

4:45 PM - 6:00 PM Meet the Professor Session
Aspirin and Nonsteroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention (M04)-TICKETED SESSION E451b

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
The Global Status of HPV Vaccination S100b

9:30 AM - 12:30 PM Oral Abstract Session
Cancer Prevention/Epidemiology S100b

11:30 AM - 12:45 PM Clinical Problems in Oncology
Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION E451a

4:45 PM - 6:00 PM Education Session
The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions? E Hall D1

MONDAY, JUNE 7, 2010
9:45 AM - 11:00 AM Clinical Problems in Oncology
Treatment of Barrett’s Esophagus to Prevent Esophageal Cancer (C12)-TICKETED SESSION E451a

2:00 PM - 6:00 PM Poster Discussion Session
Cancer Prevention/Epidemiology E450b

CENTRAL NERVOUS SYSTEM TUMORS

FRIDAY, JUNE 4, 2010
1:00 PM - 2:15 PM Education Session
Neurologic Complications of Cancer Therapies S100b

2:45 PM - 4:00 PM Education Session
Geriatric Issues in Neuro-oncology S100b

4:30 PM - 5:45 PM Education Session
Improving Clinical Trial Outcome in Neuro-oncology S100b

SATURDAY, JUNE 5, 2010
8:00 AM - 1:00 PM Poster Discussion Session
Central Nervous System Tumors S103

3:00 PM - 6:00 PM Oral Abstract Session
Central Nervous System Tumors S100b
PROGRAM BY TRACK
Central Nervous System Tumors continued

SUNDAY, JUNE 6, 2010
8:00 AM - 12:00 PM General Poster Session
Central Nervous System Tumors S Hall A2

4:45 PM - 6:00 PM Education Session
Stem Cells in Neuro-oncology S100b

MONDAY, JUNE 7, 2010
1:15 PM - 2:30 PM Clinical Problems in Oncology
Nonglial and Heritable Central Nervous System Tumors (C14)-TICKETED SESSION E451a

3:00 PM - 4:15 PM Education Session
Caring for the Child with Brain Cancer S504

3:00 PM - 4:15 PM Clinical Problems in Oncology
Neuro-oncology for Medical Oncologists (C15)-TICKETED SESSION E451a

TUESDAY, JUNE 8, 2010
9:30 AM - 10:45 AM Education Session
Supportive Care for Patients with Non-small Cell Lung Cancer E353

CLINICAL TRIALS

FRIDAY, JUNE 4, 2010
1:00 PM - 3:15 PM Extended Education Session
Fundamentals of Clinical Trial Design and Methodology S100a

1:00 PM - 3:30 PM Extended Education Session
Grant Writing Workshop I: Basic Grant Writing S106a

3:45 PM - 6:00 PM Extended Education Session
Advanced Concepts in Clinical Trial Design and Methodology S100a

4:00 PM - 6:00 PM Extended Education Session
Grant Writing Workshop II: Improving Your Grant Writing Skills (Small Group Discussions) S106a

4:45 PM - 6:00 PM Clinical Problems in Oncology
Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION E451a

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Clinical Trials in Survivorship Populations: Emerging Concepts and Barriers to Application S100a

1:15 PM - 2:30 PM Education Sessions
Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All E353

Improving Access to Clinical Trials S100a

3:00 PM - 4:15 PM Education Sessions
International Collaboration in Clinical Trials: Special Emphasis on Ethics and Regulatory Issues S100a

Update on Gastrointestinal Noncolorectal Malignancies: What’s New since the 2009 ASCO Annual Meeting? N Hall B1

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Session
Impact of Health Literacy on Health Care, Decision Making, and Consent E353

8:00 AM - 12:00 PM Trials in Progress Poster Session
Trials in Progress Poster Session S Hall A2
9:45 AM - 11:00 AM Education Session
Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction? E Hall D2

9:45 AM - 11:00 AM Meet the Professor Session
Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION E451b

9:45 AM - 11:30 AM Education Session
Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute’s Clinical Trials and Translational Research Advisory Committee S100a

11:30 AM - 12:45 PM Education Session
Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials S100b

1:15 PM - 2:30 PM Education Session
NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting S404

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions
Developing Drugs in Special Populations: Organ Dysfunction Studies E354b
Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice S100b

DEVELOPMENTAL THERAPEUTICS

FRIDAY, JUNE 4, 2010

2:45 PM - 4:00 PM Education Session
Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets E Hall D1

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Sessions
Melanoma Immunotherapy: Current Status, Future Opportunities S406 (Vista Room)
The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer S504

8:00 AM - 1:00 PM Poster Discussion Session
Developmental Therapeutics—Clinical Pharmacology and Immunotherapy E450a

1:00 PM - 4:00 PM Oral Abstract Session
Developmental Therapeutics—Experimental Therapeutics E Hall D2

4:30 PM - 6:00 PM Clinical Science Symposium
PARP Inhibition: DNA Repair as the Target E Arie Crown Theater

SUNDAY, JUNE 6, 2010

8:00 AM - 9:30 AM Clinical Science Symposium
The MEK Pathway E354a

9:45 AM - 11:15 AM Clinical Science Symposium
Smoothened/Hedgehog/Gamma Secretase E353

11:30 AM - 12:45 PM Education Session
Evaluating the Evidence and Marketing of Pharmacogenomic Tests E353

2:00 PM - 6:00 PM Poster Discussion Session
Developmental Therapeutics—Experimental Therapeutics E450b

4:45 PM - 6:00 PM Education Session
New Technology in Cancer Immune Therapy E353
PROGRAM BY TRACK
Developmental Therapeutics continued

MONDAY, JUNE 7, 2010
8:00 AM - 9:30 AM Clinical Science Symposium
Paths for Clinical Development of PI3K Inhibition E Arie Crown Theater

8:00 AM - 12:00 PM General Poster Sessions
Developmental Therapeutics—Clinical Pharmacology and Immunotherapy S Hall A2
Developmental Therapeutics—Experimental Therapeutics S Hall A2

9:45 AM - 11:00 AM Meet the Professor Session
Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION E451b

11:30 AM - 12:45 PM Education Session
Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials S100b

1:15 PM - 2:30 PM Education Sessions
Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice? N Hall B1

Immunonjugates as Cancer Therapeutics S100b

4:45 PM - 6:00 PM Education Session
Oral Chemotherapy: A Hard Pill to Swallow S406 (Vista Room)

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Sessions
Developing Drugs in Special Populations: Organ Dysfunction Studies E354b
Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice S100b

9:30 AM - 12:30 PM Oral Abstract Session
Developmental Therapeutics—Clinical Pharmacology and Immunotherapy E354a

9:45 AM - 11:00 AM Education Session
Even Patients with Liver Dysfunction Can Get Chemotherapy! E354b

ETHICS

FRIDAY, JUNE 4, 2010
2:45 PM - 4:00 PM Education Session
Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities E353

4:45 PM - 6:00 PM Clinical Problems in Oncology
Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION E451a

SATURDAY, JUNE 5, 2010
3:00 PM - 4:15 PM Special Session
Health Care Reform: Resetting the Clock E Arie Crown Theater

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges S100a

MONDAY, JUNE 7, 2010
9:45 AM - 11:00 AM Education Session
Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient E353

11:30 AM - 12:45 PM Education Session
Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials S100b
1:15 PM - 2:30 PM Education Session
Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce E353

3:00 PM - 4:15 PM Education Session
Navigating Conflicts of Interest in Medicine and Research: Proper Interactions with Industry in a Time of Increasing Scrutiny S100b

4:45 PM - 6:00 PM Education Session
Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity? S100b

GASTROINTESTINAL (COLORECTAL) CANCER

FRIDAY, JUNE 4, 2010
1:00 PM - 3:15 PM Extended Education Session
Sex and the Survivor E Arie Crown Theater

2:45 PM - 4:00 PM Education Session
Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets E Hall D1

SATURDAY, JUNE 5, 2010
1:15 PM - 2:30 PM Education Session
Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) E354b

3:00 PM - 4:15 PM Meet the Professor Session
Clinical Management of Hereditary Colorectal Cancer (M03)-TICKETED SESSION E451b

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
Controversies in the Management of Colorectal Cancer N Hall B1

9:30 AM - 12:30 PM Oral Abstract Session
Gastrointestinal (Colorectal) Cancer E Hall D1

9:45 AM - 11:00 AM Education Session
Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat S100a

11:30 AM - 12:30 PM Clinical Problems in Oncology
Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION E451a

2:00 PM - 6:00 PM General Poster Session
Gastrointestinal (Colorectal) Cancer S Hall A2

4:45 PM - 6:00 PM Education Sessions
Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How? S404
Physical Activity in Cancer Populations: What’s New? E354b

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Session
Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold S100a

TUESDAY, JUNE 8, 2010
8:00 AM - 12:00 PM Poster Discussion Session
Gastrointestinal (Colorectal) Cancer S403

9:45 AM - 11:00 AM Clinical Problems in Oncology
The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION E451a
PROGRAM BY TRACK
Gastrointestinal (Noncolorectal) Cancer

GASTROINTESTINAL (NONCOLORECTAL) CANCER

FRIDAY, JUNE 4, 2010
2:00 PM - 6:00 PM Poster Discussion Session
Gastrointestinal (Noncolorectal) Cancer E450b

SATURDAY, JUNE 5, 2010
1:15 PM - 2:45 PM Clinical Science Symposium
Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life N Hall B1
3:00 PM - 4:15 PM Education Session
Update on Gastrointestinal Noncolorectal Malignancies: What’s New since the 2009 ASCO Annual Meeting? N Hall B1

SUNDAY, JUNE 6, 2010
2:00 PM - 6:00 PM General Poster Session
Gastrointestinal (Noncolorectal) Cancer S Hall A2
4:45 PM - 6:00 PM Education Session
The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions? E Hall D1

MONDAY, JUNE 7, 2010
9:45 AM - 11:00 AM Education Session
Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction? E Hall D2
9:45 AM - 11:00 AM Clinical Problems in Oncology
Treatment of Barrett’s Esophagus to Prevent Esophageal Cancer (C12)-TICKETED SESSION E451a
1:15 PM - 2:30 PM Education Session
Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice? N Hall B1
3:00 PM - 6:00 PM Oral Abstract Session
Gastrointestinal (Noncolorectal) Cancer E Hall D1
4:45 PM - 6:00 PM Clinical Problems in Oncology
Advances in Hereditary Pancreatic Cancer (C13)-TICKETED SESSION E451a

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Session
Developing Drugs in Special Populations: Organ Dysfunction Studies E354b
9:45 AM - 11:00 AM Education Session
Even Patients with Liver Dysfunction Can Get Chemotherapy! E354b
9:45 AM - 11:00 AM Clinical Problems in Oncology
The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION E451a
11:30 AM - 12:45 PM Clinical Problems in Oncology
Hepatocellular Carcinoma: Is This Patient a Transplant, Resection, or Chemoembolization Candidate? (C19)-TICKETED SESSION E451a

GENERAL ONCOLOGY

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Cancer Fatigue and Contributing Factors: Recognition and Treatment E354b
1:15 PM - 2:30 PM Education Sessions
Evolving Standards of Care in Advanced Renal Cell Carcinoma  E Hall D1
Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions)  E354b

4:45 PM - 6:00 PM Education Session
Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer  N Hall B1

SUNDAY, JUNE 6, 2010
7:30 AM - 9:00 AM Highlights of the Day
Highlights of the Day I including Clinical Trials Participation Awards  E Hall D1
9:45 AM - 11:00 AM Education Session
Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat  S100a

1:00 PM - 4:00 PM Plenary Session
Plenary Session including Science of Oncology Award and Lecture  N Hall B1

MONDAY, JUNE 7, 2010
7:30 AM - 9:00 AM Highlights of the Day
Highlights of the Day II including Partners in Progress Award  E Hall D1

11:30 AM - 12:45 PM Education Session
Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer  E Arie Crown Theater

3:00 PM - 4:15 PM Education Session
Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness  S404

TUESDAY, JUNE 8, 2010
7:30 AM - 9:00 AM Highlights of the Day
Highlights of the Day III  E Hall D1
8:00 AM - 9:15 AM Education Session
Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment  E353
9:30 AM - 10:45 AM Education Session
Supportive Care for Patients with Non-small Cell Lung Cancer  E353
11:30 AM - 12:45 PM Education Session
Management of the Elderly Patient with Cancer  S100b

GENITOURINARY CANCER

FRIDAY, JUNE 4, 2010
1:00 PM - 3:15 PM Extended Education Session
Advances in Prevention of Major Malignancies  E354b

SATURDAY, JUNE 5, 2010
8:00 AM - 9:30 AM Clinical Science Symposium
Genetic and Molecular Predictors in Genitourinary Malignancies  E Hall D2

1:15 PM - 2:30 PM Education Session
Evolving Standards of Care in Advanced Renal Cell Carcinoma  E Hall D1

2:00 PM - 6:00 PM Poster Discussion Session
Genitourinary (Nonprostate) Cancer  E450a
PROGRAM BY TRACK
Genitourinary Cancer continued

SUNDAY, JUNE 6, 2010
9:30 AM - 12:30 PM Oral Abstract Session
Genitourinary (Prostate) Cancer E Hall D2

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Session
Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy? E354b

8:00 AM - 9:15 AM Clinical Problems in Oncology
The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease (C11)-TICKETED SESSION E451a

8:00 AM - 1:00 PM Poster Discussion Session
Genitourinary (Prostate) Cancer E450a

9:30 AM - 10:45 AM Education Session
Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer S406 (Vista Room)

11:30 AM - 12:45 PM Education Session
Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer E Arie Crown Theater

1:00 PM - 5:00 PM General Poster Session
Genitourinary Cancer S Hall A2

1:15 PM - 2:30 PM Education Session
Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions E Hall D2

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Session
Localized Prostate Cancer: Reducing Mortality and Burden of Therapy E Arie Crown Theater

9:30 AM - 12:30 PM Oral Abstract Session
Genitourinary (Testes, Kidney, and Bladder) Cancer E Arie Crown Theater

GERIATRIC ONCOLOGY

FRIDAY, JUNE 4, 2010
2:45 PM - 4:00 PM Education Session
Geriatric Issues in Neuro-oncology S100b

3:30 PM - 4:45 PM Education Session
Management of Older Patients with Lymphoma and Myeloma E354b

SATURDAY, JUNE 5, 2010
8:00 AM - 11:00 AM Special Session
Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available) S106a

1:15 PM - 2:30 PM Education Sessions
Improving Access to Clinical Trials S100a

Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) E354b

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges S100a

9:45 AM - 11:00 AM Education Session
Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat S100a
11:30 AM - 1:00 PM Clinical Science Symposium
Optimizing Care of the Elderly and Underserved S100a

4:45 PM - 6:00 PM Special Session
B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology S100a

4:45 PM - 6:00 PM Education Session
Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How? S404

MONDAY, JUNE 7, 2010

8:00 AM - 9:15 AM Education Session
Disparities in Cancer Care S404

9:30 AM - 10:45 AM Education Session
Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer S406 (Vista Room)

11:30 AM - 12:45 PM Education Session
Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer E Arie Crown Theater

1:15 PM - 2:30 PM Education Session
Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions E Hall D2

4:45 PM - 6:00 PM Education Session
Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity? S100b

TUESDAY, JUNE 8, 2010

8:00 AM - 9:15 AM Education Sessions
Building Bridges for Successful Breast Cancer Survivorship Care E354a
Localized Prostate Cancer: Reducing Mortality and Burden of Therapy E Arie Crown Theater

11:30 AM - 12:45 PM Education Session
Management of the Elderly Patient with Cancer S100b

GYNECOLOGIC CANCER

SATURDAY, JUNE 5, 2010

8:00 AM - 9:15 AM Education Session
Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation E Arie Crown Theater

1:15 PM - 2:30 PM Education Session
Future Directions in the Management of Endometrial Cancer E Arie Crown Theater

2:00 PM - 6:00 PM General Poster Session
Gynecologic Cancer S Hall A2

4:45 PM - 6:00 PM Clinical Problems in Oncology
Complex and Recurrent Gynecologic Cancers: What’s an Oncologist to Do? (C06)-TICKETED SESSION E451a

SUNDAY, JUNE 6, 2010

8:00 AM - 9:15 AM Education Session
HPV Status and Clinical Decision Making for Patients with Oropharynx Cancer E Hall D2

9:30 AM - 12:30 PM Oral Abstract Session
Gynecologic Cancer E Arie Crown Theater
PROGRAM BY TRACK
Gynecologic Cancer continued

2:00 PM - 6:00 PM Poster Discussion Session
Gynecologic Cancer E450a

MONDAY, JUNE 7, 2010
9:45 AM - 11:15 AM Clinical Science Symposium
Novel Therapies and Approaches for Management of Gynecologic Cancers E Arie Crown Theater

3:00 PM - 4:15 PM Education Session
Integrated Considerations in the Management of the Patient with Advanced Ovarian Cancer
E Arie Crown Theater

HEAD AND NECK CANCER

FRIDAY, JUNE 4, 2010
1:00 PM - 2:15 PM Education Session
Use of Induction Chemotherapy in Clinical Practice S406 (Vista Room)

2:00 PM - 6:00 PM Poster Discussion Session
Head and Neck Cancer S403

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
HPV Status and Clinical Decision Making for Patients with Oropharynx Cancer E Hall D2

8:00 AM - 12:00 PM General Poster Session
Head and Neck Cancer S Hall A2

9:45 AM - 11:00 AM Clinical Problems in Oncology
Therapeutic Choices for Patients with Intermediate-stage Head and Neck Cancer (C08)-TICKETED SESSION E451a

MONDAY, JUNE 7, 2010
9:45 AM - 11:00 AM Education Session
Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction? E Hall D2

9:45 AM - 11:15 AM Clinical Science Symposium
Promising Targeted Therapies for Head and Neck Cancer E354a

11:30 AM - 12:45 PM Clinical Problems in Oncology
Management of Less Common Head and Neck Cancers (C16)–TICKETED SESSION E451a

3:00 PM - 6:00 PM Oral Abstract Session
Head and Neck Cancer E354b

HEALTH SERVICES RESEARCH

FRIDAY, JUNE 4, 2010
1:00 PM - 3:15 PM Extended Education Sessions
Cancer and Thrombosis: Risk, Prevention, and Treatment E354a
Childhood Cancer Survivorship: Lessons Learned and Future Steps S504

4:30 PM - 5:45 PM Education Session
Electronic Health Records in Oncology: A Requirement for 2014 E353

SATURDAY, JUNE 5, 2010
8:00 AM - 1:00 PM Poster Discussion Session
Health Services Research S403
SUNDAY, JUNE 6, 2010
4:45 PM - 6:00 PM Clinical Problems in Oncology
Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management (C10)-TICKETED SESSION E451a

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Special Session
Cancer Survivors: A Challenge to Health Care Systems Worldwide S100b

8:00 AM - 9:15 AM Education Sessions
Disparities in Cancer Care S404
Health Disparities in Lung Cancer: Race, Sex, and Genes E Hall D2
Impact of Health Literacy on Health Care, Decision Making, and Consent E353

9:30 AM - 12:30 PM Oral Abstract Session
Health Services Research S404

9:45 AM - 11:30 AM Education Session
Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute’s Clinical Trials and Translational Research Advisory Committee S100a

11:30 AM - 12:45 PM Education Session
Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the “New Bad News” E353

1:00 PM - 5:00 PM General Poster Session
Health Services Research S Hall A2

3:00 PM - 4:15 PM Education Session
Caring for the Child with Brain Cancer S504

4:45 PM - 6:00 PM Education Session
Oral Chemotherapy: A Hard Pill to Swallow S406 (Vista Room)

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Sessions
Comparative Effectiveness Research in Oncology: Opportunities and Challenges S404
Localized Prostate Cancer: Reducing Mortality and Burden of Therapy E Arie Crown Theater

9:30 AM - 10:45 AM Education Session
Closing the Loop: Evidence, Guidelines, Reporting, and Quality S100a

11:30 AM - 12:45 PM Education Session
Management of the Elderly Patient with Cancer S100b

INTERNATIONAL

SATURDAY, JUNE 5, 2010
1:15 PM - 2:30 PM Education Session
The Global Burden of Cancer: The Worldwide Challenge of Cancer Control S100b

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
The Global Status of HPV Vaccination S100b
PROGRAM BY TRACK
International continued

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Special Session
Cancer Survivors: A Challenge to Health Care Systems Worldwide S100b

8:00 AM - 9:15 AM Education Session
Disparities in Cancer Care S404

TUESDAY, JUNE 8, 2010
9:00 AM - 12:00 PM Special Session
Advancing Pain and Palliative Care Globally for Patients with Cancer S504

LEUKEMIA, MYELODYSPLASIA, AND TRANSPLANTATION

FRIDAY, JUNE 4, 2010
3:30 PM - 4:45 PM Education Session
Current Challenges for Cellular Therapies S504

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Curable and Highly Treatable Leukemias: How Do I Optimize Outcome? E354a

8:00 AM - 12:00 PM General Poster Session
Leukemia, Myelodysplasia, and Transplantation S Hall A2

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Sessions
Allogeneic Transplantation Advances and Controversies E354b

Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia S504

4:45 PM - 6:00 PM Education Session
Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia E354a

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Session
Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia E354a

9:30 AM - 12:30 PM Oral Abstract Session
Leukemia, Myelodysplasia, and Transplantation E354b

1:15 PM - 2:30 PM Education Session
The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment E354b

2:00 PM - 6:00 PM Poster Discussion Session
Leukemia, Myelodysplasia, and Transplantation E450a

3:00 PM - 4:15 PM Education Session
Acute Leukemia: Integration of Novel Diagnostic and Therapeutic Measures E354a

LUNG CANCER

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Cancer Fatigue and Contributing Factors: Recognition and Treatment E354b

8:00 AM - 9:30 AM Clinical Science Symposium
Molecularly Targeted Trials in Lung Cancer E Hall D1
1:15 PM - 2:30 PM Clinical Problems in Oncology
Improving Outcomes for Patients with Locally Advanced Lung Cancer (C04)-TICKETED SESSION
E451a

3:00 PM - 5:30 PM Oral Abstract Session
Lung Cancer—Local-Regional and Adjuvant Therapy E Hall D1

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Meet the Professor Session
Controversies in Stage IIIA Non-small Cell Lung Cancer (M05)-TICKETED SESSION E451b

8:00 AM - 12:00 PM General Poster Sessions
Lung Cancer—Local-Regional and Adjuvant Therapy S Hall A2
Lung Cancer—Metastatic S Hall A2

9:45 AM - 11:00 AM Education Session
Therapy for Patients with Activating Mutations of the Epidermal Growth Factor Receptor N Hall B1

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Session
Health Disparities in Lung Cancer: Race, Sex, and Genes E Hall D2

8:00 AM - 1:00 PM Poster Discussion Session
Lung Cancer—Metastatic E450b

9:45 AM - 11:00 AM Education Session
Seminal Advances in Lung Cancer Research 2010: Translational and Clinical E Hall D1

1:15 PM - 2:30 PM Special Session

3:00 PM - 4:15 PM Education Session
Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness S404

3:00 PM - 5:30 PM Oral Abstract Session
Lung Cancer—Metastatic E Hall D2

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Session
Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment E353

8:00 AM - 9:15 AM Clinical Problems in Oncology
Debates in Adjuvant Therapy: Chemotherapy versus Observation for Node-negative Non-small Cell Lung Cancer and Radiotherapy versus Observation for Node-positive Non-small Cell Lung Cancer (C17)-TICKETED SESSION E451a

8:00 AM - 1:00 PM Poster Discussion Session
Lung Cancer—Local-Regional and Adjuvant Therapy E450b

9:30 AM - 10:45 AM Education Session
Supportive Care for Patients with Non-small Cell Lung Cancer E353

LYMPHOMA AND PLASMA CELL DISORDERS

FRIDAY, JUNE 4, 2010
2:00 PM - 6:00 PM Poster Discussion Session
Lymphoma and Plasma Cell Disorders E450a

3:30 PM - 4:45 PM Education Session
Management of Older Patients with Lymphoma and Myeloma E354b
SATURDAY, JUNE 5, 2010
8:00 AM - 12:00 PM General Poster Session
Lymphoma and Plasma Cell Disorders S Hall A2

1:00 PM - 4:00 PM Oral Abstract Session
Lymphoma E354a

4:30 PM - 6:00 PM Clinical Science Symposium
Novel Therapies for Myeloma E354a

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Clinical Problems in Oncology
Immunosuppression in Patients with Lymphoma and Myeloma (C07)-TICKETED SESSION E451a

9:30 AM - 12:30 PM Oral Abstract Session
Myeloma E354b

9:45 AM - 11:00 AM Meet the Professor Session
Nontransplant Options for Mantle Cell Lymphoma (M06)-TICKETED SESSION E451b

11:30 AM - 12:45 PM Education Session
Survivorship in Lymphoma E354a

4:45 PM - 6:00 PM Meet the Professor Session
Cutaneous B-cell Lymphoma (M08)-TICKETED SESSION E451b

MONDAY, JUNE 7, 2010
1:15 PM - 2:30 PM Education Sessions
Complications of Myeloma and Myeloma Therapies E354a
Immunon conjugates as Cancer Therapeutics S100b
Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma S504

MELANOMA/SKIN CANCERS

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Melanoma Immunotherapy: Current Status, Future Opportunities S406 (Vista Room)

9:45 AM - 11:00 AM Clinical Problems in Oncology
Ocular Melanoma (C03)-TICKETED SESSION E451a

1:00 PM - 2:15 PM Meet the Professor Session
Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention (M02)-TICKETED SESSION E451b

1:00 PM - 4:00 PM Oral Abstract Session
Melanoma/Skin Cancers S406 (Vista Room)

4:30 PM - 6:00 PM Clinical Science Symposium
Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets S406 (Vista Room)

4:45 PM - 6:00 PM Education Session
Cutaneous Cancer Syndromes E353

SUNDAY, JUNE 6, 2010
8:00 AM - 12:00 PM General Poster Session
Melanoma/Skin Cancers S Hall A2

4:45 PM - 6:00 PM Education Session
Nonmelanoma Skin Cancers: New Insights, New Directions S406 (Vista Room)
MONDAY, JUNE 7, 2010
8:00 AM - 12:00 PM Poster Discussion Session
Melanoma/Skin Cancers S403

11:30 AM - 12:45 PM Clinical Problems in Oncology
Management of Less Common Head and Neck Cancers (C16)-TICKETED SESSION E451a

FRIDAY, JUNE 4, 2010
1:00 PM - 2:15 PM Education Session
Neurologic Complications of Cancer Therapies S100b

1:00 PM - 3:15 PM Extended Education Sessions
Cancer and Thrombosis: Risk, Prevention, and Treatment E354a
Sex and the Survivor E Arie Crown Theater

3:30 PM - 4:45 PM Education Session
Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications E Arie Crown Theater

4:30 PM - 5:45 PM Education Session
Electronic Health Records in Oncology: A Requirement for 2014 E353

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session
Cancer Fatigue and Contributing Factors: Recognition and Treatment E354b

8:00 AM - 9:15 AM Clinical Problems in Oncology
When Onco-cardiology Meets Cardio-oncology: A Global Perspective (C02)-TICKETED SESSION E451a

1:15 PM - 2:30 PM Education Sessions
A Family’s Year with Cancer S404
Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions) E354b

3:00 PM - 6:00 PM Oral Abstract Session
Patient and Survivor Care E354b

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges S100a

8:00 AM - 9:15 AM Clinical Problems in Oncology
Immunosuppression in Patients with Lymphoma and Myeloma (C07)-TICKETED SESSION E451a

9:45 AM - 11:15 AM Clinical Science Symposium
Pharmacologic Treatment of Cancer-related Fatigue: Does It Make a Difference? E354a

11:30 AM - 12:45 PM Education Session
Survivorship in Lymphoma E354a

11:30 AM - 12:45 PM Clinical Problems in Oncology
Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION E451a

11:30 AM - 1:00 PM Clinical Science Symposium
Optimizing Care of the Elderly and Underserved S100a

4:45 PM - 6:00 PM Education Session
Physical Activity in Cancer Populations: What’s New? E354b
PROGRAM BY TRACK
Patient and Survivor Care continued

4:45 PM - 6:00 PM Clinical Problems in Oncology
Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management (C10)-TICKETED SESSION E451a

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Sessions
Impact of Health Literacy on Health Care, Decision Making, and Consent E353
Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy? E354b
8:00 AM - 9:15 AM Clinical Problems in Oncology
The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease (C11)-TICKETED SESSION E451a

9:30 AM - 10:45 AM Education Session
Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer S406 (Vista Room)

9:45 AM - 11:00 AM Education Session
Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient E353

11:30 AM - 12:45 PM Education Session
Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer E Arie Crown Theater

1:00 PM - 5:00 PM General Poster Session
Patient and Survivor Care S Hall A2

1:15 PM - 2:30 PM Education Sessions
Complications of Myeloma and Myeloma Therapies E354a
Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions E Hall D2

4:45 PM - 6:00 PM Education Session
Oral Chemotherapy: A Hard Pill to Swallow S406 (Vista Room)

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Sessions
Building Bridges for Successful Breast Cancer Survivorship Care E354a
Comparative Effectiveness Research in Oncology: Opportunities and Challenges S404

8:00 AM - 12:00 PM Poster Discussion Session
Patient and Survivor Care E450a

9:00 AM - 12:00 PM Special Session
Advancing Pain and Palliative Care Globally for Patients with Cancer S504

9:30 AM - 10:45 AM Education Sessions
Closing the Loop: Evidence, Guidelines, Reporting, and Quality S100a
Supportive Care for Patients with Non-small Cell Lung Cancer E353

9:45 AM - 11:00 AM Education Session
Even Patients with Liver Dysfunction Can Get Chemotherapy! E354b

9:45 AM - 11:00 AM Clinical Problems in Oncology
The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION E451a

11:30 AM - 12:45 PM Education Session
Management of the Elderly Patient with Cancer S100b
PEDIATRIC ONCOLOGY

FRIDAY, JUNE 4, 2010
1:00 PM - 3:15 PM Extended Education Session  
Childhood Cancer Survivorship: Lessons Learned and Future Steps  
S504

3:30 PM - 4:45 PM Education Sessions  
Current Challenges for Cellular Therapies  
S504

SATURDAY, JUNE 5, 2010
8:00 AM - 9:15 AM Education Session  
The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer  
S504

9:45 AM - 11:00 AM Meet the Professor Session  
Germ Cell Tumors in Children, Adolescents, and Young Adults (M01)-TICKETED SESSION  
E451b

1:15 PM - 2:30 PM Education Session  
New Treatments for Sarcoma in Children, Adolescents, and Young Adults  
S504

3:00 PM - 4:15 PM Special Session  
Pediatric Oncology Award and Lecture  
S504

4:30 PM - 5:45 PM Clinical Science Symposium  
Signaling in Pediatric Cancer Comes to the Clinic  
S504

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session  
Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia  
S504

9:30 AM - 12:30 PM Oral Abstract Session  
Pediatric Oncology I  
S504

11:30 AM - 12:45 AM Education Session  
Evaluating the Evidence and Marketing of Pharmacogenomic Tests  
E353

2:00 PM - 6:00 PM Poster Discussion Session  
Pediatric Oncology  
S Hall A2

2:00 PM - 6:00 PM General Poster Session  
Pediatric Oncology  
S Hall A2

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Sessions  
The Biology and Treatment of Wilms Tumor  
S504

Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?  
S406 (Vista Room)

9:30 AM - 12:30 PM Oral Abstract Session  
Pediatric Oncology II  
S504

1:15 PM - 2:30 PM Education Session  
Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma  
S504

3:00 PM - 4:15 PM Education Session  
Caring for the Child with Brain Cancer  
S504
### PROGRAM BY TRACK

**Pediatric Oncology continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:45 PM - 6:00 PM</td>
<td><strong>Education Sessions</strong></td>
</tr>
<tr>
<td></td>
<td>Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer <em>S504</em></td>
</tr>
<tr>
<td></td>
<td>Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity? <em>S100b</em></td>
</tr>
</tbody>
</table>

### PRACTICE MANAGEMENT AND INFORMATION TECHNOLOGY

**FRIDAY, JUNE 4, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM - 2:15 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>Clinical Practice: The Challenge of Financial Survival <em>E353</em></td>
</tr>
<tr>
<td>2:45 PM - 4:00 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities <em>E353</em></td>
</tr>
<tr>
<td>4:30 PM - 5:45 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>Electronic Health Records in Oncology: A Requirement for 2014 <em>E353</em></td>
</tr>
</tbody>
</table>

**SATURDAY, JUNE 5, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 9:15 AM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>How to Use Data to Improve Practice: Nexus of Quality and Efficiency <em>E353</em></td>
</tr>
<tr>
<td>1:15 PM - 2:30 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All <em>E353</em></td>
</tr>
<tr>
<td>3:00 PM - 4:15 PM</td>
<td><strong>Special Session</strong></td>
</tr>
<tr>
<td></td>
<td>Health Care Reform: Resetting the Clock <em>E Arie Crown Theater</em></td>
</tr>
<tr>
<td>3:00 PM - 4:15 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>Managing Survivorship in a Community Practice <em>E353</em></td>
</tr>
</tbody>
</table>

**SUNDAY, JUNE 6, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 9:15 AM</td>
<td><strong>Special Session</strong></td>
</tr>
<tr>
<td></td>
<td>Forum on Reimbursement <em>E Arie Crown Theater</em></td>
</tr>
<tr>
<td>11:30 AM - 12:45 PM</td>
<td><strong>Meet the Professor Session</strong></td>
</tr>
<tr>
<td></td>
<td>Electronic/Digital Resources in Oncology: Value versus Distraction (M07)-TICKETED SESSION <em>E451b</em></td>
</tr>
</tbody>
</table>

**MONDAY, JUNE 7, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 AM - 12:45 PM</td>
<td><strong>Special Session</strong></td>
</tr>
<tr>
<td></td>
<td>The Hospital/Physician Relationship: Tensions Arising <em>E354a</em></td>
</tr>
<tr>
<td>11:30 AM - 12:45 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the &quot;New Bad News&quot; <em>E353</em></td>
</tr>
<tr>
<td>1:15 PM - 2:30 PM</td>
<td><strong>Education Session</strong></td>
</tr>
<tr>
<td></td>
<td>NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting <em>S404</em></td>
</tr>
</tbody>
</table>

**TUESDAY, JUNE 8, 2010**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 AM - 11:00 AM</td>
<td><strong>Special Session</strong></td>
</tr>
<tr>
<td></td>
<td>Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/Radiological Society of North America Joint Session <em>S404</em></td>
</tr>
</tbody>
</table>
PROFESSIONAL DEVELOPMENT

FRIDAY, JUNE 4, 2010
1:00 PM - 3:30 PM Extended Education Sessions
Grant Writing Workshop I: Basic Grant Writing S106a
On the Shoulders of Giants: Historical Perspective on Drug Development and Renal Cancer E350

1:00 PM - 4:00 PM Extended Education Session
Maintenance of Certification and Lifelong Learning Workshop (MOC)-TICKETED SESSION E451a

2:45 PM - 4:00 PM Education Session
Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities E353

3:30 PM - 4:45 PM Education Session
Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications E Arie Crown Theater
Career Choices in Oncology: Options in Academic, Private Practice, Industry, and Government S404

4:00 PM - 6:00 PM Extended Education Session
Grant Writing Workshop II: Improving Your Grant Writing Skills (Small Group Discussions) S106a

4:45 PM - 6:00 PM Clinical Problems in Oncology
Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION E451a

SATURDAY, JUNE 5, 2010
7:30 AM - 8:00 AM Education Session
How to Navigate the Annual Meeting (Fellows and Junior Faculty Only) S501

8:00 AM - 9:15 AM Education Session
How to Use Data to Improve Practice: Nexus of Quality and Efficiency E353

1:15 PM - 2:30 PM Education Session
A Family’s Year with Cancer S404

3:00 PM - 4:15 PM Education Session
Update on Gastrointestinal Noncolorectal Malignancies: What’s New since the 2009 ASCO Annual Meeting? N Hall B1

SUNDAY, JUNE 6, 2010
10:30 AM - 12:30 PM Special Session
Training Program Directors’ Special Session—Addressing the Competencies: Professionalism and Practice-based Learning S404

11:30 AM - 12:45 PM Meet the Professor Session
Electronic/Digital Resources in Oncology: Value versus Distraction (M07)-TICKETED SESSION E451b

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Meet the Professor Session
Contract Negotiation for Your First Job (M09)-TICKETED SESSION E451b

9:45 AM - 11:00 AM Education Session
Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient E353

9:45 AM - 11:00 AM Meet the Professor Session
Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION E451b

11:30 AM - 12:45 PM Education Session
Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the “New Bad News” E353
1:15 PM - 2:30 PM Education Sessions
Controversies in the Management of Metastatic Breast Cancer E Hall D1
Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce E353
NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting S404

3:00 PM - 4:15 PM Education Session
Physician Burnout: How to Survive and Stay Happy in Oncology E353

SARCOMA

SATURDAY, JUNE 5, 2010
1:15 PM - 2:30 PM Education Session
New Treatments for Sarcoma in Children, Adolescents, and Young Adults S504

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
Controversies in the Management of Desmoid Tumors S406 (Vista Room)

9:45 AM - 11:00 AM Education Session
Creative Approaches to Advanced and Metastatic Sarcoma S406 (Vista Room)

11:30 AM - 12:45 PM Education Session
Lessons Learned from Clinical Trials in Gastrointestinal Stromal Tumor S406 (Vista Room)

2:00 PM - 6:00 PM General Poster Session
Sarcoma S Hall A2

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Session
Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics? S406 (Vista Room)

1:00 PM - 4:00 PM Oral Abstract Session
Sarcoma S406 (Vista Room)

TUESDAY, JUNE 8, 2010
8:00 AM - 12:00 PM Poster Discussion Session
Sarcoma S103

SPECIAL SESSIONS

FRIDAY, JUNE 4, 2010
3:30 PM - 4:45 PM Special Session
ASCO/American Society of Hematology Joint Session E354a

7:00 PM - 9:00 PM Special Session
(Presented during a Private Function)
Distinguished Achievement Award
Special Recognition Award

SATURDAY, JUNE 5, 2010
8:00 AM - 11:00 AM Special Session
Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available) S106a
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 AM - 12:00 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Opening Session with Presidential Address, NCI Director’s Address, David A. Karnofsky Memorial Award and Lecture, and The ASCO Cancer Foundation Donor Recognition Awards</td>
<td>N Hall B1</td>
</tr>
<tr>
<td>3:00 PM - 4:15 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Health Care Reform: Resetting the Clock</td>
<td>E Arie Crown Theater</td>
</tr>
<tr>
<td>3:00 PM - 4:15 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Pediatric Oncology Award and Lecture</td>
<td>S504</td>
</tr>
<tr>
<td>SUNDAY, JUNE 6, 2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 AM - 9:00 AM</td>
<td>Highlights of the Day</td>
<td>Highlights of the Day I including Clinical Trials Participation Awards</td>
</tr>
<tr>
<td>8:00 AM - 9:15 AM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Forum on Reimbursement</td>
<td>E Arie Crown Theater</td>
</tr>
<tr>
<td>10:30 AM - 12:30 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Training Program Directors’ Special Session—Addressing the Competencies: Professionalism and Practice-based Learning</td>
<td>S404</td>
</tr>
<tr>
<td>1:00 PM - 4:00 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Plenary Session including Science of Oncology Award and Lecture</td>
<td>N Hall B1</td>
</tr>
<tr>
<td>4:45 PM - 6:00 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology</td>
<td>S100a</td>
</tr>
<tr>
<td>MONDAY, JUNE 7, 2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 AM - 9:00 AM</td>
<td>Highlights of the Day</td>
<td>Highlights of the Day II including Partners in Progress Award</td>
</tr>
<tr>
<td>8:00 AM - 9:15 AM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Cancer Survivors: A Challenge to Health Care Systems Worldwide</td>
<td>S100b</td>
</tr>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>Trials in Progress Poster Session</td>
<td>Trials in Progress Poster Session</td>
</tr>
<tr>
<td>9:45 AM - 11:00 AM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>ASCO–American Cancer Society Award and Lecture</td>
<td>S100b</td>
</tr>
<tr>
<td>9:45 AM - 11:30 AM</td>
<td>Education Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute’s Clinical Trials and Translational Research Advisory Committee</td>
<td>S100a</td>
</tr>
<tr>
<td>11:30 AM - 12:45 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>The Hospital/Physician Relationship: Tensions Arising</td>
<td>E354a</td>
</tr>
<tr>
<td>12:00 PM - 1:00 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
<tr>
<td></td>
<td>ASCO Annual Business Meeting including Statesman Awards (ASCO Members Only)</td>
<td>Hyatt McCormick Place Regency Ballroom</td>
</tr>
<tr>
<td>1:15 PM - 2:30 PM</td>
<td>Special Session</td>
<td>Special Session</td>
</tr>
</tbody>
</table>

53
PROGRAM BY TRACK
Special Sessions continued

4:45 PM - 6:00 PM Special Session
From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—An ASCO/American Association for Cancer Research Joint Session S404

6:30 PM - 9:30 PM Special Session
Answers to Cancer: Annual Meeting Public Forum Sheraton Chicago Hotel & Towers, Chicago Ballroom 10

TUESDAY, JUNE 8, 2010
7:30 AM - 9:00 AM Highlights of the Day
Highlights of the Day III E Hall D1

9:00 AM - 12:00 PM Special Session
Advancing Pain and Palliative Care Globally for Patients with Cancer S504

9:45 AM - 11:00 AM Special Session
Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/Radiological Society of North America Joint Session S404

TUMOR BIOLOGY

FRIDAY, JUNE 4, 2010
2:45 PM - 4:00 PM Education Session
Application of Epigenetics to Diagnosis and Therapy S406 (Vista Room)

SATURDAY, JUNE 5, 2010
8:00 AM - 12:00 PM General Poster Session
Tumor Biology S Hall A2

2:00 PM - 6:00 PM Poster Discussion Session
Tumor Biology S103

SUNDAY, JUNE 6, 2010
8:00 AM - 9:15 AM Education Session
PARP Inhibitors and More in DNA Repair E353

4:45 PM - 6:00 PM Education Sessions
New Technology in Cancer Immune Therapy E353
Stem Cells in Neuro-oncology S100b

MONDAY, JUNE 7, 2010
8:00 AM - 9:15 AM Education Sessions
Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold S100a
Health Disparities in Lung Cancer: Race, Sex, and Genes E Hall D2
The Biology and Treatment of Wilms Tumor S504

1:15 PM - 2:30 PM Education Session
Immunoconjugates as Cancer Therapeutics S100b

1:15 PM - 2:45 PM Clinical Science Symposium
Unraveling the Cancer Genome: Clinical Implications of Next-generation Technologies S100a

3:00 PM - 6:00 PM Oral Abstract Session
Tumor Biology S100a

TUESDAY, JUNE 8, 2010
8:00 AM - 9:15 AM Education Session
Omics: Toward Personalizing Care S100a

9:45 AM - 11:00 AM Education Session
Angiogenesis: Where Do We Go from Here? S100b
American Society of Clinical Oncology
46th Annual Meeting

Meeting Program

Note: Sessions in which Special Awards are presented are shaded in gray
Friday, June 4, 2010

1:00 PM - 2:15 PM
EDUCATION SESSIONS

Bone Therapy in Breast Cancer: Why, When, and What’s Next?
Location: E Hall D1
CME credit: 1.25
Track(s): Breast Cancer

Gabriel N. Hortobagyi, MD, FACP—Chair
University of Texas M. D. Anderson Cancer Center
Systemic Therapy for Bone Metastasis: Past, Present, and Future

Theresa Guise, MD
Indiana University School of Medicine
The Bone Microenvironment and the Potential Antitumor Effects of Bone Therapy

Catherine H. Van Poznak, MD
University of Michigan
Is There a Role for Bisphophonates in the Adjuvant Setting?

Clinical Practice: The Challenge of Financial Survival
Location: E353
CME credit: 1.25
Track(s): Practice Management and Information Technology

Jeffery C. Ward, MD—Chair
Puget Sound Cancer Centers
The Hospital Refuge: Oasis or Mirage?

Elaine L. Towle, CMPE
Oncology Metrics
The Changing Face of Oncology Practice

William M. Jordan, DO
The Center for Cancer and Blood Disorders
Creating a Product for the Future

Neurologic Complications of Cancer Therapies
Location: S100b
CME credit: 1.25
Track(s): Central Nervous System Tumors; Patient and Survivor Care

Patrick Y. Wen, MD—Chair
Dana-Farber Cancer Institute
Central Nervous System Complications (Including Effects of Targeted Therapies)

David Schiff, MD
University of Virginia Medical Center
Peripheral Neuropathies

Michelle Monje, MD, PhD
Stanford University
Radiation and Chemotherapy Effects on Cognition (Including “Chemo Brain”)
Use of Induction Chemotherapy in Clinical Practice
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Head and Neck Cancer

Everett E. Vokes, MD—Chair
The University of Chicago
Combined Modality Therapy in Perspective

Marshall R. Posner, MD
Dana-Farber Cancer Institute
Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck in Clinical Practice

Jonathan Jay Beitler, MD, MBA, FACR
Emory University Winship Cancer Institute
Radiation Oncology Perspective
Friday, June 4, 2010

1:00 PM - 3:15 PM
EXTENDED EDUCATION SESSIONS

Advances in Prevention of Major Malignancies
Location: E354b
CME credit: 2.25
Track(s): Cancer Prevention/Epidemiology; Breast Cancer; Genitourinary Cancer

Victor G. Vogel, MD—Chair
American Cancer Society

Ian Thompson, MD
University of Texas Health Science Center at San Antonio
5-alpha Reductase Inhibitors for Prostate Cancer Prevention

Monica M. Bertagnolli, MD
Brigham and Women’s Hospital
Chemoprevention of Colorectal Cancer

Jack Cuzick, PhD
Wolfson Institute of Preventive Medicine
SERMs in the Prevention of Breast Cancer

Cancer and Thrombosis: Risk, Prevention, and Treatment
Location: E354a
CME credit: 2.25
Track(s): Health Services Research; Patient and Survivor Care

Gary H. Lyman, MD, MPH—Chair
Duke Comprehensive Cancer Center
Review of Currently Available Guidelines for the Prevention of Cancer-associated Thrombosis

Alok A. Khorana, MD
University of Rochester
Review of the Incidence and Prevalence of Cancer-associated Thrombosis

Howard A. Liebman, MD
University of Southern California
Risk of Venous Thromboembolism in Patients Receiving Newer Cancer Therapies

Charles W. Francis, MD
University of Rochester
Prevention of Venous Thromboembolism in Hospitalized Medical Patients

Ajay Kumar Kakkar, MD
Thrombosis Research Institute
Prevention of Venous Thromboembolism in Surgical Cancer Patients

Mark Norman Levine, MD
Henderson Research Institute
Prevention of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy

Anna Falanga, MD
Ospedali Riuniti di Bergamo
Current and Future Clinical Trials of Venous Thromboembolism Prophylaxis in Cancer Patients
Craig M. Kessler, MD
Lombardi Comprehensive Cancer Center
Diagnosis and Initial Treatment of Venous Thromboembolism in Cancer Patients

Agnes Y. Y. Lee, MD, MSc, FRCP(C)
University of British Columbia
Special Populations and Extended Anticoagulation of Cancer Patients for the Prevention of Recurrent Venous Thromboembolism

Childhood Cancer Survivorship: Lessons Learned and Future Steps
Location: S504
CME credit: 2.25
Track(s): Health Services Research; Pediatric Oncology

Kevin C. Oeffinger, MD—Chair
Memorial Sloan-Kettering Cancer Center

Smita Bhatia, MD, MPH
City of Hope National Medical Center
Current Guidelines for Follow-up of the Survivors of Pediatric Cancers: Current New Areas of Research Including Issues Related to Genetic Susceptibility to Toxicities

Christopher Recklitis, MPH, PhD
Dana-Farber Cancer Institute
Long-term Pyschosocial Effects Following the Treatment of Pediatric Cancers

Gregory T. Armstrong, MD, MSCE
St. Jude Children’s Research Hospital
The Childhood Cancer Survivor Study (CCSS)

Leslie L. Robison, PhD
St. Jude Children’s Research Hospital
The Childhood Cancer Survivor Study (CCSS)

Fundamentals of Clinical Trial Design and Methodology
Location: S100a
CME credit: 2.25
Track(s): Clinical Trials

Michael Paul Link, MD—Chair
Stanford University School of Medicine
Overview and Introduction of Speakers

James L. Abbruzzese, MD
University of Texas M. D. Anderson Cancer Center
Clinical Trials Issues and Design

Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Statistical Principles in Clinical Trials

Steven Joffe, MD, MPH
Dana-Farber Cancer Institute
Ethics in Cancer Clinical Trials

Ian Tannock, MD, PhD
Princess Margaret Hospital
Practical Considerations in Clinical Trial Design
Sex and the Survivor
Location: E Arie Crown Theater
CME credit: 2.25
Track(s): Patient and Survivor Care; Breast Cancer; Gastrointestinal (Colorectal) Cancer

Leslie R. Schover, PhD—Chair
University of Texas M. D. Anderson Cancer Center
Overview of Current Strategies to Prevent and Treat Cancer-related Sexual Dysfunction

Patricia A. Ganz, MD
University of California, Los Angeles Schools of Medicine and Public Health
Preventing and Treating Sexual Dysfunction in Women with Breast Cancer

Stacy Tessler Lindau, MD, MAPP
The University of Chicago
Gynecologic Approach to Women’s Cancer-related Sexual Dysfunction

John Mulhall, MD
Memorial Sloan-Kettering Cancer Center
Urologic Treatment of Men’s Cancer-related Sexual Dysfunction

Francesco Di Fabio, MD
Southampton University Hospitals NHS Trust, Southampton General Hospital
Sexuality in Survivors of Colorectal Cancer

Michelle Marion Rhodes, PhD
Prairie View A&M University
SPIRIT: Peer Counseling to Promote Reproductive Health in African-American Breast Cancer Survivors

Sharon L. Bober, PhD
Dana-Farber Cancer Institute
Sexual Impact of Being at High Genetic Risk for Cancer
1:00 PM - 3:30 PM  
EXTENDED EDUCATION SESSIONS

Grant Writing Workshop I: Basic Grant Writing  
Location: S106a  
CME credit: 2.5  
Track(s): Professional Development; Clinical Trials

Mary L. (Nora) Disis, MD—Chair  
University of Washington  
Grant Writing Pearls

Jonathan S. Wiest, PhD  
National Cancer Institute  
National Cancer Institute Training and Career Development Grants

Jennifer C. King, PhD  
The ASCO Cancer Foundation  
The ASCO Cancer Foundation Grants Program

Merrill J. Egorin, MD  
University of Pittsburgh Cancer Institute  
Choosing a Mentor and Obtaining Letters of Support

Charles M. Rudin, MD, PhD  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
Choosing a Mentor and Obtaining Letters of Support

Donna S. Neuberg, ScD  
Dana-Farber Cancer Institute  
Statistical Considerations

William G. Blum, MD  
The Ohio State University  
R21 Grants, Perseverance, and Resubmission

On the Shoulders of Giants: Historical Perspective on Drug Development and Renal Cancer  
Location: E350  
CME credit: 2.5  
Track(s): Professional Development

Lisa A. Carey, MD—Chair  
University of North Carolina  
Moderator

Manuel Hidalgo, MD, PhD  
Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III  
Drug Development

Robert John Motzer, MD  
Memorial Sloan-Kettering Cancer Center  
Renal Cancer

William Kaelin, MD  
Dana-Farber Cancer Institute  
Breakout Session—Renal Cell Biologist

Vicki Leigh Keedy, MD  
Vanderbilt University Medical Center  
Breakout Session—Case Study Presenter

Michelle Wan Yee Lau, MD  
Beth Israel Deaconess Medical Center  
Breakout Session—Case Study Presenter
Friday, June 4, 2010

1:00 PM - 4:00 PM
EXTENDED EDUCATION SESSION

Maintenance of Certification and Lifelong Learning Workshop (MOC)-TICKETED SESSION
Location: E451a
CME credit: 0
Track(s): Professional Development

Hyman Bernard Muss, MD—Chair
University of North Carolina at Chapel Hill
MOC Module Presenter

Matthew I. Milowsky, MD
Memorial Sloan-Kettering Cancer Center
MOC Module Presenter

Philip Jay Bierman, MD
University of Nebraska
MOC Module Presenter
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Gastrointestinal (Noncolorectal) Cancer
Display Time: 2:00 PM - 6:00 PM
Display Location: E450b
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E354a
CME credit: 1
Track(s): Gastrointestinal (Noncolorectal) Cancer

Gauri R. Varadhachary, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Andrea Wang-Gillam, MD, PhD—Co-Chair
Washington University of St. Louis

Discussion
5:00 PM  Peter C. Enzinger, MD (Abstracts #4013–4017)
Dana-Farber Cancer Institute

Discussion
5:15 PM  Stephen Swisher, MD (Abstracts #4018–4023)
University of Texas M. D. Anderson Cancer Center

Discussion
5:30 PM  Jennifer J. Knox, MD, FRCP (Abstracts #4024–4030)
Princess Margaret Hospital

Discussion
5:45 PM  Milind M. Javle, MD (Abstracts #4033–4037)
University of Texas M. D. Anderson Cancer Center

Brd. 1  5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4013)

Brd. 2  Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). (Abstract #4014)

Brd. 3  Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report. (Abstract #4015)

Brd. 5  Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer. (Abstract #4017)

Brd. 6  Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer: Tolerability and feasibility of a phase III study. (Abstract #4018)
E. Bajetta, I. Floriani, M. Di Bartolomeo, R. Labianca, A. Falcone, A. Santoro, R. Casaretti, E. Pasquini, A. Martoni, C. Carlimagni
Friday, June 4, 2010

Brd. 7 Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. (Abstract #4019) A. F. Okines, R. Langley, F. H. Cafferty, S. P. Stenning, S. Falk, M. T. Seymour, D. Smith, G. W. Middleton, F. Y. Coxon, D. Cunningham

Brd. 8 Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): Analyses of operative morbidity, operation time, and blood loss. (Abstract #4020) T. Sano, M. Sasaki, T. Shibata, S. Yamamoto, A. Tsuburaya, A. Nashimoto, S. Ito, M. Kaji, H. Furukawa, N. Fukushima, Japan Clinical Oncology Group

Brd. 9 Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX7) for locally advanced gastric cancer: Final results of a prospective multicenter phase II study (BJSA-01) with 2 years follow-up. (Abstract #4021) J. Ji, A. Wu, Z. Li, Y. Liu, R. Li, Z. Zhang, S. Wang, Y. Ye, F. Li


Brd. 15 European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres. (Abstract #4027) B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini, S. Ezzidin, R. Hoffman, F. Fiore, on behalf of the European Network on Radioembolization Using Y90 Microspheres (ENRY)

Brd. 16 The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program. (Abstract #4028) W. V. Wong, F. Mo, G. S. Liem, T. Mok, A. T. Chan, H. L. Chan, W. Yeo, S. L. Chan

Brd. 17 Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma. (Abstract #4029) M. Kang, J. Lee, T. Kim, S. Lee, D. Park, D. Seo, M. Kim

**Brd. 19** Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). (Abstract #4031)
E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, S. Patyna, R. C. Chao, D. Lu

**Brd. 20** The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it? (Abstract #4032)
L. Saltz, M. Gollub, D. L. Reidy

**Brd. 21** A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. (Abstract #4033)

**Brd. 22** ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). (Abstract #4034)

**Brd. 23** A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). (Abstract #4035)

**Brd. 24** The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study. (Abstract #4036)

**Brd. 25** A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study. (Abstract #4037)
Friday, June 4, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Head and Neck Cancer
Display Time: 2:00 PM - 6:00 PM
Display Location: S403
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S406 (Vista Room)
CME credit: 1
Track(s): Head and Neck Cancer

Ranee Mehra, MD—Co-Chair
Fox Chase Cancer Center
Cherie-Ann Nathan, MD—Co-Chair
Louisiana State University Medical Center

Discussion
5:00 PM  Danny Rischin, MD (Abstracts #5512–5518)
          Peter McCallum Cancer Centre

Discussion
5:15 PM  Cherie-Ann Nathan, MD (Abstracts #5520–5524)
          Louisiana State University Medical Center

Discussion
5:30 PM  Anil Chaturvedi, DVM, PhD (Abstracts #5525–5529)
          National Cancer Institute

Discussion
5:45 PM  Ranee Mehra, MD (Abstracts #5530–5536)
          Fox Chase Cancer Center

Brd. 1 Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC). (Abstract #5512)

Brd. 2 Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68–72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). (Abstract #5513)

Brd. 3 TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer. (Abstract #5514)

Brd. 4 Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis. (Abstract #5515)

Brd. 5 Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: Ten-year results of the 94–01 GORTEC randomized study. (Abstract #5516)
G. Calais, S. Chapet, Y. Pointreau, E. Bardet, C. Sire, T. Germain

Brd. 6 Need for postradiotherapy neck dissection by tumor site and nodal stage for head and neck cancer. (Abstract #5517)
Brd. 7  Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5518)
A. Marwaha, N. W. Choong, S. Firtat, C. J. Schultz, D. Wang, S. J. Wong

Brd. 9  Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer. (Abstract #5520)

Brd. 10  Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial. (Abstract #5521)

Brd. 11  Comparison of primary site biopsies and transverse surgical sections of squamous cell carcinoma of the head and neck for translational research analysis. (Abstract #5522)
M. Hampek, S. Mörtel, J. Wagenblast, A. Eckardt, T. Stöver

Brd. 12  Association of circulating tumor cells with lymph node metastasis in squamous cell carcinoma of the head and neck region (SCCHN). (Abstract #5523)
I. Tinhofer, T. Hristozova, R. Konschak, A. Fusi, V. Budach, U. Keilholz

Brd. 13  Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving induction chemotherapy and definitive chemoradiotherapy. (Abstract #5524)
S. Kim, D. Yoon, Y. Cho, S. Nam, S. Choi, S. Lee, J. Lee, J. Kim, K. Cho

Brd. 14  Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. (Abstract #5525)

Brd. 15  A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity. (Abstract #5526)
A. D. Colevas, C. A. Clarke, D. Lichtensztajn, E. T. Chang

Brd. 16  Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners. (Abstract #5527)

Brd. 17  Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (Abstract #5528)

Brd. 18  Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP). (Abstract #5529)
H. Cao, S. Kwok, X. Shi, R. Bala, B. Pinsky, A. D. Colevas, N. Pourmand, A. Koong, C. Kong, Q. Le

Brd. 19  An open-label, randomized study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVA) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study. (Abstract #5530)

Brd. 20  Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5531)
Friday, June 4, 2010

Brd. 21 A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). (Abstract #5532)

Brd. 22 Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene polymorphisms. (Abstract #5533)

Brd. 23 Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial. (Abstract #5534)
R. Mesia, A. Rueda, R. Vera, A. Lozano, J. A. Medina, D. Aguiar Bujanda III, F. Arias de la Vega, G. Triana, M. Guix, R. Lopez

Brd. 24 Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study. (Abstract #5535)

Brd. 25 Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. (Abstract #5536)
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Lymphoma and Plasma Cell Disorders
Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E354b
CME credit: 1
Track(s): Lymphoma and Plasma Cell Disorders

Nancy Bartlett, MD—Co-Chair
Washington University
Robert Z. Orlowski, MD, PhD—Co-Chair
University of Texas M. D. Anderson Cancer Center

Discussion
5:00 PM  Giampaolo Merlini, MD, PhD (Abstracts #8022–8026)
University of Pavia
*New Developments in Amyloidosis*

Discussion
5:15 PM  Robert Z. Orlowski, MD, PhD (Abstracts #8027–8032)
University of Texas M. D. Anderson Cancer Center
*Personalized Therapy and New Agents in Myeloma*

Discussion
5:30 PM  Lawrence D. Kaplan, MD (Abstracts #8033–8035)
University of California, San Francisco
*Approaches for HIV-associated Lymphoma*

Discussion
5:45 PM  Nancy Bartlett, MD (Abstracts #8036–8042)
Washington University
*Novel Agents in Lymphoma*

Brd. 1  Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial. (Abstract #8022)
V. Sanchorawala, V. Bolejack, J. Crowley, A. Hoering, K. T. Finn, S. Fennessey, D. C. Seldin, B. Barlogie

Brd. 2  Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study. (Abstract #8023)

Brd. 3  Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. (Abstract #8024^)

Brd. 4  A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis. (Abstract #8025)

Brd. 5  Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis. (Abstract #8026)

Brd. 6  Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene *PSMD4*. (Abstract #8027)
J. D. Shaughnessy, P. Qu, E. Tian, R. Edmondson, B. P. Nair, S. Waheed, Y. Alsayed, F. Van Rhee, J. Haessler, J. Crowley, B. Barlogie
Brd. 7 Response of newly diagnosed myeloma with \textit{1q21} amplification to bortezomib-based PAD induction therapy. (Abstract \#8028^)


Brd. 8 Dose-escalation study of carfilzomib (\textit{CFZ}) + lenalidomide (\textit{LEN}) + low-dose dexamethasone (\textit{Dex}) (\textit{CRd}) in relapsed/refractory multiple myeloma (R/R MM). (Abstract \#8029)


Brd. 9 Phase Ib study of oral panobinostat (\textit{LBH589}) + lenalidomide (\textit{LEN}) + dexamethasone (\textit{DEX}) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (Abstract \#8030^)


Brd. 10 Phase I study of combined vorinostat (\textit{V}), lenalidomide (\textit{L}), and dexamethasone (\textit{D}) in patients (pts) with relapsed or refractory multiple myeloma (MM). (Abstract \#8031)


Brd. 11 Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. (Abstract \#8032)


Brd. 12 Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt’s lymphoma (BL): Preliminary results of a multicenter phase II study. (Abstract \#8033)


A. M. Levine


M. Hentrich, M. Berger, C. Hoffmann, J. M. Siehl, T. Wolf, J. Rockstroh, G. Fältkenheuer, K. Arasteh, F. A. Mosthaf Sr., C. Wyen, German HIV-related Lymphoma Study Group

Brd. 15 Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin’s lymphoma. (Abstract \#8036)


Brd. 16 Lenalidomide (\textit{LEN}) in patients with transformed lymphoma: Results from a large international phase II study (\textit{NHL-003}). (Abstract \#8037)


Brd. 17 Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with non-germinal center B-cell phenotype to lenalidomide (\textit{L}) alone or in combination with rituximab (\textit{R}). (Abstract \#8038)


Brd. 18 Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. (Abstract \#8039)

Brd. 19  Enzastaurin in patients with follicular lymphoma: Results of a phase II study. (Abstract #8040)

Brd. 20  Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. (Abstract #8041)
J. L. Vacirca, P. I. Acs, B. J. Shimkus, P. J. Rosen

Brd. 21  Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). (Abstract #8042)

Brd. 22  Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL). (Abstract #8043)

Brd. 23  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. (Abstract #8044)

Brd. 24  Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial. (Abstract #8045)
F. M. Foss, N. N. Sjak-Shie, A. Goy, R. Advani, E. D. Jacobsen

Brd. 25  A phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas. (Abstract #8046)
D. A. Mulford, B. L. Pohlman, P. A. Hamlin, F. Young, E. Pamer, S. M. Horwitz
Friday, June 4, 2010

2:45 PM - 4:00 PM
EDUCATION SESSIONS

Application of Epigenetics to Diagnosis and Therapy
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Tumor Biology

Jean Pierre Issa, MD—Chair
University of Texas M. D. Anderson Cancer Center
Use of Epigenetic Information for Individualized Cancer Care

Gerd P. Pfeifer, PhD
City of Hope
Cancer Epigenetics: Basic Biology

Paul Cairns, PhD
Fox Chase Cancer Center
Can We Use Epigenetics in Early Detection of Cancer?

Creating Teams That Work: Hiring Right, Communication Skills, and Disruptive Personalities
Location: E353
CME credit: 1.25
Track(s): Practice Management and Information Technology; Ethics; Professional Development

John Vernon Cox, DO—Chair
Texas Oncology
Disruptive Behaviors: Is There a Solution?

Gay G. Cox, JD
Lessons from Life: How to Optimize Communication in Multidisciplinary Conferences (Or with Your Teenager)

John McCracken, PhD
University of Texas at Dallas
Behavioral Fit: A Tool for Success in Assimilation of a New Hire

Future Treatment Approaches toward Colorectal Cancer: New Therapeutic Pathways, New Targets
Location: E Hall D1
CME credit: 1.25
Track(s): Gastrointestinal (Colorectal) Cancer; Developmental Therapeutics

Josep Tabernero, MD—Chair
Vall d’Hebron University Hospital
Membrane Receptors as Targets for Therapeutic Approaches in Colorectal Cancer

Wells A. Messersmith, MD
University of Colorado
Intracellular Components of Signal Transduction Pathways as Therapeutic Targets in Colorectal Cancer

Scott Kopetz, MD
University of Texas M. D. Anderson Cancer Center
Small- and Large-molecule Angiogenesis Inhibitors: Excitement and Disappointments
Geriatric Issues in Neuro-oncology
Location: S100b
CME credit: 1.25
Track(s): Central Nervous System Tumor; Geriatric Oncology

Lauren E. Abrey, MD—Chair
Memorial Sloan-Kettering Cancer Center
Geriatric Neuro-oncology: Overview with Lessons from Primary CNS Lymphoma

Glenn S. Bauman, MD
London Regional Cancer Program
Radiotherapy of Brain Tumors in the Elderly: Issues and Controversies

Alba Ariela Brandes, MD
ASL Bologna
Glioblastoma in the Elderly
Friday, June 4, 2010

3:30 PM - 4:45 PM
SPECIAL SESSION

ASCO/American Society of Hematology Joint Session
Location: E354a
CME credit: 1.25
Track(s): Special Session

Douglas W. Blayney, MD—Co-Chair
University of Michigan

Hal E. Broxmeyer, PhD—Co-Chair
Indiana University

Mark J. Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for Fit3 Mutant AML Patients in First Relapse

Noopur S. Raje, MD
Massachusetts General Hospital Cancer Center
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma

Mathias J. Rummel, MD, PhD
University Hospital Giessen
Bendamustine plus Rituximab Is Superior with Respect to Progression-free Survival and CR Rate When Compared to CHOP plus Rituximab as First-line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL

Peter Borchmann, MD
University Hospital of Cologne
Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (GY) Is the New Standard of Care in the Treatment of Patients with Early-stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSH) HD10
3:30 PM - 4:45 PM
EDUCATION SESSIONS

Current Challenges for Cellular Therapies
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Leukemia, Myelodysplasia, and Transplantation

John M. Cunningham, MBBS—Chair
The University of Chicago Medical Center
When Should Immunablative Therapies Be Considered in the Treatment of Pediatric Cancer?

Laurence Cooper, MD, PhD
University of Texas M. D. Anderson Cancer Center
Adoptive Cellular Therapies Utilizing Gene-modified Lymphocytes

Wing H. Leung, MD, PhD
St. Jude Children’s Research Hospital
The Role of NK Cells in Transplant and Nontransplant Scenarios

Management of Older Patients with Lymphoma and Myeloma
Location: E354b
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders; Geriatric Oncology

Vicki A. Morrison, MD—Chair
University of Minnesota
Approaches to Diffuse Large Cell Lymphoma in Very Elderly Patients

Stuart M. Lichtman, MD
Memorial Sloan-Kettering Cancer Center
Using the Geriatric Assessment and Related Strategies in the Practical Management of Lymphoma and Myeloma Patients

Jesús San-Miguel, MD, PhD
Hospital Clínico Universitario
New and Old: New Regimens for Older Multiple Myeloma Patients

Update on Patient Safety: Basic Science, Practical Strategies in Oncology Practice, and Discussing Complications
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Patient and Survivor Care; Professional Development

James Bagian, MD—Chair
Veterans Health Administration

Saul Weingart, MD, PhD
Dana-Farber Cancer Institute

Glenn D. Steele, MD, PhD
Geisinger Health System
Friday, June 4, 2010

3:30 PM - 6:00 PM  
EXTENDED EDUCATION SESSION

Career Choices in Oncology: Options in Academic, Private Practice, Industry, and Government  
Location: S404    
CME credit: 0    
Track(s): Professional Development

John E. Pippen, MD, FACP—Chair  
Sammons Cancer Center  
Hybrid: Academia and Private Practice

Angelo Di Leo, MD, PhD  
Sandro Pitigliani Medical Oncology Unit  
Career Options in Academia

R. Steven Paulson, MD  
Texas Oncology PA  
Career Options in Private Practice

Mace L. Rothenberg, MD  
Pfizer Oncology  
Career Options in Industry

Richard Pazdur, MD  
U.S. Food and Drug Administration  
Career Options in Government

3:45 PM - 6:00 PM  
EXTENDED EDUCATION SESSION

Advanced Concepts in Clinical Trial Design and Methodology  
Location: S100a    
CME credit: 2.25    
Track(s): Clinical Trials

Richard Simon, DSc—Chair  
National Institutes of Health  
New Designs for Phase III Clinical Trials

Mark J. Ratain, MD  
The University of Chicago  
Innovative Designs: Randomized Phase II Trials

Yu Shyr, PhD  
Vanderbilt-Ingram Cancer Center  
Advanced Statistical Considerations: Things You Think You Can Do, But . . .
4:00 PM - 6:00 PM
EXTENDED EDUCATION SESSION

Grant Writing Workshop II: Improving Your Grant Writing Skills (Small Group Discussions)
Location: S106a
CME credit: 2
Track(s): Professional Development; Clinical Trials

Bruce E. Johnson, MD—Chair
Dana-Farber Cancer Institute

Alex A. Adjei, MD, PhD
Roswell Park Cancer Institute

William G. Blum, MD
The Ohio State University

Mary L. (Nora) Disis, MD
University of Washington

Merrill J. Egorin, MD
University of Pittsburgh Cancer Institute

Dawn L. Hershman, MD
New York Presbyterian

Jennifer C. King, PhD
The ASCO Cancer Foundation

Donna S. Neuberg, ScD
Dana-Farber Cancer Institute

Charles M. Rudin, MD, PhD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eric Jay Small, MD
University of California, San Francisco
Friday, June 4, 2010

4:30 PM - 5:45 PM
EDUCATION SESSIONS

Electronic Health Records in Oncology: A Requirement for 2014
Location: E353
CME credit: 1.25
Track(s): Practice Management and Information Technology; Health Services Research; Patient and Survivor Care

Peter Paul Yu—Chair
Palo Alto Medical Foundation
Interoperability: Getting the Relevant Information to the Right Place in Real Time

Jonathan B. Perlin, MD, PhD, MSHA, FACP, FACMI
Hospital Corporation of America
So You Want Me to Adopt EHR by 2014?

Lawrence N. Shulman, MD
Dana-Farber Cancer Institute
Getting More out of Your EHR

Improving Clinical Trial Outcome in Neuro-oncology
Location: S100b
CME credit: 1.25
Track(s): Central Nervous System Tumors

Timothy Cloughesy, MD—Chair
University of California, Los Angeles
Optimal Trial Endpoints in the Era of Antiangiogenic Therapies: Lessons Learned from Bevacizumab

Ingo K. Mellinghoff, MD
Memorial Sloan-Kettering Cancer Center
Optimizing the Role of Genotyping for Patient Care and Trial Design

Donald A. Berry, PhD
University of Texas M. D. Anderson Cancer Center
Novel Trial Design in Neuro-oncology

Molecular Profiling in Breast Cancer: Ten Years Later
Location: E Hall D1
CME credit: 1.25
Track(s): Breast Cancer; Cancer Genetics

George W. Sledge, MD—Chair
Indiana University School of Medicine
How to Integrate Molecular Profiling with Standard Pathology in Clinical Practice

Charles M. Perou, PhD
University of North Carolina at Chapel Hill
The Past and The Future of Molecular Profiling

Richard Iggo, MD, PhD
Bergonié Institute
Do Other Clinically Relevant Subtypes Exist?
4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Talking with Your Patients about Clinical Trials (C01)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Clinical Trials; Ethics; Professional Development

Stephen S. Grubbs, MD—Chair
Medical Oncology Hematology Consultants, PA
Community Perspective

Afshin Dowlati, MD
Case Western Reserve University
Academic Perspective

Mary Lou Smith, JD, MBA
Research Advocacy Network
Patient Advocacy Perspective

7:00 PM - 9:00 PM
SPECIAL SESSION

(Presented during a Private Function)

Distinguished Achievement Award

Eli Glatstein, MD
University of Pennsylvania School of Medicine

Special Recognition Award

Patrick J. Loehrer Sr., MD
Indiana University School of Medicine
Saturday, June 5, 2010

7:30 AM - 8:00 AM
EDUCATION SESSION

How to Navigate the Annual Meeting (Fellows and Junior Faculty Only)
Location: S501
Track(s): Professional Development

John E. Pippen, MD, FACP—Chair
Sammons Cancer Center

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Cancer Fatigue and Contributing Factors: Recognition and Treatment
Location: E354b
CME credit: 1.25
Track(s): Patient and Survivor Care; Breast Cancer; General Oncology; Lung Cancer

Ann Malone Berger, RN, PhD, AOCN, FAAN—Chair
University of Nebraska Medical Center
Cancer-related Fatigue: Who Gets It and How Long Does It Last?

Eduardo Bruera, MD
University of Texas M. D. Anderson Cancer Center
Do Medications Work to Decrease Cancer-related Fatigue?

Bernadine Cimprich, RN, PhD, CS, FAAN
University of Michigan
Nonpharmacologic Interventions to Decrease Fatigue
Clinical Trials in Survivorship Populations: Emerging Concepts and Barriers to Application
Location: S100a
CME credit: 1.25
Track(s): Clinical Trials

Melissa M. Hudson, MD—Chair
St. Jude Children’s Research Hospital
Promoting Health during and beyond Cancer Therapy

Melinda L. Irwin, PhD, MPH
Yale University
Conducting Clinical Trials of Physical Activity in Cancer Survivors

Janette L. Vardy, MD, PhD
The University of Sydney
Clinical Trials in Cancer Survivors with Chemotherapy-related Cognitive Impairment

Curable and Highly Treatable Leukemias: How Do I Optimize Outcome?
Location: E354a
CME credit: 1.25
Track(s): Leukemia, Myelodysplasia, and Transplantation

Moshe Talpaz, MD—Chair
University of Michigan
Therapy for CML: What Is the Best TKI? When? And Beyond?

Bayard L. Powell, MD
Wake Forest University
Update on Acute Promyelocytic Leukemia

Giuseppe Saglio, MD
University of Turin
Monitoring Recommendations: What Defines Resistance?

How to Use Data to Improve Practice: Nexus of Quality and Efficiency
Location: E353
CME credit: 1.25
Track(s): Practice Management and Information Technology; Professional Development

Robert D. Siegel, MD—Chair
The Helen & Harry Gray Cancer Center
Getting More out of QOPI

Peter G. Ellis, MD
University of Pittsburgh Medical Center Cancer Center
Challenge of Reducing Disease-specific Variation in Care

David C. Fryefield, MD
Willamette Valley Cancer Institute
Quality and Efficiency: Continuous Improvement Tools for the Oncology Practice
Saturday, June 5, 2010

Melanoma Immunotherapy: Current Status, Future Opportunities
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Melanoma/Skin Cancers; Developmental Therapeutics

Patrick Hwu, MD—Chair
University of Texas M. D. Anderson Cancer Center
Adoptive T-cell Transfer

Jedd D. Wolchok, MD, PhD
Memorial Sloan-Kettering Cancer Center
Checkpoint Blockade

Craig L. Slingluff, MD
University of Virginia Health System
Melanoma Vaccines

Micronutrient Supplementation versus Dietary Modification of Cancer Prevention: Which Is Better?
Location: S100b
CME credit: 1.25
Track(s): Cancer Prevention/Epidemiology

Peter Gann, MD, ScD—Chair
University of Illinois at Chicago
Epidemiology versus Clinical Trials as Evidence for Propensity of Dietary Components/Micronutrients to Prevent Cancer

Eric A. Klein, MD
Cleveland Clinic Taussig Cancer Institute
The Use of Antioxidant Micronutrient Supplements for Cancer Prevention: Lessons from SELECT

John A. Milner, PhD
National Cancer Institute
Vitamin D: Should We Be Supplementing to Prevent Cancer?

The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Developmental Therapeutics

Alice L. Yu, MD, PhD—Chair
University of California, San Diego
Progress in Treatment of High-risk Neuroblastoma with Immunotherapy

Mitchell S. Cairo, MD
Columbia University
Update on Immunotherapy Strategies in the Treatment of Lymphomas in Children, Adolescents, and Young Adults

Douglas Yee, MD
Masonic Cancer Center, University of Minnesota
The Efficacy of Epitope-specific IGFR1 Antibodies in Therapy of Pediatric, Adolescent, and Young Adult Solid Tumors
**Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation**

Location: E Arie Crown Theater  
CME credit: 1.25  
Track(s): Breast Cancer; Cancer Genetics; Gynecologic Cancer

**Abram Recht, MD—Chair**  
Beth Israel Deaconess Medical Center  
*Radiation Therapy and Hereditary Breast Cancer*

**Marian B. E. Menke-Pluymers, MD, PhD**  
Erasmus University Medical Center  
*Surgical Options for Breast Cancer Patients with a BRCA 1/2 Mutation or a Familial Predisposition*

**Susan M. Domchek, MD**  
Abramson Cancer Center  
*Systemic Therapy in BRCA1 and BRCA2 Mutation Carriers with Breast Cancer*

---

**8:00 AM - 9:15 AM**  
**CLINICAL PROBLEMS IN ONCOLOGY**

When Onco-cardiology Meets Cardio-oncology: A Global Perspective (C02)-TICKETED SESSION

Location: E451a  
CME credit: 1.25  
Track(s): Patient and Survivor Care

**Stefan D. Anker, MD, PhD—Chair**  
Charité Universitätsmedizin Berlin  
*Cardiac Problems in Oncology Patients beyond Cardiotoxicity: A Road to Cancer Cachexia*

**Erica L. Mayer, MD**  
Dana-Farber Cancer Institute  
*Patterns of Cardiotoxicity with Novel Therapies and Management Issues*

**Daniel John Lenihan, MD**  
Vanderbilt University  
*Pathophysiology of Cardiotoxicity in Chemotherapy and Targeted Therapy*
Saturday, June 5, 2010

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Genetic and Molecular Predictors in Genitourinary Malignancies
Location: E Hall D2
CME credit: 1.5
Track(s): Genitourinary Cancer

Andrew J. Armstrong, MD, ScM—Co-Chair
Duke University Medical Center
Adam Stuart Kibel, MD—Co-Chair
Washington University School of Medicine

8:00 AM  Predicting prostate-cancer-specific death: Is it in the cancer? (Abstract #4500)
G. E. Ayala, B. J. Miles, C. T. Freund, R. Li, A. Frolov, M. M. Ittmann, D. Kadmon,
P. T. Scardino, T. Wheeler, D. Rowley

8:15 AM  Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). (Abstract #4501)
B. I. Rini, M. Zhou, H. Aydin, P. Elson, T. Maddala, D. Knezevic, L. Parodi,
R. M. Bukowski, W. F. Novotny, J. W. Cowens

Discussion
8:30 AM  To be determined

8:45 AM  Evaluation of the genetic component of early-onset prostate cancer. (Abstract #4502)
K. A. Cooney, C. A. Salinas, A. M. Ray, Y. Wang, E. M. Lange, K. A. Zuhlke

9:00 AM  Susceptibility loci associated with prostate cancer progression and mortality. (Abstract #4503)
D. J. Gallagher, V. Joseph, A. Cronin, A. J. Vickers, V. E. Reuter, H. I. Scher,
J. Eastham, H. Lilja, T. Kirchhoff, K. Offit

Discussion
9:15 AM  Elaine Ostrander, PhD (Abstracts #4502–4503)
National Human Genome Research Institute
Emerging Evidence for a Genetic Risk of Prostate Cancer
8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Molecularly Targeted Trials in Lung Cancer
Location: E Hall D1
CME credit: 1.5
Track(s): Lung Cancer

Marvaretta Miesha Stevenson, MD—Co-Chair
Duke University Medical Center
Heather A. Wakelee, MD—Co-Chair
Stanford University

8:00 AM Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). (Abstract #7500)

Discussion
8:15 AM D. Ross Camidge, MD, PhD (Abstract #7500)
University of Colorado, Denver
IGF1R: Where Do We Go from Here?

8:30 AM A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. (Abstract #LBA7501)

Discussion
8:45 AM Bruce E. Johnson, MD (Abstract #LBA7501)
Dana-Farber Cancer Institute
Where Does This TRAIL Lead Us?

9:00 AM Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (Abstract #LBA7502)

Discussion
9:15 AM Ravi Salgia, MD, PhD (Abstract #LBA7502)
The University of Chicago
Combinations of Targeted Agents
Saturday, June 5, 2010

8:00 AM - 11:00 AM
SPECIAL SESSION

Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available)
Location: S106a
CME credit: 3 Track(s): Special Session; Geriatric Oncology

Kathryn A. Bylow, MD—Co-Chair
Medical College of Wisconsin

Hyman Bernard Muss, MD—Co-Chair
University of North Carolina at Chapel Hill

Arash Naeim, MD
University of California, Los Angeles
Comparative Effectiveness

Arti Hurria, MD
City of Hope National Medical Center
Defining Frailty

Norman E. Sharpless, MD
University of North Carolina School of Medicine
Biomarkers

William Dale, MD, PhD
The University of Chicago
Decision Making
8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Cancer Prevention/Epidemiology
Location: S Hall A2
Tracks(s): Cancer Prevention/Epidemiology

Brd. 1A High prevalence of BRCA1/2 germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history. (Abstract #1534)
C. Saura, G. Sánchez-Ollé, N. Bosch, N. Gadea, M. Masas, A. Tenes, S. Gutierrez-Enríquez, O. Díez, J. Baselga, J. Balmaña

Brd. 1B Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital. (Abstract #1535)
P. R. Duncan, J. T. Lin, R. Feddersen

Brd. 1C Effect of BRCA1 gene and estrogen-receptor α on regulation of serum estradiol levels in women with breast cancer. (Abstract #1536)
J. Kim, S. Lee, K. H. Oktay

Brd. 1D Association of death receptor 4 variant (Glu228Ala) with ovarian cancer risk in BRCA1-mutation carriers. (Abstract #1537)
M. G. Dick, B. Versmold, C. Engel, C. Sutter, R. K. Schmutzler, German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC)

Brd. 1E Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history. (Abstract #1538)

Brd. 1F Publication bias in translational research and number of polymorphisms analyzed in genetic association studies. (Abstract #1539)

Brd. 1G MUTYH gene mutations in Spanish individuals with multiple colorectal adenomas without APC gene mutation. (Abstract #1540)

Brd. 1H Association between XRCC1 gene haplotype tagging single nucleotide polymorphisms and non-small cell lung cancer in Korean patients. (Abstract #1541)
G. Lee, J. Kim, D. Kim, S. Kim, H. Kim, J. Kang, S. Oh

Brd. 2A Mutation position in BRCA-associated breast cancers. (Abstract #1542)
F. Meric-Bernstam, A. Gutierrez-Barrera, J. K. Litton, L. Mellor-Crummey, K. Ready, A. M. Gonzalez-Angulo, K. H. Lu, G. N. Hortobagyi, B. Arun

Brd. 2B Association of HER2 655 ile→Val polymorphism with pathological response to neoadjuvant chemotherapy and trastuzumab in breast cancer. (Abstract #1543)
A. M. Astorga

Brd. 2C Is lobular breast cancer mainly inherited from the father? (Abstract #1544)
H. L. Olsson, C. Ellberg

Brd. 2D Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers. (Abstract #1545)

Brd. 2E Pilot program of fast-track germline genetic analyses as part of integrated breast, ovarian, or gastrointestinal personalized cancer care program. (Abstract #1546)
O. Caron, B. Bressac-de-Paillerets, D. Malka, A. Remenieras, C. Bourgier, C. Uzan, M. Spielmann, M. Blayau, T. Frébourg, S. Delalogue
Saturday, June 5, 2010

Brd. 2F  Disparities in referral by risk profile for genetic counseling of high-risk individuals: A disease-specific analysis of mutation frequencies of 1,193 patients presenting for presumptive hereditary breast ovarian cancer (HBOC) or colorectal cancer syndromes (CCS). (Abstract #1547)

Brd. 2G  Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3. (Abstract #1548)

Brd. 2H  Analysis of plasma proteome from BRCA1/BRCA2 mutation carriers as modifier risk factor of breast cancer. (Abstract #1549)

Brd. 3A  A unique community-based family cancer registry. (Abstract #1550)
N. Y. Gabrail, C. L. Smith, J. Fox

Brd. 3B  Promoter methylation of p16INK4A, RASSF1A, and RAR2b genes in tumor DNA from patients with breast cancer (BC) in correlation with clinical recurrence. (Abstract #1551)

Brd. 3C  Type II diabetes and breast cancer. (Abstract #1552)
K. D. Erickson, J. P. Pierce, R. E. Patterson, T. R. Reid, L. Natarajan, S. Flatt, B. A. Parker, D. Heath

Brd. 3D  Does dietary estrogen intake from meat relate to the incidence of hormone-dependent cancers? (Abstract #1553)
Y. Handa, H. Fujita, Y. Watanabe, S. Honma, M. Kaneuchi, H. Minakami, R. Kishi

Brd. 3E  A multi-analyte serum test for the early diagnosis of non-small cell lung cancer. (Abstract #1554)

Brd. 3F  Lung cancer risk and polymorphisms in UGT1A6. (Abstract #1555)
L. Kua, R. A. Soo, A. Khoo, S. Lee, T. Chin, P. Chong, D. Nur, R. C. Soong, B. C. Goh, W. Yong

Brd. 3G  Breast density and calculated breast cancer risk. (Abstract #1556)
F. B. Khan, F. Kingsley, K. Dittus, B. L. Sussman, M. E. Wood

Brd. 3H  Method of detection of DCIS to predict HER2 overexpression. (Abstract #1557)
S. Schrading, E. Wardelmann, W. Kuhn, H. H. Schild, C. K. Kuhl

Brd. 4C  The accuracy of the HPV-associated diseases risk assessment inventory for detecting cervical dysplasias in medically underserved women in the United States. (Abstract #1560)
M. S. Cyrus-David, W. Wang, G. Siddiqui

Brd. 4D  Economic value of disability adjusted life years lost to cancers: 2008. (Abstract #1561)
R. M. John, H. Ross

Brd. 4E  The association between the use of statin and breast cancer recurrence. (Abstract #1562)
Y. Chae, M. E. Valsecchi, J. Kim, A. M. Desai, W. J. Tester

Brd. 4F  A prospective study of combined colon and endometrial cancer screening in women with Lynch syndrome: A novel patient-centered approach. (Abstract #1563)
Factors influencing long-term altered quality of life, sexual functioning, and menopausal symptoms after prophylactic bilateral salpingo-oophorectomy (PBSO) among high-risk women (wm). (Abstract #1564)

Influence of thiozolidinediones (TZD) exposure on the progression of oral leukoplakia (L) and erythroplakia (E) to the development of head and neck cancer (HNC). (Abstract #1565)
A. Kunthur, E. Siegel, R. Govindarajan

High-precision tissue acquisition in the evaluation of breast microcalcifications. (Abstract #1567)
J. Janssens, R. Harries, S. Lawson

Barriers to colorectal cancer screening among African American population. (Abstract #1568)
Z. M. Bo, V. Ghevariya, M. Ahluwalia, K. Veerabhadrappa, G. M. Villani, S. Anand

Determinants of low cell yield in random fine needle aspiration (rFNA) procedures of the breast in healthy women unselected by risk. (Abstract #1569)

Knowledge of cancer risk factors. (Abstract #1570)
K. M. Gil, S. Yeropoli, B. Fish, L. Schnegg, J. L. Savitski

Mammography utilization in women age 40 to 49: The French EDIFICE survey. (Abstract #1571)

Young age at first live birth and long duration of breast feeding: Are they universally accepted protective factors against breast cancer? A case control study of the Cancer Research Group in Pakistan. (Abstract #1572)

Do Asian breast cancer patients younger than age 40 have more aggressive biologic characteristics than their western counterparts? A comparison between Shanghai and Vienna. (Abstract #1573)
M. M. Tea, L. Fan, Z. Shao, C. F. Singer

Fecundity after childhood cancer: A nationwide, population-based study. (Abstract #1574)
M. Cvancarova, M. R. Forman, S. D. Fossa

Trends in incidence and location of colorectal cancer in the colonoscopy era. (Abstract #1575)
D. Pulte, S. B. Chalasani, H. Brenner

Predictors of independent living status in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #1576)

Differing age patterns in chronic myeloid leukemia by racial ethnic group. (Abstract #1577)
A. M. Mendizabal, W. F. Anderson, P. Garcia-Gonzalez, P. H. Levine

Characterization of 25-OH vitamin D (Vit D) and factors associated with obesity in patients with high-risk breast cancer (BC): NCIC CTG MA.21. (Abstract #1578)

Risk of metachronous contralateral testicular germ cell tumor (met-TGCT) among 7,248 Norwegian patients (1953–2007). (Abstract #1579)
K. E. Andreassen, T. Grotmol, M. Cvancarova, T. B. Johannesen, S. D. Fossa
Saturday, June 5, 2010

Brd. 6G  The effect of age on delay in diagnosis and stage of breast cancer. (Abstract #1580)
A. H. Partridge, M. E. Hughes, Y. Wong, S. B. Edge, R. L. Theriault, D. W. Blayney,
J. C. Niland, E. P. Winer, J. C. Weeks, R. M. Tamimi

Brd. 6H  Innate immunity-related sequence variants as predictors of breast cancer risk among women of African descent. (Abstract #1581)
K. S. Kimbro, G. M. Opredal, B. G. Burns, T. T. VanGleve, W. Tang, M. Bouzyk,
L. R. Kidd

Brd. 7A  Is tumor size important in HER2-positive breast cancer? (Abstract #1582)
C. Parise, K. Bauer, V. Caggiano

Brd. 7B  Incidence of early-onset multiple myeloma among families with endometrial carcinoma. (Abstract #1583)
A. R. Sama, W. Gonsalves, X. Fang, H. T. Lynch, S. Thome

Brd. 7C  Breast cancer and high-risk diagnosis in core biopsies stratified by ethnicity. (Abstract #1584)
E. Kim, J. Sharko, B. Drohan, C. Roche, M. Specht, M. Gadd, B. L. Smith,
K. S. Hughes

Brd. 7D  Epidemiologic risk factors associated with breast cancer subtypes. (Abstract #1585)
A. Bambhroliya, M. Bondy, P. Thompson, A. Sahin, J. L. Murray, R. Zhou,
K. Sexton, A. M. Brewster

Brd. 7E  The influence of ER on small HER2-positive invasive breast cancers. (Abstract #1586)
V. Caggiano, C. Parise, K. Bauer

Brd. 7F  Frequency of L858R and D746–750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies. (Abstract #1587)
A. T. Dimou, K. N. Syrigos, S. Agarwal, L. Lozovatsky, V. Zolota, V. K. Anagnostou,
D. Rimm

Brd. 7G  A significant dietary change after breast cancer diagnosis: Early results of a United Kingdom prospective multicenter study. (Abstract #1588)

Brd. 7H  Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study. (Abstract #1589)
C. Murphy, D. Mallam, S. Stein, S. Patil, J. Howard, N. T. Sklarin, M. Gemignani,
C. Hudis, A. D. Seidman

Brd. 8A  Mortality for non-AIDS-defining cancers among people with AIDS. (Abstract #1590)
A. Zucchetto, B. Suligoi, A. De Paoli, S. Pennazza, M. Spina, S. Bruzzone,
G. Rezza, U. Tirelli, L. Dal Maso, D. Serraino

Brd. 8B  Clinical and pathologic characteristics of Hispanic breast cancer patients in a tertiary care safety net hospital. (Abstract #1591)
A. de las Morenas, T. P. Ahern, C. L. Rosenberg

Brd. 8C  Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada. (Abstract #1592)
C. M. Kelly, T. Gomes, M. Duong-Hua, K. I. Pritchard, L. F. Paszat, D. N. Juurlink

Brd. 8D  Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter? (Abstract #1593)
S. Muhsen, M. Morrogh, A. P. Andrade, R. Sakr, W. Paik, M. Morrow, T. A. King

Brd. 8E  Longitudinal self-reported and serum-based assessment of tobacco or nicotine use in head and neck cancer patients during definitive radiotherapy or chemoradiotherapy. (Abstract #1594)
M. R. Kudrimoti, S. M. Arnold, J. Valentino, M. Randall, G. W. Warren
Brd. 8F Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study. (Abstract #1595)

Brd. 8G Characteristics and behavior of invasive breast cancer developed despite prior oophorectomy. (Abstract #1596)

Brd. 8H Incidental finding of pulmonary nodule on CT pulmonary angiogram (CTPA) in view of current surveillance recommendations: Is any lung cancer screening protocol applicable? (Abstract #1597)
O. C. Enrizo, T. Baykaner, M. J. Janicek

Brd. 9A Prevalence of anal squamous intraepithelial lesions in HIV-positive and HIV-negative men who have sex with men in Thailand. (Abstract #1598)

Brd. 9B Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer. (Abstract #1599)

Brd. 9C Recurrence pattern in early-stage breast cancer in a minority cohort. (Abstract #1600)
S. B. Sreenivasappa, B. Ciobanu, S. Sandhu, F. Feitosa, J. Samuel

Brd. 9D Influence of market access conditions on utilization of innovative drugs in Europe: The cases of trastuzumab and cetuximab. (Abstract #1601)
J. Misset, M. Toumi, L. Krukowski, M. Lamure, S. Aballea

Brd. 9E Molecular profiles of breast cancer in Ilorin, Nigeria. (Abstract #1602)

Brd. 9F Colon cancer disparities: A SEER-based analysis of epidemiologic data on Asian and Pakistani immigrants in the United States. (Abstract #1603)
R. N. Rahman, A. M. Hossain, J. Abraham

Brd. 9G Analysis of the geographical distribution of cancer in Israel. (Abstract #1604)
A. Zick, Y. Rottenberg, M. Barchana, M. Shirav-Schwartz, T. Peretz

J. A. Malmgren, M. K. Atwood, H. G. Kaplan

Brd. 10A Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends. (Abstract #1606)
M. A. Gubens, C. Clément-Duchêne, H. A. Wakelee

Brd. 10B Comorbidities of the underserved and minority patient with cancer presenting to a public safety-net hospital: A deterrent for clinical trial participation? (Abstract #1607)
S. N. Wolff, Z. Britkani, P. Millner, K. Palka, D. Wujcik

Brd. 10C Characteristics of adult osteosarcoma patients: Results from an ongoing postmarketing drug safety surveillance study. (Abstract #1608)
K. D. Midkiff, A. Gilsenan, Y. Wu, D. Masica, E. Andrews
8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Leukemia, Myelodysplasia, and Transplantation
Location: S Hall A2
Tracks(s): Leukemia, Myelodysplasia, and Transplantation

Brd. 11B Thymic renewal and antileukemic effect in adults after haploidentical transplantation and suicide gene therapy. (Abstract #6534)
C. Bordignon, L. Vago, G. Oliveira, D. Ghio, M. Lupo Stanghellini, J. Peccatori, A. Bondanza, A. Lambiase, F. Ciceri, C. Bonini

Brd. 11F First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. (Abstract #6535)

Brd. 11G EPOCH-FR: A novel salvage regimen for patients with lymphoid malignancies being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation. (Abstract #6536)

Brd. 11H A prospective feasibility study of clofarabine (CLO) cyto reduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS. (Abstract #6537)

Brd. 12A ⁹⁰y-ibritumomab tiuxetan followed by reduced-intensity conditioning (RIC) and allogeneic stem-cell transplantation (SCT) in patients with high-risk relapsed, refractory, or transformed follicular lymphoma (FL). (Abstract #6538)
K. Abou-Nassar, K. Stevenson, J. H. Antin, A. Freedman

Brd. 12B Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT). (Abstract #6539)

Brd. 12F Single-nucleotide polymorphism analysis of candidate genes in chronic GVHD. (Abstract #6540)
W. B. Clark, K. D. Brown-Gentry, F. G. Schuening, D. C. Crawford, M. H. Jagasia

Brd. 12G Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen. (Abstract #6541)

Brd. 12H Is there a relationship between glucocorticoid (GC) dose and performance on functional outcome measures? (Abstract #6542)
J. S. Scheetz, C. A. Brown, N. V. Paddison, G. S. Morris, K. Shin

Brd. 13A Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF). (Abstract #6543)

Brd. 13B CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: Potential predictor of early engraftment. (Abstract #6544)
K. Prabhash, N. Khattry, V. Alai, A. Joshi, A. V. Bakshi, S. Kannan, P. Sastry, P. M. Parikh, J. Kode
Brd. 13C Results of new cases of APL treatment by arsenic trioxide and long-term follow-up: Is it time for using arsenic trioxide in first-line treatment? (Abstract #6545) 
A. Ghavamzadeh, K. Alimoghaddam, S. Ghaffari, S. Rostami, M. Jahani, M. Iravani, S. Mousavi, M. Jalili, N. Alizadeh, A. Khodabande, Hematology, Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences

Brd. 13D Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression. (Abstract #6546) 

Brd. 13E The relationship of cigarette smoking to invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy (IC). (Abstract #6547) 

Brd. 13F Dynamic of morphologic and molecular remission in patients (pts) with APL treated with frontline ATRA and arsenic trioxide (ATO). (Abstract #6548) 
M. Ayoubi, H. Kantarjian, J. E. Cortes, S. Faderl, G. García-Manero, S. Wen, J. Fiorentino, X. Huang, R. Luthra, F. Ravandi Kashani

Brd. 13G Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies. (Abstract #6549) 

Brd. 13H Correlation of RASGRP1/APTX ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination. (Abstract #6550) 
G. Martinelli, S. Paolini, C. Papayannidis, E. Ottaviani, S. Parisi, I. Iacobucci, A. Curti, D. Cilloni, G. Saglio, A. Candoni, M. Baccarani

Brd. 14A Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison. (Abstract #6551) 
S. Faderl, F. Ravandi Kashani, G. Borthakur, T. M. Kadia, E. Jabbour, G. Garcia-Manero, M. Brandt, S. Pierce, H. Kantarjian

Brd. 14B Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). (Abstract #6552) 
G. Borthakur, E. Jabbour, X. Wang, J. E. Cortes, F. Ravandi Kashani, T. M. Kadia, J. Bass, M. Brandt, H. Kantarjian

Brd. 14C Association of lymphocytosis following treatment with dasatinib with response and outcome. (Abstract #6553) 
C. A. Schiffer, J. E. Cortes, G. Saglio, P. le Coutre, E. Bahceci, D. Dejardin, N. P. Shah

Brd. 14D Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients. (Abstract #6554) 

Brd. 14E Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8 abnormalities. (Abstract #6555) 
S. R. Mohan, M. A. Sekeres, Y. Saunthararajah, J. P. Maciejewski
Saturday, June 5, 2010

Br. 14F Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd. (Abstract #6556)
T. P. Hughes, P. D. le Coutre, R. E. Clark, G. Saglio, R. A. Larson, Q. Yin, E. Demirhan, A. Hoeneckopp, A. Hochhaus, H. Kantarjian

Br. 14G Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML. (Abstract #6557)
D. Rizzieri, K. Stockerl-Goldstein, A. Wei, R. H. Herzig, F. Erlandsson, R. K. Stuart

Br. 14H A clinico-genomic model of performance status in acute myeloid leukemia. (Abstract #6558)
A. Rao, C. Acharya, H. J. Cohen, D. Rizzieri, A. Potti

Br. 15A Obesity, a risk factor for acute myeloid leukemia? Roswell Park Cancer Institute weighs in on the obesity debate. (Abstract #6559)
H. J. Lee

Br. 15B Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC). (Abstract #6560)
R. R. Yehia, D. Rangachari, K. A. Reiss, A. Blackford, A. Bardia, H. Carraway, V. Steams, R. J. Arceci, J. E. Karp

Br. 15C Hypocellular acute myeloid leukemia: Better or worse prognosis. (Abstract #6561)
A. Al-Kali, S. N. Konoplev, E. Lin, T. M. Kadia, S. Faderl, F. Ravandi Kashani, M. Ayoubi, M. Brandt, H. Kantarjian, G. Borthakur

Br. 15D The role of FLT3 in sole trisomy 8 acute myeloid leukemia. (Abstract #6562)

Br. 15E The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL. (Abstract #6563)

Br. 15F Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS). (Abstract #6564)
D. A. Macdonald, S. E. Assouline, J. Brandwein, S. Kamel-Reid, E. A. Eisenhauer, S. Couban, A. Foo, B. Leber

Br. 15G Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients. (Abstract #6565)
M. Danese, R. Griffiths, M. Gleeson, S. Satram-Hoang, K. B. Knopf, J. Mikhail, C. M. Reyes

Br. 15H Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6566)
Y. Chen, H. Kantarjian, G. Garcia-Manero, Z. Estrov, M. Konopleva, E. Jabbour, T. M. Kadia, B. Williams, S. George, G. Borthakur

Br. 16A BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #6567)

Br. 16B Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies. (Abstract #6568)

Br. 16C Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy. (Abstract #6569)
G. Saglio, J. E. Cortes, C. A. Schiffer, P. le Coutre, E. Jabbour, E. Bahceci, A. Lambert, N. P. Shah
Brd. 16D Race and overall survival in acute myeloid leukemia. (Abstract #6570)
J. M. Birenbaum, Y. Ning, M. Tidwell, I. Gojo, M. R. Baer

Brd. 16E Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine. (Abstract #6571)
A. Fullmer, G. Borthakur, T. M. Kadia, G. Garcia-Manero, E. Jabbour

Brd. 16F CPX-351 IN AML after failed induction with cytarabine and daunorubicin. (Abstract #6572)

Brd. 16G Incidence of unconventional infections (UC) in patients with acute myelogenous leukemia (AML) treated with clofarabine (CLO)-containing induction therapy. (Abstract #6573)
R. Knoebel, A. R. McQuary, E. Estey, P. S. Becker

Brd. 16H Activity of azacitidine in chronic myelomonocytic leukemia. (Abstract #6574)
R. B. Costa

Brd. 17A BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia. (Abstract #6575)
A. H. Teitelbaum, H. J. Henk, V. Bollu

Brd. 17B Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. (Abstract #6576)

Brd. 17C Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile. (Abstract #6577)
F. Shihadeh, V. K. Reed, A. Mazloom, J. Phan, H. Kantarjian, S. Faderl, B. S. Dabaja

Brd. 17D A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (Panax quinquefolium) extract (CVT-E002) in patients with chronic lymphocytic leukemia: Effect on respiratory infection and antibiotic use. (Abstract #6578)

Brd. 17E Epidemiology, risk factors, and outcomes of invasive fungal infection in adults with acute myelogenous leukemia undergoing intensive induction chemotherapy. (Abstract #6579)
K. Lu, D. Neofytos, A. Blackford, A. H. Seung, J. E. Karp

Brd. 17F Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML). (Abstract #6580)

Brd. 17G Serum interleukin-6, cardiovascular disease, and mortality in chronic lymphocytic leukemia. (Abstract #6581)
D. E. Dawe, J. Yoon, S. Gibson, J. B. Johnston

Brd. 17H Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine. (Abstract #6582)
M. A. Sekeres, S. L. Allen, S. R. Mohan, A. S. Lundberg, H. P. Erba

Brd. 18A Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study. (Abstract #6583)

Brd. 18B Four routinely recorded parameters define four distinct prognostic groups in AML. (Abstract #6584)
J. R. Novotny, H. Nueckel, A. Aisenbrey, U. Duehrsen
Brd. 18C United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry. (Abstract #6585)
R. C. Hermann, C. B. Miller, R. Catchatourian, D. Snyder, D. Williams, M. Juma, J. E. Cortes

Brd. 18D Effect of the presence of P-glycoprotein (MDR1) on the ability of AML patients to achieve complete remission: Results of a meta-analysis of the literature. (Abstract #6586)
J. Marie, A. S. Lundberg, A. Ajami

Brd. 18E Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older. (Abstract #6587)

Brd. 18F Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis. (Abstract #6588)

Brd. 18G High-dose of daunorubicin as induction treatment for adults with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia. (Abstract #6589)

Brd. 18H Prevalence of familial malignancy in a prospectively screened cohort of patients with leukemia. (Abstract #6590)
A. Prasad, D. Liu, M. Rasul, N. Ahmed, K. Seiter

Brd. 19A Detection of combinations of cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH) probes. (Abstract #6591)
M. T. Schweizer, Y. Zhang, R. Kunnavakkam, T. Karrison, M. M. Le Beau, R. A. Larson

Brd. 19B Molecular characterization of normal karyotype acute myeloid leukemia in Korean patients. (Abstract #6592)
Y. Choi, J. Lee, D. Kim, J. Ahn, S. Lim, S. Kim, E. Hur, M. Seol, K. Lee

Brd. 19C Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India. (Abstract #6593)

Brd. 19D Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. (Abstract #6594)
N. Ghadyalpatil, K. Prabhash, H. Menon, R. Nair, S. Banavali, V. Noronha, V. Wabale, R. Singh, G. Goyal, V. Ostwal

Brd. 19E Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience. (Abstract #6595)
R. Pandey

N. Gottschalk, E. F. Lampeter, V. R. Jacobs

Brd. 19G Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs). (Abstract #6597)

Brd. 19H Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. (Abstract #6598)
Brd. 20A  JAK2 V617F mutation positives in the general population. (Abstract #6599)  
S. E. Bojesen, C. Nielsen, H. Birgens, B. G. Nordestgaard, L. Kjaer, H. Hasselbalch

E. Kim, F. Pan, S. Peng, R. Fleurence

Brd. 20C  Hematologic outcomes of MDS treatment with hypomethylating agents in community practice. (Abstract #6601)  

Brd. 20D  Increased of overall survival (OS) and malignancies (K) during tyrosine kinase inhibitors (TKI) in a real life cohort of patients (pts) with a chronic myeloid leukemia (CML). (Abstract #6602)  

Brd. 20E  Eltrombopag effect on the engraftment efficiency of human hematopoietic stem cells in a NOD/SCID xenotransplant model. (Abstract #6603)  

Brd. 20F  Nonsteroidal anti-inflammatory drugs (NSAIDs) or EP4 receptor antagonism enhances hematopoietic stem and progenitor cell (HSPC) mobilization and facilitates faster hematopoietic recovery after myeloablation. (Abstract #6604)  
J. Hoggatt, P. Singh, A. Hoggatt, J. M. Speth, L. M. Pelus

Brd. 20G  Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). (Abstract #6605)  
N. Pemmaraju, H. Kantarjian, S. Faderl, G. Garcia-Manero, T. M. Kadia, G. Borthakur, J. E. Cortes, F. Ravandi Kashani

Brd. 20H  Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes. (Abstract #6606)  

Brd. 21A  Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS). (Abstract #6607)  

Brd. 21B  Identification of genes with different methylation profiles between RAEB and RCMD in myelodysplastic syndrome. (Abstract #6608)  
S. Lee, H. Kwon, S. Kim, S. Oh, K. Kwon, J. H. Lee, Y. Lee, D. Seo, J. Han, H. Kim

Brd. 21C  Effect of phosphoinositide-phospholipase c beta1 monoallelic deletion in low-risk MDS patients treated with darbepoetin. (Abstract #6609)  
P. Spadaro, V. Pitini, C. Arrigo, M. Ingemi

Brd. 21D  In vitro activation of CMV-specific T-cell response using CyaA toxoids delivering peptide antigenic epitopes derived from pp65 protein. (Abstract #6610)  
J. Jelinek, I. Adkins, P. Sebo, J. Michalek

Brd. 21E  Myelodysplastic syndrome (MDS) patients at a VA medical center: Comorbidity and survival. (Abstract #6611)  

Brd. 21F  A prospective multicenter observational study for decitabine treatment in Korean patients with myelodysplastic syndrome. (Abstract #6612)  
J. Lee, J. Jang, K. Lee, C. Jung, J. Park, S. Yoon, Y. Joo, Y. Kim, S. Park, Y. Min
Saturday, June 5, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Lymphoma and Plasma Cell Disorders
Location: S Hall A2
Tracks(s): Lymphoma and Plasma Cell Disorders

Brad 22A Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL). (Abstract #8047)

Brad 22B Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. (Abstract #8048)


Brad 22D Transcriptome adaptation caused by vorinostat/bexarotene combination therapy in advanced cutaneous T-cell lymphoma. (Abstract #8050)

Brad 22E Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience. (Abstract #8051)

Brad 22F Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma. (Abstract #8052)
K. Yim, I. Chau, A. Horwich, C. Dearden, G. Morgan, A. Wotherspoon, A. Attygalle, B. Sharma, D. Cunningham

Brad 22G Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). (Abstract #8053)

Brad 22H Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival. (Abstract #8054)
A. R. Shustov, B. Pro, S. M. Horwitz, E. D. Jacobsen, A. Boyd, S. M. Fruchtman, O. O’Connor

Brad 23A Duration of response in three phase III studies of denileukin diftitox in cutaneous T-cell lymphoma (CTCL). (Abstract #8055)
M. Duvic, H. M. Prince

Brad 23B T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant. (Abstract #8056)

Brad 23C ABVD chemotherapy with interferon for advanced-stage classical Hodgkin’s lymphoma: A 10-year follow-up study. (Abstract #8057)
Brd. 23D Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin’s lymphoma (HL)? (Abstract #8058)
A. Gallamini, A. Biggi, S. Chauvie, A. Bianchi, S. Conti, F. Fiore, R. Sorosio, J. Vose, D. L. Thomas, M. E. Juweid

Brd. 23E Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study. (Abstract #8059)

Brd. 23F Relapse of Hodgkin’s lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. (Abstract #8060)

Brd. 23G Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma. (Abstract #8061)
M. Hutchings, L. Kostakoglu, A. Loft, M. Coleman, L. Specht

Brd. 23H Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. (Abstract #8062)

Brd. 24A Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin’s lymphoma treated with AVBD. (Abstract #8063)
R. Patil, F. J. Hernandez-Ilizaliturri, A. Elefante, M. S. Czuczman

Brd. 24B Results of the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). (Abstract #8064)

Brd. 24C Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin’s lymphoma (NHL). (Abstract #8065)

Brd. 24D Phase II study of short course CHOP-rituximab followed by 90-y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Extended follow-up and predictors of relapse. (Abstract #8066)

Brd. 24E Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). (Abstract #8067)

Brd. 24F CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab. (Abstract #8068)
H. E. Kohrt, R. Hout, M. Goldstein, K. Weiskopf, L. Chen, T. Tedder, R. Levy

Brd. 24G Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (Abstract #8069)
Saturday, June 5, 2010


Brd. 26G Comparison of contrast-enhanced CT, PET/CT, PET, and low-dose noncontrast enhanced CT imaging of diffuse large B-cell (DLBCL), follicular (FL), small lymphocytic/CLL (CLL/SLL), and marginal zone lymphomas (MZL). (Abstract #8079) E. A. Chong, D. A. Torigian, A. Alavi, J. Svoboda, S. Nasta, L. H. Downs, S. J. Schuster


Brd. 27A High-dose sequential chemotherapy and rituximab (R-HDS) supported by autologous stem cell transplantation (ASCT) in patients (pts) with systemic B-cell lymphoma with CNS involvement (SCNSL) at diagnosis or relapse: Interim analysis of feasibility and activity of a phase II trial. (Abstract #8081) A. Assanelli, K. Patti, S. Cortelazzo, L. Rigacci, L. Devizzi, M. Foppoli, A. Mulé, F. Ciceri, C. Tarella, A. J. Ferreri, on behalf of the Intergruppo Italiano Linfomi
Brd. 27B Quality of life in 269 poor-risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98–3 randomized trial. (Abstract #8082)
N. Mounier, N. Heutte, C. Haioun, P. Feugier, B. Coiffier, H. Tilly, C. Ferme, J. Gabarre, F. Morchhauser, C. Gisselbrecht

Brd. 27C Clinicopathological differences between EBV-positive and EBV-negative diffuse large B-cell lymphoma. (Abstract #8083)
B. E. Beltran, D. Morales, A. Capellino, R. Miranda, J. Castillo

Brd. 27D Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poor-prognosis diffuse large B-cell lymphoma and grade III follicular lymphoma. (Abstract #8084)

Brd. 27E Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab. (Abstract #8085)

Brd. 27F Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinition and update of clinical efficacy and safety. (Abstract #8086)
R. E. Martell, A. Younes, S. E. Assouline, D. Rizzieri, S. Fox, M. A. Drouin, J. Wilhelm, M. Mehran, J. M. Besterman, R. H. Van Der Jagt

Brd. 27G Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies. (Abstract #8087)

Brd. 27H Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance. (Abstract #8088)
C. Casulo, J. Maragulia, A. D. Zelenetz, Lymphoma Service, Department of Medicine

Brd. 28A Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL). (Abstract #8089)

Brd. 28B Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation. (Abstract #8090)
L. Zhang, J. Kosek, P. Schafer, J. B. Bartlett

Brd. 28C Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents. (Abstract #8091)

Brd. 28D The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC). (Abstract #8092)

Brd. 28E Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase. (Abstract #8093)
Brd. 28F Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). (Abstract #8094)
W. Riaz, F. J. Hernandez-Ilizaliturri, C. Mavis, P. Tsai, M. S. Czuczman

Brd. 28G Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. (Abstract #8095)
M. J. Barth, F. J. Hernandez-Ilizaliturri, C. Mavis, P. Tsai, J. F. Gibbs, M. S. Czuczman

Brd. 28H Rituximab-related (R-R) reactivation of hepatitis B virus (HBV) in lymphoma: Analysis of FDA safety reports and a systematic literature review with meta-analysis. (Abstract #8096)

Brd. 29A Late phase II study of amrubicin in previously untreated patients with non-Hodgkin’s lymphoma (NHL). (Abstract #8097)

Brd. 29B Effect of a rituximab-based regimen on the incidence of CNS relapse in patients with diffuse large B-cell lymphoma. (Abstract #8098)
M. Mahrous, R. Buckstein, E. Pliiotis, M. C. Cheung, N. L. Berinstein

Brd. 29C Cladribine plus rituximab for the initial treatment of mantle cell lymphoma. (Abstract #8099)
T. Pindyck, S. E. Spurgeon, C. Y. Okada, E. E. Epner

Brd. 30A Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL). (Abstract #8100)
C. Flowers, M. Taylor, J. Hirata, H. Dillon, A. D. Zelenetz, J. D. Hainsworth, J. R. Cerhan, E. S. Rogers, J. W. Friedberg, B. K. Link

Brd. 30B Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B-cell lymphoma treated with R-CHOP. (Abstract #8101)
S. Kim, B. Kang, Y. Chae, J. Kim, Y. Kim, S. Sohn

Brd. 30C 18F-fluorodeoxglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients. (Abstract #8102)
D. M. Lamonica, T. Hahn, D. Drumsta, M. Achakzai, M. S. Czuczman, F. J. Hernandez-Ilizaliturri

Brd. 31A Maximum standardized uptake (SUVmax) on initial 18FDG-PET/CT as prognostic value in patients with diffuse large B-cell lymphoma. (Abstract #8103)

Brd. 31B Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin’s lymphoma (NHL). (Abstract #8104)
D. Belada, J. Mayer, M. S. Czuczman, I. W. Flinn, B. Durbin-Johnson, G. L. Bray

Brd. 31C Radioimmunotherapy for consolidation and relapse therapy for aggressive B-cell non-Hodgkin lymphoma: Retrospective analysis of the International RIT-Network. (Abstract #8105)

Brd. 32A A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. (Abstract #8106)
V. A. Morrison, J. L. Johnson, S. Jung, J. P. Leonard, B. D. Cheson
Brd. 32B  Association of maintenance rituximab with clinical outcome in rituximab-naive patients with Waldenström's macroglobulinemia (WM) who respond to a rituximab-containing regimen. (Abstract #8107)

Brd. 32C  Association of CR/VGPR with progression-free survival in rituximab-naive WM patients undergoing rituximab-based therapy, as predicted by polymorphisms in FcγRIIIA-158. (Abstract #8108)

Brd. 33A  Long-term follow-up of patients with lymphoplasmacytic lymphoma (Waldenström’s macroglobulinemia) who were treated with alemtuzumab. (Abstract #8109)
J. D. Soumerai, Z. R. Hunter, M. Boxer, B. S. Kahl, L. I. Ioakimidis, C. J. Patterson, S. P. Treon

Brd. 33B  Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström’s macroglobulinemia, and effect on miRNA expression. (Abstract #8110)

Brd. 33C  Association of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, with MGUS and multiple myeloma in different ethnic groups. (Abstract #8111)
S. Grass, S. Iida, A. Wikowicz, N. Fadie, A. Inagaki, K. Preuss, M. Ziepert, R. Ueda, M. Pfriemischalu

Brd. 34A  Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenström’s macroglobulinemia (WM), and applicability to patients expressing FcγRIIIA-158 F/F. (Abstract #8112)

Brd. 34B  Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma. (Abstract #8113)

Brd. 34C  Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenström’s macroglobulinemia (WM). (Abstract #8114)

Brd. 35A  Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma. (Abstract #8115)

Brd. 35B  Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols. (Abstract #8116)
B. P. Nair, N. Petty, S. Waheed, A. Hoering, F. Van Rhee, E. J. Anaissie, R. Lorsbach, C. Bailey, B. Barlogie

Brd. 35C  Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications. (Abstract #8117)

Brd. 35D  BIK (Bcl2-Interacting Killer) CpG methylation status as a potential predictive biomarker of relapsed/refractory multiple myeloma disease. (Abstract #8118)
Brd. 35E Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM). (Abstract #8119)
J. Crowley, J. D. Shaughnessy, V. Bolejack, E. J. Anaissie, F. Van Rhee, B. Barlogie

Brd. 35F Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures. (Abstract #8120)
A. Hoering, J. D. Shaughnessy, J. Haessler, R. Sexton, F. Van Rhee, Y. Alsayed, S. Waheed, B. P. Nair, J. Crowley, B. Barlogie

Brd. 35G Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T), and bortezomib (V). (Abstract #8121)

Brd. 35H Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk. (Abstract #8122)
J. Sawyer, J. D. Shaughnessy, J. Haessler, A. Hoering, B. Barlogie

Brd. 36A Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of M-CA for survival in total therapy protocols (TT1, TT2, TT3). (Abstract #8123)
J. Haessler, B. P. Nair, J. Sawyer, A. Hoering, J. D. Shaughnessy, B. Barlogie

Brd. 36B Expression of erythropoietin receptors by plasma cells from patients with multiple myeloma express: Potential relevance to pharmacological use of erythropoietin. (Abstract #8124)
P. S. Becker, C. P. Miller, B. L. Wood, S. Chien, W. Bensinger, F. Shahijanian, C. A. Blau

Brd. 36C Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (Abstract #8125)

Brd. 36D Gene expression profiling (GEP) analysis of CD138-purified plasma cells (PC) obtained from MRI-defined focal lesions (FL) under CT guidance: Applying the 70 gene risk model and comparison with data generated on random samples (RS) from multiple myeloma (MM) treated with total therapy 2, 3, 4, and 5 (TT2, TT3, TT4 and TT5). (Abstract #8126)
Y. Qiang, R. van Hemert, T. Brown, J. D. Shaughnessy, F. Van Rhee, A. Hoering, B. Barlogie

Brd. 36E Retrospective analysis of multiple myeloma survival outcomes in veterans: Focus on racial differences, age, and novel therapies. (Abstract #8127)

Brd. 36F Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. (Abstract #8128)

Brd. 36G Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study. (Abstract #8129)
Brd. 36H MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials. (Abstract #8130)

Brd. 37A A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM). (Abstract #8131)

Brd. 37B Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM). (Abstract #8132)

Brd. 37C Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). (Abstract #8133^)

Brd. 37D A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM). (Abstract #8134)

Brd. 37E Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI). (Abstract #8135)

Brd. 37F The Arkansas experience with autotransplantation (AT) for older patients (OP, age > 65) with multiple myeloma (MM). (Abstract #8136)
E. J. Anaissie, M. Grazziutti, J. Szymonifka, B. P. Nair, Y. Alsayed, S. Waheed, A. Hoering, B. Barlogie

Brd. 37G Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study. (Abstract #8137)
A. Guenther, P. Baumann, R. Burger, W. Klaaber, R. Schmidmaier, M. Gramatzki

Brd. 37H Predicting 10+ year survivors in total therapy 1 (TT1) for multiple myeloma (MM). (Abstract #8138)
S. Waheed, Y. Alsayed, R. Sexton, A. Hoering, B. Barlogie

Brd. 38A A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. (Abstract #8139)

Brd. 38B Bone marker assessment as a guide to chronic use of aminobisphophonates in multiple myeloma. (Abstract #8140)

Brd. 38C Mechanism of the antmyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor. (Abstract #8141)
S. Z. Usmani, R. D. Bona, G. Chiosis, Z. Li

Brd. 38D Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)? (Abstract #8142)
Brd. 38E  A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. (Abstract #8143)

Brd. 38F  An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission. (Abstract #8144)

Brd. 38G  Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: A retrospective analysis. (Abstract #8145)

Brd. 38H  Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)? (Abstract #8146)
J. Willey, K. E. Lemke, M. E. Williams, M. R. Green, S. Lonial

Brd. 39A  Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies. (Abstract #8147)

Brd. 39B  Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma. (Abstract #8148)
B. M. Elliott, S. Peti, D. Lee, K. Osman, L. M. Isola, E. Scigliano, L. Kostakoglu

Brd. 39F  Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma. (Abstract #8149)
M. Veeraputhiran, Z. Singh, B. Barlogie, M. Cottler-Fox

Brd. 39G  Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. (Abstract #8150)

Brd. 39H  Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression. (Abstract #8151)
S. J. Harrison, H. Quach, J. Dean, A. Milner, M. C. Copeman, H. M. Prince
8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Tumor Biology
Location: S Hall A2
Tracks(s): Tumor Biology

Brd. 40A  **EGFR** mutations in men and cigarette smokers with lung adenocarcinoma.  
(Abstract #10538)

Brd. 40B  Molecular types and prognostic markers PA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial.  
(Abstract #10539)

Brd. 40F  Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial.  
(Abstract #10540)
J. D. Hainsworth, D. R. Spigel, M. S. Rubin, R. V. Boccia, E. P. Fox, I. Firdaus, M. G. Erlander, C. Schnabel, F. A. Greco

Brd. 41A  Analysis of the methylation profile of 49 cancer-related regions in human breast cancer.  
(Abstract #10543)

Brd. 41B  Prospective multicentric trial evaluating prognostic and predictive value of circulating tumor cells in first-line chemotherapy metastatic breast patients.  
(Abstract #10544)

Brd. 41E  Early operable primary breast cancer in elderly (> 70 years) women: Are they biologically different from their younger counterparts?  
(Abstract #10547)
K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis

Brd. 41F  Can cetuximab specific IgE antibodies predict cetuximab-induced anaphylaxis?  
(Abstract #10548)
B. Dupont, D. Mariotte, M. Galais, K. Bouhier, B. Le Mauff, J. Reimund, R. Fonseca

Brd. 41G  Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy.  
(Abstract #10549)
A. M. Gown, C. C. Tse, L. C. Goldstein, P. L. Kandalaft, H. C. Hwang
Brd. 41H Identification of DNA methylation changes in esophageal cancer before/after chemoradiation therapy using a MCA-microarray and bisulfate pyrosequencing. (Abstract #10550)

Brd. 42A Prediction of response to neoadjuvant therapy in breast cancer using plasma and tumor proteomic analyses. (Abstract #10551)

Brd. 42B Value of quantitative DNA fingerprinting in classification of second breast tumors and association with outcome. (Abstract #10552)
B. L. Schlechter, P. S. Larson, Q. Yang, R. Klett, K. Armstrong, A. de las Morenas, C. L. Rosenberg

Brd. 42C CpG-b oligodeoxynucleotides potently activate human NK cells and sensitize chronic lymphocytic leukemia cells to NK cell-mediated killing. (Abstract #10553)

Brd. 42D Use of a combination of 5-fluouracil pathway genes to predict treatment outcome of S-1 monotherapy in advanced gastric cancer. (Abstract #10554)
G. Kim, H. Jeung, S. Y. Rha, J. K. Roh, S. Noh, H. C. Chung

Brd. 42E Use of CD8 and Foxp3 immune infiltrates after neoadjuvant chemotherapy to predict survival in HER2-overexpressing breast cancer patients. (Abstract #10555)
F. Ghiringhelli, B. P. Coudert, L. Arnould, P. Fumoleau, S. Ladoire

Brd. 42F Efficient detection of EGFR alterations in lung adenocarcinomas. (Abstract #10556)
M. G. Denis, S. Theoleyre, C. Chaplais, H. Gourdet, S. Caulet-Maugendre, H. Le Ho, R. Corre, H. Lena, C. Sagan, J. Bennouna

Brd. 42G Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib. (Abstract #10557)

Brd. 42H Biomarkers of early operable primary breast cancer in elderly (≥ 70 years) women (EPC) and their correlation with breast cancer-specific survival (BCSS). (Abstract #10558)
B. M. Syed, A. R. Green, E. C. Paish, D. A. Morgan, I. O. Ellis, K. Cheung

Brd. 43A Clinical significance of 18F-alpha-methyl tyrosine PET as a potential surrogate marker of LAT1 expression for predicting prognosis of non-small cell lung cancer. (Abstract #10559)

Brd. 43B Correlation of expression of circadian genes with liver metastasis and outcomes in colorectal cancer. (Abstract #10560)

Brd. 43C Epigenetic silencing of Dab-2 in head and neck cancer. (Abstract #10561)

Brd. 43D The single-nucleotide polymorphism A>G rs397768 in APC gene as a new biomarker of response to chemotherapy in advanced colorectal cancer. (Abstract #10562)
J. Villa Guzman, R. Zarate, V. Boni, A. Gomez, J. De la Haba, E. Bandres, J. Garcia-Foncillas, E. Aranda
Brd. 43E Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM). (Abstract #10563)

Brd. 43F Use of peripheral blood mRNA signatures to distinguish colorectal cancer patients from colonoscopy-negative patients. (Abstract #10564)

Brd. 43H Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC). (Abstract #10566)

Brd. 44A Prognostic value of serum protein biomarkers in patients with epithelial ovarian cancer. (Abstract #10567)
M. Wang, S. Bush, S. A. Ghamande, J. She

Brd. 44B Relationship of expression level of CD133 with tumor angiogenesis and prognosis of hepatocellular carcinoma after liver transplantation. (Abstract #10568)
Y. Xu, J. Fan

Brd. 44C Lung cancer autoantibody signature as indicator of early disease. (Abstract #10569)
T. V. Pedchenko, R. Mernaugh, D. Pareh, P. P. Massion

Brd. 44D Evaluation of the prognostic value of UBE2C mRNA levels in early breast cancer. (Abstract #10570)

Brd. 44E Use of T-cell proliferation to predict survival and recurrence in patients with resected colorectal liver metastases. (Abstract #10571)

Brd. 44F Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy. (Abstract #10572)

Brd. 44G Markers of anaerobic glycolysis as predictive factor in neoadjuvant chemoradiotherapy of rectal cancer. (Abstract #10573)
D. Sun, B. Shim, J. Jung, K. Lee, H. Kim, S. Hong, S. Kim, H. Cho

Brd. 44H SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). (Abstract #10574)

Brd. 45A Gene expression differences in current versus former smokers lung squamous preneoplasia. (Abstract #10575)

Brd. 45B Molecular profiling of pulmonary pleomorphic carcinoma: Implications for targeted treatment of a rare lung malignancy. (Abstract #10576)
Y. Kim, S. Lee, Y. Choi, J. Park, J. Lee, Y. Park, J. Ahn, K. Park, M. Ahn

Brd. 45C Role of the type III TGF-b receptor in mediating immunosuppression during breast cancer progression. (Abstract #10577)
B. A. Hanks, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, G. C. Blobe
Brd. 45D Use of circulating and tumor-infiltrating myelomonocytic cells to predict survival in human malignant pleural mesothelioma (MPM). (Abstract #10578)
B. Burt, T. Tillemann, R. Bueno, D. Sugarbaker

Brd. 45E Impact of a gene expression-based tissue of origin test on diagnosis and recommendations for first-line chemotherapy. (Abstract #10579)
M. Laouri, J. S. Nystrom, M. Halks-Miller, W. D. Henner

Brd. 45F Circulating exosomes may provide a more sensitive platform to monitor disease progression compared to circulating tumor cells. (Abstract #10580)

Brd. 45G Use of peripheral blood mRNA signature to distinguish patients with breast cancer from benign breast disease and nonconclusive mammography. (Abstract #10581)

Brd. 45H Predictive value of the Theros Breast Cancer Index (TBCI) for distant recurrence and overall survival (OS) in comparison to Adjuvant! Online and clinicopathologic characteristics in women with lymph node (LN)-negative, ER-positive breast cancer (BCa). (Abstract #10582)

Brd. 46A MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma. (Abstract #10583)

Brd. 46B Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC). (Abstract #10584)

Brd. 46C Evaluation of macrophage inflammatory protein-3 alpha (MIP-3a) as a serum marker for prognosis of colorectal cancer. (Abstract #10585)
T. Iwata, K. Tanaka, Y. Inoue, Y. Toiyama, J. Hiro, S. Saigusa, Y. Mohri, C. Miki, T. Tabata, M. Kusunoki

Brd. 46D Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients. (Abstract #10586)

Brd. 46E D-dimer levels and prediction of overall survival in cancer patients. (Abstract #10587)
C. Ay, D. Dunkler, R. Vormittag, P. Quehenberger, R. Pirker, O. Wagner, C. Zielinski, I. Pabinger

Brd. 46F The prognostic relevance of CXC-chemokines in stage II and III colorectal cancer (CRC) tissue and inflammatory infiltrate. (Abstract #10588)
O. Oladipo, S. Conlon, T. O’Grady, C. Purcell, C. Wilson, P. Maxwell, M. Stevenson, E. Kay, R. H. Wilson, D. J. Waugh

Brd. 46G Relations of circadian clocks genes with endocrine, proliferation, differentiation, and P53 mutation status in human locally invasive primary breast cancer. (Abstract #10589)

Brd. 46H Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer. (Abstract #10590)
Brd. 47A  Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and -negative oropharyngeal squamous cell carcinoma (OSCC). (Abstract #10591)

Brd. 47B  Implication of the alternative NF-kappa B pathway in prostate cancer progression. (Abstract #10592)

Brd. 47C  Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB). (Abstract #10593)

Brd. 47D  Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors. (Abstract #10594)
A. Zupa, G. Improta, J. Deng, M. Aieta, P. Musto, L. A. Liotta, C. Belluco, E. Mammano, J. D. Wulffkuhle, E. Petricoin III

Brd. 47E  Nuclear expression of aryl hydrocarbon receptor and prognosis for non-small lung cancer. (Abstract #10595)
H. Chang

Brd. 47F  Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy. (Abstract #10596)
K. Mason, J. Pickett, C. Ware, H. Hirai, P. Strack, S. D. Shumway, K. Ang, T. A. Buchholz, L. Milas, C. A. Buser

Brd. 47G  Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. (Abstract #10597)
M. Abdel-Wahab, A. Schally, F. Rick, L. Szalontay, J. Varga, Y. Shi, M. Zarandi, A. Pollack

Brd. 47H  Clinicopathologic features of lung cancer with EML4-ALK translocation. (Abstract #10598)
T. Mitsudomi, K. Suda, K. Tomizawa, Y. Yatabe

Brd. 48A  Evaluation of ADAM28 as a serological and histochemical marker for non-small cell lung cancers. (Abstract #10599)
H. Kuroda, M. Shimoda, M. Kawamura, H. Nomori, Y. Okada

Brd. 48B  Effect of plasma SPARC on outcome in cancer models. (Abstract #10600)
N. Desai, M. Piacente, X. Liu, O. D’Cruz, L. Hwang, X. Lin, S. Ran, S. Markovic, K. N. Trieu

Brd. 48C  Evaluation of the hedgehog pathway as a therapeutic target for preventing the progress to invasive-stage from noninvasive-stage breast cancer. (Abstract #10601)

Brd. 48D  Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment. (Abstract #10602)
N. Normanno, M. Gallo, L. Lamura, A. De Luca

Brd. 48E  Clinical relevance of the detection of tumor cells in the bone marrow of patients before lung cancer surgery. (Abstract #10603)
R. Nakahara, M. Anraku, A. Ui, N. Oohata, H. Matsuguma, S. Igarashi, K. Yokoi

Brd. 48F  Molecular markers for epithelial-mesenchymal transition (EMT) and tumor aggressiveness in breast carcinoma. (Abstract #10604)
Saturday, June 5, 2010

Brd. 48G Risk partitioning model shows need to address time dependence of breast cancer recurrence. (Abstract #10605)


Brd. 48H Role and prognostic value of placenta growth factor (PIGF) in colorectal carcinomas. (Abstract #10606)

M. Baek, S. Bae, S. Cho, D. Jeong, C. Kim

Brd. 49A Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer. (Abstract #10607)


Brd. 49B BRCA1 expression evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in operable breast cancer. (Abstract #10608)

P. Potemski, E. Pluciennik, A. K. Bednarek, R. Kusinska, S. Debska, R. Kubiak, R. M. Kordek

Brd. 49C Gene set comparison analyses of gene expression signatures for the acquired chemotherapy resistance. (Abstract #10609)

H. K. Kim, I. J. Choi, C. G. Kim, J. E. Green

Brd. 49D Activation of the PI3K pathway and prognostic information in epithelial ovarian cancer. (Abstract #10610)


Brd. 49E Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC). (Abstract #10611)


Brd. 49F Comparison of folate derivate levels in mucosa and tumor tissue in the course of antifolate treatment with pemetrexed. (Abstract #10612)


Brd. 49G Involvement of angiogenesis genes in pathologic response of advanced ovarian carcinoma. (Abstract #10613)


Brd. 49H Tumor characteristics and patient outcomes in ductal compared with lobular carcinoma. (Abstract #10614)

S. Nour, M. Mokri, H. Afshin Alavi, S. Shariat Torbaghan, M. Atri, K. Visvanathan

Brd. 50A Substratification of 70-gene high-risk breast cancers with a validated 80-gene molecular subtyping profile. (Abstract #10615)

F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas

Brd. 50B Prognostic significance of immunoglobulin kappa C in node-negative breast cancer is both conserved across and independent from molecular subtypes. (Abstract #10616)

M. Schmidt, I. Petry, D. Boehm, A. Lebrecht, H. Koelbl, M. Gehrmann, J. G. Hengstler

Brd. 50C C-src: A potential target for the treatment of triple-negative breast cancer. (Abstract #10617)


Brd. 50D Cancers involving the lung mediate human marrow cell phenotype change. (Abstract #10618)

P. J. Quesenberry, J. Aliotta, M. Del Tatro, M. Dooner, G. A. Colvin

Brd. 50E Metabotropic glutamate receptor-1: A new molecular target for the therapy of triple-negative breast cancer. (Abstract #10619)

Brd. 50F Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study. (Abstract #10620)

Brd. 50G Triple-negative breast cancers: Biomarkers and outcomes. (Abstract #10621)

Brd. 50H Effect of matrix metalloproteinase-2 on the ability of human dendritic cells to prime inflammatory T_h2 cells via an IL-12 and OX40L dependent pathway. (Abstract #10622)
E. Godefroy

Brd. 51A Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC. (Abstract #10623)
E. Sanmartin, E. Jantus, A. Blasco, R. Sirera, C. Caballero, S. Gallach, R. M. Bremnes, N. del Pozo, A. Berrocal, C. Camps

Brd. 51B Use of quantum dots-based immunofluorescence nanotechnology for quantitative HER2 and ER detection in breast cancer tissue array to identify correlations in HER2-overexpressed and ER-positive breast cancer. (Abstract #10624)
C. Chen, Y. Li, J. Peng, H. S. Xia, Y. P. Gong, D. W. Pang

Brd. 51C Effect of calcyclin-binding protein on proliferation and tumorigenicity of pancreatic cancer. (Abstract #10625)
X. Chen

Brd. 51D Toll-like receptor (TLR) 7 and TLR8 expression in CD133+ cells in colorectal cancer and role for inflammation-induced TLRs in tumorigenesis and tumor progression. (Abstract #10626)
M. Gasser, M. Grimm, M. Kim, A. Rosenwald, C. T. Germer, A. Waaga-Gasser

Brd. 51E Detection of aberrant SHP-1 promoter methylation, an implication in advanced non-small cell lung cancer. (Abstract #10627)
C. Vinayanuwaitikun, V. Sriuranpong, A. Mutirangura

Brd. 51F Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells. (Abstract #10628)
C. Grandclement, R. Bedel, B. Kantelip, A. Bouard, V. Mougey, M. Klagsbrun, C. Ferrand, P. Tiberghien, X. B. Pivot, C. Borg

Brd. 51G EMMPRIN up-regulates VEGFR-2 through HIF-2alpha mediated mechanism: Consequences on angiogenesis and tumor progression. (Abstract #10629)
F. Bougatef, S. Menashi, C. Quemener, B. Naimi, M. Podgorniak, C. Dosquet, F. M. Calvo, C. Lebbé, S. Mourah

Brd. 51H Evaluation of the combined expression of chemokine SDF-1α and its receptor CXCR4 as a marker for prognosis in gastric cancer. (Abstract #10630)

Brd. 52A Evaluation of CYP24A1 mRNA expression as a prognostic marker and predictor of calcitriol activity in lung adenocarcinoma. (Abstract #10631)

Brd. 52B Integrated genomics-based discovery of new oncoproteins as a biomarker and a molecular target for lung cancer. (Abstract #10632)
Y. Daigo, A. Takano, Y. Nakamura

Brd. 52C Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens. (Abstract #10633)
Brd. 52D DNA repair biomarker alterations in breast cancer relevant to adjuvant chemotherapy treatment decisions. (Abstract #10634)
K. M. Sprott, X. Wang, W. Pierceall, J. Kutok, T. Heikkinen, P. Heikkila, J. Bartek, D. T. Weaver, C. Blomqvist, H. Nevanlinna

Brd. 52E MicroRNAs as a potential prognostic factor in gastric cancer. (Abstract #10635)

Brd. 52F Use of immunohistochemical profiling of node-negative breast carcinomas for prediction of metastatic risk. (Abstract #10636)

Brd. 52G Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization. (Abstract #10637)

Brd. 52H Circulating tumor cells: Multimarker gene profile for tailoring chemotherapeutical response in adeno carcinomas. (Abstract #10638)
N. Fersis, I. Kubisch, D. Ernst, A. de Albuquerque, S. Kaul, G. Stamminger, U. Stoelzel, A. Teubner

Brd. 53A MMP-7 serum levels as predictor or prognostic of cetuximab benefit in the treatment of advanced colorectal cancer: Results from a HCB-05 prospective trial. (Abstract #10639)

Brd. 53B HIF-1α and EGFR as prognostic factors for therapy response and 1-year locoregional recurrence not for distant metastasis and 2-year OS in unresectable stage IIIA NSCLC treated with combined chemoradiotherapy. (Abstract #10640)
Y. Yang, J. Yu, L. Xing, X. Sun, M. Hu, D. Mu, A. Han

Brd. 53F Correlations of mRNA expression levels of genes in the targeted pathways and Kras mutation status in patients with colorectal cancer. (Abstract #10641)
D. Yang, W. Zhang, T. Winder, P. O. Bohanes, Y. Ning, K. D. Danenberg, A. B. El-Khoueiry, P. M. Wilson, M. J. Labonte, H. Lenz

Brd. 53G Prediction of survival in early-stage non-small cell lung cancer based on kinase activity profiles. (Abstract #10642)
R. Ruijtenbeek, V. Thijsen, R. van Suylen, L. Houkes, R. de Wijn, R. Hilhorst, A. C. Dingemans

Brd. 53H Analysis of the prognostic role of regulatory T-lymphocyte-associated marker expression in resectable NSCLC. (Abstract #10643)
M. Usó, R. Sirera, A. Blasco, E. Jantus, E. Palomares, C. Caballero, R. M. Brennes, J. Galbis, R. Guijarro, C. Camps

Brd. 54A Role of antiapoptotic STAT3 and BCL-2 signaling in promoting lung tumor cells to survive against combined MET-/EGFR-targeted inhibitors. (Abstract #10644)

Brd. 54B Pregnancy-associated breast cancer: Characterization and potential chemoprevention with anti-inflammatory treatment. (Abstract #10645)

Brd. 54F Correlation of PITX2 gene expression and invasive potential of breast cancer cells. (Abstract #10646)
R. Aft, S. Pillai, N. Dasgupta, T. Fleming, M. Watson

Brd. 54G Correlation of the Oncotype DX recurrence score with a composite index comprised of ER, PR, HER2, and breast tumor grade. (Abstract #10647)
J. Geradts, S. M. Bean, R. C. Bentley, W. Barry
8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Breast Cancer—Metastatic
Display Time: 8:00 AM - 12:00 PM
Display Location: E450b
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E Hall D1
CME credit: 1
Track(s): Breast Cancer

Anne F. Schott, MD—Co-Chair
University of Michigan
Hope S. Rugo, MD—Co-Chair
University of California, San Francisco

Discussion
12:00 PM  David A. Cameron, MD (Abstracts #1012–1016)
Edinburgh University

Discussion
12:15 PM  Lisa A. Carey, MD (Abstracts #1017–1021, 1031)
University of North Carolina at Chapel Hill

Discussion
12:30 PM  Catherine H. Van Poznak, MD (Abstracts #1022–1026)
University of Michigan

Discussion
12:45 PM  Nancy U. Lin, MD (Abstracts #1027–1030)
Dana-Farber Cancer Institute

Brd. 1  A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). (Abstract #1012)
K. Miller, L. Gianni, F. Andre, V. Dieras, R. L. Mahtani, N. Harbeck, J. E. Huang, T. Shih, Y. Choi, H. A. Burris III

Brd. 2  Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. (Abstract #1013^)

Brd. 3  Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. (Abstract #1014)

Brd. 4  Correlation of cyclin D1, A870G, polymorphism, and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine. (Abstract #1015)
M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, R. D. Ladner, T. Winder, P. O. Bohanes, Y. Ning, H. Lenz

Brd. 5  Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. (Abstract #1016)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. (Abstract #1018)

A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. (Abstract #1019)

Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients. (Abstract #1020)
C. Seynaeve, A. Jager, M. Hooning, C. H. Van Deurzen, M. Bontenbal, J. Blom, M. Collee, A. Ouweland van den, M. Kriege

Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). (Abstract #1021)

A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capcitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study. (Abstract #1022)

Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review. (Abstract #1023)

Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial. (Abstract #1024)
A. Stopeck, L. Fallowfield, D. Patrick, C. S. Cleeland, R. H. De Boer, G. G. Steger, Y. Qian, Q. Jiang, R. D. Dansey, K. Chung

Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial. (Abstract #1025)
L. Fallowfield, D. Patrick, J. Body, A. Lipton, K. S. Tonkin, Y. Qian, Q. Jiang, R. D. Dansey, K. Chung

Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study (NIS). (Abstract #1026)
I. J. Diel, T. Hesse, C. A. Lerchenmuller, M. Schmidt

The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases. (Abstract #1027)

A graded prognostic assessment (GPA) for women with breast cancer and brain metastases. (Abstract #1028)

Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. (Abstract #1029)
A. Niwinska, M. Murawska, K. Pogoda
Brd. 19  Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. (Abstract #1030)

Brd. 20  Male breast cancer in Veterans Affair population: Retrospective analysis of VACCR database. (Abstract #1031)
Saturday, June 5, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Central Nervous System Tumors
Display Time: 8:00 AM - 12:00 PM
Display Location: S103
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: S100b
CME credit: 1
Track(s): Central Nervous System Tumors

David Peereboom, MD—Co-Chair
Cleveland Clinic
Deric M. Park, MD—Co-Chair
University of Pittsburgh Cancer Institute

Discussion
12:00 PM  John L. Villano, MD, PhD (Abstracts #2009–2012)
The University of Chicago

Discussion
12:15 PM  Martin Kelly Nicholas, MD, PhD (Abstracts #2013–2017)
The University of Chicago

Discussion
12:25 PM  Michael Prados, MD (Abstracts #2018–2023)
University of California, San Francisco

Discussion
12:40 PM  Kurt A. Jaeckle, MD (Abstracts #2024–2029)
Mayo Clinic Florida

Discussion
12:50 PM  Eric L. Chang, MD (Abstracts #2030–2032)
University of Texas M. D. Anderson Cancer Center

Brd. 1  ANG1005: Results of a phase I study in patients with recurrent malignant glioma. (Abstract #2009)

Brd. 2  Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase Ia study. (Abstract #2010)
K. Fink, T. Mikkelsen, L. B. Nabors, P. Ravin, S. R. Plotkin, D. Schiff, C. Hicking, M. Picard, D. A. Reardon

Brd. 3  Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). (Abstract #2011)
D. Schiff, D. A. Reardon, S. Kesari, T. Mikkelsen, J. F. De Groot, L. Fichtel, T. E. Coyle, E. Wong, C. Eaton, B. Silver

Brd. 4  Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. (Abstract #2012)

Brd. 5  Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS Consortium study. (Abstract #2013)
S. A. Grossman, X. Ye, G. J. Lesser, A. E. Sloan, C. Carson, S. Piantadosi

Brd. 6  Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). (Abstract #2014)
Brd. 7  The efficacy of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma: Multicenter study. (Abstract #2015)

Brd. 8  Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D. (Abstract #2016)

Brd. 9  Testosterone levels in men undergoing treatment for malignant gliomas. (Abstract #2017)
M. Holdhoff, X. Ye, L. Blair, S. A. Grossman, J. O. Blakeley

Brd. 10 NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. (Abstract #2018)

Brd. 11 Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas. (Abstract #2019)
S. S. Ong, V. K. Puduvalli

Brd. 12 Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy. (Abstract #2020)

Brd. 13 Radiographic patterns of relapse in glioblastoma. (Abstract #2021)
M. C. Chamberlain

Brd. 14 Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? (Abstract #2022)
E. Franceschi, A. A. Brandes, A. Tosoni, A. Bacci, L. Morandi, F. Spagnolli, R. Degli Esposti, S. Bartolini, R. Poggi, M. Ermani

Brd. 15 Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). (Abstract #2023)
J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, H. S. Friedman

Brd. 16 Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab. (Abstract #2024)

Brd. 17 Deletion of NFKBIA in malignant gliomas. (Abstract #2025)

Brd. 18 Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme. (Abstract #2026)
C. Heidemans-Hazelaar, A. Y. Verbeek, H. M. Oosterkamp Sr., B. Van der Kallen, C. J. Vecht

Brd. 19 Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study. (Abstract #2027)

Brd. 20 CD133 expression in glioblastoma recurring after radiation therapy. (Abstract #2028)
T. Cenci, R. Pallini, M. Martini, L. R. Vitiani, N. Montano, F. Pierconti, R. De Maria, L. Larocca
**Saturday, June 5, 2010**

**Brd. 21** Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendrogial tumors: A translational study of the EORTC Brain Tumor Group. (Abstract #2029)

M. Preusser, R. Hoeftberger, A. Woehrer, M. Kouwenhoven, M. Kros, A. Idbaih, A. A. Brandes, H. Heinzl, T. Gorlia, M. J. Van Den Bent

**Brd. 22** Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases. (Abstract #2030)

A. Thiagaragan, Y. Yamada, D. M. Lovelock, B. W. Cox, M. J. Zelefsky, M. Bilsky

**Brd. 23** Chemotherapy (CT) alone for epidural spinal cord compression (ESCC) from germ cell tumors (GCT). (Abstract #2031)

C. Grommes, G. J. Bosl, L. M. DeAngelis

**Brd. 24** Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST). (Abstract #2032)

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy
Display Time: 8:00 AM - 12:00 PM
Display Location: E450a
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E354b
CME credit: 1
Track(s): Developmental Therapeutics

Razelle Kurzrock, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Lesley Seymour, MD, PhD—Co-Chair
Queen’s University

Discussion
12:00 PM  David J. Stewart, MD (Abstracts #2515–2520)
          University of Texas M. D. Anderson Cancer Center

Discussion
12:15 PM  Ravi Salgia, MD, PhD (Abstracts #2521–2525)
          The University of Chicago

Discussion
12:30 PM  Lesley Seymour, MD, PhD (Abstracts #2526–2531)
          Queen’s University

Discussion
12:45 PM  Razelle Kurzrock, MD (Abstracts #2532–2538)
          University of Texas M. D. Anderson Cancer Center

Brd. 1  Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1? (Abstract #2515)
          S. Postel-Vinay, C. A. Gomez-Roca, L. R. Molife, B. Anghan, J. Soria, S. B. Kaye, X. Paoletti

Brd. 2  Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience. (Abstract #2516)

Brd. 3  An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi). (Abstract #2517)

Brd. 4  Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved? (Abstract #2518)
          D. Olmos, on behalf of the European Drug Development Network (EDDN)

Brd. 5  Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience. (Abstract #2519)
          S. M. Alam, R. S. Fehrmann, D. Olmos, K. Shah, M. Puglisi, D. Sarker, A. Brunetto, S. Postel-Vinay, R. D. Baird, L. R. Molife

Brd. 6  VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints. (Abstract #2520)
          M. Sharma, T. Karrison, M. L. Maitland, W. M. Stadler, M. J. Ratain

Brd. 7  The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population). (Abstract #2521)
          M. Jäger, A. Schoberth, M. Hennig, A. Burges, M. Heiss, P. Wimberger, B. Schmalfeldt, H. Lindhofer
Br. 8 Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC). (Abstract #2522)

Br. 9 Radioimmunotherapy (RIT) with $^{131}$I-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial. (Abstract #2523)
G. Del Conte, P. A. Erba, A. Fasolo, C. Chiesa, C. Grana, H. Menssen, D. Neri, G. Mariani, E. Bombardieri, L. Gianni

Br. 10 First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. (Abstract #2524)

Br. 11 Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. (Abstract #2525)

Br. 12 Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies. (Abstract #2526)

Br. 13 Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium trial. (Abstract #2527)

Br. 14 AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. (Abstract #2528)

Br. 15 A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. (Abstract #2529)

Br. 16 Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. (Abstract #2530)

Br. 17 Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. (Abstract #2531)
T. Evans, C. R. Lindsay, E. Chan, B. Tait, S. A. Michael, S. Day, A. W. Stephens, A. Franke, S. Poondru, I. Puzanov

Br. 18 Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy. (Abstract #2532)
J. L. Rubenstein, C. Kadoch, V. S. Wong, W. Hyun, C. Lowell

Br. 19 A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #2533)
Brd. 20  A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). (Abstract #2534)

Brd. 21  A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies. (Abstract #2535)
S. Nallapareddy, S. G. Eckhardt, C. L. O’Bryant, S. Eppers, S. Diab, M. A. Kane, C. D. Weekes, J. L. Spratlin, W. A. Messersmith, S. Leong

Brd. 22  A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors. (Abstract #2536)

Brd. 23  Targeted cancer therapies: FDA approval overview. (Abstract #2537)
P. Cortazar, P. Keegan, R. L. Justice, J. R. Johnson, R. Pazdur

Brd. 24  Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors. (Abstract #2538)
Saturday, June 5, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Health Services Research
Display Time: 8:00 AM - 12:00 PM
Display Location: S403
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: S504
CME credit: 1
Track(s): Health Services Research

Elissa Ozanne, PhD—Co-Chair
Massachusetts General Hospital

Benjamin D. Smith, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center

Discussion
12:00 PM Elena B. Elkin, PhD (Abstracts #6009–6015)
Memorial Sloan-Kettering Cancer Center
*Role of Cost and Comparative Effectiveness Research in Guiding Health Policy*

Discussion
12:15 PM Jennifer Malin, MD (Abstracts #6016–6020)
Veterans Affairs Greater Los Angeles
*Oncology Guidelines: Adherence and Appraisal*

Discussion
12:30 PM Stephen B. Edge, MD (Abstracts #6021–6027)
Roswell Park Cancer Institute
*Patterns of Cancer Care*

Discussion
12:45 PM Benjamin Djulbegovic, MD, PhD (Abstracts #6028–6033)
University of South Florida
*Clinical Trials and Decision Making*

Brd. 1 Burden of illness estimates of metastatic breast cancer (MBC) in the United States. (Abstract #6009)
S. Sorenson, A. Benedict, D. A. Yardley, M. Martin, K. B. Knopf, F. Pan, J. Goh, C. Giorgetti, C. Chen

Brd. 2 Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing? (Abstract #6010)
T. Younis, D. Rayson, C. Skedgel

Brd. 3 Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers. (Abstract #6011)

Brd. 4 Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis. (Abstract #6012)
J. H. Hayes, D. A. Ollendorf, M. J. Barry, S. D. Pearson, P. M. McMahon

Brd. 5 Year one evaluation of regional pay for quality (P4Q) oncology program. (Abstract #6013)
J. A. Scott, W. Wong, T. Olson, B. V. Fortner

Brd. 6 Conflicts of interest in economic analyses presented at the American Society of Clinical Oncology Annual Meeting. (Abstract #6014)
S. Jang, Y. Chae, N. S. Majhail

Brd. 7 Does increasing insurance improve outcomes for U.S. cancer patients? (Abstract #6015)
J. K. Smith, J. E. Carroll, S. Ng, S. A. Shah, T. P. McDade, J. F. Tseng
Brd. 8  Surgeon influence on patient appraisal of ASCO breast cancer quality indicators.  (Abstract #6016)
S. T. Hawley, A. S. Hamilton, J. Graff, S. J. Katz

Brd. 9  The impact of audit and feedback on nodal harvest in colorectal cancer (CRC).  (Abstract #6017)
G. A. Porter, R. Urquhart, J. Bu, P. Johnson, E. Grunfeld

Brd. 10 Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida Initiative for Quality Cancer Care (FIQCC).  (Abstract #6018)
T. Tanvetyanon, M. Corman, W. J. Fulp, J. Lee, P. B. Jacobsen, FIQCC Consortium Members

Brd. 11 Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence.  (Abstract #6019)
N. N. Massanweh, J. O. Park, R. S. Yeung, J. Bruix, R. B. Etzioni, R. G. Symons, L. Baldwin, D. R. Flum

Brd. 12 Scientific evidence underlying National Comprehensive Cancer Network Clinical Practice Guidelines.  (Abstract #6020)
T. K. Poonacha, R. S. Go

Brd. 13 End-of-life care for elderly patients with advanced lung cancer in the United States and Ontario.  (Abstract #6021)

Brd. 14 Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival.  (Abstract #6022)

Brd. 15 Trends in prostatectomy: Centralization, robotics, and access to care.  (Abstract #6023)
K. B. Stitzenberg, Y. Wong, M. E. Nielsen, R. Uzzo

Brd. 16 PSA surveillance in men with localized prostate cancer.  (Abstract #6024)

Brd. 17 Restoration of medical oncology services at Charity Hospital in New Orleans after Hurricane Katrina: A 2-year experience of the Louisiana State University Health Sciences Center (LSUHSC).  (Abstract #6025)
B. C. Boulmay, R. E. Harmon, T. L. Lin, J. T. Cole

Brd. 18 Appropriateness of cardiovascular (CV) care in cancer survivors (CS).  (Abstract #6026)
W. Y. Cheung, M. L. McBride, R. Levin, S. Setoguchi

Brd. 19 Estimation of the U.S. rate of neutropenic complications for cancer hospital discharges.  (Abstract #6027)
M. Dickson, C. M. Kozma, R. Barron, V. M. Chia, J. C. Legg, J. Malin

Brd. 20 Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs).  (Abstract #6028)
B. Seruga, L. Sterling, L. Wang, I. Tannock

Brd. 21 A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.  (Abstract #6029)
V. C. Tam, I. Tannock, J. Rauw, M. K. Krzyzanowska

Brd. 22 The assessment of cost and other barriers to patient clinical trial participation in the community setting.  (Abstract #6030)
Saturday, June 5, 2010

Brd. 23  Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials. (Abstract #6031)  
B. You, H. K. Gan, G. R. Pond, E. X. Chen

Brd. 24  Influence of nonclinical patient factors on decisions to recommend breast cancer adjuvant chemotherapy. (Abstract #6032)  

Brd. 25  Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC). (Abstract #6033)  
D. Ksienski, S. Gill
9:30 AM - 12:00 PM
SPECIAL SESSION

Opening Session with Presidential Address, NCI Director’s Address, David A. Karnofsky Memorial Award and Lecture, and The ASCO Cancer Foundation Donor Recognition Awards
Location: N Hall B1
CME credit: 1.5
Track(s): Special Session

Daniel D. Van Hoff, MD—Karnofsky Award Recipient
Translational Genomics Research Institute
The Last Twelve Weeks

9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

Germ Cell Tumors in Children, Adolescents, and Young Adults
(M01)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Pediatric Oncology

A. Lindsay Frazier, MD
Dana-Farber Cancer Institute
Saturday, June 5, 2010

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY

Ocular Melanoma (C03)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Melanoma/Skin Cancers

J. William Harbour, MD—Chair
Washington University School of Medicine
Background and Treatment of Primary Ocular Melanoma

James F. Pingpank Jr., MD, FACS
University of Pittsburgh Medical Center
Regional Therapy for Ocular Melanoma

Takami Sato, MD, PhD
Jefferson Medical College
Systemic Therapy for Metastatic Ocular Melanoma

1:00 PM - 2:15 PM
MEET THE PROFESSOR SESSION

Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention
(M02)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Cancer Prevention/Epidemiology; Melanoma/Skin Cancers

Aleksandar Sekulic, MD, PhD
Mayo Clinic
1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Developmental Therapeutics—Experimental Therapeutics
Location: E Hall D2
CME credit: 3
Track(s): Developmental Therapeutics

Michael L. Maitland, MD, PhD—Co-Chair
The University of Chicago
Richard H. Wilson, MD—Co-Chair
Queen's University Belfast

1:00 PM  First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. (Abstract #3006)

1:15 PM  Dual inhibition of IGFR and mTOR pathways. (Abstract #3007)
A. Naing, P. LoRusso, S. Gupta, R. S. Benjamin, E. Rohren, H. X. Chen, L. Doyle, D. A. Berry, H. M. Amin, R. Kurzrock

1:30 PM  A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. (Abstract #3008)

1:45 PM  First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. (Abstract #3009)

Discussion
2:00 PM  Manuel Hidalgo, MD, PhD (Abstracts #3006–3009)
Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III
Drugging the IGF1R/Akt/mTOR Signaling Network

2:15 PM  Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. (Abstract #3010)

2:30 PM  A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. (Abstract #3011)

2:45 PM  Phase I first-in-human study of the centromere-associated protein E (CENP-E) inhibitor GSK923295 in patients with advanced solid tumors (study CPE107602). (Abstract #3012)
Saturday, June 5, 2010

Discussion
3:00 PM  Johann Sebastian De Bono, MD, PhD (Abstracts #3010–3012)
Drug Development Unit, The Royal Marsden NHS Foundation Trust and The
Institute of Cancer Research

Novel Agents and Targets in Mitosis

3:15 PM  Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients
with advanced refractory cancer. (Abstract #3013)
D. S. Mendelson, M. S. Gordon, L. S. Rosen, H. Hurwitz, M. K. Wong, B. J. Adams,
D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh

3:30 PM  A first-in-human phase I study to evaluate the fully human monoclonal
antibody MNRP1685A (anti-NRP1) administered intravenously every three
weeks in patients with advanced solid tumors. (Abstract #3014)
C. D. Weekes, P. Hegde, Y. Xin, R. Yu, H. Xiang, M. Beeram, L. Gore,
R. K. Brachmann, A. Patnaik

Discussion
3:45 PM  To be determined
1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Lymphoma
Location: E354a
CME credit: 3
Track(s): Lymphoma and Plasma Cell Disorders

Kenneth Stuart Cohen, MD—Co-Chair
The University of Chicago
John Leonard, MD—Co-Chair
Weill Cornell Medical College

1:00 PM Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. (Abstract #8004)

1:15 PM Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. (Abstract #8005)
R. Pettengell, N. Schmitz, C. Gisselbrecht, D. Caballero, P. Colombat, E. Conde, B. Metzner, J. A. Walewski, C. Geisler, A. Goldstone, European Group for Blood and Marrow Transplantation

Discussion
1:30 PM Richard I. Fisher, MD (Abstracts #8004–8005)
University of Rochester Medical Center
Role of Maintenance Therapy in Follicular Lymphoma

1:45 PM Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. (Abstract #8006)
F. Fiore, K. Patti, S. Viviani, A. Rossi, F. Di Raimondo, M. Cantonetti, T. Feldman, A. Biggi, S. Barrington, A. Gallamini

2:00 PM Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin’s lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSC). (Abstract #8007)

Discussion
2:15 PM Ralph M. Meyer, MD (Abstracts #8006–8007)
Canadian Cancer Society Clinical Trials Group
Improving Outcomes in Hodgkin Lymphoma

2:30 PM Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial. (Abstract #8008)

2:45 PM Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm). (Abstract #8009)
Saturday, June 5, 2010

Discussion
3:00 PM  Joachim Yahalom, MD (Abstracts #8008–8009)  Memorial Sloan-Kettering Cancer Center  
What Is the Role of Radiation in Large Cell Lymphoma?

3:15 PM  A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. (Abstract #8010)  

3:30 PM  Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study. (Abstract #8011)  

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Melanoma/Skin Cancers
Location: S406 (Vista Room)
CME credit: 3
Track(s): Melanoma/Skin Cancers

Tim Eisen, PhD, FRCP—Co-Chair
University of Cambridge/Cancer Research UK
Thomas Gajewski, MD, PhD—Co-Chair
The University of Chicago

1:00 PM  E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. (Abstract #8504)

1:15 PM  Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. (Abstract #8505)
A. M. Eggermont, S. Suciu, P. Rutkowski, J. Marsden, A. Testori, P. Corrie, S. Aamdal, P. A. Ascierto, P. Patel, A. Spatz, EORTC Melanoma Group

1:30 PM  Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. (Abstract #LBA8506)

Discussion
1:45 PM  Michael S. Sabel, MD, FACS (Abstracts #8504–LBA8506)
University of Michigan

2:00 PM  Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM). (Abstract #8507)

2:15 PM  First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group study (E1602). (Abstract #8508)

2:30 PM  Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. (Abstract #8509)
Saturday, June 5, 2010

Discussion
2:45 PM  Antoni Ribas, MD (Abstracts #8507–8509)
          University of California, Los Angeles

3:00 PM  Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study.
          (Abstract #8510)
          E. Maubec, P. Petrow, P. Duvillard, C. Laouenan, X. Duval, L. Lacroix, M. Bagot,
          S. J. Faivre, F. Mentre, M. Avril

3:15 PM  Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. (Abstract #8511)
          K. T. Flaherty, S. J. Lee, L. M. Schuchter, L. E. Flaherty, J. J. Wright, P. D. Leming,
          J. M. Kirkwood

3:30 PM  A phase III random assignment trial comparing percutaneous hepatic perfusion with melphan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. (Abstract #LBA8512)
          J. F. Pingpank, M. S. Hughes, H. R. Alexander, M. B. Faries, J. S. Zager, R. Royal,
          E. D. Whitman, C. W. Nutting, G. P. Siskin, S. S. Agarwala

Discussion
3:45 PM  Dirk Schadendorf, MD (Abstracts #8510–LBA8512)
          University Hospital Essen
1:15 PM - 2:30 PM
EDUCATION SESSIONS

A Family’s Year with Cancer
Location: S404
CME credit: 1.25
Track(s): Professional Development; Patient and Survivor Care

Lidia Schapira, MD—Chair
Massachusetts General Hospital
The Impact of Cancer on Families

David Treadway, PhD

Kate Treadway, MD
Harvard Medical School

Evolving Standards of Care in Advanced Renal Cell Carcinoma
Location: E Hall D1
CME credit: 1.25
Track(s): Genitourinary Cancer; General Oncology

Primo Lara Jr., MD—Chair
University of California, Davis
Toward Individualizing Therapy in Advanced Renal Cell Cancer

Christopher W. Ryan, MD
Oregon Health & Science University
Systemic Therapies in Advanced Renal Cell Cancer: Current Status

Eric Jonasch, MD
University of Texas M. D. Anderson Cancer Center
Integration of Nephrectomy in Advanced Renal Cell Cancer Management

Future Directions in the Management of Endometrial Cancer
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Gynecologic Cancer

David E. Cohn, MD—Chair
The Ohio State University
Surgically Staging of Endometrial Cancer: The Controversy Continues

Carien Creutzberg, MD, PhD
Leiden University Medical Center
Optimizing Adjuvant Therapy in the Treatment of Early-stage Endometrial Cancer Patients

Gini F. Fleming, MD
The University of Chicago
Incorporating Novel Biologic Therapies into Endometrial Cancer Treatment
Saturday, June 5, 2010

Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All
Location: E353
CME credit: 1.25
Track(s): Practice Management and Information Technology; Clinical Trials

Robin Zon, MD, FACP—Chair
Michiana Hematology-Oncology
Structuring/Marketing a Program for Success

Gary Irvin Cohen, MD
Greater Baltimore Medical Center
The Critical Role of Creating a Research Team

Dee Anna Smith
Sarah Cannon Research Institute
Negotiating a Contract: Knowing Cost to Effectively Budget for Pharma Trials

---

Improving Access to Clinical Trials
Location: S100a
CME credit: 1.25
Track(s): Clinical Trials; Geriatric Oncology

Derek Raghavan, MD, PhD—Chair
Cleveland Clinic
Overcoming Barriers to Access to Cancer Care and Cancer Trial Enrollment in Minority Populations

J. Phillip Kuebler, MD, PhD
Columbus Oncology Associates
Overcoming Barriers to Clinical Trials: Increasing Accrual through Partnership with Community Oncologists

Hyman Bernard Muss, MD
University of North Carolina at Chapel Hill
Overcoming Barriers to Clinical Trial Accrual in the Elderly Population and Patients with Comorbidities
Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions)
Location: E354b
CME credit: 1.25
Track(s): Gastrointestinal (Colorectal) Cancer; General Oncology; Geriatric Oncology; Patient and Survivor Care

This session will offer enhanced audience participation through the use of web and mobile technologies. At any time during the session, attendees can send questions to faculty via text (SMS), e-mail, or Twitter. Floor microphones will also be available.

Howard S. Hochster, MD—Chair
New York University
Management of Oxaliplatin-induced Neurotoxicity

Bruce D. Minsky, MD
The University of Chicago
Managing and Reducing Side Effects of Pelvic Radiation

Mario E. Lacouture, MD
Northwestern University
Dermatologic Toxicities of Targeted Therapy in Colorectal Cancer

New Treatments for Sarcoma in Children, Adolescents, and Young Adults
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Sarcoma

Stephen X. Skapek, MD—Chair
The University of Chicago
Treatment of Childhood, Adolescent, and Young Adult Sarcoma: Where Do We Go from Here?

R. Lor Randall, MD, FACS
University of Utah
Optimal Approaches for Achieving Local Control in Children, Adolescents, and Young Adults with Sarcoma

Douglas S. Hawkins, MD
Seattle Children’s Hospital and Regional Medical Center
Optimal Strategies for Controlling Metastatic Disease in Children, Adolescents, and Young Adults with Sarcoma

The Global Burden of Cancer: The Worldwide Challenge of Cancer Control
Location: S100b
CME credit: 1.25
Track(s): Cancer Prevention/Epidemiology; International

Max D. Parkin, MD—Chair
Cancer Research UK
Causes of Preventable Cancer in the World: From Tobacco to Tanning Boxes (The Expanding List of IARC Class I Carcinogens)

Prabhat Jha, MD, DPhil
University of Toronto
Tobacco as a Cause of Worldwide Cancer Mortality

Mei Hwei Chang, MD
National Taiwan University Hospital
Prevention of Hepatocellular Carcinoma via Universal Vaccination against Hepatitis B
Saturday, June 5, 2010

1:15 PM - 2:30 PM
CLINICAL PROBLEMS IN ONCOLOGY

Improving Outcomes for Patients with Locally Advanced Lung Cancer (C04)-
TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Lung Cancer

Julie R. Brahmer, MD—Chair
The Johns Hopkins University
Systemic Therapy for Locally Advanced NSCLC including the Role of Treatment Post
Chemoradiotherapy

Douglas E. Wood, MD
University of Washington
Surgical Management of Locally Advanced Lung Cancer

Jeffrey Bogart, MD
SUNY Upstate Medical University
Stage III NSCLC: Does Better Technology Equal Better Treatment?
1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life
Location: N Hall B1
CME credit: 1.5
Track(s): Gastrointestinal (Noncolorectal) Cancer

David Linehan, MD—Co-Chair
Washington University School of Medicine
Colin D. Weekes, MD, PhD—Co-Chair
University of Colorado Cancer Center

1:15 PM  Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). (Abstract #4000)
P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, S. Patyna, D. Lu, R. C. Chao, E. Raymond

1:30 PM  A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). (Abstract #4001)
A. T. Phan, J. C. Yao, D. R. Fogelman, K. R. Hess, C. S. Ng, S. A. Bullock, P. Malinowski, E. Regan, M. Kulke

1:45 PM  Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. (Abstract #4002)

Discussion
2:00 PM  Kjell E. Oberg, MD, PhD (Abstracts #4000–4002)
Uppsala University

2:15 PM  Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. (Abstract #4003)

Discussion
2:30 PM  Ian Chau, MD (Abstract #4003)
Royal Marsden Hospital
Saturday, June 5, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Genitourinary (Nonprostate) Cancer
Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E Hall D2
CME credit: 1
Track(s): Genitourinary Cancer

Leonard Joseph Appleman, MD, PhD—Co-Chair
University of Pittsburgh Medical Center
George Philips, MD, MBBS, MPH—Co-Chair
University of Vermont

Discussion

5:00 PM  Daniel J. George, MD (Abstracts #4520–4526)
Duke University Medical Center
*Prediction and Prognosis in Renal Cell Carcinoma*

Discussion

5:15 PM  Ulka N. Vaishampayan, MD (Abstracts #4527–4530)
Wayne State University
*Trial Design and Drug Development in Renal Cell Carcinoma*

Discussion

5:25 PM  Mary Gospodarowicz, MD (Abstracts #4531–4538)
Princess Margaret Hospital
*Germ Cell Tumors: Is Radiation Under- or Overused?*

Discussion

5:40 PM  Matthew I. Milowsky, MD (Abstracts #4539–4541)
Memorial Sloan-Kettering Cancer Center
*Is There a Role for Targeted Therapy in Advanced Urothelial Cancer?*

Discussion

5:50 PM  Seth P. Lerner, MD (Abstracts #4542–4543)
Baylor College of Medicine
*New Therapies in Non-muscle-invasive Urothelial Cancer*

Brd. 1  Association of germline genetic markers in *IL8, HIF1A, VEGFA, and VEGFR2* with treatment response to pazopanib in renal cell carcinoma. (Abstract #4520)
H. A. Ball, C. Xu, C. N. Sternberg, N. Bing, D. Rajagopalan, C. F. Spraggs, V. E. Mooser, R. G. Amado, L. R. Cardon, L. Pandite

Brd. 2  Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib. (Abstract #4521)
K. Eechoute, A. A. van der Veldt, H. Gelderblom, J. A. Gietema, H. Guchelaar, N. Van Erp, E. Boven, J. B. Haanen, R. Mathijssen, J. A. Wessels

Brd. 3  Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. (Abstract #4522)

Brd. 4  A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study. (Abstract #4523)
Brd. 5 The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. (Abstract #4524)

Brd. 6 Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4525)
S. Halabi, B. I. Rini, W. M. Stadler, E. J. Small

Brd. 7 Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma. (Abstract #4526)

Brd. 8 Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. (Abstract #4527)

Brd. 9 A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). (Abstract #4528^)

Brd. 10 Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). (Abstract #4529)

Brd. 12 Results from SWENOTECA V: A population-based protocol for seminomatous testicular cancer. (Abstract #4531)

Brd. 13 Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group study. (Abstract #4532)

Brd. 14 Cardiovascular risk in long-term testicular cancer survivors. (Abstract #4533)

Brd. 15 Total treatment burden in stage I seminoma patients. (Abstract #4534)

Brd. 16 Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. (Abstract #4535)
P. W. Chung, G. Daugaard, S. Tyldesley, T. Panzarella, C. K. Kollmannsberger, M. K. Gospodarowicz, P. R. Warde

Brd. 17 Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies. (Abstract #4536)

Brd. 18 Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy. (Abstract #4537)
D. Lewinshtein, C. R. Porter

Brd. 19 Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. (Abstract #4538)
A. Horwich, S. D. Fossa, S. P. Stenning, J. M. Bliss, E. Hall
Saturday, June 5, 2010

Brd. 20  Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. (Abstract #4539)

Brd. 21  First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. (Abstract #4540)

Brd. 22  Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). (Abstract #4541)

Brd. 23  Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. (Abstract #4542)
L. J. Barlow, M. A. Laudano, M. J. Mann, M. Desai, D. P. Petrylak, M. C. Benson, J. M. McKiernan

Brd. 24  Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial. (Abstract #4543)
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Tumor Biology
Display Time: 2:00 PM - 6:00 PM
Display Location: S103
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S100a
CME credit: 1
Track(s): Tumor Biology

Charles D. Lopez, MD, PhD—Co-Chair
Oregon Health & Science University

Vered Stearns, MD—Co-Chair
The Johns Hopkins University

Discussion
5:00 PM Richard Simon, DSc (Abstracts #10513–10517)
National Institutes of Health

Discussion
5:15 PM Gerold Bepler, MD, PhD (Abstracts #10518–10521)
H. Lee Moffitt Cancer Center & Research Institute

Discussion
5:30 PM David Paul Carbone, MD, PhD (Abstracts #10522–10530)
Vanderbilt University Medical Center

Discussion
5:45 PM Robert Arthur Kratzke, MD (Abstracts #10531–10537)
University of Minnesota

Brd. 1 Utilization of genomic signatures for chemotherapy response in prospective clinical studies. (Abstract #10513)

Brd. 2 Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. (Abstract #10514)

Brd. 3 Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy. (Abstract #10515)
M. M. Magbanua, S. E. Davis, J. Crothers, E. Sosa, C. M. Haqq, L. van’t Veer, L. Esserman

Brd. 4 Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay. (Abstract #10516)

Brd. 5 Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC. (Abstract #10517)
T. John, D. Kohler, N. Yanagawa, M. Pintilie, M. Li, D. Panchal, N. Pham, S. Der, F. A. Shepherd, M. S. Tsao

Brd. 6 Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis. (Abstract #10518)
Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. (Abstract #10519)

Value of a serum proteomic signature in the non-invasive evaluation of lung nodules. (Abstract #10520)

Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules. (Abstract #10521)

Association of TS and ERCC1 mRNA expressions with overall survival in patients enrolled in CONFIRM 1 and 2. (Abstract #10522)

Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer. (Abstract #10523)

Association of GRP78 gene polymorphism rs391957 with tumor recurrence in gastric and colon cancer patients. (Abstract #10524)

Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC). (Abstract #10525)
S. Jiralerspong, S. Liu, S. L. Palla, G. B. Mills, M. Hung, G. N. Hortobagyi, A. M. Gonzalez-Angulo

MicroRNA deregulation in peripheral nerve sheath tumor progression. (Abstract #10526)

Chemobiological screening for identification of molecular targets for thymic epithelial cancers. (Abstract #10527)
O. D. Cang, Y. Polar, Y. Liu, M. Ivan, K. Fearn, J. Ding, S. S. Badve, G. W. Sledge, P. J. Loehr, A. A. Cardoso

Molecular classification of non-small cell lung cancer using a four protein quantitative assay. (Abstract #10528)

KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy. (Abstract #10529)

Prognostic implications of mutations in the epidermal growth factor receptor (EGFR) and KRAS among never-smokers with adenocarcinoma of the lung. (Abstract #10530)

J. Kim, E. S. Kim, D. Liu, J. Lee, L. Solis, P. Yuan, C. Behrens, W. K. Hong, I. I. Wistuba, H. Lee
Brd. 20  Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer. (Abstract #10532)

Brd. 21  ALK gene rearrangements in unselected Caucasians with non-small cell lung carcinoma (NSCLC). (Abstract #10533)

Brd. 22  A Japanese nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004. (Abstract #10534)

Brd. 23  A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue. (Abstract #10535)

Brd. 24  Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis. (Abstract #10536)
V. Rimkunas, K. Crosby, M. Kelly, M. Silver, K. Hincman, R. Polakiewicz, D. Li, X. Zhou, H. Haack

Brd. 25  ALK chromosomal alterations in colon cancer patients. (Abstract #10537)
General Poster Session

Breast Cancer—Local-Regional and Adjuvant Therapy

Location: S Hall A2
Tracks(s): Breast Cancer

Brd. 1A  
DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients. (Abstract #536)
R. C. Coombes, J. M. Bliss, M. Espie, F. Erdkamp, J. J. Wals, A. Tres, R. E. Coleman, J. Reise, D. Cooper, P. Hupperets

Brd. 1B  
Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC). (Abstract #537)

Brd. 1C  
An epidemiologic study of the effect of adjuvant radiotherapy on 2D tumor characteristics and prognosis of contralateral breast cancer (CBC). (Abstract #538)
M. E. Sandberg, M. Hartman, S. Eloranta, A. Ploner, P. Hall, K. Czene

Brd. 1D  
The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive patients. (Abstract #539)
R. Yerushalmi, R. Woods, K. A. Gelmon, C. Speers, P. Ravdin

Brd. 1E  
Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin +/- trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC). (Abstract #540)
G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender

Brd. 1F  
Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial. (Abstract #541)

Brd. 1G  
Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. (Abstract #542)

Brd. 1H  
Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. (Abstract #543)
F. Marme, W. Werft, A. Benner, B. Burwinkel, H. Sinn, C. Sohn, P. Lichter, M. Hahn, P. Altevogt, A. Schnieweiss

Brd. 2A  
Prospective randomized trial comparing postoperative adjuvant concurrent versus sequential hormonal and different radiation fractionation schedule in breast cancer patients. (Abstract #544)
M. S. Barsoum, M. M. El Mongi, E. M. Khalil, H. E. Eisa, I. M. Hamed, G. A. Attia

Brd. 2B  
Predictive value of a gene signature evaluated in multiple chemotherapy regimens for breast cancer. (Abstract #545)
M. Fournier, K. Martin
Brd. 2C Breast conservation (BCT) for DCIS: A prospective study of how MRI impacts management (MGMT). (Abstract #546)

Brd. 2D Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study. (Abstract #547)
V. Georgoulis, V. Bozionelou, S. Agelaki, M. Perraki, S. Apostolaki, G. Kallergi, K. Kalbakis, N. E. Androulakis, A. Xyrafas, D. Mavroudis

Brd. 2E The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. (Abstract #548)
R. H. Alvarez, G. Bianchini, L. Hsu, M. Cristofanilli, F. J. Esteva, L. Pusztai, A. Buzdar, G. N. Hortobagyi, V. Valero

Brd. 2F Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. (Abstract #549)

Brd. 2G Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant trials. (Abstract #550)
F. Andre, M. Delorenzi, A. Goubar, M. Lacroix, C. Desmedt, V. Scott, C. Sotiriou, M. Mathieu, S. Delaloge, L. Pusztai

Brd. 2H Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (Abstract #551)

Brd. 3A Final analysis of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306). (Abstract #552)

Brd. 3B Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG): A new technology for sentinel node navigation. (Abstract #553)
M. Nakagawa, M. Morimoto, T. Nagao, Y. Nakagawa Sr., A. Tangoku

Brd. 3C Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer patients. (Abstract #554)
C. Thomssen, E. J. Kantelhardt, K. Plueckhahn, C. Veyret, D. Augustin, V. Hanf, D. Paepke, C. Meisner, G. Von Minckwitz, N. Harbeck, on behalf of the NNBC-3 Europe Study Group

Brd. 3D The role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity. (Abstract #555)

Brd. 3E Predictive response factors (PRF) in an open, nonrandomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable HER2-negative breast cancer (BC). (Abstract #556)
P. Sanchez Rovira, J. De la Haba, M. Fernández-Navarro, M. Seguí, A. Llombart-Cussac, A. Anton, E. Alba, E. Aranda
Saturday, June 5, 2010

Brd. 3F  Comparison of 21-gene recurrence score (RS) in African-American (AA) and Caucasian (C) patients with hormone receptor (HR)-positive early-stage breast cancer. (Abstract #557)

Brd. 3G  Effect of dose-dependent interaction between tamoxifen and antidepressants on patient adherence in breast cancer patients. (Abstract #558)
F. W. Frueh, J. Tinnirello, M. Khalid, N. J. Markward, M. Subar, R. E. Aubert, R. S. Epstein

Brd. 3H  BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)—Cardiac safety analysis. (Abstract #559)
D. Rayson, T. Suter, S. van der Vegt, A. Lluch, J. Van Den Bosch, G. Lopez-Vivanco, A. M. Van Gent, H. Wildiers, L. Provencher, D. Richel

Brd. 4A  Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. (Abstract #560)

Brd. 4B  Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade. (Abstract #561)
M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van ’t Veer

Brd. 4C  Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14. (Abstract #562)

Brd. 4D  Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. (Abstract #563)
H. Kolesnikov-Gauthier, L. Vanlemmens, M. Baranzelli, P. Carpentier, S. Habbas, P. Vennin, V. Servent, C. Fournier, J. Bonneterre

Brd. 4E  Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC). (Abstract #564)
M. Cotto, J. Toro, V. Carlo, R. Vaquer, O. A. Pavia, M. Bruno, E. Rivera, M. M. Echenique, V. Negron, F. Cabanillas

Brd. 4F  Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E. (Abstract #565)

Brd. 4G  Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy. (Abstract #566)

Brd. 4H  Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC). (Abstract #567)
Brd. 5A Prospective study of wide local excision and endocrine therapy without radiotherapy (WORTH) for node-negative, estrogen receptor-positive early breast cancer with negative histologic margins (WORTH trial, Protocol 1): Five-year interim results. (Abstract #568)  

Brd. 5B Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. (Abstract #569)  

Brd. 5C Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial. (Abstract #570)  
M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, on behalf of the TARGIT Trialists’ Group

Brd. 5D Cardiovascular safety of adjuvant bevacizumab for breast cancer. (Abstract #571)  

Brd. 5E Association of gene copy number alterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathologic tumor subtypes in early-stage breast cancer. (Abstract #572)  

Brd. 5F Primary endocrine therapy for early operable primary breast cancer in elderly women: Survival analysis of a large series from a single institution. (Abstract #573)  
W. Al-Khyatt, B. M. Syed, D. A. Morgan, A. R. Green, I. O. Ellis, K. Cheung

Brd. 5G Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care? (Abstract #574)  

Brd. 5H Chemotherapy (CT) versus tamoxifen (T) versus chemotherapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial. (Abstract #575)  
F. Boccardo, P. Guglielmini, A. Marasco, A. Rubagotti

Brd. 6A Randomized phase II trial of preoperative lapatinib versus placebo in HER2-positive breast cancer. (Abstract #576)  

Brd. 6B Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ. (Abstract #577)  
R. S. Punglia, J. S. Wong, H. J. Burstein, J. C. Weeks

Brd. 6C Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer. (Abstract #578)  
D. L. Hershman, T. H. Shao, L. Kushi, D. Buono, W. Tsai, L. Fehrenbacher, A. I. Neugut

Brd. 6D Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC). (Abstract #579)  
Brd. 6E Outcomes differences in tumors < 1 cm by age and breast cancer subtype. (Abstract #580)

Brd. 6F Adjuvant chemotherapy and lymph node irradiation in breast cancer patients with axillary lymph node micrometastases or isolated tumor cells. (Abstract #581)

Brd. 6G Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS+RT). (Abstract #582)
J. Goswami, S. Goyal, H. Wu, M. S. Moran, B. G. Haffty

Brd. 6H Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a and T1b breast cancers. (Abstract #583)
H. K. Chew, M. Brown

Brd. 7A Comorbidities’ impact on survival after treatment for early breast cancer. (Abstract #584)
L. H. Land, S. O. Dalton, M. Jensen, M. Ewertz

Brd. 7B MDR1/ABCB1 single nucleotide polymorphism (SNP) as a possible prognostic factor in breast cancer patients receiving docetaxel and doxorubicin neoadjuvant chemotherapy. (Abstract #585)
H. Kim, B. Keam, S. Im, H. Ham, S. Han, D. Oh, W. Han, T. Kim, D. Noh, Y. Bang

Brd. 7C Correlation between quantitative HER2 protein level and pathologic complete response (pCR) in HER2-positive (+) breast cancer patients (pts) treated with neoadjuvant (NEO) dose-dense (dd) chemotherapy plus trastuzumab. (Abstract #586)

Brd. 7D Do older patients with T1a lesions require sentinel lymph node biopsy? (Abstract #587)

Brd. 7E Use of sequential FDG-PET/CT to guide extent of axillary lymph node dissection in breast cancer receiving neoadjuvant chemotherapy. (Abstract #588)
B. Keam, S. Im, Y. Koh, S. Han, D. Oh, K. Kang, T. Kim, I. Park, D. Noh, Y. Bang

Brd. 7F Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC). (Abstract #589)

Brd. 7G The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. (Abstract #590)

Brd. 7H Obesity and tumor characteristics in nodal-positive early-stage breast cancer: Results of the German ADEBAR study. (Abstract #591)

Brd. 8A Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer. (Abstract #592)
Brd. 8B Is the difference in reexcision rate of various margin assessment methods due solely to difference in volume excised? (Abstract #593)

Brd. 8C Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041). (Abstract #594)
A. Buzdar, V. Suman, F. Meng-Bernstam, J. C. Boughhey, A. M. Leitch, G. W. Unzeitig, M. J. Ellis, M. Ewer, K. Hunt

Brd. 8D A prospective study to evaluate the role of 2-[18f] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. (Abstract #595)

Brd. 8E Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices. (Abstract #596)

Brd. 8F The prognostic impact of age in patients with triple-negative breast cancer. (Abstract #597)
C. Liedtke, O. Gluz, L. Kiesel, G. N. Hortobagyi, L. Pusztai, A. M. Gonzalez-Angulo

Brd. 8G Utility of the vulnerable elders survey for predicting sixth-month functional decline among older patients with newly diagnosed breast cancer. (Abstract #598)
C. Owusu, M. D. Schluchter, S. M. Koroukian, P. Bakaki, N. A. Berger

Brd. 8H Weight change during adjuvant chemotherapy regimens for breast cancer. (Abstract #599)
R. M. Speck, A. DeMichele

Brd. 9A Use of PET to assess tumor metabolism and blood flow by tumor subtype in locally advanced breast cancer. (Abstract #600)

Brd. 9B Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression. (Abstract #601)

Brd. 9C Evidence for change in prognostic stratification of breast tumor subtypes. (Abstract #602)
S. S. Dawood, A. Buzdar, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo

Brd. 9D Is short interval mammogram necessary after breast-conservation surgery and radiation treatment in breast cancer patients? (Abstract #603)
R. V. Hymas, D. K. Gaffney, B. T. Parkinson, T. Belnap, W. T. Sause

Brd. 9E Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBD), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). (Abstract #604)
Saturday, June 5, 2010

Brd. 9F What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study. (Abstract #605)

Brd. 9G HER2 testing: A health economics perspective on alternative test strategies. (Abstract #606)
J. A. Lee, M. F. Press


Brd. 10A Expression of forkhead-box protein A1 (FOXA1) as a significant prognostic and predictive marker for ER-positive breast cancer. (Abstract #608)

Brd. 10B The influence of mammoplasty in axillary lymphatic drainage patterns and sentinel lymph node detection. (Abstract #609)
C. Bouteille, C. Soler, A. Steiner, B. Geissler, E. Gremillet

Brd. 10C Effect of neoadjuvant alternating taxane- and anthracycline-based dose-dense regimen for operable breast cancer on prognosis in triple-negative tumors with a complete histological response. (Abstract #610)

Brd. 10D Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer. (Abstract #611)

Brd. 10E Breast cancer patients access to screening, radiotherapy, and cancer drugs in 18 European, Asian, and Latin American countries. (Abstract #612)
N. E. Wilking, J. Bergh, B. Jönsson, F. Kasteng

Brd. 10F The impact of the radiotherapy boost in ductal carcinoma in situ. (Abstract #613)

Brd. 10G Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes. (Abstract #614)

Brd. 10H Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers. (Abstract #615)

Brd. 11A Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in adjuvant/primary chemotherapy for early breast cancer, impact in cardiac function: A pilot study. (Abstract #616)
N. Davidson, A. Chalkidou, D. Houghton

Brd. 11B Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer. (Abstract #617)
M. Gemignani, S. Patil, E. Brogi, S. M. Larson, M. Morrow, N. Pandit-Taskar

Brd. 11F Notch and Jak/STAT signaling pathways in breast carcinoma of luminal and basal/triple-negative immunophenotypes. (Abstract #618)
Brd. 11G  Germline single nucleotide polymorphisms (SNPs) in XRCC3, XRCC1, and XPD, and survival outcomes after adjuvant chemotherapy (CT) in early breast cancer (EBC) patients (pts). (Abstract #619)
E. Castro, V. Reguero, A. Garcia, R. Leno, S. Ciria, L. Mezquita, E. Sanchez, C. A. Rodriguez, R. Gonzalez, J. J. Cruz

Brd. 11H  Neoadjuvant chemotherapy (NCT) in operable HR-positive and TN breast cancer (BC): A randomized study comparing standard schedule to response-adapted sequence. (Abstract #620)

Brd. 12A  Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. (Abstract #621)
V. Guarneri, M. Chavez-Mac Gregor, L. Hsu, W. F. Symmans, J. K. Litton, E. A. Mittendorf, P. F. Conte, G. N. Hortobagyi, A. M. Gonzalez-Angulo

Brd. 12B  Meta-analysis on the impact of post-mastectomy radiotherapy on breast reconstruction outcome. (Abstract #622)
M. J. Barry, M. R. Kell

Brd. 12F  Correlation of 18FDG PET-CT with SPET-CT lymphoscintigraphy to guide surgical management of the axilla in patients with T2 or T3 breast cancer. (Abstract #623)
C. Soler, E. Gremillet, C. Bouteille, A. Steiner, B. Geissler

Brd. 12G  Early operable primary breast cancer in elderly (age 70 and older) women (EPC): Changing pattern of management and clinical outcome over 36 years. (Abstract #624)
S. J. Johnston, B. M. Syed, L. Winterbottom, H. Kennedy, D. A. Morgan, K. Cheung

Brd. 12H  High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy. (Abstract #625)

Brd. 13A  Aromatase inhibitor and tamoxifen’s impact on breast cancer recurrence among survivors in a large HMO. (Abstract #626)

Brd. 13B  Correlation of levels of serum 25-hydroxyvitamin D (25-OHD) and lymph node positivity in operable breast cancer: A Turkish Oncology Group study. (Abstract #627)

Brd. 13C  Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients. (Abstract #628)

Brd. 13D  A phase I/II study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22. (Abstract #629)

Brd. 13E  Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. (Abstract #630)

Brd. 13F  Trends in the use of implantable partial breast radiation therapy for early-stage breast cancer in the United States. (Abstract #631)
A. M. Abbott, E. B. Habermann, T. M. Tuttle
Brd. 13G Clinical relevance of TNM staging system according to breast cancer (BC) subtypes. (Abstract #632)
Y. Park, S. Lee, J. Kong, E. Cho, Y. Choi, J. Lee, S. Nam, J. Yang, J. Ahn, Y. Im

Brd. 13H Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane chemotherapy in LABC? (Abstract #633)

Brd. 14A Prognostic value of CD44s in the NCI randomized trial on breast conservation with 25-year follow-up. (Abstract #634)

Brd. 14B Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC). (Abstract #635)

Brd. 14C The expression patterns of STAT-3, phosphorylated STAT-3, P38 MAP-kinase, and phosphorylated P38 MAP-kinase in triple-negative breast cancers and their prognostic significance. (Abstract #636)

Brd. 14D Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer. (Abstract #637)

Brd. 14E Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer. (Abstract #638)

Brd. 14F Early therapeutic intervention based on blood tumor markers (TMs) in patients with primary breast cancer (PBC). (Abstract #639)
J. F. Robertson, J. Mathew, P. Prinsloo, A. Agrawal, E. Gutteridge, E. Merenah, K. Cheung

Brd. 14G Independent comparison of three mathematical models for predicting the risk of additional nodal metastases after positive sentinel lymph node biopsy in early breast cancer. (Abstract #640)
Y. Moghaddam, M. Falzon, L. Fulford, N. R. Williams, M. R. Keshtgar

Brd. 14H Composite and component expression score correlations in ER-positive breast cancer. (Abstract #641)

Brd. 15A Comparison of a novel molecular assay with touch imprint and permanent histology of sentinel lymph nodes in early-stage breast cancer. (Abstract #642)
S. Saha, S. Sirop, B. Chakravarty, D. Wiese, M. Soni, A. Singla, E. Quiachon, W. Liu, A. Ahsan, J. Badin

Brd. 15B Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger. (Abstract #643)
D. Rey-Herin, A. D. Bouhnik, S. Cortaredona, V. Seror, M. K. Bendiane, Y. Odadia, P. Viens

Brd. 15C Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response. (Abstract #644)
I. Ghorbel, S. Heymann, S. Delaloge, A. Belaid, F. Azoury, C. Mazouni, C. Balleyguier, P. Vielh, H. Marsiglia, C. Bourgier
Brd. 15D  Dose-dense chemotherapy in nonmetastatic breast cancer patients: A systematic review and meta-analysis. (Abstract #645)

Brd. 15E  MicroRNA expression to classify breast cancer and predict relapse. (Abstract #646)
J. De La Cruz, V. Scott, C. Richon, P. Dessen, S. Delaloge, M. Mathieu, A. Goubar, S. Vagner, V. Lazar, F. Andre

Brd. 15F  Influence of primary systemic therapy on minimal residual disease in primary breast cancer. (Abstract #647)

Brd. 15G  Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer: Predictive factors for pathological response. (Abstract #648)

Brd. 15H  Indocyanine green fluorescence imaging system for sentinel lymph node biopsy in early breast cancer patients. (Abstract #649)

Brd. 16A  Management and outcome of HER2-positive breast cancer treated with and without adjuvant trastuzumab: The Imperial College London experience. (Abstract #650)

Brd. 16B  Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers. (Abstract #651)
M. A. Bollet, L. Belin, V. Dieras, F. Thibault, F. Reyal, F. Campana, Y. M. Kirova, J. Pierga, B. Sigal-Zafrani, A. Fourquet

Brd. 16C  Phase II study of the combination of gemcitabine plus carboplatin as neoadjuvant treatment in locally advanced breast cancer. (Abstract #652)
V. Srimuninnimit, S. Ithimakin, C. Akewanlop, A. Ratanawichtrasin, V. Veerasan, S. Rojananin, P. Prasartong-osoth

Brd. 16D  Clinicopathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis. (Abstract #653)

Brd. 16E  Outcome of patients with nonmetastatic breast cancer receiving nitrogen-containing bisphosphonates: A comparative analysis from the Metropolitan Detroit Cancer Surveillance System (MDCSS). (Abstract #654)
Z. A. Nahleh, J. Abrams, A. Bhargava, K. Nirmal, J. J. Graff

Brd. 16F  Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: Therapeutic versus preemptive use of lamivudine. (Abstract #655)
B. Sohn, J. Ahn, K. Jung, G. Gong, S. Ahn, S. Kim

Brd. 16G  Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. (Abstract #656)
J. Karnon, S. Kaura

Brd. 16H  Breast carcinoma with amplified HER2: A gene expression signature specific for trastuzumab resistance and poor prognosis. (Abstract #657)
Brd. 17A  An advanced computerized decision support technology to support breast multidisciplinary meetings. (Abstract #658)
V. Patkar, D. Acosta, T. Davidson, A. Jones, J. Fox, M. R. Keshtgar

Brd. 17B  Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells. (Abstract #659)

Brd. 17C  The influence of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in stage I-II estrogen receptor-positive breast cancer: Experience at a single center with a uniform treatment policy. (Abstract #660)

Brd. 17D  Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells. (Abstract #661)

Brd. 17E  Differential response from neoadjuvant chemotherapy across breast cancer subtypes. (Abstract #662)

Brd. 17F  Local effects of tamoxifen versus aromatase inhibitors (AI) on breast tissue: A longitudinal dynamic contrast enhanced (DCE) breast MRI cohort study. (Abstract #663)
C. K. Kuhl, S. Schrading, W. Kuhn, H. H. Schild

Brd. 17G  Microscopic disease after neoadjuvant therapy in inflammatory breast cancer. (Abstract #664)
A. Lodhi, K. Mosalpuria, S. Krishnamurthy, S. Jackson, C. Hall, E. Andreopoulou, B. Singh, V. Valero, A. Lucci

Brd. 17H  Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes. (Abstract #665)
F. Siedentopf, W. Schoenegg, M. Kaufmann, M. Debled, N. J. Robert

Brd. 18A  Timing of genetic testing relative to breast cancer surgery. (Abstract #666)

Brd. 18B  Assessment of concomitant versus sequential aromatase inhibitor with radiotherapy for postmenopausal women with early-stage breast cancer. (Abstract #667)
N. M. Abd El-Bary, T. Hashem

Brd. 18C  HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit. (Abstract #668)

Brd. 18D  The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort. (Abstract #669)
F. O. Ademuyiwa, A. Miller, S. B. Edge, M. A. Thorat, G. W. Sledge, S. S. Badve

Brd. 18E  A multicenter study to determine the optimum duration of neoadjuvant letrozole on tumor regression to permit breast-conserving surgery: Final analyses. (Abstract #670)

Brd. 18F  Nasal septum perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer? (Abstract #671)
A. Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, J. Bonneterre
Brd. 18G Observational GHEA study: Adjuvant trastuzumab treatment of HER2-positive breast carcinomas in the Italian clinical setting compared to HERA trial. (Abstract #672)
M. Campiglio, E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, S. Ménard

Brd. 18H Association between c-myc amplification and other biologic features and prognosis in primary breast cancer. (Abstract #673)
E. Pietri, L. Medri, S. Bravaccini, E. Scarpi, A. Rocca, R. Maltoni, L. Cecconetto, S. Sarti, T. Ibrahim, D. Amadori

Brd. 19A Indocyanine green (ICG) fluorescence imaging versus radioactive colloid for sentinel lymph node identification in patients with breast cancer. (Abstract #674)
N. Tagaya, M. Tsumuraya, A. Nakagawa, Y. Iwasaki, H. Kato, K. Kubota

Brd. 19B Predictive factors of ductal spreading in preoperative breast cancer patients. (Abstract #675)

Brd. 19C Lymphatic and vascular invasion patterns in triple-negative breast cancer. (Abstract #676)
S. Yaman, B. Gumuskaya, C. Ozkan, S. Aksoy, G. Guler, M. K. Altundag

Brd. 19D Progesteron receptor status as a predictor of progression-free survival and overall survival in patients with early breast cancer. (Abstract #677)

Brd. 19E Comparative evaluation of two methods of chemotherapy dose calculation according to body surface area and body mass index in obese females with breast cancer. (Abstract #678)
T. Refaat, S. Abdelmoneim, Y. Rostom

Brd. 19F The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women. (Abstract #679)
C. E. Holmes, J. Jasielec, J. E. Levis, J. Skelly, H. B. Muss

Brd. 19G Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC +/- H) based on HER2 status in large and inflammatory breast cancer (BC). (Abstract #680)
R. S. Mehta, T. Schubbert, D. Jackson

Brd. 19H A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamid followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer. (Abstract #681)

Brd. 20B Pathologic response rate for high-risk operable breast cancer after TNCF semi-intensive neoadjuvant chemotherapy: Updated data with long-term results. (Abstract #683)

Brd. 20C First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. (Abstract #684)

Brd. 20D Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer. (Abstract #685)
K. S. Lee, I. Park, J. Ro, H. S. Kang, S. W. Kim, S. Lee, S. Y. Jung, Y. Kwon
SATURDAY
Saturday, June 5, 2010

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Breast Cancer—Metastatic
Location: S Hall A2
Tracks(s): Breast Cancer

Brd. 21A  Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM). (Abstract #1032)

Brd. 21B  Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy. (Abstract #1033)
M. Giuliano, A. Giordano, L. Hsu, B. C. Handy, N. T. Ueno, E. Andreopoulou, R. H. Alvarez, V. Valero, G. N. Hortobagyi, M. Cristofanilli

Brd. 21C  Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. (Abstract #1034)

Brd. 21D  Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA+TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective. (Abstract #1035)
V. Hastings, T. E. Delea, M. Amonkar, K. Lykopoulos, J. Díaz, S. R. Johnston

Brd. 21E  Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. (Abstract #1036)

Brd. 21F  Early detection of recurrent breast cancer using metabolite profiling. (Abstract #1037)
V. Asiago, L. Alvarado, N. Shanaiah, N. Gowda, K. Owusu-Sarfo, R. Ballas, D. Raftery

Brd. 21G  A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). (Abstract #1038)

Brd. 21H  Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers. (Abstract #1039)

Brd. 22A  Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results. (Abstract #1040)

Brd. 22B  Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase I/bII studies. (Abstract #1041*)
Brd. 22C Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer. (Abstract #1042)
D. Tabagari, G. Nemsadze, M. Janjalia, M. Jincharadze, J. Shan

Brd. 22D Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. (Abstract #1043)

Brd. 22E Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival. (Abstract #1044)

Brd. 22F Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT). (Abstract #1045)
F. Cuppone, E. Bria, I. Sperduti, V. Vaccaro, C. Nistico, P. Carlini, M. Milella, A. Fabi, D. Giannarelli, F. Cognetti

Brd. 22G Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer. (Abstract #1046)

Brd. 22H High-throughput technologies to personalize medical treatment in patients with metastatic breast cancer. (Abstract #1047)

Brd. 23A Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC). (Abstract #1048*)
S. D. Patterson, M. T. Davis, J. R. Mackey, M. Martin, Y. Hei, M. B. Bass

Brd. 23B Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC). (Abstract #1049)

Brd. 23C Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer. (Abstract #1050)

Brd. 23D Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048). (Abstract #1051)

Brd. 23E Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy. (Abstract #1052)

Brd. 23F Association of receptor activator of NF-kb (RANK) expression with bone metastasis in breast carcinomas. (Abstract #1053)
D. Santini, B. Vincenzi, A. Russo, C. Ortega, C. Porta, S. Galluzzo, N. M. La Verde, C. Carotti, R. Addeo, G. Tonini
Brd. 23G A double-blind, randomized, prospective, phase II trial of capecitabine (Cap) plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatment. (Abstract #1054)

Brd. 23H Correlations between efficacy and early changes in biomarkers in a metastatic breast cancer (mBC) clinical trial with sunitinib malate. (Abstract #1055)
K. Keyvanjah, W. Carley, Oncology Business Unit, Pfizer Global Research and Development

Brd. 24A Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer. (Abstract #1056)

Brd. 24B Risk of renal failure associated with IV bisphosphonate use in patients with metastatic breast cancer. (Abstract #1057)
W. J. Langeberg, K. Chung, M. J. Lage

Brd. 24C Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden. (Abstract #1058)
T. Foukakis, T. Fornander, T. Lekberg, H. Hellborg, J. Adolfsson, J. Bergh, on behalf of the Stockholm Breast Cancer Study Group

Brd. 24D Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer. (Abstract #1059)
A. Fabi, A. Di Benedetto, R. Merola, G. Metro, M. Mottolese, P. Papaldo, G. Ferretti, P. Vici, I. Sperduti, F. Cognetti

Brd. 24E Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast. (Abstract #1060)
P. Fedele, L. Orlando, P. Schiavone, P. Rizzo, N. Calvani, M. D’Amico, A. Marino, F. Sponziello, A. Nacci e S. Cinieri

Brd. 24F Long-term effect of fulvestrant on signaling elements in breast cancer. (Abstract #1061)

Brd. 24G Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results. (Abstract #1062)
M. Jain, N. Raizada, R. Kuttan, J. Shan, R. Digumarti

Brd. 24H Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer. (Abstract #1063)
S. P. Neciosup, H. L. Gomez, W. R. Cruz, F. F. Dorni, J. A. Pinto, J. M. Cotrina, J. F. Suarez, V. E. Carlos, L. Mauricio, C. Vallejos Sologuren

Brd. 25A Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC). (Abstract #1064)
R. Griffiths, K. Lindquist, D. Lalla, J. F. Doan, M. G. Brammer, M. Danese

Brd. 25B BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies. (Abstract #1065)
M. H. Schuler, M. M. Uttenreuther-Fischer, M. J. Piccart-Gebhart, N. Harbeck, on behalf of the study group and trial team

Brd. 25F Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer. (Abstract #1066)
Brd. 25G  Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC). (Abstract #1067)

C. Matuschek, E. Boelke, W. Budach, H. Prisack, H. Taskin, M. Peiper, M. Rezai, H. Bojar

Brd. 26A  Survival benefit of neck dissection for patients with breast cancer with supraclavicular lymph node metastasis. (Abstract #1069)
S. Chen

Brd. 26B  Incorporation of a comprehensive geriatric assessment (CGA) into a randomized phase III trial for metastatic breast cancer (MBC): The PELICAN study. (Abstract #1070)

Brd. 26F  The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. (Abstract #1071)
T. Kim, H. Lee, S. Han, D. Oh, S. Im, Y. Bang

Brd. 26G  Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy. (Abstract #1072)
K. Gunzer, H. de Mont-Serrat, M. M. Uttenreuther-Fischer, J. Misset, on behalf of study group and trial team

Brd. 26H  Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC). (Abstract #1073)
W. J. Gradishar, F. Dalenc, V. G. Kaklamani, F. Costa, T. P. Sahoo, J. Segalla, D. Lokanatha, H. Pincyowski, V. Raina, J. Baselga

Brd. 27A  A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007. (Abstract #1074)

Brd. 27B  Breast cancer metastasis gene signature: The search for the holy grail. (Abstract #1075)
R. E. Ellsworth, L. A. Field, B. Love, J. L. Kane, J. A. Hooke, C. D. Shriver

Brd. 27C  Effect of the novel oncomir MiR-301 on tumor proliferation and invasion in human breast cancer. (Abstract #1076)

Brd. 27D  Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months. (Abstract #1077)
L. B. Petruzelka, V. Ganju, D. Becquart, P. F. Conte, N. Tubiana-Mathieu, M. J. Gil Gil, M. Morand, N. Vaissiere, G. Villanova, A. Chan

Brd. 27E  Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX). (Abstract #1078)
G. Curigliano, M. Alkalay, M. A. Locatelli, L. Fumagalli, S. Giudici, F. Bertolini, V. Galimberti, G. Viale, F. Nole, A. Goldhirsch
Saturday, June 5, 2010

Brd. 27F  Primary tumor tissue levels of TIMP-1 and outcome following chemotherapy with docetaxel monotherapy or docetaxel in combination with gemcitabine in patients with locally advanced or metastatic breast cancer. (Abstract #1079) C. L. Jørgensen, E. Balslev, K. D. Bjerre, A. Bartels, S. Møller, B. Ejertsen, N. Brünner, D. L. Nielsen

Brd. 27G  Treatment and outcome of metastatic HER2-positive breast cancer relapsing post adjuvant trastuzumab exposure. (Abstract #1080) J. Krell, C. R. James, D. Shah, P. Riddle, R. Ahmad, K. Hogben, R. C. Coombes, P. Madden, S. Cleator, C. Palmieri


Brd. 28A  Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience. (Abstract #1082) S. Spazzapan, D. Crivellari, S. Tumolo V, A. Russo

Brd. 28B  Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC). (Abstract #1083) P. Gomez, H. H. Roche, F. Costa, J. Segalla, H. Pinczowski, S. Cabral Filho, E. Ciruelos, B. M. Van Eyl, J. Baselga

Brd. 28C  Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research. (Abstract #1084) E. D. Saad, A. Katz, L. Pusztai, P. M. Hoff, M. E. Buyse


Brd. 28F  16α-[18F]fluoro-17β-estradiol (FES)-PET to detect ER-positive tumor lesions in patients with breast cancer with a diagnostic dilemma. (Abstract #1087) M. van Kruchten, A. W. Glaudemans, E. F. De Vries, C. P. Schroder, E. De Vries, G. Hospers

Brd. 28G  HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast cancer. (Abstract #1088) S. Han, J. Ro, A. Paquet, W. Huang, J. Weidler, K. S. Lee, I. Park, D. Oh, S. Im, T. Kim

Brd. 28H  Combination with zoledronic acid (ZA) and sunitinib (SU) to reduce severity of osteolytic lesions in bone metastases. (Abstract #1089) C. Schem, D. O. Bauerschlag, A. Lorenzen, S. Tiwari, H. Kalthoff, C. C. Glueer, W. Jonat

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brd. 30B</td>
<td>Circulating tumor cells (CTCs) and association with survival in molecular subtypes (MST) of metastatic breast cancer (MBC). (Abstract #1094)</td>
<td>M. Graham, N. Fleming, A. Pinto, E. Dropkin</td>
</tr>
<tr>
<td>Brd. 31A</td>
<td>Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both. (Abstract #1096)</td>
<td>A. T. Fojo, W. D. Stein, J. Wilkerson, S. E. Bates</td>
</tr>
<tr>
<td>Brd. 31B</td>
<td>A phase II cross-over study of docetaxel versus vinorelbine in anthracycline-resistant, advanced breast cancer. (Abstract #1097)</td>
<td>C. C. Alifrangis, D. Shipway, O. Gojis, M. Emson, D. Mackie, R. C. Coombes, C. Palmieri</td>
</tr>
<tr>
<td>Brd. 32C</td>
<td>Prediction of response in advanced breast cancer (ABC) patients who received trastuzumab-paclitaxel (TP): HER2 FISH ratio, expression of class III beta tubulin (bTubIII), and immunoglobulin G fragment C receptor (FCGR) polymorphisms. (Abstract #1101)</td>
<td>J. Ahn, M. Jung, J. Koo, Y. Moon, B. Park, S. Kim, S. Park, S. Hong, J. Kim, J. Sohn</td>
</tr>
<tr>
<td>Brd. 33A</td>
<td>Serum-transforming growth factor-α (TGF-α) and response to lapatinib plus capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC). (Abstract #1102)</td>
<td>J. Rhee, S. Han, Y. Cha, H. Kim, D. Oh, S. Im, J. Ro, Y. Im, Y. Bang, T. Kim</td>
</tr>
</tbody>
</table>
Brd. 33C Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guidelines (GL) for imaging work-up of patients with metastatic breast cancer: An analysis from the commercial managed care claims PharMetrics (PM) and SEER/Medicare (SM) databases. (Abstract #1104)

Brd. 34A Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer. (Abstract #1105)

Brd. 34B Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs). (Abstract #1106)

Brd. 34C Quality-of-life outcomes of patients with breast cancer in an integrative cancer treatment setting. (Abstract #1107)
E. D. Staren, D. Gupta, D. P. Braun

Brd. 35A Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience. (Abstract #1108)
P. Papaldo, G. Metro, A. Felici, M. Russillo, D. Pellegrini, A. Fabi, G. Ferretti, M. Introna, F. Cognetti

Brd. 35B Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). (Abstract #1109)

Brd. 35C Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences. (Abstract #1110)

Brd. 35D Taiwanese patients with breast cancer with brain metastasis (BM) enrolled in the Lapatinib Expanded Access Program (LEAP). (Abstract #1111)

Brd. 35E Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m² of doxorubicin (D). (Abstract #1112)

Brd. 35F Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T). (Abstract #1113)

Brd. 35G A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase Ib study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC). (Abstract #1114)
T. P. Sahoo, V. G. Kaktamani, D. Lokanatha, V. Raina, S. Bondarde, M. Jain, L. S. Schwartzberg, W. J. Gradishar

Brd. 35H A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib. (Abstract #1115)
N. W. Peacock, S. F. Jones, D. A. Yardley, J. C. Bendell, J. R. Infante, P. B. Murphy, H. A. Burris III
Brd. 36A  A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC). (Abstract #1116)
D. Mavroudis, I. Boukovinas, C. Christophyllakis, N. Xenidis, P. Papakotoulas, N. A. Malamos, S. Kakolyris, A. Polyzos, V. Georgoulas

Brd. 36B  Comparison of hormone receptor and HER2 status in resected brain metastases and primary breast cancer. (Abstract #1117)

Brd. 36C  Gemcitabine plus cisplatin in pretreated metastatic breast cancer. (Abstract #1118)
G. L. Moura

Brd. 36D  Cardiac safety of nonpegylated liposomal doxorubicin in patients with advanced breast cancer treated with myocet plus vinorelbine or myocet plus cyclophosphamide in a randomized phase II trial. (Abstract #1119)
V. Lorusso, G. A. De Giorgi, M. Ciccarese, V. E. Chiuri, F. Giotta, R. Bordonaro, E. Maiello, S. Pisconti, S. Cinieri, G. Colucci

Brd. 36E  Underuse of anthracyclines in women with HER2-positive advanced breast cancer. (Abstract #1120)

Brd. 36F  Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). (Abstract #1121)

Brd. 36G  Lack of differences in nephrotoxicity of intravenous bisphosphonates in metastatic breast cancer. (Abstract #1122)

Brd. 36H  Pathological characteristics and prognosis of a cohort of 74 patients (pts) with breast cancer (BC) with neoplastic meningitis (NM). (Abstract #1123)
N. Kotecki, E. Le Rhun, M. Baranzelli, M. Faire-Pierret, F. Zairi, F. Dubois, P. Devos, J. Bonneterre

Brd. 37A  Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer. (Abstract #1124)

Brd. 37B  Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases. (Abstract #1125)
V. A. Gorbunova, M. B. Bychkov, D. R. Naskhletashvili, G. E. Chmutin, V. B. Karahan, V. A. Alishin, E. A. Moskvina, Department of Neurooncology, Department of Chemotherapy

Brd. 37C  Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial. (Abstract #1126)

Brd. 37D  An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update. (Abstract #1127)

Brd. 37E  Safety and efficacy of metronomic nonpegylated liposomal doxorubicin in heavily pretreated advanced breast cancer. (Abstract #1128)
L. Manso
Saturday, June 5, 2010

Brd. 37F Concomitant gemcitabine, cisplatin, anastrazole, and zoledronic acid in HER2-negative metastatic breast cancer in postmenopausal women. (Abstract #1129)  
S. Ahmed, A. W. Goraya, M. Hafeez, H. Khan

Brd. 37G Impact of BMI on clinical outcome of HER2-positive breast cancer. (Abstract #1130)  
V. Parolin, E. Fiorio, A. Mercanti, M. Riolfi, G. L. Cetto, E. Surmacz, A. Molino

Brd. 37H Recurrence and survival after pulmonary metastasis in triple-negative breast cancer. (Abstract #1131)  

Brd. 38A Factors associated with the choice of taxane monotherapy or combination in the management of advanced breast cancer: Results of an international observational study. (Abstract #1132)  
C. Camci, E. Firoiu, M. Gumus, F. Hurtado de Mendoza, M. A. Chavez-Zamudio, N. Davidson, M. Brychta, M. Donadio, V. Soldatenkova, K. A. Berhadji

Brd. 38B Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study. (Abstract #1133)  

Brd. 38C Changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer. (Abstract #1134)  
G. Kesisis, P. Touplikioti, E. Yiannaki, F. Paulidou, F. Ziouti, M. Koumpanaki, I. Boukouvinas, L. Kontovinis, A. H. Kortsaris, K. Papazisis

Brd. 38D Selective internal radiation therapy (SIRT) for treatment of patients with breast cancer with metastatic liver disease. (Abstract #1135)  

Brd. 38E After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting—A single-institution experience. (Abstract #1136)  

Brd. 38F Prospective evaluation of megestrol acetate after aromatase inhibitor failure in advanced endocrine responsive breast cancer: Preliminary results. (Abstract #1137)  
J. Bines, R. Dienstmann, O. Metzger, A. C. Gonçalves, W. M. Claudino, M. F. Costa, R. M. Obadia, I. A. Small

Brd. 38G Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: A prospective multicenter trial focusing on tolerability and cardiotoxicity. (Abstract #1138)  
U. Basso, A. Roma, C. Falcì, A. Brunello, P. Fiduccia, L. Vamvakas, A. Bononi, M. Gusella, A. Banzato, S. Monfardini

Brd. 38H Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC). (Abstract #1139)  
A. Chan, D. Yamamoto, R. Bell

Brd. 39A CD4 levels as a prognostic marker for metastatic breast cancer. (Abstract #1140)  
H. J. Boyle, O. Tredan, S. Chabaud, A. Bajard, D. Perol, T. D. Bachelot

Brd. 39B Long-term progression-free survival (PFS) in patients with metastatic breast cancer (BC) treated with tandem autologous followed by allogeneic stem cell transplantation (SCT). (Abstract #1141)  


Brd. 39H Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer. (Abstract #1144) M. Kiechle, N. S. Simstich, U. R. Schwarz-Boeger, S. Paepke


Brd. 40G Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis. (Abstract #1148) R. Borson, W. G. Harker, J. E. Reeves, J. Bromund, L. Zhao, D. F. Tai, D. A. Yardley

Brd. 40H Comparison of dual-probe CISH with FISH in the determination of HER2/chromosome 17 for patients with breast cancer in China. (Abstract #1149) G. Ren, Y. Bai, M. Han, B. Wang

Brd. 41A HER2 as a prognostic factor in metastatic breast cancer treated with taxanes. (Abstract #1150) E. Parkes, S. M. McKenna, J. J. McAleer, J. Clarke, A. J. Clayton, C. R. James


Brd. 41D Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer. (Abstract #1153) T. N. Fehm, B. K. Rack, W. Janni, P. A. Fasching, J. Zeitz, E. Solomayer, B. Aktas, S. Kasimir-Bauer, K. Pantel, V. Mueller, on behalf of the DETECT Study Group

Brd. 41E Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. (Abstract #1154) N. U. Lin, N. Ramakrishna, W. J. Younger, A. M. Storniolo, S. E. Come, R. S. Gelman, E. Eisenberg, E. P. Winer
Saturday, June 5, 2010

Brd. 41F Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC). (Abstract #1155)

Brd. 41G Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study. (Abstract #1156)

Brd. 41H Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials. (Abstract #1157)
2:00 PM - 6:00 PM  
GENERAL POSTER SESSION

Gynecologic Cancer  
Location: S Hall A2  
Tracks(s): Gynecologic Cancer

Brd. 45A  Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer.  
(Abstract #5034)  

Brd. 45B  Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.  
(Abstract #5035)  

Brd. 45C  Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.  
(Abstract #5036)  
P. Sabbatini, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska, G. Scambia, E. Pujade-Lauraine, J. B. Vermorken, J. Pfisterer

Brd. 45D  Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab.  
(Abstract #5037)  

Brd. 45E  A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.  
(Abstract #5038)  

Brd. 45F  Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study.  
(Abstract #5039)  

Brd. 45G  The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin.  
(Abstract #5040)  

Brd. 45H  Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).  
(Abstract #5041)  

(Abstract #5042)  

Brd. 46B  Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations.  
(Abstract #5043)  
Brd. 46C Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial. (Abstract #5044)
M. Brundage, M. Gropp, F. Mefti, K. Mann, B. Lund, V. Gebski, G. Wolfram, N. Reed, S. Pignata, A. Ferrero

Brd. 46D Safety and tolerability of a novel IL-12 gene therapeutic administered in combination with carboplatin/docetaxel in patients with recurrent ovarian cancer. (Abstract #5045)

Brd. 46E Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). (Abstract #5046)

Brd. 46F Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) Protocol 0102. (Abstract #5047)

Brd. 46G Prognostic role of lymph node status in primary advanced ovarian cancer after complete resection or residual disease less than 1 cm: Results of a meta-analysis of the AGO-OVAR meta-database. (Abstract #5048)

Brd. 46H Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer. (Abstract #5049)

Brd. 47A Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors. (Abstract #5050)

Brd. 47B Intraperitoneal mitoxantrone in the treatment of recurrent ascites from progressive epithelial ovarian cancer. (Abstract #5051)
M. Marinaccio, E. Mele, E. De Marino, R. Catacchio, C. Pellegrino, F. Sozzi, S. Schonauer

Brd. 47C The impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: A retrospective Japan clear cell carcinoma study. (Abstract #5052)

Brd. 47D How does 18F-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer? (Abstract #5053)

Brd. 47E Laparoscopic hysterectomy versus abdominal hysterectomy in early-stage endometrial cancer. (Abstract #5054)
M. J. Mourtis, C. J. Bijen, K. M. Vermeulen, A. G. Zee, G. de Bock

Brd. 47F ERCC1 status in patients with locally advanced cervical cancer treated with RT or CRT: A multicenter clinicopathologic analysis. (Abstract #5055)
C. M. Doll, A. W. Fyles, C. Aquino-Parsons, M. Pintiliie, A. Klimowicz, S. Petrillo, M. Milosevic, S. P. Lees-Miller, B. A. Clarke, A. M. Magliocco

Brd. 47G The combination of 18F-fluorodeoxy-glucose and 16alpha-[18F]fluoro-17beta-estradiol positron emission tomography for identifying leiomyosarcoma in uterine smooth muscle tumors. (Abstract #5056)
Y. Yoshida, T. Kurokawa, Y. Sawamura, A. Shinagawa, F. Kotsuji
Brd. 47H Low-grade serous primary peritoneal carcinoma. (Abstract #5057)
D. M. Gershenson, C. C. Sun, A. Malpica, M. Deavers, D. C. Bodurka,
K. M. Schmeler

Brd. 48A Significance of the hedgehog (Hh) pathway in ovarian cancer xenograft
growth. (Abstract #5058)
B. R. Rueda, C. McCann, W. B. Growdon, R. Foster, M. D. Curley, R. W. Ross,
J. Proctor, J. MacDougall

Brd. 48B A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully
human antibody, in advanced ovarian cancer. (Abstract #5059)
D. K. Armstrong, T. J. Herzog, L. M. Reyno, M. Vincent, L. Jackson, P. Sabatini

Brd. 48C Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients
(pts) with a platinum-free interval (PFI) of 6 to 12 months. (Abstract #5060)
J. del Campo, T. Ciuleanu, C. Sessa, A. M. Westermann, A. Roszak, S. Chan,
T. Hogberg, P. Zintl, Y. C. Park, C. N. Krasner

Brd. 48D A novel proteomics biomarker panel as a diagnostic tool for patients with
ovarian cancer. (Abstract #5061)
C. K. Hogdall, E. Fung, I. J. Christensen, L. Nedergaard, S. A. Engelholm,
A. L. Petri, S. Risum, L. Lundvall, A. T. Pedersen, E. V. Høgdall

Brd. 48E New aspects in the treatment of cervical cancer complicated by pregnancy:
Laparoscopic nodal evaluation before oncologic treatment delay.
(Abstract #5062)
G. Favero, V. Chiantera, A. Oleszczuk, V. Galotta, H. Hertel, J. Herrmann,
C. Köhler, A. Schneider

Brd. 48F Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian
cancer: Single or combination chemotherapy? (Abstract #5063)
G. Adams, J. M. Zekri, H. Wong, J. A. Green

Brd. 48G Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone
and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer
(rEOC). (Abstract #5064)
F. Muggia, T. Safra, L. Borgato, A. Gandhi, G. Mancinc, A. Gabizon, L. Liebes

Brd. 48H Preclinical evaluation of PARP inhibition as a treatment for endometrioid
endometrial carcinomas. (Abstract #5065)
K. J. Dedes, D. Wetterskog, A. M. Mendes-Pereira, R. Vatcheva, R. Natrajan,
M. B. Lambros, C. J. Lord, A. Ashworth, J. S. Reis-Filho

Brd. 49A Development of a gene expression–based test for the detection of
endometrial cancer in uterine aspirates. (Abstract #5066)
E. Rosell, C. Pérez, A. Ortega, C. Nieto, A. Doll, A. Gil, J. Ponce, M. Abal,
J. Reventós, T. Maes

Brd. 49B Concurrent weekly cisplatinum versus gemcitabine with radiation in
advanced carcinoma cervix: A study on 120 patients. (Abstract #5067)
D. R. Samanta, S. N. Senapati, L. Pattanayak, A. Mohanty, S. K. Giri

Brd. 49D Prognostic role of dendritic cells and T lymphocytes in the clinical outcomes
of stage III ovarian cancer. (Abstract #5069)
W. Ding, M. J. Maurer, K. Kalli, L. Murphy, L. C. Hartmann, K. L. Knutson,
A. C. Clayton

Brd. 49E The prognostic and predictive value of CA-125 regression during
neoadjuvant chemotherapy for advanced ovarian or primary peritoneal
carcinoma. (Abstract #5070)
N. Vasudev, I. Trigonis, D. A. Cairns, G. Hall, D. Jackson, T. Perren
Brd. 49F  Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planned 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR). (Abstract #5071)

Brd. 49G  Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. (Abstract #5072)
L. Helpman, R. Kupets, R. S. Saad, M. A. Khalifa, N. Ismiil, Z. Ghorab, V. Dube, S. Nofech-Mozes

Brd. 49H  Characteristics and outcomes of pharmaceutical versus nonpharmaceutical affiliated phase III clinical trials on targeted agents for cancer therapy. (Abstract #5073)

Brd. 50A  Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines. (Abstract #5074)

Brd. 50B  The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study. (Abstract #5075)

Brd. 50C  Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma. (Abstract #5076)
M. M. Leitao, M. L. Hensley, R. R. Barakat, R. O’Cearbhaill, R. A. Soslow

Brd. 50D  CA125 response to bevacizumab in recurrent ovarian cancer. (Abstract #5077)

Brd. 50E  Angiogenesis-related gene profile to predict outcome to multimodal therapy in advanced ovarian carcinoma. (Abstract #5078)

Brd. 50F  Expression of tumor-associated antigen C-terminal binding protein-2 in epithelial ovarian tumors and effect on response to HDAC inhibitors in vitro. (Abstract #5079)
L. M. Barroilhet, J. Yang, K. Hasselblatt, W. Welch, R. S. Berkowitz, S. Ng

Brd. 50G  The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study. (Abstract #5080)

Brd. 50H  Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies. (Abstract #5081)

Brd. 51A  Time to platinum resistance (TTPR) as a novel surrogate end-point for trials in ovarian cancer. (Abstract #5082)
I. Pokataev, A. Tryakin, D. Kanagavel, A. Tjulandin, M. Stenina, M. Fedyanin, S. Tjulandin
Brd. 51B Sequential angiogenic blockade for the treatment of recurrent ovarian cancer. (Abstract #5083)

Brd. 51C Interval from neoadjuvant chemotherapy to interval debulking surgery in advanced ovarian cancer: Is this a prognostic indicator? (Abstract #5084)
R. Hariprasad, L. Kumar, A. Mookerjee, V. Radhakrishnan, S. Kumar, S. Mathur, S. Thulkar

Brd. 51D Associations between age and quality of life in advanced ovarian cancer. (Abstract #5085)

Brd. 51E Effects of treatment by temsirolimus on patients with clear cell carcinoma of the ovary. (Abstract #5086)

Brd. 51F Regulation of proliferation in endometrial carcinoma cell line by the epidermal growth factor receptor and estrogen receptor beta. (Abstract #5087)
J. H. Farley, M. Clark, T. J. Wu

Brd. 51G Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. (Abstract #5088)

Brd. 51H Interleukin-6 as a therapeutic target in advanced ovarian cancer. (Abstract #5089)

Brd. 52A Relative conditional survival in 41,476 patients with ovarian cancer. (Abstract #5090)
R. Ware, L. Baldwin, B. Huang, T. Tucker, S. Goodrich, I. Podzielinski, C. P. DeSimone, F. Ueland, J. Vannagell, L. G. Seamon

Brd. 52B Fertility-sparing management with progestin for young women with early-stage endometrial cancer and complex hyperplasia with atypia. (Abstract #5091)

Brd. 52C Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204). (Abstract #5092)
S. Stein, H. S. Hochster, F. Muggia, S. V. Blank, J. P. Curtin, I. Shapiro, G. L. Goldberg, A. Tiersten

Brd. 52D Combination therapy with paclitaxel, carboplatin, and megestrol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study. (Abstract #5093)

Brd. 52E Rapid, durable restoration of malignant ascites-derived antigen presenting cell immunogenicity by toll-like receptor agonists. (Abstract #5094)
S. Jean, S. F. Adams, A. Facciabene, X. Peng, G. Coukos

Brd. 52F Vaginal cuff brachytherapy combined with carboplatin and paclitaxel as adjuvant therapy for high-intermediate-risk patients with endometrial carcinoma. (Abstract #5095)
Saturday, June 5, 2010

Brd. 52G  Prognosis and prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). (Abstract #5096)

Brd. 52H  Sexual activity and functioning in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. (Abstract #5097)
T. M. Michelsen, A. A. Dahl, C. Trope, A. Dørum

Brd. 53A  The efficacy and toxicity of belotecan (CKD-602) combined with platinum in patients with recurrent epithelial ovarian cancer. (Abstract #5098)
Y. Kim, S. Lee, S. Kim, D. Kim, J. Kim, J. Nam, Y. T. Kim

Brd. 53B  Proliferation and lymphangiogenesis markers, and risk of lymph-nodal metastasis in early cervical cancer. (Abstract #5099)
S. Bognlo, A. Buender, P. Mathevet, F. Lecuru

Brd. 53F  Prognostic impact of primary surgical outcome on survival after recurrence in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials. (Abstract #5100)

Brd. 53G  Relationship between ERCC1 C8092A and Mad1 G558A polymorphism with disease progression, and survival in patients with advanced epithelial ovarian cancer treated with induction chemotherapy with carboplatine paclitaxel (PC). (Abstract #5101)

Brd. 53H  Interrelated bowel symptoms to fecal incontinence among gynecologic cancer survivors. (Abstract #5102)
G. Dunberger

Brd. 54A  Inactivation of O6-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation: A key factor of epithelial ovarian carcinogenesis in specific histologic types. (Abstract #5103)
H. Roh, W. Joo, S. Lee, H. Yoo

Brd. 54B  Neoadjuvant chemotherapy in second trimester pregnant patients with cervical cancer: First study on in vivo concentrations of cisplatinum in fetal and maternal compartments. (Abstract #5104)
S. Marnitz, A. H. Schmittel, K. Hasenbein, G. Favero, A. Schneider, C. Köhler

Brd. 54F  Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial. (Abstract #5105)

Brd. 54G  What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients. (Abstract #5106)

Brd. 54H  A phase I study of the infectivity enhanced CRAAd Ad5-Δ24RGD for recurrent gynecologic cancer. (Abstract #5107)

Brd. 55A  A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111. (Abstract #5108)

Brd. 55B  Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for advanced ovarian cancer. (Abstract #5109)
Brd. 55C  Prognostic relevance of resection margin distance for loco-regional control in vulvar cancer. (Abstract #5110)

Brd. 55D  Predictive value of circulating tumor cells for response to therapy in women with recurrent epithelial ovarian cancer. (Abstract #5111)

Brd. 55E  Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): The role of a new chemotherapy (CT) induced apoptosis assay. (Abstract #5112)

Brd. 55F  Ten-year relative survival for ovarian cancer. (Abstract #5113)
L. Baldwin, R. Ware, B. Huang, T. Tucker, S. Goodrich, I. Podzielinski, C. P. DeSimone, J. Vannagell, F. Ueland, L. G. Seamon

Brd. 55G  Intraperitoneal chemotherapy: Who, what, when, and how in diverse academic settings. (Abstract #5114)
L. R. Boyd, A. Novetsky, T. L. Pua, B. Pothuri, J. P. Curtin, R. C. Wallach, S. V. Blank

Brd. 55H  A cross sectional study on intestinal and bladder symptoms in gynecologic malignancies. (Abstract #5115)
K. Pushpalatha, P. K. Julka, J. B. Sharma, K. Suñesh Kumar, K. K. Roy, D. Sharma, L. Kumar

Brd. 56A  Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy. (Abstract #5116)
V. Michalki, S. Gennatas, C. G. Gennatas

Brd. 56B  Chemoradiation followed by adjuvant hysterectomy for the treatment of stage IB-2 cervical cancer: 10-year experience. (Abstract #5117)
G. E. Bigsby, R. W. Holloway, S. Ahmad, M. D. Sombeck, G. Ebra, N. J. Finkler

Brd. 56C  The impact of age on first-line chemotherapy treatment of epithelial ovarian cancer and primary peritoneal carcinoma. (Abstract #5118)
E. Larbi, T. K. Madhuri, S. Essapen, A. Michael

Brd. 56D  Clinical significance of selected angiogenesis and lymphangiogenesis modulators and markers in ovarian cancer patients. (Abstract #5119)
D. Klasa-Mazurkiewicz, T. Milczek, M. Jarzab, J. Narkiewicz, B. Lipińska, D. Wydra

Brd. 56E  Excision repair cross-complementation group 1 (ERCC1) expression as a predictor for response of neoadjuvant chemotherapy for locally advanced uterine cervix cancer. (Abstract #5120)
S. Jeon, S. Hong, E. Jeon, M. Jang, H. Won, S. Park, M. Lee, J. Byun, J. Kang, Y. Hong

Brd. 56F  Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). (Abstract #5121)

Brd. 56G  The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy. (Abstract #5122)

Brd. 56H  Cisplatin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma. (Abstract #5123)
Saturday, June 5, 2010

3:00 PM - 4:15 PM
SPECIAL SESSION

Health Care Reform: Resetting the Clock
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Practice Management and Information Technology; Ethics; Special Session

Joseph S. Bailes, MD—Chair
Texas Oncology
J. James Rohack, MD
American Medical Association

3:00 PM - 4:15 PM
SPECIAL SESSION

Pediatric Oncology Award and Lecture
Location: S504
CME credit: 1.25
Track(s): Special Session; Pediatric Cancer

Sharon B. Murphy, MD
Institute of Medicine
Pediatric Oncology: A Model Rapid Learning Health Care System (RLHS)
3:00 PM - 4:15 PM
EDUCATION SESSIONS

International Collaboration in Clinical Trials: Special Emphasis on Ethics and Regulatory Issues
Location: S100a
CME credit: 1.25
Track(s): Clinical Trials

Robert Leo Comis, MD—Chair
Coalition of Cancer Cooperative Groups
*Overview of International Collaboration in Cancer Clinical Trials*

Denis A. Lacombe, MD
European Organisation for Research and Treatment of Cancer
*European Perspective on International Collaborative Clinical Trials*

Edward Lloyd Trimble, MD
National Cancer Institute
*Review of National Cancer Institute Symposium on Implementation of International Collaborative Clinical Trials in Cancer Therapies*

Managing Survivorship in a Community Practice
Location: E353
CME credit: 1.25
Track(s): Practice Management and Information Technology

Marina Z. Khitrik-Palchuk, MD—Chair
Commonwealth Hematology-Oncology
*From the Ground Up: Use of Nonphysician Providers in Survivorship Care*

Barbara A. Parker, MD
University of California, San Diego
*Defining Survivorship: What Are the Pieces?*

Scott D. Siegel, PhD
Helen F. Graham Cancer Center
*Facilitation of a Survivorship Program with the Local Cancer Center*

Update on Gastrointestinal Noncolorectal Malignancies: What’s New since the 2009 ASCO Annual Meeting?
Location: N Hall B1
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Clinical Trials; Professional Development

Mark Krasna, MD—Chair
St. Joseph Medical Center
*Review of the Results of Surgical Trials including Neoadjuvant and Adjuvant Therapy in Upper Gastrointestinal Malignancies over the Past Year*

Albert C. Lockhart, MD
Washington University School of Medicine
*Progress in the Treatment of Esophageal and Gastric Cancers: What’s New since the 2009 ASCO Annual Meeting?*

Anthony B. El-Khoueiry, MD
University of Southern California
*Hepatobiliary and Pancreatic Cancers since the 2009 ASCO Annual Meeting: Steady Steps Forward and a Long Way to Go*
Saturday, June 5, 2010

3:00 PM - 4:15 PM
MEET THE PROFESSOR SESSION

Clinical Management of Hereditary Colorectal Cancer (M03)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Cancer Genetics; Gastrointestinal (Colorectal) Cancer

Randall Burt, MD
University of Utah

3:00 PM - 4:15 PM
CLINICAL PROBLEMS IN ONCOLOGY

Central Nervous System Metastases: From Local to Systemic Therapy (C05)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Breast Cancer

Matthew G. Ewend, MD—Chair
University of North Carolina at Chapel Hill
The Integration of Surgery and Radiation Therapy in the Management of Central Nervous System Metastasis in Breast Cancer

Nancy U. Lin, MD
Dana-Farber Cancer Institute
Systemic Treatment Options and Opportunities in Breast Cancer Patients with Central Nervous System Metastases

Michael J. Glantz, MD
Penn State Hershey Medical Center
To Protect and Defend: Novel Treatment and Prevention Options for Patients with Metastatic Breast Cancer and Leptomeningeal Disease
3:00 PM - 5:30 PM
ORAL ABSTRACT SESSION

Lung Cancer—Local-Regional and Adjuvant Therapy
Location: E Hall D1
CME credit: 2.5
Track(s): Lung Cancer

Katherine Pisters, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Joe B. Putnam, MD—Co-Chair
Vanderbilt University Medical Center

3:00 PM  A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study. (Abstract #7000)

Discussion
3:15 PM  Steven M. Keller, MD (Abstract #7000)
Montefiore Medical Center
Invasive Mediastinal Staging: Necessary and Often Overlooked

3:30 PM  Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. (Abstract #7002^)

Discussion
3:45 PM  Bonnie S. Glisson, MD (Abstracts #7001–7002^)
University of Texas M. D. Anderson Cancer Center
Small Cell Lung Carcinoma: New Approaches for an Orphan Illness

4:00 PM  Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer. (Abstract #7003)
V. Westeel, B. J. Milleron, E. A. Quoix, M. Puyraveau, D. Moro-Sibilot, D. Braun, B. Lebeau, E. Lemarié, D. Debieuvre, A. G. Depierre, on behalf of the Intergroupe Francophone de Cancerologie Thoracique (IFCT)

4:15 PM  A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). (Abstract #CRA7004)

4:30 PM  A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 (Abstract #LBA7005)

Discussion
4:45 PM  David Harpole, MD (Abstracts #7003–LBA7005)
Duke University Medical Center
Evolution of Multimodality Therapy in Early-stage NSCLC
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC). (Abstract #LBA7007)

P. Fidias, T. A. Ciuleanu, O. Gladkov, G. M. Manikhas, I. N. Bondarenko, A. Pluzanska, R. Ramlau, T. J. Lynch

Discussion
5:15 PM
Julie R. Brahmer, MD (Abstract #LBA7007)
The Johns Hopkins University
Novel Therapeutics in Non-small Cell Lung Cancer
3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Central Nervous System Tumors
Location: S100b
CME credit: 3
Track(s): Central Nervous System Tumors

John Frederick De Groot, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Myrna Rachel Rosenfeld, MD, PhD—Co-Chair
University of Pennsylvania

3:00 PM NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). (Abstract #LBA2001)

3:15 PM Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). (Abstract #LBA2002)

Discussion
3:30 PM
The Johns Hopkins University

A. A. Brandes, E. Franceschi, A. Tosoni, G. Frezza, R. Agati, A. Maestri, C. Ghimienton, V. Mazzocchi, L. Scopece, M. Ermani

4:00 PM Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS). (Abstract #2004)

4:15 PM Phase II study of preirradiation chemotherapy for CNS germ cell malignancies: Long-term complications. (Abstract #2005)
S. I. Robinson, J. C. Buckner, C. Raffel, J. E. Hammack, B. W. Scheithauer, W. Wu, E. G. Shaw

Discussion
4:30 PM
To be determined

4:45 PM Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). (Abstract #2006)
P. Y. Wen, M. Prados, D. Schiff, D. A. Reardon, T. Cloughesy, T. Mikkelsen, T. Batchelor, J. Drappatz, M. C. Chamberlain, J. F. De Groot

5:00 PM A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. (Abstract #LBA2007)

5:15 PM Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. (Abstract #2008)
T. Cloughesy, J. J. Vredenburgh, B. Day, A. Das, H. S. Friedman, for the BRAIN Investigators

Discussion
5:30 PM
Alba Ariela Brandes, MD (Abstracts #2006–2008)
ASL Bologna
Saturday, June 5, 2010

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Patient and Survivor Care
Location: E354b
CME credit: 3
Track(s): Patient and Survivor Care

Teresa Gilewski, MD—Co-Chair
Memorial Sloan-Kettering Cancer Center
Barbara A. Murphy, MD—Co-Chair
Vanderbilt University Medical Center

3:00 PM  Hepatitis B screening and positivity prior to chemotherapy. (Abstract #9008)
J. Hwang, M. Fisch, H. Zhang, M. A. Kallen, M. Routbort, L. Lal, J. Vierling,
M. Suarez-Almazor

3:15 PM  Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a
population initiating immunosuppressive therapy. (Abstract #9009)
E. Ludwig, R. B. Mendelsohn, Y. Taur, M. Kamboj, S. Nagula, K. Sepkowitz,
A. D. Zelenetz

Discussion
3:30 PM  Sandra L. Wong, MD, MS (Abstracts #9008–9009)
University of Michigan Health Systems

3:45 PM  Yield from risk-based screening in adults treated for cancer in childhood.
(Absent #9010)
M. M. Hudson, V. G. Nolan, K. K. Ness, G. T. Armstrong, D. M. Green, K. R. Krull,
S. L. Spunt, M. Metzger, D. K. Srivastava, L. L. Robison

4:00 PM  Executive functions in aging adult survivors of childhood leukemia.
(Absent #9011)
L. L. Robison, M. M. Hudson

4:15 PM  Contrasting effects of religious/spiritual support from religious communities
versus medical teams on advanced cancer patient end-of-life care. (Abstract
#9012)
T. A. Balboni, M. E. Paulk, M. J. Balboni, A. C. Phelps, T. Vanderweele,
A. A. Wright, S. Block, H. G. Prigerson

Discussion
4:30 PM  Betty R. Ferrell, RN, PhD, FAAN (Abstracts #9010–9012)
City of Hope

4:45 PM  Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP
randomized, controlled clinical trial among 410 cancer survivors. (Abstract
#9013)
K. M. Mustian, O. Palesh, L. Sprod, L. J. Peppone, C. E. Heckler, J. S. Yates,
P. S. Reddy, M. Melnik, J. K. Giguere, G. R. Morrow

5:00 PM  Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP
randomized, double-blind, placebo-controlled trial of 510 cancer patients.
(Absent #9014)

5:15 PM  A meta-analysis of results from two randomized, double-blind studies of
denosumab versus zoledronic acid (ZA) for treatment of bone metastases.
(Absent #9015)
A. Lipton, A. Stopeck, R. von Moos, D. H. Henry, G. E. Richardson,
G. I. Rodriguez, H. P. Bourgeois, C. Ke, S. June, R. D. Dansey

(Abstract #9016^)

Discussion
5:45 PM Teresa Gilewski, MD (Abstracts #9013–9016^)
Memorial Sloan-Kettering Cancer Center
Saturday, June 5, 2010

4:30 PM - 5:45 PM
CLINICAL SCIENCE SYMPOSIUM

Signaling in Pediatric Cancer Comes to the Clinic
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology

Julia Lynne Glade Bender, MD—Chair
Columbia University

4:30 PM  Lexatumumab: Results of a phase I trial in pediatric patients with advanced solid tumors. (Abstract #9500)

4:45 PM  A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). (Abstract #CRA9501)

5:00 PM  A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study. (Abstract #9502)

Discussion
5:15 PM  Richard Greg Gorlick, MD (Abstracts #9500–9502)
The Children's Hospital

*Signaling comes to the Clinic*
4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Novel Therapies for Myeloma
Location: E354a
CME credit: 1.5
Track(s): Lymphoma and Plasma Cell Disorders

Asher Alban Akmal Chanan-Khan, MD—Co-Chair
Roswell Park Cancer Institute
Shaji Kumar, MD—Co-Chair
Mayo Clinic

4:30 PM Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). (Abstract #8000)

4:45 PM Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (Abstract #8001)
J. F. San-Miguel, O. Sezer, D. S. Siegel, A. Guenther, J. Blade, I. W. Prosser, B. Bengoudifa, M. Klebsattel, P. M. Bourquelot, K. C. Anderson

Discussion
5:00 PM Paul Gerard Guy Richardson, MD (Abstracts #8000–8001)
Dana-Farber Cancer Institute
Novel Proteosome and HDAC Inhibitors in Myeloma

5:15 PM Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM). (Abstract #8002)

5:30 PM Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. (Abstract #8003)

Discussion
5:45 PM Sagar Lonial, MD (Abstracts #8002–8003)
Winship Cancer Institute at Emory University
New Immunomodulatory Agents and Antibodies in Myeloma
Saturday, June 5, 2010

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets
Location: S406 (Vista Room)
CME credit: 1.5
Track(s): Melanoma/Skin Cancers

Kevin B. Kim, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center

David B. Solit, MD—Co-Chair
Memorial Sloan-Kettering Cancer Center

4:30 PM  Clinical outcome and pathologic features associated with NRAS mutation in cutaneous melanoma. (Abstract #8500)

4:45 PM  Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. (Abstract #8501)

Discussion
5:00 PM  Neal Rosen, MD, PhD (Abstracts #8500–8501)
Memorial Sloan-Kettering Cancer Center

5:15 PM  Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438. (Abstract #8502)

5:30 PM  Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. (Abstract #8503)

Discussion
5:45 PM  Grant A. McArthur, PhD (Abstracts #8502–8503)
Peter MacCallum Cancer Centre
4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

PARP Inhibition: DNA Repair as the Target
Location: E Arie Crown Theater
CME credit: 1.5
Track(s): Developmental Therapeutics

Patrick Johnston, MD, PhD—Co-Chair
Queen's University Belfast
Eunice Lee Kwak, MD, PhD—Co-Chair
Massachusetts General Hospital

Discussion
4:30 PM Alan Hilary Calvert, MD
Cancer Research Unit
PARP as a Therapeutic Target

4:45 PM Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide. (Abstract #3000)

5:00 PM First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. (Abstract #3001)

5:15 PM Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. (Abstract #3002)

Discussion
5:30 PM James H. Doroshow, MD (Abstracts #3000–3002)
National Cancer Institute
State of Development for PARP Inhibition
Saturday, June 5, 2010

4:45 PM - 6:00 PM
EDUCATION SESSIONS

**Cutaneous Cancer Syndromes**
Location: E353  
*CME credit: 1.25*  
Track(s): Cancer Genetics; Melanoma/Skin Cancers

**Sancy Ann Leachman, MD—Chair**  
University of Utah  
*Overview of Cutaneous Cancer Syndromes*

**Hensin Tsao, MD**  
Massachusetts General Hospital  
*Melanoma Genetics and Risk Assessment*

**Stephen B. Gruber, MD, PhD**  
University of Michigan  
*Advances in Cowden’s Syndrome*

---

**Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer**
Location: N Hall B1  
*CME credit: 1.25*  
Track(s): Breast Cancer; General Oncology

**Lisa A. Carey, MD—Chair**  
University of North Carolina at Chapel Hill  
*What’s New in HER2-positive Breast Cancer?*

**Mitchell Dowsett, PhD**  
Royal Marsden Hospital  
*What’s New in Hormone Receptor-positive Breast Cancer?*

**Olufunmilayo I. Olopade, MBBS, FACP**  
The University of Chicago  
*What’s New in Triple-negative Breast Cancer?*
4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION

Aspirin and Nonsteroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention (M04)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Cancer Prevention/Epidemiology

John A. Baron, MD
Dartmouth Medical School

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Complex and Recurrent Gynecologic Cancers: What’s an Oncologist to Do? (C06)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Gynecologic Cancer

Seiko Diane Yamada, MD—Chair
The University of Chicago
Recurrence Germ Cell Tumor of the Ovary

Martee Leigh Hensley, MD, MSc
Memorial Sloan-Kettering Cancer Center
Management of Recurrent Leiomyosarcoma of the Uterus

John H. Farley, MD
Uniformed Services University of the Health Sciences
Management of Recurrent Low-grade Serous Ovarian Carcinoma
Sunday, June 6, 2010

7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY

Highlights of the Day I including Clinical Trials Participation Awards
Location: E Hall D1
CME credit: 1.5
Track(s): Special Session; General Oncology

Everett E. Vokes, MD—Co-Chair
The University of Chicago
Douglas W. Blayney, MD—Co-Chair
University of Michigan

7:30 AM
Clinical Trials Participation Awards

7:45 AM
Bruce D. Cheson, MD
Georgetown University Hospital
Lymphoma and Plasma Cell Disorders

8:00 AM
Alan B. Sandler, MD
Oregon Health & Science University
Lung Cancer—Local-Regional and Adjuvant Therapy

8:15 AM
Gretchen Genevieve Kimmick, MD
Duke University Medical Center
Patient and Survivor Care

8:30 AM
F. Stephen Hodi, MD
Dana-Farber Cancer Institute
Melanoma/Skin Cancers

8:45 AM
Question and Answer
8:00 AM - 9:15 AM
SPECIAL SESSION

Forum on Reimbursement
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Practice Management and Information Technology; Special Session

Joseph S. Bailes, MD—Co-Chair
Texas Oncology

Steven Stranne, MD, JD—Co-Chair
Bryan Cave LLP
Sunday, June 6, 2010

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Allogeneic Transplantation Advances and Controversies
Location: E354b
CME credit: 1.25
Track(s): Leukemia, Myelodysplasia, and Transplantation

Koen van Besien, MD—Chair
The University of Chicago
Advances in Alternative Donor Transplant

Parameswaran Hari, MD, MRCP, MS
Medical College of Wisconsin
Reduced Intensity, Myeloablative, and Transplant Lite: What’s in a Name?

Marcos J. G. De Lima, MD
University of Texas M. D. Anderson Cancer Center
Transplant for Acute Myeloid Leukemia: Who Should be Transplanted in CR1?

Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges
Location: S100a
CME credit: 1.25
Track(s): Geriatric Oncology; Ethics; Patient and Survivor Care

Antonella Surbone, MD, PhD, FACP—Chair
New York University
Ethical and Social Implications of Caregiving to Elderly Cancer Patients

Lea Baider, PhD
Hadassah University Hospital
Beyond the Possible: Appraising the Needs of Elderly Cancer Patients’ Caregivers

Lodovico Balducci, MD
H. Lee Moffitt Cancer Center & Research Institute
The Spirituality of the Home Caregiver

Controversies in the Management of Colorectal Cancer
Location: N Hall B1
CME credit: 1.25
Track(s): Gastrointestinal (Colorectal) Cancer

Axel Grothey, MD—Chair
Mayo Clinic Rochester
Is There an Optimal Treatment Strategy for Advanced Colorectal Cancer?

David L. Bartlett, MD
University of Pittsburgh Medical Center
Treatment of Colorectal Cancer with Peritoneal Carcinomatosis: Knife, Drugs, or Both?

Claus Roedel, MD
University of Erlangen
Neoadjuvant Therapy of Rectal Cancer: How Can We Make It Better?
Controversies in the Management of Desmoid Tumors
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Sarcoma

Murray F. Brennan, MD—Chair
Memorial Sloan-Kettering Cancer Center
Local Management of Desmoid Tumors

Sylvie Bonvalot, MD, PhD
Institut Gustave Roussy
Nonoperative Management of Desmoids with or without Systemic Therapy

Alexander Lazar, MD, PhD
University of Texas M. D. Anderson Cancer Center
Molecular Markers of Desmoid Recurrence

HPV Status and Clinical Decision Making for Patients with Oropharynx Cancer
Location: E Hall D2
CME credit: 1.25
Track(s): Head and Neck Cancer; Gynecologic Cancer

Maura L. Gillison, MD, PhD—Chair
The Ohio State University
Clinical Implications of Human Papillomavirus Etiology of Head and Neck Cancers: An Update

Andy Trotti, MD
University Medical Service Association
The Development of Prospective HPV-specific Head and Neck Cancer Clinical Trials

Lisa F. Licitra, MD
Istituto Nazionale Tumori
Biological Correlates of HPV Tumor Status

Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Leukemia, Myelodysplasia, and Transplantation

Stephen Hunger, MD—Chair
The Children’s Hospital
Converging Approaches to Treating Childhood, Adolescent, and Young Adult ALL

Charles Grenfell Mullighan, MBBS, MSc, MD
St. Jude Children’s Research Hospital
New Insights into the Biological Basis of ALL

Ching-Hon Pui, MD
St. Jude Children’s Research Hospital
Treatment Options for High-risk Pediatric and Adolescent ALL
Sunday, June 6, 2010

PARP Inhibitors and More in DNA Repair
Location: E353
CME credit: 1.25
Track(s): Tumor Biology

Nicola J. Curtin, PhD—Chair
Newcastle University
PARP Inhibitors’ Function and Opportunities for Combination Therapy

James M. Ford, MD
Stanford University Medical Center
DNA Repair: Nuts and Bolts

Thomas Helleday, PhD
University of Oxford
DNA Repair Defect in BRCA Mutant Cells: A New Therapeutic Road

The Global Status of HPV Vaccination
Location: S100b
CME credit: 1.25
Track(s): Cancer Prevention/Epidemiology; International

Patti Gravitt, MS, PhD—Chair
The Johns Hopkins University
HPV Vaccines for the Developing World: Review and New Approaches to Broaden HPV Coverage and Reduce Vaccination Costs

Laura A. Koutsky, PhD, MSPH
University of Washington
Long-term Efficacy of Prophylactic Monovalent HPV Vaccines in Developing Countries

Mark A. Kane, MD, MPH
World Health Organization
Barriers to the Introduction of HPV Vaccines into the Developing World: Should Boys be Vaccinated?
8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Controversies in Stage IIIA Non-small Cell Lung Cancer (M05)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Lung Cancer

Renato Martins, MD, MPH
University of Washington
Controversies in Stage IIIA NSCLC

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY

Immunosuppression in Patients with Lymphoma and Myeloma (C07)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care

Francine M. Foss, MD—Chair
Yale University Cancer Center
Impact of T-cell Directed Therapies on Immunocompetence

Myron Stefan Czuczman, MD
Roswell Park Cancer Institute
Prolonged B-cell Suppression from Anti-CD20 Therapies: What Are the Risks?

John Zaia, MD
City of Hope
Prevention, Surveillance, and Management of Viral Reactivation in the Setting of Immunosuppressive Therapies for Lymphoma and Myeloma
Sunday, June 6, 2010

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

The MEK Pathway
Location: E354a
CME credit: 1.5
Track(s): Developmental Therapeutics

Alex A. Adjei, MD, PhD—Chair
Roswell Park Cancer Institute

Discussion
8:00 AM David B. Solit, MD
Memorial Sloan-Kettering Cancer Center
Introduction

8:15 AM Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. (Abstract #2503)

8:30 AM First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. (Abstract #2504)
J. Delord, N. Houede, A. Awada, A. Taamma, S. J. Faivre, T. Besse-Hammer, A. Italiano, C. Vignaud, M. Donica, E. Raymond

8:45 AM Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. (Abstract #2505)

Discussion
9:00 AM Patricia LoRusso, DO (Abstracts #2503–2505)
Karmanos Cancer Institute
Closing
8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Central Nervous System Tumors
Location: S Hall A2
Tracks(s): Central Nervous System Tumors

Brd. 1A  Predictive impact of IDH1 or IDH2 mutations on outcome and response to temozolomide in low-grade gliomas. (Abstract #2033)
C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, J. Laflaire, B. Boisselier, A. Idbah, K. Hoang-Xuan, M. Sanson, J. Delattre

Brd. 1B  Prognostic factors for glioblastoma (GBM) in individuals age 70 and older: A study of 446 patients from two tertiary centers. (Abstract #2034)

Brd. 1C  Prognostic and predictive markers in recurrent high-grade glioma (HGG): Results from the BR12 randomized trial. (Abstract #2035)
M. Brada, V. P. Collins, K. Ichimura, L. C. Thompson, R. Gabe, S. P. Stenning, BR12 Collaborators

Brd. 1D  Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). (Abstract #2036)

Brd. 1E  Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. (Abstract #2037)

Brd. 1F  Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). (Abstract #2038)
A. Brickhouse, J. J. Vredenburgh, S. Gururangan, D. A. Reardon, A. Desjardins, K. Peters, J. E. Herndon, J. Norfleat, J. Marcello, H. S. Friedman

Brd. 1G  Open-label, dose confirmation, and dosimetry study of interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results. (Abstract #2039)

Brd. 1H  Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL). (Abstract #2040)

Brd. 2A  Quality-of-life concordance between patients with malignant gliomas (MG) and their caregivers. (Abstract #2041)

Brd. 2B  18F-FET-PET hypermetabolic brain lesions: A correlation study to MRI and histopathologic findings. (Abstract #2042)
A. Muigg, M. Nowosielski, J. Schwetz, T. Gotwald, D. Putzer, H. Maier, G. Stockhammer, M. Hutterer

Brd. 2C  Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. (Abstract #2043)
Brd. 2D  Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients. (Abstract #2044)
J. Baurain, T. Boterberg, D. Devriendt, F. Hammouch, G. Cosnard, N. Whenham, P. M. Clement, C. Mitine, L. Renard

Brd. 2E  Long-term survival from the initial trial of bevacizumab and irinotecan. (Abstract #2045)

Brd. 2F  Secondary hematologic malignancies associated with temozolomide (TMZ) in patients with glioma. (Abstract #2046)
H. Momota, Y. Narita, Y. Miyakita, S. Shibui

Brd. 2G  Influence of vascular endothelial growth factor (VEGF) single nucleotide polymorphisms (SNPs) on prognosis of glioblastoma (GB) patients. (Abstract #2047)

Brd. 2H  Radiotherapy with or without temozolomide in elderly glioblastoma patients: Treatment results and prognostic factors. (Abstract #2048)

Brd. 3A  A mesenchymal/stem cell predictor of survival of patients with malignant gliomas. (Abstract #2049)

Brd. 3B  Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation in patients with GBM. (Abstract #2050)
N. A. Butowski, K. Lamborn, M. C. Polley, J. L. Clarke, A. Nicole, M. Page, S. Nicol, D. Thornton, S. M. Chang, M. Prados

Brd. 3C  Use of functional protein pathway activation mapping in glioblastoma samples to differentiate long-term from short-term survivors along with pathway-driven molecular subgroups. (Abstract #2051)

Brd. 3D  Expression of endoglin CD105 and nestin to assess neoangiogenesis in peritumor tissue of glioblastoma. (Abstract #2052)
G. Sica, G. Lama, C. Anile, M. Geloso, G. La Torre, P. De Bonis, G. Maira, L. Lauriola, M. Jhanwar-Uniyal, A. Mangiola

Brd. 3E  MGMT promoter methylation and IDH1 mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme. (Abstract #2053)

Brd. 3F  Pseudoprogression after treatment with the TGF-beta 2 inhibitor trabedersen in high-grade glioma patients. (Abstract #2054)

Brd. 3G  Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. (Abstract #2055)

Brd. 3H  Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma. (Abstract #2056)
Brd. 4A Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. (Abstract #2057)

Brd. 4B Whole-brain radiotherapy with concurrent fixed-dose daily temozolomide for brain metastases treatment: A randomized phase II trial. (Abstract #2058)
C. Gamboa-Vignolle, O. G. Arrieta Rodriguez, T. Ferrari-Carballo

Brd. 4C Use of bevacizumab to facilitate up-front chemoradiation in poor-risk patients with glioblastoma multiforme by improving neurologic function. (Abstract #2059)
R. M. Green, E. A. Woyshner, L. Nghiemphu, A. Lai, T. Cloughesy

Brd. 4D Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results. (Abstract #2060)
K. Peters, A. Desjardins, J. J. Vredenburgh, B. Dryman, S. Gururangan, H. S. Friedman, D. A. Reardon

Brd. 4E Evaluation of three stratification systems predicting recurrence and prognosis in patients with brain metastases after tumor removal and whole-brain irradiation. (Abstract #2061)

Brd. 4F Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond. (Abstract #2062)

Brd. 4G Use of FLAIR MRI in determining glioblastoma response to cediranib. (Abstract #2063)
E. R. Gerstner, Q. Chen, T. Batchelor, A. G. Sorensen

Brd. 4H Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study. (Abstract #2064)

Brd. 5A Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). (Abstract #2065)

Brd. 5B A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one to three brain metastases: Preliminary results. (Abstract #2066^)
S. Brem, C. A. Meyers, M. Booth-Jones, S. Jain, M. G. Ewend

Brd. 5C Levels of circulating endothelial cells in relapsing glioblastoma patients responding to bevacizumab. (Abstract #2067)
M. Eoli, A. Calleri, L. Cuppini, P. Mancuso, E. Prodi, S. Pellegratta, C. L. Solero, M. Bruzzone, F. Bertolini, G. Finocchiaro

Brd. 5D A prospective trial on the efficacy of a multiparametric imaging biomarker for early identification of GBM patients resistant to first-line therapy. (Abstract #2068)

Brd. 5E Phase I/IIa trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. (Abstract #2069)
Brd. 5F  Temozolomide and radiation therapy in elderly patients affected by glioblastomas: A pooled analyses of three prospective phase II trials. (Abstract #2070)

Brd. 5G  High-dose radiation therapy using photons and carbon ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using carbon ion radiotherapy. (Abstract #2071)
S. E. Combs, A. von Deimling, J. Debus, D. Schulz-Ertner, C. Hartmann

Brd. 5H  Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. (Abstract #2072)

Brd. 6A  Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. (Abstract #2073)
J. Kirkpatrick, J. J. Vredenburgh, D. A. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. E. Herndon, J. Marcello, S. Woodring, H. S. Friedman

Brd. 6B  Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study. (Abstract #2074)

Brd. 6C  Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM). (Abstract #2075)
K. C. Shih, D. R. Spigel, H. A. Burris III, R. H. Brown, G. C. Shepard, J. D. Hainsworth

Brd. 6D  MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network. (Abstract #2076)

Brd. 6E  Preoperative blood parameters as biomarkers for high-grade gliomas. (Abstract #2077)
M. Rosenthal, K. M. Field, P. Gibbs, T. Wohlers, C. Drummond

Brd. 6F  Longitudinal analysis of physiologic MRI parameters in patients with newly diagnosed glioblastoma multiforme to predict outcome. (Abstract #2078)

Brd. 6G  Characterization of pseudoprogression in patients with glioblastoma: Is histology the gold standard? (Abstract #2079)
L. Melguizo, J. Bruner, N. Guha-Thakurta, K. R. Hess, V. K. Puduvalli

Brd. 6H  Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study. (Abstract #2080)

Brd. 7A  Accuracy of a modeling algorithm to optimize perfusion MRI detection of glioma recurrence. (Abstract #2081)

Brd. 7B  Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme. (Abstract #2082)
V. Velchetti, B. Peterson, D. Levitt, O. Prakash
Brd. 7C  Phase I/II study of vandetanib for patients with recurrent malignant gliomas.  
(Abstract #2083)  
K. A. McNicol, T. N. Kreisl, F. M. Iwamoto, J. Sul, H. A. Fine

Brd. 7D  Correlation of cognitive symptoms with cognitive performance among brain cancer patients after radiation therapy.  
(Abstract #2084)  
S. R. Rapp, L. D. Case, M. E. Loghin, C. A. Meyers, T. J. Saphner,  
B. G. Sleckman, V. W. Stieber, J. N. Atkins, J. K. Giguere, E. G. Shaw

Brd. 7E  A new gene expression-based diagnostic test to predict prognosis of gliomas for the support of histopathologic diagnosis.  
(Abstract #2085)  
K. Kato, M. Shirahata, S. Kawarazaki, R. Matoba, J. Takahashi

Brd. 7F  Circulating endothelial cells, microparticles, and markers of inflammation and coagulation in glioblastoma patients before and after protracted temozolomide and radiotherapy.  
(Abstract #2086)  
G. Reynes, V. Martinez-Sales, V. Vila, T. Fleitas, M. Martin, E. Reganon

Brd. 7G  Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).  
(Abstract #2087)  
A. Benouaich-Amiel, E. Mazza, C. Massard, P. Caviani, F. Fiorentini, A. Scaburri,  
M. A. Pacciarini, E. Calvo

Brd. 8A  CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.  
(Abstract #2089)  
S. Gururangan, J. J. Vredenburgh, A. Desjardins, K. Peters, J. E. Herndon,  
R. E. McLendon, D. Janney, H. S. Friedman, D. A. Reardon

Brd. 8B  Assessment of diffusion parameters in scans prior to progression in GBM patients following antiangiogenic therapy.  
(Abstract #2090)  
L. Jalilian, E. Essock-Burns, S. Cha, S. M. Chang, N. A. Butowski, S. J. Nelson

Brd. 8C  Study of quality of life in brain tumor patients treated with three-dimensional conformal radiotherapy.  
(Abstract #2091)  
V. S. Vankamamidi, V. R. Sunkavalli, K. J. Naidu, M. Malik, S. Pamidighantam

Brd. 8D  Using a prospective comprehensive database to define features that impact the outcome of patients with glioblastoma multiforme.  
(Abstract #2092)  

Brd. 8E  Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity.  
(Abstract #2093)  
P. R. Lowenstein, Y. Mineharu, G. King, M. Candolfi, W. Xiong, H. Assi, K. Yagiz,  
K. Kroeger, S. Bannykh, M. Castro

Brd. 8F  A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression.  
(Abstract #2094)  
W. P. Mason, K. Belanger, G. A. Nicholas, I. Vallieres, D. Mathieu, A. Desjardins,  
P. Kavan, A. M. Omuro, D. Reymond

Brd. 8G  A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.  
(Abstract #2095)  
K. F. Grossmann, J. H. Ward, W. L. Akerley, M. J. Glantz, J. F. De Groot, R. Aiken,  
J. J. Olson, Y. Matsuoka, M. K. Yu, R. L. Jensen

Brd. 9A  Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107).  
(Abstract #2097)  
S. Phuphanich, J. Rudnick, M. Mazer, H. Q. Wang, N. Serrano, J. Richardson,  
C. Wheeler, M. Singh, K. Black, J. Yu

Brd. 9B  New therapeutic approach for brain tumors: Intranasal administration of Ras inhibitor perillyl alcohol.  
(Abstract #2098)  
C. O. Fonseca
Sunday, June 6, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Head and Neck Cancer
Location: S Hall A2
Tracks(s): Head and Neck Cancer

Brd. 10A  Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). (Abstract #5537)
A. M. Egloff, J. Lee, A. E. Vaezi, C. J. Langer, A. A. Forastiere, H. Quon, B. Burtness, J. R. Grandis, Department of Pathology, University of Pittsburgh

Brd. 10B  Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. (Abstract #5538)

Brd. 10C  Analysis of ERCC1 (excision repair crosscomplementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. (Abstract #5539)

Brd. 10D  ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT). (Abstract #5540)

Brd. 10E  Expression and prognostic significance of X-ray crosscomplementation group 1 (XRCC1) in head and neck squamous cell carcinoma patients undergoing concurrent chemoradiation. (Abstract #5541)
M. Ang, N. Zhao, M. Hayward, M. Patel, X. Yin, M. D. Wilkerson, W. K. Funkhouser Jr., K. Fritchie, A. Olshan, D. N. Hayes

Brd. 10F  Use of angiopoietin-1 expression in squamous cell carcinoma of the head and neck to predict disease-free survival. (Abstract #5542)

Brd. 10G  Correlation of expression of haptoglobin and recurrence in head and neck squamous cell cancer. (Abstract #5543)
Y. Su, C. Lee, S. Hong, H. Lin, S. Li, C. Yu, Y. Tung

Brd. 10H  Outcomes in HPV-associated oropharyngeal squamous cell carcinoma after postoperative or definitive nonsurgical therapy. (Abstract #5544)

Brd. 11A  Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera. (Abstract #5545)

Brd. 11B  Prognosis of HPV-positive squamous cell carcinoma of tonsil-expressing high level of p16 and low level of EGFR. (Abstract #5546)

Brd. 11F  Use of T-cell infiltrate to predict long-term survival following local therapy in tongue cancer patients. (Abstract #5547)
Brd. 11G Prognostic value of biomarkers in tissue microarrays (TMAs) of squamous cell carcinomas of the oral tongue (SCCOT). (Abstract #5548)

Brd. 11H Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck cancer. (Abstract #5549)

Brd. 12A The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. (Abstract #5550)

Brd. 12B Expression of drug-resistance-related proteins in nasopharyngeal cancer (NPC) patients treated with cisplatin-based concurrent chemoradiotherapy. (Abstract #5551)
Y. Hwang, H. Lee, J. Jeong, S. Kang, M. Ahn, J. Han, J. Kim, C. Kim, J. Choi

Brd. 12G Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). (Abstract #5553)

Brd. 12H A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). (Abstract #5554)

Brd. 13A A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study. (Abstract #5555)

Brd. 13B A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma. (Abstract #5556)
W. T. Lim, C. Thng, C. K. Toh, B. Chowbay, B. C. Goh, S. Leong, S. P. Ivy, Q. Ng, D. S. Tan, E. Tan

Brd. 13C Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro. (Abstract #5557)
A. Brohl, K. Steadman, B. Kallakury, J. F. Deeken

Brd. 13D Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC). (Abstract #5558)

Brd. 13E Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer. (Abstract #5559)
A. W. Gramza, J. Patterson, J. Peters, M. Kaufman, S. Wise, D. Flynn

Brd. 13F Mature results of a phase I trial of bortezomib, cisplatin, and radiotherapy for advanced or recurrent head and neck cancer. (Abstract #5560)
R. S. Axelrod, P. H. Ahn, G. J. Kubicek, P. R. Anne, D. Cognetti, A. Dicker, M. Machtay
Sunday, June 6, 2010

Brd. 13G  Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. (Abstract #5561)
J. Kao, S. H. Packer, M. Teng, V. Gupta, K. Mišiukiewicz, E. M. Genden

Brd. 13H  HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN. (Abstract #5562)
D. Soulieres, B. Fortin, E. Winquist, D. Charpentier, E. Harnett, W. Walsh, W. Parulek

Brd. 14A  The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report. (Abstract #5563)

Brd. 14B  Interim safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab)-paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). (Abstract #5564)

Brd. 14C  Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck. (Abstract #5565)
M. Gupta, V. Madhodia, N. Gupta, K. T. Bhowmik

Brd. 14D  Hyperfractionated radiation therapy and concurrent chemotherapy for advanced head and neck cancer. (Abstract #5566)
K. A. AL Saleh, R. Safwat, A. Bedair, A. AL Basmy

Brd. 14E  Concurrent chemoradiation in stage II laryngeal carcinomas. (Abstract #5567)
R. Rajendranath, A. Surendranath, A. Vasanthan

Brd. 14F  Network meta-analysis (MA) of taxane-based neoadjuvant chemotherapy (NCT) for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). (Abstract #5568)
J. McGhie, E. Winquist

Brd. 14G  Induction chemotherapy with carboplatin and paclitaxel followed by radiotherapy and concurrent weekly carboplatin plus paclitaxel in locally advanced nasopharyngeal carcinoma in a nonendemic population. (Abstract #5569)
G. Numico, M. Airoldi, P. Gabriele, A. Gabriele, M. Garzaro, L. Raimondo, F. Pedani, F. Beatrice, G. Pecorari, C. Giordano

Brd. 14H  Phase II study of synchronous chemoradiotherapy with capecitabine in patients with locally advanced squamous cell carcinoma of the head and neck. (Abstract #5570)
A. Jegannathen, K. Mais, A. Sykes, L. Lee, B. Yap, A. Birzgalis, J. Homer, D. Ryder, N. Slevin

Brd. 15A  Organ preservation using carboplatin, capecitabine, docetaxel, and radiotherapy in head and neck cancer: A phase II study. (Abstract #5571)

Brd. 15B  Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. (Abstract #5572)

Brd. 15C  The persistence of symptom burden after radiation treatment for head and neck cancer (HNC). (Abstract #5573)
Brd. 15D Oncologically endoscopic nasopharyngectomy for T1/T2a and selected T2b/T3 nasopharyngeal malignancies with nasopharynx resurfaced with posterior pedicle nasal mucoperiosteum flap. (Abstract #5574) M. Chen


Brd. 15F Chemotherapy-enhanced accelerated radiotherapy for intermediate-volume hypopharyngeal cancer. (Abstract #5576) M. Kawashima, R. Hayashi, M. Tahara, T. Ogino


Brd. 16H Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). (Abstract #5586) M. E. Cabanillas, R. Kurzrock, S. I. Sherman, A. M. Tsimberidou, S. Waguespack, A. Naing, N. Busaidy, R. Gagel, J. J. Wright, D. S. Hong
Sunday, June 6, 2010

Brd. 17A  A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. (Abstract #5587)

Brd. 17B  Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer (ATC) in the United States: A period prevalence SEER database study 1973–2006. (Abstract #5588)

Brd. 17C  Combination therapy with sunitinib and bortezomib in adult patients with radiodine refractory thyroid cancer. (Abstract #5589)

Brd. 17D  Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): A compassionate use program. (Abstract #5590)

Brd. 17E  Intensity-modulated radiation therapy combined with concurrent and adjuvant chemotherapy in anaplastic thyroid carcinoma: A single-institution study. (Abstract #5591)

Brd. 17F  Use of cystatin C as a biomarker for glomerular filtration rate in patients with head and neck cancer receiving cisplatin-based chemotherapy. (Abstract #5592)
E. Boelke, G. Schieren, W. Budach, C. Matuschek, M. Peiper, S. Gripp, G. Steinbach, M. Pelzer, C. Antke, D. Hermens

Brd. 17G  Effects of aprepitant use in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with high-dose cisplatin and radiation (RT). (Abstract #5593)
M. Ong, J. Martin, L. Sax, D. S. Ernst, E. Winquist

Brd. 17H  Prognostic significance of epithelitis by concurrent cetuximab and radiotherapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC) patients (Pts). (Abstract #5594)
J. J. Grau, A. Tagliapietra, E. Verger, M. Caballero, C. Muñoz, L. Alos

Brd. 18A  Economic burden of resected squamous cell carcinoma of the head and neck (SCCHN) in a U.S.-managed care population. (Abstract #5595)
B. Chastek, M. Amonkar, N. Samant

Brd. 18B  Survival from head and neck cancers based on socioeconomic status in Asians. (Abstract #5596)

Brd. 18C  Stress and depression in head and neck cancer patients by primary surgery versus primary radiotherapy treatment modality. (Abstract #5597)

Brd. 18D  Comparison of quality of lives between voice-rehabilitated and nonrehabilitated laryngectomies in a developing world community. (Abstract #5598)
B. T. Varghese, A. Mathew, P. Sebastian

Brd. 18E  Do the treatment outcome priorities of head and neck cancer patients change after undergoing radiation treatment? (Abstract #5599)
Brd. 18F  The relationship of presenting symptom burden and survival in patients with head and neck cancer (HNC). (Abstract #5600)

Brd. 18G  Routine versus clinically indicated post-treatment surveillance in head and neck cancer. (Abstract #5601)
Sunday, June 6, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Lung Cancer—Local-Regional and Adjuvant Therapy
Location: S Hall A2
Tracks(s): Lung Cancer

Brd. 19A Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model. (Abstract #7027)
E. Bria, M. Mottolese, I. Sperduti, P. Visca, B. Antoniani, F. Facciolo, F. Di Modugno, F. Cognetti, P. Nisticò, M. Milella

Brd. 19B Prognostic value of three microRNA expression profiles in early-stage squamous cell lung cancer (SqCLC). (Abstract #7028)
M. T. Skrzypski, A. Szymanowska, E. Jassem, P. Czapiewski, R. Rzepko, W. Biernat, R. Pawwski, W. Rzyman, J. Jassem

Brd. 19C VDAC1 and prognosis in surgically resected non-small cell lung cancer. (Abstract #7029)
C. M. Grills, K. J. O’Byrne, K. Gately, D. A. Fennell

Brd. 19D Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer. (Abstract #7030)

Brd. 19E Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection. (Abstract #7031)
E. S. Kim, A. A. Vaporciyan, J. Xing, M. Huang, M. R. Spitz, S. M. Lippman, J. Gu, J. A. Roth, X. Wu

Brd. 19F Use of serum autoantibodies to identify early-stage lung cancer. (Abstract #7032)

Brd. 19G Demographics of populations at high risk of lung cancer and results of the Early CDT-Lung test. (Abstract #7033)

Brd. 19H Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation. (Abstract #7034)

Brd. 20A Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor. (Abstract #7035)

Brd. 20B Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). (Abstract #7036)
A. K. Nowak, M. Millward, R. J. Francis, A. Hasani, A. A. van der Schaaf, T. Seguard, A. W. Musk, M. J. Byrne

Brd. 20C CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). (Abstract #7037)

Brd. 20D A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18FDG-PET. (Abstract #7038)
Brd. 20E  A new prognostic score in patients with malignant pleural mesothelioma. (Abstract #7039)
G. Selvaggi, A. Billè, M. Gisabella, L. Righi, L. Errico, P. Borasio, F. Ardissone

Brd. 20F  A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM). (Abstract #7040)

Brd. 20G  Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM). (Abstract #7041)
E. Lorenzi, L. Gianoncelli, P. Zucali, G. Ceresoli, F. De Vincenzo, M. Simonelli, C. Ripa, L. Giordano, A. Santoro

Brd. 20H  Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. (Abstract #7042)

Brd. 21A  A multimodality treatment for malignant pleural mesothelioma patients with or without lymph node metastases. (Abstract #7043)

Brd. 21B  Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer. (Abstract #7044)

Brd. 21C  Pretreatment positron emission tomography (PET) scan standardized uptake value (SUV) as a prognostic variable for overall survival in limited-stage small cell lung cancer (L-SCLC). (Abstract #7045)
D. R. Gomez, G. W. Gladish, X. Wei, P. Allen, J. D. Cox, M. O’Reilly, J. J. Erasmus, F. V. Fossella, R. Komaki

Brd. 21D  A phase II trial of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer. (Abstract #7049)

Brd. 21F  Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC). (Abstract #7050)
J. Heymach, B. S. Glisson, R. C. Doebele, C. Huang, D. R. Gandara, S. Le Scouiller, M. A. Marotti, D. R. Camidge
Sunday, June 6, 2010

**Br. 22A** Long-acting somatostatin analogues survival differences in limited- and extensive-disease SCLC patients. (Abstract #7051)


**Br. 22B** Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). (Abstract #7052)


**Br. 22C** Retrospective study of irinotecan plus cisplatin induction followed by concurrent thoracic irradiation with irinotecan plus cisplatin chemotherapy for limited-disease small cell lung cancer. (Abstract #7053)

J. Jeong, J. Sung, H. Pyo, K. Cho, H. Kim, J. Han, T. Yun, G. Lee, J. Lee

**Br. 22D** A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC). (Abstract #7054)


**Br. 22E** Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC). (Abstract #7055)


**Br. 22F** Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. (Abstract #7056)

N. Ready, F. Dunphy, H. Pang, R. Heinze, J. Crawford, E. E. Vokes

**Br. 22G** Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC). (Abstract #7057)


**Br. 23A** Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Report of a Japan Clinical Oncology Group study (JCOG0204). (Abstract #7059)


**Br. 23B** Evaluation of neoadjuvant “window of opportunity” trials with targeted therapy in patients with surgically resectable non-small cell lung cancer. (Abstract #7060)


**Br. 23C** Does induction chemoradiation effect perioperative mortality and overall survival in patients undergoing pneumonectomy for non-small cell lung cancer? (Abstract #7061)

J. Oxenberg, T. Li, B. Egleston, M. Goldberg, W. J. Scott

**Br. 23D** Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemotherapy-naive patients with NSCLC stage IB-IIIA (INN06-study): Preliminary results. (Abstract #7062)


**Br. 23E** Docetaxel plus cisplatin versus vinorelbine plus cisplatin as adjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer: Preliminary result of phase II pilot trial CHL001/TAX622. (Abstract #7063)

D. Chu, G. Wu, B. Han, X. Song, G. Chen, C. Zhou, Q. Wang, S. Wu, Y. Wang, W. Zi-Ping
Brd. 23F Multimodal management of locally advanced (N2) non-small cell lung cancer (NSCLC): Is there a role for surgical resection? A single institution experience. (Abstract #7064)

Brd. 23G The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN 01–24/USO-023. (Abstract #7065)
N. H. Jayaram, M. A. Neubauer, C. S. Johnson, T. Breen, C. E. Williams, N. H. Hanna

Brd. 23H Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience. (Abstract #7066)

Brd. 24A Influence of surgical interventions on survival in patients with stage IIIb non-small cell lung cancer (NSCLC): The Fox Chase Cancer Center (FCCC) experience. (Abstract #7067)
W. J. Scott, C. Aggarwal, A. Lebenthal, B. Egleston, H. Borghaei, R. Mehra, N. Somaiah, A. Turaka, G. R. Simon

Brd. 24B Surgeon-determined variability in quality of surgical resection of lung cancer. (Abstract #7068)

Brd. 24C Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. (Abstract #7069)
A. Recht, J. M. Varlotto, L. N. Medford-Davis, E. Schaefer, J. C. Flickinger, M. M. DeCamp

Brd. 24D Review of mediastinal lymph node examination (mLNE) in a lung cancer resection (LCR) cohort. (Abstract #7070)

Brd. 24E Accuracy of endobronchial ultrasound-directed transbronchial needle aspiration (EBUS-TBNA) for mediastinal staging in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #7071)

Brd. 24F Does the revised TNM staging system for lung cancer better estimate actuarial rates of local/regional recurrence after surgery? (Abstract #7072)

Brd. 24G Solitary pulmonary nodules (SPNs): Outcome of 6-year follow-up by a VA multidisciplinary lung cancer group. (Abstract #7073)

Brd. 24H Examination of the influence that lymphatic and venous involvement gives consequence of stage I non-small cell lung cancer in new TNM classification. (Abstract #7074)
K. Kojima, N. Fujiwara, H. Arai

Brd. 25A Racial disparities on the use of invasive and noninvasive staging in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #7075)

Brd. 25B Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV). (Abstract #7076)
Sunday, June 6, 2010

Brd. 25F Use of PET-measured response in involved mediastinal lymph nodes to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with induction therapy (IT) and surgery. (Abstract #7077)


Brd. 25G A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation. (Abstract #7078)


Brd. 25H Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC). (Abstract #7079)

S. Senan, C. Gundy, C. J. Haasbeek, B. J. Slotman, N. K. Aaronson, F. J. Lagerwaard

Brd. 26A Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter study. (Abstract #7080)

A. Pennathur, R. I. Whyte, A. Zajac, D. G. Brachman, W. E. Gooding, N. A. Christie, H. C. Urschel, B. W. Loo, D. E. Heron, J. D. Luketich, the Multicenter Stereotactic Radiosurgery Investigators for the Treatment of Lung Cancer

Brd. 26B Photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways more than 1.0 cm in diameter. (Abstract #7081)

J. Usuda, N. Ikeda, H. Kato, T. Ohira

Brd. 26F Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update. (Abstract #7082)


Brd. 26G Randomized phase II trial of tegafur-uracil (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small cell lung cancer: NJLCCG 0601. (Abstract #7083)


Brd. 26H Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. (Abstract #7084)

Y. Ohe, Y. Nishiwaki, A. Yokoyama, M. Kawahara, K. Takeda, T. Shibata, T. Tamura, N. Sajo, M. Fukuoka

Brd. 27A N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). (Abstract #7085)


Brd. 27B A phase I dose-escalation study using three-dimensional conformal radiotherapy with concurrent cisplatin and S-1 in patients with stage III non-small cell lung cancer. (Abstract #7086)


Brd. 27C A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non-small cell lung cancer (NSCLC). (Abstract #7087)

A. M. Brade, A. Bezjak, R. M. MacRae, S. A. Laurie, L. Wang, S. Capobianco, F. A. Shepherd
Brd. 27D Vinorelbine and cisplatin concurrently combined with thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: A long-term safety and efficacy report. (Abstract #7088)
H. Horinouchi, I. Sekine, M. Sumi, K. Noda, Y. Nishiwaki, K. Mori, T. Tamura

Brd. 27E Can we predict 2-year survival for radical radiation dosing schedules in advanced non-small cell lung cancer through a meta-analysis based predictive model? (Abstract #7089)
W. Sharieff

Brd. 27F Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. (Abstract #7090)

Brd. 27G A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC). (Abstract #7091)

Brd. 27H Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: Preliminary results of a phase II study. (Abstract #7092)

Brd. 28A Cisplatin (CDDP) and oral vinorelbine (NVBO) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC) treatment: Clinical experience in five institutions in Spain. (Abstract #7093)

Brd. 28B Outcomes of patients with stage III (clinical N2) NSCLC: A VACCR analysis. (Abstract #7094)
A. Ganti, W. Gonsalves, I. Aldoss, F. R. Loberiza Jr.

Brd. 28C Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital. (Abstract #7095)
C. Benson, R. S. Kristeleit, S. Ashley, S. Dolly, C. Mikropoulos, M. O’Brien, S. Popat

Brd. 28D Volumetric analysis of advanced thymic malignancies. (Abstract #7096)
J. Force, A. Rajan, E. Dombi, S. M. Steinberg, G. Giaccone

Brd. 28E Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. (Abstract #7097)
P. Yang, J. Ebbert, L. Chhatwani, J. A. Wampfler, S. Stoddard, F. Zhang, M. de Andrade, M. Aubry

Brd. 28F Baseline results of lung cancer screening program for family lung cancer risk with low-dose spiral CT in Taiwan. (Abstract #7098)
C. Wang, Y. Tsai, Y. Cheung, H. Ko, Y. Ni, P. Feng, Y. Chen, P. Yang, G. Chang
Sunday, June 6, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Lung Cancer—Metastatic
Location: S Hall A2
Tracks(s): Lung Cancer

Brd. 31A  A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504 (Abstract #7536)
H. Le Caer, F. Barlesi, R. Corre, H. Jullian, S. Bota, L. Falchero, A. Vergnenegre, C. Dujon, J. Y. Delhoume, C. Chouaid

Brd. 31B  Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). (Abstract #7537)

Brd. 31C  EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC). (Abstract #7538)
G. Liu, D. Cheng, A. Le Maitre, N. Liu, Z. Chen, L. Seymour, K. Ding, F. A. Shepherd, M. S. Tsao

Brd. 32A  Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. (Abstract #7539)
M. Chang, J. Lee, C. Jung, Y. Park, J. Ahn, K. Park, M. Ahn

Brd. 32B  Biomarker analyses from a phase I study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #7540)
E. Felip, M. Ranson, S. Cedres, M. Brewster, V. Mcnally, M. Venturi, A. Passioukov, G. Ross, D. Galdermans

Brd. 32C  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma. (Abstract #7541)

Brd. 33A  EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer. (Abstract #7542)

Brd. 33B  Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib. (Abstract #7543)
S. Heon, B. Y. Yeap, G. J. Britt, M. S. Rabin, D. M. Jackman, B. E. Johnson

Brd. 33C  Clinicopathologic differences between lung cancer with EGFR gene major (exon 19 deletions and exon 21 L858R) and other minor mutations. (Abstract #7544)

Brd. 34A  The usefulness of 18f-fluorothymidine (FLT) and 18F-FDG PET for early prediction of response to erlotinib therapy in patients with advanced non-small cell lung cancer. (Abstract #7545)
Brd. 34B  Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC): results of the nonrandomized phase II study TaxErb. (Abstract #7546)

Brd. 34C  A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7547)
B. Cho, S. Kim, D. S. Heo, S. Kang, H. Kim, D. Lee, D. Kim, M. Jung, J. Choi, J. Kim

Brd. 35A  Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers. (Abstract #7548)

Brd. 35B  Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion. (Abstract #7549)
M. Taron, C. Queralt, C. Mayo, I. de Aguirre, A. Gasco, A. Insa, R. Palmero, C. Camps, J. Sanchez, R. Rosell

Brd. 35C  Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib. (Abstract #7550)

Brd. 35D  Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. (Abstract #7551)

Brd. 35E  The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib. (Abstract #7552)

Brd. 35F  Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy. (Abstract #7553)

Brd. 35G  SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). (Abstract #7554)

Brd. 35H  Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations. (Abstract #7555)

Brd. 36A  First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology. (Abstract #7556)

Brd. 36B  Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. (Abstract #7557)
G. J. Riely, Y. Y. Janjigian, C. G. Azzoli, M. Pietanza, L. M. Krug, N. A. Rizvi, M. G. Kris, V. A. Miller, W. Pao, M. S. Ginsberg
Brd. 36C  Association of gender and passive smoking with epidermal growth factor receptor mutations in never-smokers with non-small cell lung cancer: A prospective study based on detailed passive smoking questionnaire. (Abstract #7558)

Brd. 36D  A phase II study of gefitinib versus vinorelbine or gemcitabine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer based on epidermal growth factor receptor mutation status. (Abstract #7559)

Brd. 36E  Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation status in cytologic stained smears of non-small cell lung cancer (NSCLC) patients. (Abstract #7560)

Brd. 36F  First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study). (Abstract #7561)

Brd. 36G  Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations. (Abstract #7562)
V. Ludovini, F. Bianconi, L. Pistola, R. Chiari, F. R. Tofanetti, A. Siggillino, E. Baldelli, R. Colella, M. G. Mameli, L. Crino

Brd. 36H  Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma. (Abstract #7563)

Brd. 37A  Effect of tumor-specific KRAS mutational status on impact of anti-EGFR therapy in non-small cell lung cancer (NSCLC). (Abstract #7564)
M. C. Garassino, M. Marabese, M. Broggini, C. Lauricella, I. Floriani, O. Martelli, S. Marsoni, G. Gherardi, G. Farina, A. Scanni, TAILOR Study Group

Brd. 37B  Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group. (Abstract #7565)

Brd. 37C  Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC. (Abstract #7566)

Brd. 37D  Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E). (Abstract #7567)
L. R. Mileshkin, B. G. Hughes, P. Mitchell, V. Charu, B. J. Giltitz, D. Macfarlane, W. Yu, A. Pirzkall, R. Hicks, B. M. Fine

Brd. 37E  Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). (Abstract #7568)
M. R. Green, A. J. Wozniak, J. Willey, K. E. Lemke, H. J. West

Brd. 37F  Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. (Abstract #7569)
Brd. 37G  Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p). (Abstract #7570)

Brd. 37H  The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002. (Abstract #7571)

Brd. 38A  Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. (Abstract #7572)

Brd. 38B  Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. (Abstract #7573)

Brd. 38C  A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China. (Abstract #7574)
Q. Zhao, J. Zhou, J. Shentu, N. Xu, F. Tan

Brd. 38D  Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL). (Abstract #7575)

Brd. 38E  Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC). (Abstract #7576)

Brd. 38F  First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small cell lung cancer patients. (Abstract #7577)
C. Lie, M. Lin, T. Chao, J. Wang, H. Chang

Brd. 38G  Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC). (Abstract #7578)
D. Tassinari, F. Drudi, F. Carloni, S. Nicoletti, C. Possenti, C. Santelmo, L. Lazzari

Brd. 38H  Comparison of response rate of advanced non-small lung cancer patients to liposomal cisplatin versus cisplatin both combined with paclitaxel: A phase III trial. (Abstract #7579)

Brd. 39A  Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7580)
R. Govindan, C. Zergebel, K. Saito, J. H. Schiller

Brd. 39B  Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results. (Abstract #7581)

Brd. 39F  Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. (Abstract #7582)
Brd. 39G  BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). (Abstract #7583)
L. Faoro, J. D. Hainsworth, D. A. Karlin, J. E. Huang, L. Fang, F. A. Scappaticci

Brd. 39H  A randomized phase III study of cisplatin and docetaxel with or without irinotecan in pts with advanced non-small cell lung cancer: Okayama Lung Cancer Study Group OLCSG 0403. (Abstract #7584)

Brd. 40A  Phase I study of regorafenib (BAY 73–4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). (Abstract #7585)
M. S. Kies, G. R. Blumenschein Jr., O. Christensen, T. Lin, A. W. Tolcher

Brd. 40B  Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7586)

Brd. 40F  Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. (Abstract #7587)

Brd. 40G  A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #7588)

Brd. 40H  Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results. (Abstract #7589)
R. Digumarti, A. V. Suresh, G. S. Bhattacharyya, L. Dasappa, J. Shan

Brd. 41A  Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results. (Abstract #7590)

Brd. 41B  First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial. (Abstract #7591)
J. Liang, M. Ahn, J. Kang, Q. Xiu, Y. Chen, C. Yang, N. Scheuer, C. Linn, M. Orlando

Brd. 41C  Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). (Abstract #7592)
A. C. Mita, R. S. Heist, O. Aren, P. N. Mainwaring, L. Bazhenova, S. M. Gadgeel, R. H. Blum, J. Polikoff, J. Biswas, M. A. Spear

Brd. 41D  A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. (Abstract #7593)
**Brd. 41E** Phase II study of dasatinib in patients with advanced non-small cell lung cancer. (Abstract #7594)

**Brd. 41F** Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07–01). (Abstract #7595)

**Brd. 41G** PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadenocarcinoma (non-adeno) non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). (Abstract #7596)

**Brd. 41H** Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial. (Abstract #7597)

**Brd. 42A** Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC). (Abstract #7598)
J. Wang, Y. Sun, S. Qin, Endostar Phase IV Study Group

**Brd. 42B** PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. (Abstract #7599)

**Brd. 42C** A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC. (Abstract #7600)

**Brd. 42D** Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer. (Abstract #7601)

**Brd. 42E** A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7602)
D. V. Jones, C. Zergebel, K. Saito, A. Sandler

**Brd. 42F** A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). (Abstract #7603)

**Brd. 42G** Final results of a phase II trial of S-1 with biweekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy (NJLCG0701). (Abstract #7604)
Sunday, June 6, 2010

Brd. 42H Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial. (Abstract #7605)

Brd. 43A Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer. (Abstract #7606)

Brd. 43B Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501. (Abstract #7607)

Brd. 43D Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. (Abstract #7609)

Brd. 43E EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. (Abstract #7610)
G. Altavilla, M. Santarpia, C. Arrigo, M. Rizzo, G. Galletti, G. Marabello, A. Gnani, V. Piti

Brd. 43F Molecular profiling of smoking-related non-small cell lung cancer (NSCLC) phenotypes. (Abstract #7611)

Brd. 43G In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). (Abstract #7612)

Brd. 43H Eicosanoids in non-small cell lung cancer (NSCLC). (Abstract #7613)
D. H. Johnson, L. Horn, Z. Zhao, G. Milne, J. Morrow, A. Sandler, Y. Shyr, D. P. Carbone

Brd. 44A Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. (Abstract #7614)

Brd. 44B Correlation of pharmacogenetic markers with docetaxel-based chemotherapy resistance in patients with advanced/metastatic non-small cell lung cancer. (Abstract #7615)

Brd. 44C Correlation of genetic polymorphisms in folate metabolic pathway genes with clinical outcomes in pemetrexed-treated advanced NSCLC patients. (Abstract #7616)
J. Kim, J. Yun, J. Kong, S. Lee, S. Kim, J. Lee, J. Ahn, K. Park, M. Ahn

Brd. 44D Phase II trial of personalized chemotherapy in stage IV NSCLC: Clinical application of functional profiling in first-line therapy. (Abstract #7617)

Brd. 44E Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS). (Abstract #7618)
A. J. Woziak, J. Garst, M. Jahanzeb, M. P. Kosty, R. Vidaver, S. Beatty, S. Teng, E. D. Flick, A. Sing, T. J. Lynch, for the ARIES Investigators
**Brd. 44F** Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS). (Abstract #7619)
P. Kumar, N. A. Fischbach, J. R. Brahmer, D. R. Spigel, S. Beatty, S. Teng, E. D. Flick, A. Sing, T. J. Lynch, ARIES Investigators

**Brd. 44G** Expression of sonic hedgehog and its receptor patched in non-small cell lung cancer. (Abstract #7620)

**Brd. 44H** DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma (NSLA). (Abstract #7621)
J. Han, K. Yoon, Y. Lee, G. Lee, S. Yoon, K. Hwang, T. Yun, H. Kim, J. Lee

**Brd. 45A** Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. (Abstract #7622)

**Brd. 45B** Time trend in treatment-related deaths of patients with advanced non-small cell lung cancer enrolled into phase III trials of systemic treatment. (Abstract #7623)

**Brd. 45C** Progression-free survival (PFS) and overall survival (OS) in phase III trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC). (Abstract #7624)

**Brd. 45D** Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis. (Abstract #7625)

**Brd. 45E** Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S). (Abstract #7626)
R. J. Kelly, J. Force, A. Rajan, C. Keen, B. Turkbey, L. Cao, M. Raffeld, S. M. Steinberg, J. J. Wright, G. Giaccone

**Brd. 45F** Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes. (Abstract #7627)
L. Zhang, C. Zhou

**Brd. 45G** Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer. (Abstract #7628)

**Brd. 45H** Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. (Abstract #7629)

**Brd. 46A** Circulating tumor cells (CTC) in small cell lung cancer (SCLC), a promising prognostic factor. (Abstract #7630)
Brd. 46B  ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial. (Abstract #7631)
M. Schuster, J. R. Rigas, S. V. Orlov, B. Milovanovic, K. Prabhash, J. T. Smith, and the ALD518 Study Group

Brd. 46C  HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome. (Abstract #7632)


Brd. 46E  First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. (Abstract #7634)

Brd. 46F  Brain metastases (mets) in lung cancer patients (pts): Analysis of the Detroit Surveillance, Epidemiology and End Results (SEER) data. (Abstract #7635)
S. M. Gadgeel, R. Goveas, F. Vigneau, W. Quarshie, M. Islam, A. Schwartz, A. J. Wozniak, M. Cote

Brd. 46G  Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer. (Abstract #7636)
D. Morgensztern, S. N. Waqar, D. I. Kuperman, B. W. Goodgame, K. Trinkaus, R. Govindan

Brd. 46H  Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. (Abstract #7637)

Brd. 47A  Ethnic difference in toxicity in non-small cell lung cancer patients treated with chemotherapy: A systematic review on phase II and III clinical trials. (Abstract #7638)

Brd. 47B  Improving the accuracy of FNA lung biopsies in a community hospital. (Abstract #7639)
A. Higgins, A. R. Calvo, R. Pelstring
8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Melanoma/Skin Cancers
Location: S Hall A2
Tracks(s): Melanoma/Skin Cancers

Brd. 48A  Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM). (Abstract #8533)

Brd. 48B  Chemoablation of metastatic melanoma with rose bengal (PV-10). (Abstract #8534)

Brd. 48C  A phase I trial of intra-lymph node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma. (Abstract #8535)

Brd. 48D  Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naive advanced melanoma (MM) patients (pts): A phase II study. (Abstract #8536)

Brd. 48E  Plitidepsin (APL) alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). (Abstract #8537)

Brd. 48F  Evaluation of FOXP3 microsatellite polymorphisms in high-risk melanoma patients receiving adjuvant interferon. (Abstract #8538)

Brd. 48G  Screening tools for interferon-related cognitive decline in melanoma patients. (Abstract #8539)

Brd. 48H  The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma. (Abstract #8540)
R. Murali, P. T. Brown, R. Kefford, J. F. Thompson, M. B. Atkins, G. V. Long

Brd. 49A  A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. (Abstract #8541)

Brd. 49B  Prognostic factors for survival after first recurrence of melanoma. (Abstract #8542)

Brd. 49C  Correlation of polymorphic variants into the susceptibility of CDKN2 locus with melanoma outcome. (Abstract #8543)
Sunday, June 6, 2010

Brd. 49D Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. (Abstract #8544)

Brd. 49E Sunitinib therapy for metastatic melanomas with KIT aberrations. (Abstract #8545)

Brd. 49F Preclinical analyses of a new gamma-secretase inhibitor targeting notch signaling in melanoma. (Abstract #8546)

Brd. 49G Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma. (Abstract #8547)

Brd. 49H Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. (Abstract #8548)

Brd. 50A A predictive model to determine the likelihood of positive sentinel lymph node biopsy in thin melanomas. (Abstract #8549)
S. S. Venna, S. Thummala, M. Nosrati, S. P. Leong, J. R. Miller III, R. Sagebiel, M. Kashani-Sabet

Brd. 50B Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update. (Abstract #8550)
V. M. Vukovic, A. Hauschild, A. M. Eggermont, S. O’Day

Brd. 50C Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival. (Abstract #8551)

Brd. 50D Phase II/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy. (Abstract #8552)

Brd. 50E The use of integrative genomics to define molecular signatures of melanoma histologic subtypes. (Abstract #8553)

Brd. 50F Preclinical analysis of targeting miR-182 against melanoma liver metastasis. (Abstract #8554)
C. T. Huynh, M. F. Segura, S. Menendez, F. Darvishian, E. G. Marcusson, E. Hernando

Brd. 50G Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naive stage IV melanoma patients. (Abstract #8555)

Brd. 50H Patterns of recurrence in 208 patients with Merkel cell carcinoma. (Abstract #8556)
Brd. 51A  Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC. (Abstract #8557)

Brd. 51B  MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07). (Abstract #8558)

Brd. 51C  Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4720: The key to therapeutic success? (Abstract #8559)
P. Hersey, X. Zhang, C. Jiang

Brd. 51D  Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma. (Abstract #8560)
J. Lutzky, D. H. Lawson, Y. Enríquez-Nunez, D. Gabrilovich

Brd. 51E  Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma. (Abstract #8561)
P. A. Ott, K. M. Madden, R. Kannan, H. Yee, S. Mendoza, B. Dubose, L. Liebes, A. C. Pavlick

Brd. 51F  Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. (Abstract #8562)
T. Gajewski, Y. Zha, J. Clark

Brd. 51G  The impact of physician specialty on quality of melanoma care. (Abstract #8563)
J. N. Cormier, Y. T. Shih, Y. Xu, I. Pan, R. L. Askew, M. I. Ross, J. E. Gershewald, J. E. Lee, R. Royal, Y. Xing

Brd. 51H  Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma. (Abstract #8564)
L. Si, M. Han, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, Y. Kong, J. Guo

Brd. 52A  CD20-immunotargeting of malignant melanoma. (Abstract #8565)

Brd. 52B  Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and ultraviolet light. (Abstract #8566)

Brd. 52C  Changes in regional immunity and metastasis in melanoma. (Abstract #8567)

Brd. 52D  Effect of TLR4 engagement on TLR3-induced proinflammatory signaling in dendritic cells through IL-10, STAT3, and p38-dependent pathways and on antimelanoma CD8+ T-cell priming. (Abstract #8568)

Brd. 52E  Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma. (Abstract #8569)
M. Ellegaard, L. Bastholt, A. Jakobsen, F. Donskov, H. Schmidt

Brd. 52F  Identification of tyrosinase polymorphisms for use in melanoma risk assessment. (Abstract #8570)

Brd. 52G  Hair depigmentation as an indicator of durable response to CTLA-4 therapy. (Abstract #8571)
Brd. 52H  N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM). (Abstract #8572) 

Brd. 53A  Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone. (Abstract #8573) 

Brd. 53B  Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression. (Abstract #8574) 
L. Ciuffreda, C. Di Sanza, M. Desideri, M. Ricciardi, U. Cesta Incani, A. Tafuri, F. Cognetti, G. Zupi, D. Del Bufalo, M. Milella 

Brd. 53F  In vivo metabolic activity and transcriptional profiling in melanoma (MM) patients during sorafenib and dacarbazine (DTIC) treatment. (Abstract #8575) 

Brd. 53G  Role of lymph node ultrasonography (US) in the follow-up of melanoma patients to detect nodal recurrence after sentinel lymph node biopsy (SNLB): A prospective cohort study. (Abstract #8576) 

Brd. 53H  Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma. (Abstract #8577) 
L. A. Tijani, M. Luadadio, M. J. Mastrangelo, T. Sato 

Brd. 54A  Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E. (Abstract #8578) 
S. Markovic, V. Suman, V. N. Trieu, X. Liu, W. Yeh, L. Hwang, T. Treece, K. Molamed, P. Pramanik, N. Desai 

Brd. 54B  Management of cutaneous metastases by electrochemotherapy. (Abstract #8579) 
J. Gehl, L. W. Matthiessen, A. Humphreys, G. Kesselt, T. Muir 

Brd. 54F  Immunomodulatory gene expression at the fetomaternal interface and in melanoma: Tolerance meets inflammation. (Abstract #8580) 
S. G. Holtan, D. J. Creedon, A. A. Leontovich, S. Markovic 

Brd. 54G  Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis. (Abstract #8581) 
Y. Xing, Y. Bronstein, M. I. Ross, R. L. Askew, J. E. Lee, J. E. Gershenwald, R. Royal, J. N. Cormier 

Brd. 54H  Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma. (Abstract #8582) 
N. Péchuet, M. Avril, D. Kerob, B. Billemont, B. Blanchet, P. Herait, I. Gorin, M. Viguier, C. Lebbé, F. Goldwasser 

Brd. 55A  Patterns of disease spread in metastatic mucosal melanoma. (Abstract #8583) 

Brd. 55B  Targeting SRC kinase (SRC) in melanoma cells. (Abstract #8584) 

Brd. 55C  Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolomide plus bevacizumab (SAKK 50/07). (Abstract #8585) 
Brd. 55D  A phase II clinical trial of a novel combinatorial antitumor immunotherapy for patients with high-risk resected stage III and metastatic melanoma. (Abstract #8586)

Brd. 55E  Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. (Abstract #8587)

Brd. 55F  Interleukin-10 as a prognostic factor in patients treated with autologous melanoma cell vaccine. (Abstract #8588)

Brd. 55G  Electrochemotherapy with bleomycin: A local treatment with possible systemic implication. (Abstract #8589)

Brd. 55H  Dual mechanistic function of MDSC subsets in melanoma resistance. (Abstract #8590)

Brd. 56A  Immunohistochemical expression of Dicer in melanoma. (Abstract #8591)
C. Capalbo, F. Passarelli, Z. di Rocco, A. Scoppola, P. Marchetti

Brd. 56B  PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. (Abstract #8592)

Brd. 56D  Utility of 3-year torso CT and head imaging in asymptomatic patients with high-risk melanoma. (Abstract #8594)

Brd. 56E  Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center. (Abstract #8595)
R. Gutzmer, F. Schenck, I. Satzger

Brd. 56F  Prognostic relevance of increased detection of lymphovascular invasion in primary melanoma using D2-40 and CD34 compared to routine histology. (Abstract #8596)
F. Darvishian, A. E. Rose, P. J. Christos, T. Tu, R. L. Shapiro, R. S. Berman, A. C. Pavlick, H. Kaminos, M. Mazumdar, I. Osman

Brd. 56G  Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma. (Abstract #8597)
Sunday, June 6, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Cancer Prevention/Epidemiology
Location: S100b
CME credit: 3
Track(s): Cancer Prevention/Epidemiology

Frank Sinicrope, MD—Co-Chair
Mayo Clinic
Eva Szabo, MD—Co-Chair
National Cancer Institute

9:30 AM Lynch syndrome *TACSTD1* family with predominant colorectal cancer. (Abstract #1500)

9:45 AM Association of Lynch syndrome and risk of invasive cervical cancer. (Abstract #1501)
Y. C. Antill, J. Dowty, A. Win, T. Thompson, N. M. Lindor, S. Gallinger, I. Winship, M. A. Jenkins

Discussion
10:00 AM Stephen B. Gruber, MD, PhD (Abstracts #1500–1501)
University of Michigan

M. T. Milano, H. Li, M. H. Gail, L. S. Constine, L. B. Travis

10:30 AM Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients. (Abstract #1503)
S. H. Giordano, S. Jiralerspong, A. Lopez, L. Feng, E. S. Kim, A. M. Gonzalez-Angulo, G. N. Hortobagyi

10:45 AM Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer. (Abstract #1504)
J. Y. Chang, S. M. Lippman, J. Lee, M. Huang, X. Wu

Discussion
11:00 AM To be determined

11:15 AM A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer. (Abstract #1505)
M. J. Higgins, T. M. Prowell, A. Blackford, S. Slater, P. Argani, H. Green, N. Khouri, R. Blumenthal, J. E. Garber, V. Stearns

11:30 AM Characterizing benign breast disease in women at high risk for breast cancer. (Abstract #1506)

11:45 AM Breast cancer outcome and estrogen plus progestin use in postmenopausal women. (Abstract #1507)

Discussion
12:00 PM Powel H. Brown, MD, PhD (Abstracts #1505–1507)
University of Texas M. D. Anderson Cancer Center
9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Gastrointestinal (Colorectal) Cancer
Location: E Hall D1
CME credit: 3
Track(s): Gastrointestinal (Colorectal) Cancer

Tanios S. Bekaii-Saab, MD—Co-Chair
The Ohio State University Medical Center
Chris R. Garrett, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center

9:30 AM Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). (Abstract #3501)

9:45 AM Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. (Abstract #3502)

10:00 AM Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). (Abstract #3526)

Discussion
10:15 AM
Alan Paul Venook, MD (Abstracts #3501, 3502, 3526)
University of California, San Francisco

10:30 AM Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. (Abstract #3503)

10:45 AM Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. (Abstract #3504)
A. Roth, D. Klingbiel, P. Yan, R. Fiocca, M. Delorenzi, R. Labianca, D. Cunningham, E. Van Cutsem, F. Bosman, S. Tejpar

11:00 AM Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial. (Abstract #3505)
S. Tejpar, V. Popovici, M. Delorenzi, E. Budinska, H. Estrella, M. Mao, P. Yan, S. Weinrich, E. Van Cutsem, A. Roth

11:15 AM Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. (Abstract #3506)
C. Bokemeyer, C. Kohne, P. Rougier, C. Stroh, M. Schlichting, E. Van Cutsem
Sunday, June 6, 2010

Discussion
11:30 AM Charles Fuchs, MD (Abstracts #3503–3506)
Dana-Farber Cancer Institute

11:45 AM Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. (Abstract #CRA3507)

12:00 PM Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. (Abstract #3508)

Discussion
12:15 PM Louis M. Weiner, MD (Abstracts #CRA3507–3508)
Georgetown University Medical Center
**9:30 AM - 12:30 PM**
**ORAL ABSTRACT SESSION**

**Genitourinary (Prostate) Cancer**
Location: E Hall D2  
*CME credit: 3*
Track(s): Genitourinary Cancer

**Dana E. Rathkopf, MD—Co-Chair**  
Memorial Sloan-Kettering Cancer Center

**Evan Y. Yu, MD—Co-Chair**  
University of Washington

**9:30 AM**  
Intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94–0110; NCT00002633). (Abstract #CRA4504)


**9:45 AM**  
Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. (Abstract #4505)

N. Mottet, M. Peneau, J. Mazeron, V. Molinie, P. Richaud

**10:00 AM**  
Surgical outcomes and implications for cure in active surveillance patients who undergo delayed radical prostatectomy. (Abstract #4506)

B. J. Trock, Z. Feng, P. Landis, J. I. Epstein, B. Carter

**Discussion**

**10:15 AM**  
Anthony V. D’Amico, MD, PhD (Abstracts #4504–4506)  
Dana-Farber Cancer Institute

*Early Prostate Cancer: How Much Therapy Is Too Much?*

**10:30 PM**  
A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. (Abstract #LBA4507)


**Discussion**

**10:45 AM**  
Robert E. Coleman, MD, MBBS (Abstract #LBA4507)  
Weston Park Hospital

*The Role of RANKL in Castration-resistant Prostate Cancer*

**11:00 AM**  
Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). (Abstract #4508^)


**11:15 AM**  
Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. (Abstract #4509)

Sunday, June 6, 2010

Discussion

11:30 AM  Ian Tannock, MD, PhD (Abstracts #4508–4509)
Princess Margaret Hospital
Chemotherapy for Castration-resistant Prostate Cancer: Looking beyond Docetaxel and Mitoxantrone

11:45 AM  A randomized, multicenter, international phase II study of tasquinimod in chemotherapy-naïve patients with metastatic castrate-resistant prostate cancer (CRPC). (Abstract #4510)

12:00 PM  A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. (Abstract #LBA4511)

Discussion

12:15 PM  William L. Dahut, MD (Abstracts #4510–LBA4511)
National Cancer Institute
Angiogenic Targeting in Castration-resistant Prostate Cancer
9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Gynecologic Cancer
Location: E Arie Crown Theater
CME credit: 3
Track(s): Gynecologic Cancer

Ernst Lengyel, MD, PhD—Co-Chair
The University of Chicago
Amit M. Oza, BSc, MBBS, MD, FRCPC, FRCP—Co-Chair
Princess Margaret Hospital

9:30 AM  
A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). (Abstract #5003)  
The University of Chicago

Discussion
9:45 AM  
Usha Menon, MD (Abstract #5003)  
University College London
High-risk Ovarian Cancer Screening: Is It Useful?

10:00 AM  
A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors. (Abstract #5004)  
National Cancer Institute
P. Konstantinopoulos, D. Spentzos, B. Karlan, T. Taniguchi, E. Fountzilas, N. Francoeur, D. A. Levine, S. A. Cannistra

Discussion
10:15 AM  
Elise C. Kohn, MD (Abstract #5004)  
National Cancer Institute
Relevance of BRCAness in Selecting Therapy?

10:30 AM  
Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup study. (Abstract #5005)  
NOGGO

10:45 AM  
RTOG 0417: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. (Abstract #5006)  
University of Michigan

Discussion
11:00 AM  
Patricia J. Eifel, MD (Abstracts #5005–5006)  
University of Texas M. D. Anderson Cancer Center
The Next Step in Chemoradiation for Cervical Cancer

11:15 AM  
Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. (Abstract #5013)  
University of New Mexico

Discussion
11:30 AM  
Claire F. Verschraegen, MD (Abstract #5013)  
University of New Mexico
Chemotherapy of the Future in Platinum-resistant Disease

11:45 AM  
Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report. (Abstract #LBA5008)  
University of Michigan
M. G. Teneriello, A. N. Gordon, P. Lim, M. Janicek

Discussion
12:00 PM  
Ronald J. Buckanovich, MD (Abstract #LBA5008)  
University of Michigan
Maintenance and Consolidation in Ovarian Cancer
Myeloma
Location: E354b
CME credit: 3
Track(s): Lymphoma and Plasma Cell Disorders

Andrzej J. Jakubowiak, MD, PhD—Co-Chair
University of Michigan
Todd M. Zimmerman, MD—Co-Chair
The University of Chicago

9:30 AM Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients. (Abstract #8013)

9:45 AM Comparison of reduced-dose bortezomib plus thalidomide and dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007–02 study. (Abstract #8014)

Discussion
10:00 AM Ruben Niesvizky, MD (Abstracts #8013–8014)
New York Presbyterian Hospital-Cornell Campus
Sorting through the Options for Initial Therapy of Myeloma

10:15 AM A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m²) and autologous transplantation (MEL200) in newly diagnosed myeloma patients. (Abstract #8015)
A. P. Palumbo, F. Cavallo, F. Di Raimondo, D. Ben Yehuda, P. Omedè, V. Montefusco, F. Rossini, I. Hardan, T. Caravita, M. Boccadoro

10:30 AM Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase III study. (Abstract #8016)

Discussion
10:45 AM Jean L. Harousseau, MD (Abstracts #8015–8016)
Rene Gauducheau Cancer Center
What Is the Role of Transplant for Myeloma in the Era of Novel Agents?

11:00 AM Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. (Abstract #8017)

11:15 AM Lenalidomide maintenance after transplantation for myeloma. (Abstract #8018)
Discussion

11:30 AM  Sergio Giralt, MD (Abstracts #8017–8018)
University of Texas M. D. Anderson Cancer Center
Post-transplant Maintenance Therapies

11:45 AM  Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC). (Abstract #8019)
B. Barlogie, J. D. Shaughnessy, J. Haessler, A. Hoering, F. Van Rhee, E. J. Anaissie, J. Crowley

12:00 PM  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study. (Abstract #8020)

12:15 PM  Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX Study. (Abstract #8021)
G. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, G. H. Jackson, J. A. Child
Sunday, June 6, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Pediatric Oncology I
Location: S504
CME credit: 3
Track(s): Pediatric Oncology

Steven G. DuBois, MD—Co-Chair
University of California, San Francisco
Kenan Onel, MD, PhD—Co-Chair
The University of Chicago

9:30 AM  Early results from Children’s Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). (Abstract #9503)

9:45 AM  Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). (Abstract #9504)

10:00 AM  Prognostic factors of localized extremity rhabdomyosarcomas: The results of a pooled analysis from U.S. and European cooperative groups. (Abstract #9505)

10:15 AM  Nonmetastatic osteosarcoma of the extremity: Neoadjuvant chemotherapy with methotrexate (MTX), cisplatin (CDP), doxorubicin (ADM) with or without ifosfamide (IFO)—A randomized trial of the Italian Sarcoma Group (ISG/OS-1). (Abstract #9506)
S. Ferrari, G. Cefalo, A. Tamburini, A. Comandone, F. Fagioli, P. G. Casali, G. Bisogno, M. Mercuri, P. Picci, G. Bacci

Discussion
10:30 AM  Holcombe E. Grier, MD (Abstracts #9503–9506)
Dana-Farber Cancer Institute
Pediatric Sarcomas: Where to Now?

10:45 AM  A phase II trial of proton radiotherapy for medulloblastoma: Preliminary results. (Abstract #CRA9507)

11:00 AM  Neurocognitive outcomes after proton radiation for pediatric brain tumors. (Abstract #9508)
M. B. Pulsifer, I. Delgado, N. Tarbell, K. Kuhlthau, S. M. MacDonald, T. I. Yock

Discussion
11:15 AM  Joel E. Tepper, MD
University of North Carolina
Pediatric Proton Radiotherapy

11:30 AM  Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study. (Abstract #9509)
J. H. Feusner, J. Gregory, B. K. Moser, V. Hars, C. L. Willman, B. L. Powell, R. A. Larson

12:00 PM  Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children’s Oncology Group. (Abstract #9511)

Discussion
12:15 PM  James B. Nachman, MD (Abstracts #9509–9511)
The University of Chicago
Bridging the Gap in Leukemia
Sunday, June 6, 2010

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat
Location: S100a
CME credit: 1.25
Track(s): Geriatric Oncology; Breast Cancer; Gastrointestinal (Colorectal) Cancer; General Oncology

Peter Ravdin, MD—Chair
University of Texas Health Science Center at San Antonio
Benefits of Adjuvant Therapy

Supriya Gupta Mohile, MD, MS
University of Rochester Medical Center
Estimating Life Expectancy and Benefit from Adjuvant Therapy Based on Comorbidity

Arash Naeim, MD
University of California, Los Angeles
The Importance of Shared Decision Making Regarding Adjuvant Therapy

Creative Approaches to Advanced and Metastatic Sarcoma
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Sarcoma

Brian O’Sullivan, MD—Chair
Princess Margaret Hospital
Role of Radiation for Treatment of Advanced/Metastatic Sarcoma

Raja Michael Flores, MD
Memorial Sloan-Kettering Cancer Center
Management of Sarcoma Patients with Lung Metastasis: Minimally Invasive/Nonresection Approaches

William D. Tap, MD
University of California, Los Angeles
Novel Systemic Approaches for the Management of Advanced/Metastatic Sarcoma

Therapy for Patients with Activating Mutations of the Epidermal Growth Factor Receptor
Location: N Hall B1
CME credit: 1.25
Track(s): Lung Cancer

William Pao, MD, PhD—Chair
Vanderbilt-Ingram Cancer Center
Mechanisms of Resistance to EGFR Inhibitors

Tony Mok, MD
The Chinese University of Hong Kong
Testing for EGFR in Untreated Patients: Implications for Treatment

David Michael Jackman, MD
Dana-Farber Cancer Institute
Therapy after Progression in First Line for Patients with Activating Mutation of the EGFR
9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

Nontransplant Options for Mantle Cell Lymphoma (M06)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders

John Leonard, MD
Weill Cornell Medical College

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY

Therapeutic Choices for Patients with Intermediate-stage Head and Neck Cancer (C08)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Head and Neck Cancer

Merrill S. Kies, MD—Chair
University of Texas M. D. Anderson Cancer Center
Management Strategies for Intermediate Larynx Cancer

Christopher Nutting, MD
Royal Marsden Hospital
Radiation Therapy for the Early-stage Patient

Ted Teknos, MD
The Ohio State University
Multidisciplinary Treatment of Intermediate-stage Oral Cavity Cancer
Pharmacologic Treatment of Cancer-related Fatigue: Does It Make a Difference?
Location: E354a
CME credit: 1.5
Track(s): Patient and Survivor Care

Barbara A. Murphy, MD—Co-Chair
Vanderbilt University Medical Center
Thomas J. Smith, MD—Co-Chair
Virginia Commonwealth University

9:45 AM  Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7. (Abstract #9004)
D. L. Barton, A. R. Moraska, A. Sood, J. A. Sloan, J. J. Suh, P. C. Griffin,
D. B. Johnson, A. A. Ali, P. T. Silberstein, C. L. Loprinzi

10:00 AM  Factors associated with response to methylphenidate in advanced cancer
patients with cancer-related fatigue. (Abstract #9005)
S. Yennurajalingam, J. L. Palmer, Z. Li, E. Bruera

Discussion
10:15 AM  Charles S. Cleeland, MD (Abstracts #9004–9005)
University of Texas M. D. Anderson Cancer Center

10:30 AM  A randomized double-blind placebo-controlled study of oral coenzyme Q10
to relieve self-reported cancer treatment-related fatigue in newly diagnosed
breast cancer patients. (Abstract #9006)
G. J. Lesser, L. D. Case, N. Stark, S. K. Williford, J. K. Giguere, A. Garino,
M. J. Naughton, M. Vitolins, M. Lively, E. G. Shaw, Comprehensive Cancer Center
of Wake Forest University CCOP Research Base

10:45 AM  Effect of guarana (Paullinia cupana) on fatigue in breast cancer patients
undergoing systemic chemotherapy. (Abstract #9007)
M. P. Campos, R. Riechelmann, L. C. Martins, B. J. Hassan, F. B. Casa,
A. Del Giglio

Discussion
11:00 AM  Thomas J. Smith, MD (Abstracts #9006–9007)
Virginia Commonwealth University
9:45 AM - 11:15 AM  
CLINICAL SCIENCE SYMPOSIUM

Smoothened/Hedgehog/Gamma Secretase  
Location: E353  
CME credit: 1.5  
Track(s): Developmental Therapeutics

S. Gail Eckhardt, MD—Chair  
University of Colorado Cancer Center

Discussion  
9:45 AM  Patricia LoRusso, DO  
Karmanos Cancer Institute  
Introduction

10:00 AM  A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. (Abstract #2500)  

10:15 AM  A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. (Abstract #2501)  

10:30 AM  A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. (Abstract #2502)  

Discussion  
10:45 AM  Charles M. Rudin, MD, PhD (Abstracts #2500–2502)  
Sidney Kimmel Cancer Center at Johns Hopkins  
Closing Remarks
Sunday, June 6, 2010

10:30 AM - 12:30 PM
SPECIAL SESSION

Training Program Directors’ Special Session—Addressing the Competencies: Professionalism and Practice-based Learning
Location: S404
CME credit: 2
Track(s): Special Session

**Michael P. Kosty, MD**—Chair
Scripps Clinic
*QOPI for Fellows Overview*

**Jill Gilbert, MD**
Vanderbilt University Medical Center
*Program Directors’ Experiences with QOPI for Fellows*

**Laurie Jean Lyckholm, MD**
Virginia Commonwealth University
*Program Directors’ Experiences with QOPI for Fellows*

**Timothy Jerome Moynihan, MD**
Mayo Clinic
*Professionalism*
11:30 AM - 12:45 PM
EDUCATION SESSIONS

Evaluating the Evidence and Marketing of Pharmacogenomic Tests
Location: E353
CME credit: 1.25
Track(s): Cancer Genetics; Developmental Therapeutics; Pediatric Oncology

Howard L. McLeod, PharmD—Chair
University of North Carolina at Chapel Hill
Overview of Pharmacogenomics: History, Development, and Role in FDA Labeling

Matthew P. Goetz, MD
Mayo Clinic
CYP2D6 Testing and Tamoxifen

Michael L. Maitland, MD, PhD
The University of Chicago
Clinical Cases in Pharmacogenomics

Lessons Learned from Clinical Trials in Gastrointestinal Stromal Tumor
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Sarcoma

Jean-Yves Blay, MD, PhD—Chair
University Claude Bernard
Combination Therapy with Established and Novel Targeted Agents to Improve Outcomes in Patients with Advanced GIST

Ronald P. DeMatteo, MD
Memorial Sloan-Kettering Cancer Center
The Role of Adjuvant Imatinib after Resection of Localized Primary GIST: An Update on the Z9001 Trial—Optimal Duration of Therapy

Michael C. Heinrich, MD
Oregon Health & Science University
Dosing the Unusual Patient with Non-exon 9/11 GIST

Survivorship in Lymphoma
Location: E354a
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care

David J. Straus, MD—Chair
Memorial Sloan-Kettering Cancer Center
Long-term Toxicities of Lymphoma Therapy

Rebecca L. Elstrom, MD
Weill Cornell Medical College
Imaging in Lymphoma Patients: Who, When, How, and How Long?

Jennifer Mills, MSW, MPH
New York University School of Social Work
Psychosocial Issues of Lymphoma Survivors: Cured but Not Healed?
Sunday, June 6, 2010

11:30 AM - 12:45 PM
MEET THE PROFESSOR SESSION

Electronic/Digital Resources in Oncology: Value versus Distraction (M07)-
TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Practice Management and Information Technology; Professional Development

Robert Stephen Miller, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY

Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors:
What to Do after Adjuvant Therapy? (C09)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Gastrointestinal (Colorectal) Cancer; Cancer Prevention/Epidemiology; Patient and Survivor Care

Jeffrey A. Meyerhardt, MD, MPH—Chair
Dana-Farber Cancer Institute
Beyond Standard Surgery and Chemotherapy to Lower the Risk of Tumor Recurrence in Patients with Resected Colorectal Cancer

David P. Ryan, MD
Massachusetts General Hospital
Pharmacologic Interventions to Lower the Risk of Tumor Recurrence in Patients with Resected Colorectal Cancer
11:30 AM - 1:00 PM
CLINICAL SCIENCE SYMPOSIUM

Optimizing Care of the Elderly and Underserved
Location: S100a
CME credit: 1.5
Track(s): Patient and Survivor Care; Geriatric Oncology

Gretchen Genevieve Kimmick, MD—Co-Chair
Duke University Medical Center
Jennifer A. Ligibel, MD—Co-Chair
Dana-Farber Cancer Institute

11:30 AM The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation. (Abstract #9000)

11:45 AM Predicting chemotherapy toxicity in older adults with cancer: A prospective 500-patient multicenter study. (Abstract #9001)

Discussion

12:00 PM Hyman Bernard Muss, MD (Abstracts #9000–9001)
University of North Carolina at Chapel Hill

12:15 PM Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): A population-based study. (Abstract #9002)

12:30 PM Factors contributing to high symptom burden during chemotherapy for advanced lung cancer: The risk of being underserved. (Abstract #9003)

Discussion

12:45 PM Cathy Bradley, PhD (Abstracts #9002–9003)
Virginia Commonwealth University
1:00 PM - 4:00 PM
PLENARY SESSION

Plenary Session including Science of Oncology Award and Lecture
Location: N Hall B1
CME credit: 3
Track(s): Special Session; General Oncology

Douglas W. Blayney, MD—Co-Chair
University of Michigan
Daniel F. Hayes, MD—Co-Chair
University of Michigan Medical Center

1:00 PM Frank McCormick, PhD—Science of Oncology Award Recipient
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
Success and Failure on the Ras Pathway

1:45 PM Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. (Abstract #LBA1)

Discussion
2:00 PM Elisabeth A. Eisenhauer, MD (Abstract #LBA1)
NCIC Clinical Trials Group

2:15 PM Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). (Abstract #2)

2:30 PM Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC). (Abstract #3)

Discussion
2:45 PM Martin J. Edelman, MD (Abstracts #2–3)
University of Maryland Greenebaum Cancer Center

3:05 PM A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. (Abstract #4)

Discussion
3:20 PM Vernon K. Sondak, MD (Abstract #4)
H. Lee Moffitt Cancer Center & Research Institute
Ipiilimumab: The Light at the End of the Tunnel?
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Developmental Therapeutics—Experimental Therapeutics
Display Time: 2:00 PM - 6:00 PM
Display Location: E450b
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E Hall D2
CME credit: 1
Track(s): Developmental Therapeutics

Patrick Schoffski, MD, MPH—Co-Chair
Catholic University Leuven
Ross A. Soo, MD—Co-Chair
National University Health System

Discussion
5:00 PM  Tomislav Dragovich, MD, PhD (Abstracts #3015–3018)
Arizona Cancer Center
Combinations Involving Erlotinib

Discussion
5:15 PM  David Flockhart, MD, PhD (Abstracts #3019–3022)
Indiana University School of Medicine
Improving Therapeutic Index with Diverse Methods of Modern Clinical Pharmacology

Discussion
5:30 PM  Elizabeth A. Eisenhauer, MD (Abstracts #3023–3027)
NCIC Clinical Trials Group
Design of Early-development Combination Trials

Discussion
5:45 PM  Jan H. M. Schellens, MD, PhD (Abstracts #3028–3033)
Netherlands Cancer Institute
Applying PK/PD Principles to Development of Anticancer Agents

Brd. 1  A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. (Abstract #3015)

Brd. 2  Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. (Abstract #3016)

Brd. 3  A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #3017)

Brd. 4  Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors. (Abstract #3018)

Brd. 5  Association of the hemochromatosis (HFE) gene with pazopanib-induced transaminase elevations in renal cell carcinoma. (Abstract #3019)
Sunday, June 6, 2010

Brd. 6  
Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan. (Abstract #3020)  

Brd. 7  
Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. (Abstract #3021)  

Brd. 8  
Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial. (Abstract #3022)  

Brd. 9  
Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors. (Abstract #3023)  
P. Tresca, D. Tosi, L. van Doorn, H. Fontaine, A. V. Gaast, C. Veyrat-Follet, C. Oprea, V. Dieras, F. Eskens

Brd. 10  
A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. (Abstract #3024)  
A. A. Adjei, J. A. Sosman, G. K. Dy, W. Ma, G. J. Fetterly, D. Skupien, J. A. Means, R. Savage, F. Chai, I. Puzanov

Brd. 11  
Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer. (Abstract #3025)  

Brd. 12  
Phase (P) I study of PF-00299804 (PF) combined with figitumumab (Fl; CP-751,871) in patients (pts) with advanced solid tumors (ASTs). (Abstract #3026)  
E. Calvo, W. Ma, A. W. Tolcher, M. Hidalgo, J. Soria, R. Bahleda, A. Gualberto, L. J. Denis, R. D. Millham, A. A. Adjei

Brd. 13  
A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. (Abstract #3027)  
G. Giaccone, A. Rajan, R. J. Kelly, M. Gutierrez, S. Kummar, M. Yancey, J. J. Ji, Y. Zhang, R. E. Parchment, J. H. Doroshow

Brd. 14  
Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. (Abstract #3028)  

Brd. 15  
Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data. (Abstract #3029)  

Brd. 16  
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. (Abstract #3030)  
Brd. 17  Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors. (Abstract #3031)

Brd. 18  Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. (Abstract #3032)

Brd. 19  Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study. (Abstract #3033)
Sunday, June 6, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Gynecologic Cancer
Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E Arie Crown Theater
CME credit: 1
Track(s): Gynecologic Cancer

Claire F. Verschraegen, MD—Co-Chair
University of New Mexico
Seiko Diane Yamada, MD—Co-Chair
The University of Chicago

Discussion
5:00 PM  Carol Aghajanian, MD (Abstracts #5009–5015)
Memorial Sloan-Kettering Cancer Center
Old Wines in New Bottles

Discussion
5:15 PM  Michael J. Birrer, MD, PhD (Abstracts #5016–5023)
Harvard Medical School, Massachusetts General Hospital
Biomarkers in Ovarian Cancer: Ready for Prime Time?

Discussion
5:30 PM  Angeles Alvarez Secord, MD (Abstracts #5024–5029)
Duke University Medical Center
What’s New in Endometrial Cancer?

Discussion
5:45 PM  Martin Stockler, MBBS, FRACP, MHS (Abstracts #5030–LBA5033)
NHMRC Clinical Trials Centre, University of Sydney
Mining Phase III Studies: Gold or Quicksilver?

Brd. 1  A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. (Abstract #5009)

Brd. 2  A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study. (Abstract #5010)

Brd. 3  A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer. (Abstract #5011)
B. B. Benigno, M. O. Burrell, P. Daugherty, P. Hernandez

Brd. 4  Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study. (Abstract #5012)

Brd. 5  PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. (Abstract #LBA5012b)
Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). (Abstract #5014)

Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study. (Abstract #5015)

A KRAS variant as a biomarker of ovarian cancer risk. (Abstract #5016)
J. B. Weidhaas

Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival. (Abstract #5017)
V. Engelstaedter, M. C. Cristea, J. E. Garber, S. L. Neuhausen, P. H. Frankel, S. Sand, L. Steele, U. Matulonis, J. Liu, J. Weitzel

Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study. (Abstract #5018)

Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients. (Abstract #5019)

Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas. (Abstract #5020)
D. S. Tan, M. Iravani, M. B. Lambros, A. Mackay, C. Gourley, A. Williams, W. G. McCluggage, A. Ashworth, S. B. Kaye, J. S. Reis-Filho

A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer. (Abstract #5021)
J. S. Ferriss, Y. Kim, D. Theodorescu, L. R. Duska, J. Lee

Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC). (Abstract #5022)

Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. (Abstract #5024)

Impact of microsatellite instability in overall survival of women with endometrial cancer. (Abstract #5025)
J. C. Rocha, C. B. Chaves, V. P. Leite, F. C. Moreira, D. M. Ramalho

Evaluation of insulin resistance among endometrial cancer patients. (Abstract #5026)

Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer. (Abstract #5027)
J. P. Chino, E. Jones, A. Berchuck, L. Havrilesky

Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer. (Abstract #5028)
Sunday, June 6, 2010

Brd. 21  A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer. (Abstract #5029)  

Brd. 22  Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182). (Abstract #5030)  

Brd. 23  Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial. (Abstract #5031)  
J. Kurtz, F. Hilpert, A. Dorum, A. Veillard, L. Elit, M. Buck, E. Petru, N. Reed, G. Scambia, N. Varsellona

Brd. 24  Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. (Abstract #5032)  
D. R. Spriggs, A. Iasonos, P. Sabbatini, R. E. O’Cearbhaill, H. T. Thaler

Brd. 25  Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial. (Abstract #LBA5033)  
S. Pignata, G. Scambia, A. Savarese, R. Sorio, E. Breda, F. Legge, V. Gebbia, P. Musso, C. Gallo, F. Perrone, on behalf of MITO Group
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Pediatric Oncology
Display Time: 2:00 PM - 6:00 PM
Display Location: S Hall A2
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S504
CME credit: 1
Track(s): Pediatric Oncology

Rochelle Bagatell, MD—Co-Chair
Children’s Hospital of Philadelphia

Maryam Fouladi, MD—Co-Chair
Cincinnati Children’s Hospital Medical Center

Discussion
5:00 PM  Stephen Hunger, MD (Abstracts #9521–9528)
The Children’s Hospital
Next Generation Biomarkers in Leukemia

Discussion
5:20 PM  Frank M. Balis, MD (Abstracts #9529–9538)
Children’s Hospital of Philadelphia
New Agents or Combinations in Pediatric Cancer

Discussion
5:40 PM  Mark W. Kieran, MD, PhD (Abstracts #9539–9542)
Dana-Farber Cancer Institute
Advances in CNS Therapy

Brd. 39A  High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL). (Abstract #9521)
L. E. Hogan, C. Mason, J. Meyer, J. Wang, Z. Tang, S. Brown, D. J. Morrison,
S. Hunger, E. A. Raetz, W. L. Carroll

Brd. 39B  Association of a genetic variant in the ABCC2 gene with high methotrexate plasma concentrations in pediatric malignancies. (Abstract #9522)
M. M. Hagleitner, M. J. Coenen, M. Schrauwen, S. H. Vermeulen, E. S. de Bont,
P. Hoogerbrugge, D. M. Te Loo

Brd. 39F  Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients. (Abstract #9523)
A. S. Lehmann, A. Egbelakin, S. K. Quinney, L. Li, J. L. Renbarger

Brd. 39G  ABC drug transporter gene expression in neuroblastoma. (Abstract #9524)
S. Cialfi, H. P. McDowell, P. Altavista, R. Boldrini, S. Bosco, A. Clerico, A. Jenkner,
G. Kokai, B. Pizer, C. Dominici

Brd. 39H  Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth. (Abstract #9525)
F. I. Arnaldez, C. L. Yeung, P. J. Grohar, L. J. Helman

Brd. 40A  Genetic variants in MDR1 and CYP3A5 and vincristine toxicity in children with acute lymphoblastic leukemia. (Abstract #9526)
D. M. Te Loo, M. M. Hagleitner, R. van Schie, I. M. van der Sluis, M. J. Coenen,
P. Hoogerbrugge

Brd. 40B  Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children’s Oncology Group report. (Abstract #9527)
B. Shiramizu, S. Goldman, I. Kusao, M. Agsalda, J. C. Lynch, L. Harrison,
T. G. Gross, W. Sanger, S. L. Perkins, M. S. Cairo, Children’s Oncology Group
Brd. 40F Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry. (Abstract #9528)
E. Petricoin, M. M. Ross, W. Zhou, D. Tamburro, A. Luchini, L. A. Liotta, R. E. Scully, T. L. Miller, S. E. Sallan, S. E. Lipshultz

Brd. 40G A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of Aurora A kinase: A Children’s Oncology Group Phase I Consortium study. (Abstract #9529)

Brd. 40H A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children’s Oncology Group Phase I Consortium study. (Abstract #9530)

Brd. 41A A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors. (Abstract #9531)

Brd. 41B Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study. (Abstract #9532)

Brd. 41C Phase II window of irinotecan + carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03–099. (Abstract #9533)

Brd. 41D Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma. (Abstract #9534)

Brd. 41E Phase II trial of pemetrexed in children with refractory solid tumors: A Children’s Oncology Group study. (Abstract #9535)
A. B. Warwick, S. Malempati, M. D. Krailo, A. S. Melemed, P. C. Adamson, S. Blaney

Brd. 41F Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature b-NHL: A Children’s Oncology Group report. (Abstract #9536)
M. S. Cairo, J. C. Lynch, L. Harrison, S. L. Perkins, B. Shiramizu, T. G. Gross, W. Sanger, S. Goldman

Brd. 41G A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin Disease (HD): A Children’s Oncology Group study (COG) study. (Abstract #9537)

Brd. 41H Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling interference in Ewing’s sarcoma (ES). (Abstract #9538)
Br. 42A  A pilot study using carboplatin, vincristine, and temozolomide for children with progressive/symptomatic low-grade glioma: A Children’s Oncology Group (COG) study. (Abstract #9539)  
M. M. Chintagumpala, A. Adesina, M. C. Morriss, T. Zhou, E. Holmes, C. C. Lau, A. J. Gajjar

Br. 42B  Phase I study of single-agent perifosine for recurrent pediatric solid tumors. (Abstract #9540)  

Br. 42C  Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma. (Abstract #9541)  

Br. 42D  Effect of hypothalamic/pituitary radiation exposure in low doses on fertility in female childhood cancer survivor study (CCSS) participants. (Abstract #9542)  
SUNDAY

Sunday, June 6, 2010

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Gastrointestinal (Colorectal) Cancer
Location: S Hall A2
Tracks(s): Gastrointestinal (Colorectal) Cancer

**Brd. 1A** PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. (Abstract #3534)

**Brd. 1C** Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. (Abstract #3536)

**Brd. 1D** Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). (Abstract #3537)

**Brd. 1E** Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC). (Abstract #3538)

**Brd. 1F** Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC). (Abstract #3539)

**Brd. 1G** Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). (Abstract #3540)

**Brd. 1H** Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). (Abstract #3541)

**Brd. 2A** CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC). (Abstract #3542)

**Brd. 2B** FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). (Abstract #3543)
A. Falcone, F. Loupakis, S. Cupini, E. Cortesi, A. Buonadonna, G. Tomasello, M. Banzi, M. Ronzoni, A. Zaniboni, G. Masi

**Brd. 2C** Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). (Abstract #3544)
Brd. 2D  Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314). (Abstract #3545)

Brd. 2E  Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis treated with contemporary chemotherapy. (Abstract #3546)

Brd. 2F  Outcome of 123 patients (pts) with peritoneal carcinomatosis (PC)—Limited metastases from colorectal cancer (CRC) and appendiceal adenocarcinoma (ADC): The British Columbia Cancer Agency (BCCA) experience. (Abstract #3547)
F. Aubin, S. Gill, C. Speers, H. F. Kennecke

Brd. 2G  Outcome of colorectal liver metastases vanishing under chemotherapy and finally missing after surgery. (Abstract #3548)

Brd. 2H  Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C. (Abstract #3549)

Brd. 3A  FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy. (Abstract #3550)

Brd. 3B  CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC) patients. (Abstract #3551)
C. Garufi, A. Torsello, C. Campanella, G. M. Ettorre, G. Vennarecci, E. Melucci, M. Zeuli, I. Sperduti, A. Gelibter, F. Cognetti

Brd. 3C  Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people. (Abstract #3552)

Brd. 3D  Phase II trial alternating mFOLFOX 6 and FOLFIRI (FIREFOX) regimens in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0701). (Abstract #3553)
Y. Akagi, S. Tokunaga, Y. Emi, Y. Kakeji, T. Kusumoto, H. Baba, Y. Ogata, T. Tanaka, K. Shirouzu, Y. Maehara, Kyushu Study Group of Clinical Cancer (KSCC)

Brd. 3E  Analysis of prognostic factors for 60-day mortality: Evaluation of a randomized phase III trial investigating FUFIRI versus mIROX as first-line treatment of metastatic colorectal cancer (mCRC). (Abstract #3554)
C. Giessen, A. Schalhorn, S. Stintzing, V. Heinemann

Brd. 3F  Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial. (Abstract #3555)

Brd. 3H A randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. (Abstract #3557) N. E. Kemeny, W. R. Jarnagin, M. Capanu, Y. Fong, A. Gewirtz, R. P. DeMatteo, M. I. D’Angelica


Brd. 4C Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study. (Abstract #3560) G. J. Poston, E. O’Grady, H. Z. Malik, S. W. Fenwick, M. Terlizzo, C. Byrne, M. Rees, J. Figueras, R. Adam

Brd. 4D Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy. (Abstract #3561) H. Wilke, S. Siena, A. H. Loos, K. Berghoff, C. Kohne, E. Van Cutsem

Brd. 4E Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144). (Abstract #3562) T. Winder, W. Zhang, D. Yang, Y. Ning, P. O. Bohanes, S. Hu-Lieskovan, D. J. Mauro, C. Langer, E. K. Rowinsky, H. Lenz


Brd. 4G Early magnesium modifications as a surrogate markers of efficacy of cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer patients. (Abstract #3564) B. Vincenzi, D. Santini, S. Galluzzo, F. Loupakis, P. Correale, R. Addeo, S. Del Prete, A. Falcone, G. Francini, G. Tonini

Brd. 4H Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFI RI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. (Abstract #3565^) M. Peeters, A. Cervantes-Ruiperez, A. Strickland, T. Ciuleanu, P. N. Mainwaring, V. I. Tzekova, A. Santoro, C. W. Johnson, A. Zhang, J. L. Gansert

Brd. 5A Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. (Abstract #3566^) S. Siena, J. Tabernero, D. Cunningham, P. Koralewski, P. Ruff, M. Rother, C. W. Johnson, A. Zhang, J. L. Gansert, J. Douillard
Brd. 5B Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). (Abstract #3567)
A. Sood, D. McClain, R. Seetharam, M. Al-rahamneh, A. Kaubisch, L. Rajdev, K. Tanaka, J. Mariadason, S. Goel

Brd. 5C Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer. (Abstract #3568)
E. Melucci, S. Conti, M. G. Diodoro, A. Torsello, M. Zeuli, B. Casini, C. Ercolani, F. Cognetti, C. Garufi, M. Mottolese

Brd. 5D Economic impact in the management of dermatologic toxicities (dTs) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer. (Abstract #3569)
J. H. Borovicka, M. F. Mulcahy, C. Calahan, D. P. West, M. E. Lacouture

Brd. 5E Cetuximab plus FOLFIRI: Final data from the CRRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. (Abstract #3570)

Brd. 5F Impact of the amount of tumor cells in tissue samples for detection of KRAS mutations in colorectal cancer. (Abstract #3571)

Brd. 5G KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results. (Abstract #3572)
F. Bibeau, H. Frugier, E. Crapez, P. Lamy, M. Ychou, F. Boissière-Michot

Brd. 5H Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. (Abstract #3573)

Brd. 6A Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis-targeting therapy in colorectal cancer: Novel clinical observation based upon recently discovered CEA biology. (Abstract #3574)

Brd. 6B Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis. (Abstract #3575)
G. Falprecht, K. Trautmann, M. Reimann, R. Haase, F. Ziemssen, G. Ehninger, H. Reichmann, T. Ziemssen

Brd. 6C Gene expression profiles to predict outcome following liver resection in patients with metastasis of colorectal cancer. (Abstract #3576)

Brd. 6D Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer. (Abstract #3577)

Brd. 6E Selecting colorectal cancer (CRC) patients for therapy based on mutational analysis by next generation sequencing: Are we analyzing the appropriate tumor? (Abstract #3578)
Sunday, June 6, 2010

Brd. 6F  Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer. (Abstract #3579)
J. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. Kim

Brd. 6G  Detector-C: A blood-based IVD with high sensitivity and specificity for early detection of colorectal cancer. (Abstract #3580)

Brd. 6H  Correlation between bevacizumab-related hypertension and response in mCRC patients. (Abstract #3581)

Brd. 7A  Personalized adjuvant chemotherapy for colorectal cancer based on an individual 50% inhibitory area under the concentration curve using collagen gel droplet embedded culture-drug sensitivity test. (Abstract #3582)
T. Ochiai, K. Nishimura, T. Watanabe, M. Kitajima, T. Hashiguchi, A. Nakatani, A. Muraki, N. Sakuyama, S. Futagawa, I. Nagaoka

Brd. 7B  Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. (Abstract #3583)
S. Lee, H. Won, E. Son, J. Lee, S. Park, J. Park, Y. Park, H. Lim, W. Kang

Brd. 7C  Are MGMT promoter methylation and EGFR mutations early markers of tumor progression in colorectal cancer? (Abstract #3584)
T. Wenner, B. Metzger, L. Chambeau, G. Mahon, M. Pauly, J. Kaiser, G. J. Berchem, M. Dicato

Brd. 7D  Prospective study of paresthetic neurotoxicity from oxaliplatin-based regimens in the treatment of colorectal cancer. (Abstract #3585)

Brd. 7E  Prognostic values of micrornas in patients with Dukes’ B and C colon cancer. (Abstract #3586)

Brd. 7F  Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. (Abstract #3587)

Brd. 7G  New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC). (Abstract #3588)

Brd. 7H  Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of their status in related metastases. (Abstract #3589)

Brd. 8A  Association of GRP78 polymorphisms with response and TTP in patients with mCRC treated with FOLFOX/BV or XELOX/BV. (Abstract #3590)
H. Lenz, W. Zhang, D. Yang, A. B. El-Khoueiry, Y. Ning, A. Pohl, P. O. Bohanes, K. D. Danenberg, T. Winder

Brd. 8B  Lessons from PETACC 2: No prognostic impact of KRAS-/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy. (Abstract #3591)
D. E. Aust, M. P. Lutz, M. Mauer, I. Popov, G. B. Baretton, L. Bedenne, A. Carrato, C. Kohne
Brd. 8C Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. (Abstract #3592)

Brd. 8D Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer. (Abstract #3593)

Brd. 8E Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study. (Abstract #3594)

Brd. 8F Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS). (Abstract #3595)
T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey, on behalf of the ARIES Study Investigators

Brd. 8G Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BP). (Abstract #3596)
A. L. Cohn, T. Bekaii-Saab, J. C. Bendell, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey, on behalf of the ARIES Study Investigators

Brd. 8H Molecular classes in CRC: Characterization of MSI by expression profiling in the translational study of the PETACC 3-EORTC 40993-SAKK 60-00 trial. (Abstract #3597)
M. Delorenzi, E. Budinska, V. Popovici, H. Estrella, A. Pavlicek, P. Yan, S. Weinrich, F. Bosman, S. Tejpar, A. Roth

Brd. 9A Impact of ethnicity and insurance on colorectal cancer outcomes. (Abstract #3598)
K. B. Young, J. D. Acoba

Brd. 9B Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumab in mCRC. (Abstract #3599)

Brd. 9C Use of a four gene panel of epigenetic markers to classify serrated colonic adenomas with CpG island methylator phenotype. (Abstract #3600)
J. Jenab-Wolcott, Y. Yao, W. Yan, S. Schulte, S. Harada, C. Brensinger, B. J. Giantonio, A. Rustgi, A. Sepulveda

Brd. 9D Prognostic factors for actual 5-year survivors after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal surface disease. (Abstract #3601)
P. Shen, G. Watson, J. H. Stewart IV, T. P. McCoy, E. A. Levine

Brd. 9E Global microRNA expression and survival in patients with metastatic colorectal cancer in third-line treatment with cetuximab and irinotecan. (Abstract #3602)
J. V. Schou, J. S. Johansen, B. V. Jensen, D. L. Nielsen, M. Kruhoffer

Brd. 9F Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis. (Abstract #3603)
C. D. Mullins, K. A. Bikov, N. C. Onwudiwe, B. S. Seal, N. Hanna
Sunday, June 6, 2010

Brd. 9G  Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of over 6,000 patients in randomized phase II and III studies. (Abstract #3604)

Brd. 9H  Adjuvant chemotherapy for colorectal cancer in the over 75 age group: A 10-year experience. (Abstract #3605)
R. M. Bambury, N. H. Coleman, M. M. Tharmabala, D. Gough, W. Grogan, O. S. Breathnach, Department of Medical Oncology

Brd. 10A  Predictors of lymph node count in colon adenocarcinoma. (Abstract #3606)
K. L. Mathis, R. Pendlimari, E. Green, D. J. Sargent, H. Nelson

Brd. 10B  The number of lymph nodes is influenced by the MSI phenotype in resected colorectal cancers (CRC): A study in a large monocentric series. (Abstract #3607)

Brd. 10C  Clinicopathologic factors and outcomes associated with lymph node retrieval in resectable colon cancer. (Abstract #3608)

Brd. 10D  Clinicopathologic significance of p53, hypoxia-inducible factor 1 alpha, and vascular endothelial growth factor expression in colorectal cancer. (Abstract #3609)

Brd. 10E  Mutation-based detection of molecular tumor margins in colorectal liver metastasis. (Abstract #3610)

Brd. 10F  Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients. (Abstract #3611)

Brd. 10G  Predictor-C: A tissue-based IVD predicting progression of disease in colorectal cancer UICC stages II or III. (Abstract #3612)
H. Adams, B. Hinzmann, T. Mayr, I. Klaman, A. Rosenthal

Brd. 10H  Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data. (Abstract #3613)

Brd. 11A  Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients. (Abstract #3614)
C. G. Ferreira, I. Zalcberg-Renault, F. M. Vieira, M. H. Bonamino, M. Zalis

Brd. 11B  Vitamin D levels and survival in colorectal cancer (CRC). (Abstract #3615)

Brd. 11F  Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978–1995 versus 1996–2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)—Findings from the ACCENT dataset. (Abstract #3616)

Brd. 11G  Genetic polymorphism and toxicity of adjuvant FOLFOX-4 chemotherapy in Korean colon cancer patients. (Abstract #3617)
H. Chang, S. Han, S. Kim, K. Lee, T. Kim, Y. Park, S. Shin, D. Oh, S. Im
<table>
<thead>
<tr>
<th>Abstracts</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brd. 11H</td>
<td>Reproductive history and risk of colorectal cancer in postmenopausal women. (Abstract #3618)</td>
<td>A. Zervoudakis, A. Schatzkin, H. D. Strickler, Y. Park, A. Hollenbeck, M. J. Gunter</td>
</tr>
<tr>
<td>Brd. 12A</td>
<td>The effect of opposed versus unopposed hormone replacement therapy (HRT) on the risk of colorectal cancer (CRC). (Abstract #3619)</td>
<td>K. Lin, W. Y. Cheung, J. Y. Lai, E. L. Giovannucci</td>
</tr>
<tr>
<td>Brd. 12F</td>
<td>Presurgical diagnostic accuracy of five imaging procedures in chemotherapy-naive (group A) or chemotherapy-pretreated (group B) patients with colorectal liver metastases (Italian PROMETEO Study). (Abstract #3621)</td>
<td>F. L. Rojas Llimpe, F. Di Fabio, G. Ercolani, C. Serra, P. Castellucci, S. Pini, V. Mutri, R. Gollieri, A. Martoni, C. Pinto</td>
</tr>
<tr>
<td>Brd. 12H</td>
<td>Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer. (Abstract #3623)</td>
<td>D. Villa, L. Hedden, S. Peacock, H. F. Kennecke</td>
</tr>
<tr>
<td>Brd. 13A</td>
<td>Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC). (Abstract #3624)</td>
<td>J. Ho, S. Gill, R. Woods, H. F. Kennecke</td>
</tr>
<tr>
<td>Brd. 13B</td>
<td>Characterize medical care during disease phases in metastatic colorectal cancer. (Abstract #3625)</td>
<td>X. Song, B. Barber, Z. Zhao, C. Gregory, Z. Cao</td>
</tr>
<tr>
<td>Brd. 13F</td>
<td>The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening. (Abstract #3629)</td>
<td>C. Arslan, S. Killickap, D. Rama, S. Yalcin</td>
</tr>
<tr>
<td>Brd. 13G</td>
<td>To detect Lynch syndrome patients, which colorectal cancers should be tested for microsatellite instability? (Abstract #3630)</td>
<td>B. M. Boman, K. Orio, N. J. Petrelli, M. Parker, C. Somerman, Z. Ali-Khan Catts</td>
</tr>
<tr>
<td>Brd. 14A</td>
<td>Results of a German noninterventional study (NIS) of cetuximab-based therapy in pretreated patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #3632)</td>
<td>C. Jehn, K. Stenzel, L. Böning, H. Kröning, K. Possinger, D. Lueftner</td>
</tr>
</tbody>
</table>
Sunday, June 6, 2010

Brd. 14B Timing of failure of resected rectal cancer: What is the appropriate duration of postoperative imaging? (Abstract #3633)

Brd. 14C Preoperative chemoradiotherapy (QRTP) and total mesorectal excision (TME) by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes. (Abstract #3634)

Brd. 14D A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum. (Abstract #3635)
A. D. McCollum, D. M. Kocs, P. Chada, D. A. Richards, Y. Wang, K. A. Boehm, L. Asmar, L. Munoz

Brd. 14E Preoperative chemoradiation (CRT) with concurrent capecitabine and irinotecan in MRI-defined locally advanced rectal cancer: Relationship of histologic downstaging to long-term survival end points. (Abstract #3636)

Brd. 14F Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): A randomized controlled phase II study. (Abstract #3637)
R. Marechal, B. Vos, M. Polus, T. Delaunoit, M. Peeters, P. Demetter, P. Van Houtte, A. Demols, J. Van de Stadt, J. Van Laethem

Brd. 14G Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: A phase II multicenter study of the Dutch ColoRECTal Cancer Group. (Abstract #3638)

Brd. 14H Effect of preoperative radiotherapy on local recurrences in rectal cancer patients with PIK3CA mutation. (Abstract #3639)
Y. He, L. van ’t Veer, M. Lopez Yurda, I. Mikolajewska-Hanclich, I. D. Nagtegaal, C. J. Van De Velde, C. A. Marijnen

Brd. 15A Association of intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (SWOG 9304). (Abstract #3640)

Brd. 15B Use of EGF a+61G and TS-5’UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery. (Abstract #3641)

Brd. 15C Predictors of site-specific recurrence following combined modality therapy for locally advanced rectal cancer. (Abstract #3642)

Brd. 15D Correlation of single nucleotide polymorphisms (SNPs) of hypoxia-related genes with pathologic complete response (pCR) following neoadjuvant chemoradiation (chemoXRT) for locally advanced rectal cancer. (Abstract #3643)
Brd. 15E Patterns of recurrence in rectal cancer treated with neoadjuvant chemoradiotherapy and TME. (Abstract #3644)

Brd. 15G Local excision after neoadjuvant chemoradiation for rectal cancer: Is it an acceptable treatment option? (Abstract #3646)
B. Brenner, R. Brenner, O. Puirm, N. Peled, E. Idelevich, B. Nisenbaum, E. Fenig, A. Suitches

Brd. 15H Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer. (Abstract #3647)

Brd. 16A Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy. (Abstract #3648)

Brd. 16B Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. (Abstract #3649)

Brd. 16C KRAS mutation status and clinical outcome of preoperative chemoradiation (CRT) with or without cetuximab in locally advanced rectal cancer (LARC): A pooled analysis of two phase II trials. (Abstract #3650)
S. Kim, E. Shim, H. Yeo, Y. Hong, D. Kim, T. Kim, J. Kim, S. Im, K. Jung, H. Chang

Brd. 16D Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone. (Abstract #3651)

Brd. 16E Relationship of completion of planned treatment and timing of adjuvant chemotherapy to survival in patients with colorectal cancer (CRC). (Abstract #3652)

Brd. 16F EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC). (Abstract #3653)

Brd. 16G Evaluation of serum/plasma VEGF/e-selectin and 18F-FDG PET uptake after panitumumab infusion in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTRT) (StarPan/STAR-02 phase II study). (Abstract #3654)
S. Pini, F. Di Fabio, P. Di Tullio, E. Bucca, T. Latiano, E. Perrone, M. Gion, E. Maiello, A. Martoni, C. Pinto

Brd. 16H Treatment of rectal carcinoid tumors and role of preoperative imaging. (Abstract #3655)
T. Akasu, K. Sato, S. Yamamoto, T. Matsuda, Y. Saito

Brd. 17A Do older Americans undergo stoma reversal following low anterior resection for rectal cancer? (Abstract #3656)
C. M. Dodgion, B. A. Neville, S. R. Lipsitz, D. Schrag, C. C. Greenberg

Brd. 17B Bowel dysfunction after sphincter-preserving surgery. (Abstract #3657)
Brd. 17C  The prognostic significance of tumor human papillomavirus status in patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. (Abstract #3658)
H. Yhim, E. Song, N. Lee, J. Hwang, H. Shim, I. Chung, H. Park, M. Park, C. Yim
2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Gastrointestinal (Noncolorectal) Cancer
Location: S Hall A2
Tracks(s): Gastrointestinal (Noncolorectal) Cancer

Brd. 18A Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4038)
H. Toh, P. Chen, B. I. Carr, J. J. Knox, S. Gill, J. Qian, Q. Qin, J. L. Ricker, D. M. Carlson, W. Yong

Brd. 18B Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. (Abstract #4039)

Brd. 18C Clinicopathologic characteristics of microsatellite instability (MSI) tumors in resected gastric cancer patients. (Abstract #4040)
H. J. Cho, J. Kim, S. Im, M. Kim, S. Han, D. Oh, T. Kim, H. Yang, W. Kim, Y. Bang

Brd. 18D Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer. (Abstract #4041)

Brd. 18E Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer. (Abstract #4042)
H. Li, F. Zhu, Y. Cao, L. Zhai, T. Lin

Brd. 18F KRAS, BRAF mutations, and HER2 expression in patients operated for pancreatic adenocarcinomas. (Abstract #4043)
N. A. Schultz, A. Roslin, M. Heeran, I. J. Christensen, E. V. Høgdall, T. Horn, M. Wojdemann, E. Balslev, J. S. Johansen

Brd. 18G Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs). (Abstract #4044)

Brd. 18H Comparative effectiveness of radioembolization and the standard of care for hepatocellular carcinoma: Is a randomized survival study feasible? (Abstract #4045)
R. Salem, A. Riaz, R. Lewandowski, L. Kulik, M. Abecassis, M. F. Mulcahy

Brd. 19A Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study. (Abstract #4046)

Brd. 19B Association of germline polymorphisms in genes involved in the CD44 pathway and clinical outcome in localized gastric adenocarcinoma (GA). (Abstract #4047)

Brd. 19C (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. (Abstract #4048)
Sunday, June 6, 2010

Brd. 19D  Setting the standard for advanced pancreatic ductal adenocarcinoma (A-PDAC) in 2010: Meta-regression and power analysis of phase III randomized clinical trials (RCT) evaluating gemcitabine (GEM) in combination with cisplatin (CIS), oxaliplat in (L-OHP), or capecitabine (CAP). (Abstract #4049)  
I. Sperduti, E. Bria, D. Giannarelli, M. Di Maio, A. Gelibter, V. Vaccaro, F. Cuppone, F. Cognetti, M. Milella

Brd. 19E  Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ). (Abstract #4050)  

Brd. 19F  Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/α-fetoprotein (AFP) and bilirubin (bil) levels. (Abstract #4051^)  

Brd. 19G  Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). (Abstract #4052)  

Brd. 19H  A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). (Abstract #4053)  

Brd. 20A  Association of germine polymorphism in the SPARC gene and tumor recurrence in patients with resected gastric cancer. (Abstract #4054)  
P. M. Wilson, T. Winder, D. G. Power, D. Yang, W. Zhang, Y. Ning, P. O. Bohanes, L. H. Tang, M. A. Shah, H. Lenz

Brd. 20B  Ten-year expericence of percutaneous radiofrequency ablation for hepatocellular carcinoma. (Abstract #4055)  

Brd. 20C  An analysis of the effect of smoking status on erlotinib pharmacokinetics (PKs), toxicity, and ability to dose escalate in a phase II study of erlotinib in advanced pancreatic cancer (PC). (Abstract #4056)  

Brd. 20D  Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. (Abstract #4057)  
T. Sato, T. Sato, T. Ohtsu

Brd. 20E  A multicenter phase II trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. (Abstract #4058)  

Brd. 20F  Effect of hyperacuter immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data. (Abstract #4059)  
Brd. 20G Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. (Abstract #4060)
V. Heinemann, M. P. Ebert, T. Pinter, P. Bevan, N. G. Neville, C. Mala

Brd. 20H Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912. (Abstract #4061)

Brd. 21A A single-institution (MSKCC) analysis of incidence and clinical outcomes in patients with thromboembolic events and exocrine pancreas cancer. (Abstract #4062)
A. S. Epstein, C. Crosbie, S. Gardos, G. A. Soff, M. A. Shah, D. P. Kelsen, E. M. O'Reilly

Brd. 21B Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy. (Abstract #4063)
Y. Shao, Z. Lin, T. Chen, C. Hsu, Y. Shen, A. Cheng

Brd. 21C E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus. (Abstract #4064)

Brd. 21D Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT). (Abstract #4065)

Brd. 21E Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial. (Abstract #4066)
S. Cascinu, R. Berardi, A. F. Sobrero, R. Labianca, P. Bidoli, S. Siena, D. Ferraris, S. Barni, R. Cengare, M. Monteforte

Brd. 21F Significance of pathologic response to preoperative therapy in pancreatic cancer. (Abstract #4067)
Y. S. Chun, H. S. Cooper, J. C. Watson, J. P. Hoffman

Brd. 21H Predictive value of restaging after induction concurrent chemoradiotherapy (CCRT) for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (GEJ). (Abstract #4069)

M. Geissler, R. Hofheinz, M. H. Moehler, M. Bitzer, S. H. Boeck, A. Reinacher-Schick, V. Heinemann, J. Harder

Brd. 22B Is minimally invasive oesophagectomy for cancer decreasing pulmonary complications? Results from a case-control study. (Abstract #4071)
N. Briez, G. Piessen, A. Claret, J. Triboulet, C. Mariette

Brd. 22C Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05). (Abstract #4072)

Brd. 22D Phase II trials (P2T) in advanced pancreatic cancer (APC): Systematic review with focus on the design, entry criteria, and endpoints used. (Abstract #4073)
A. Stathis, D. J. Renouf, M. J. Moore
Sunday, June 6, 2010

Brd. 22E  Extended safety and efficacy data on triple combination therapy using S-1, cisplatin, and paclitaxel in patients with advanced gastric cancer in a multicenter phase II study. (Abstract #4074)

Brd. 22F  Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial. (Abstract #4075)

Brd. 22G  A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naive pancreatic adenocarcinoma (PC). (Abstract #4076)

Brd. 22H  The impact of socioeconomic status upon specialist consultation, treatment, and outcomes for pancreatic adenocarcinoma. (Abstract #4077)
J. E. Carroll, M. M. Murphy, J. K. Smith, J. P. Simons, S. Ng, Z. Zhou, J. F. Tseng

Brd. 23A  Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches. (Abstract #4078)
M. Ter-Ovanesov, J. Kulig, F. Munasypov, Y. Bang, S. Yalcin, A. Roth, J. R. Zalcberg, E. B. Ecstein-Fraisse, C. Wu

Brd. 23B  Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone. (Abstract #4079)

Brd. 23C  Hereditary gastric cancer caused by germline CDH1 gene mutations in the Netherlands. (Abstract #4080)

Brd. 23D  Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients. (Abstract #4081)

Brd. 23E  Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts). (Abstract #4082)

Brd. 23F  A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). (Abstract #4083)
A. X. Zhu, R. S. Finn, M. F. Mulcahy, J. S. Gurtler, W. Sun, J. D. Schwartz, P. Rojas, A. Dontaabhaktuni, H. Youssoufian, K. E. Stuart

Brd. 23G  Prognostic significance of cell cycle regulating protein expressions in gastric carcinoma patients receiving adjuvant chemotherapy. (Abstract #4084)

Brd. 23H  Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer. (Abstract #4085)

Brd. 24A  Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC). (Abstract #4086)
Brd. 24B Outcome of patients with recurrent hepatocellular carcinoma after liver transplantation. (Abstract #4087)
A. Finkenstedt, I. W. Gräziadei, H. Zoller, K. Nachbaur, W. Mark, W. Vogel

Brd. 24C Relapse of hepatocellular carcinoma (HCC) after liver transplantation (LT): A single-center analysis on 139 patients in the sorafenib era. (Abstract #4088)
T. E. Pfiffer, D. Seehofer, A. Nicolaou, R. Neuhaus, H. Riess, P. Neuhaus, R. Trappe

Brd. 24D Survival of complete responder patients treated for esophageal cancer with chemoradiotherapy followed by surgery as compared to chemoradiotherapy alone: Case-control study. (Abstract #4089)
M. Messager, G. Millet, N. Briez, G. Piessen, J. Triboulet, C. Mariette

Brd. 24E Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts). (Abstract #4090)

Brd. 24F FOLFOX6 as first-line treatment in metastatic gastric cancer: Preliminary results of a phase II trial. (Abstract #4091)

Brd. 24G Outcome prediction in hepatocellular carcinoma (HCC): Comparison of alpha fetoprotein (AFP) response and conventional radiologic criteria during sorafenib treatment. (Abstract #4092)
N. Personeni, S. Bozzarelli, T. Pressiani, L. Rimassa, M. C. Tronconi, F. Sclafani, C. Carnaghi, L. Giordano, A. Santoro

Brd. 24H Association of human epidermal growth factor receptor 2 (HER2) Ile655Val polymorphism (pirm) and gender-specific time to tumor recurrence (TTR) in patients (pts) with localized gastric adenocarcinoma (GA). (Abstract #4093)
E. Y. Lin, P. O. Bohanes, D. Yang, G. Lurje, T. Winder, Y. Ning, E. Ho, L. H. Tang, M. A. Shah, H. Lenz

Brd. 25A A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine. (Abstract #4094)

Brd. 25B Association between smoking history and disease-free and overall survival in resected gastric cancer. (Abstract #4095)

Brd. 25F Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data. (Abstract #4096)
R. S. Finn, J. Raoul, D. Manekas, C. Baudelet, I. B. Walters

Brd. 25G A phase I dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. (Abstract #4097)
S. Choo, B. Chowbay, Q. Ng, C. Thng, H. Li, H. Huynh, D. Poon, M. Ang, S. Chang, H. Toh

Brd. 25H Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. (Abstract #4098)
P. Pacetti, E. Giovannetti, M. Reni, A. Mambrini, M. Ghidini, L. Gleon, N. Funel, S. Cereda, G. Peters, M. Cantore

Brd. 26A Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO Group. (Abstract #4099)

Sunday, June 6, 2010
Sunday, June 6, 2010

Brd. 26B Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). (Abstract #4100)

Brd. 26F Role of IL-6 in cachexia progression in advanced pancreatic cancer. (Abstract #4101)

Brd. 26G Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001. (Abstract #4102)
G. Treiber, on behalf of the German HCC-RAD001/Bevazicumab Multicenter Study Group

Brd. 26H HER2 status of gastric and gastroesophageal cancer (GC) patients assessed by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and high-resolution array comparative genomic hybridization (aCGH). (Abstract #4103)
Y. Y. Janjigian, V. V. Barbashina, D. P. Kelsen, L. H. Tang, D. Ilson, L. J. Tafe, J. B. Hicks, M. A. Shah

Brd. 27A A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. (Abstract #4104)

Brd. 27B Utility of post-treatment FDG-PET in predicting outcomes in anal cancer managed with chemoradiotherapy. (Abstract #4105)

Brd. 27C Concurrent chemoradiotherapy with cetuximab plus twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma. (Abstract #4106)
C. Hsu, C. Lin, J. C. Cheng, C. Yen, J. Lee, H. Wang, K. Yeh, A. Cheng, Y. Lee

Brd. 27D Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study). (Abstract #4107)
J. Li, X. Liu, B. Y. Wang, W. J. Guo, J. L. Yin, X. D. Zhu, J. Zhang, T. Liu

Brd. 27E A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer. (Abstract #4108)

Brd. 27F Overall survival and clinically deficient quality of life in patients with esophageal cancer or Barrett’s esophagus: A Mayo Clinic Esophageal Adenocarcinoma and Barrett’s Esophagus Registry Consortium study. (Abstract #4109)

Brd. 27G Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrine tumors. (Abstract #4110)

Brd. 27H Impact of a novel inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patients. (Abstract #4111)
Brd. 28A  Intensity-modulated radiotherapy for esophageal cancer: Analysis of toxicity and outcomes. (Abstract #4112)
N. Kurshan, D. Ilson, M. A. Shah, D. P. Kelsen, A. Y. Ho, Z. Zhang, Q. Mo, K. A. Goodman

Brd. 28B  Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. (Abstract #4113)

Brd. 28C  Is diabetes mellitus (DM) associated with worse outcomes in pancreatic cancer (PC)? (Abstract #4114)
O. O. Olowokure, M. S. Beg, S. Ali, A. Tandra, M. M. Safa, K. Havlin, S. A. Ahmad

Brd. 28D  Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC). (Abstract #4115)

Brd. 28E  Docetaxel, cisplatin, and capecitabine (DCX) as perioperative chemotherapy in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4116)

Brd. 28F  Association of diabetes with perineural invasion and overall survival in surgically resected patients with pancreatic cancer. (Abstract #4117)
M. A. Shama, M. Tanaka, S. A. Curley, J. L. Abbruzzese, D. Li

Brd. 28G  Registry of Gastric Cancer Treatment Evaluation (REGATE): Variations in nonsurgical therapies. (Abstract #4118)

Brd. 28H  Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients. (Abstract #4119)
R. Romeo, A. Sangiovanni, M. lavarone, S. Vavassori, C. Della Corte, M. Colombo

Brd. 29A  A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy. (Abstract #4120)

Brd. 29B  Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection. (Abstract #4121)
S. Kang, J. Choi, M. Ahn, H. Lee, S. Han, Y. Cho, J. Han, J. Kim

Brd. 29C  Results of a phase II multicenter study of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer. (Abstract #4122)

Brd. 30A  Prognostic markers for response and overall survival in patients with esophageal adenocarcinoma treated with neoadjuvant therapy. (Abstract #4123)

Brd. 30B  Early outcome of phase II study of preoperative chemotherapy (CX) with S-1 plus cisplatin for stage IV gastric cancer (StIV GC). (Abstract #4124)
Sunday, June 6, 2010

Brd. 30C Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC). (Abstract #4125)  

Brd. 31A Association of elevated tissue factor (TF) with survival and thromboembolism (TE) in pancreaticobiliary cancers (PBC). (Abstract #4126)  

Brd. 31B Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. (Abstract #4127)  

Brd. 31C Use of tumor arterial perfusion assessment and RECIST for prediction of survival and residual disease in hepatocellular carcinoma following intra-arterial infusion chemotherapy. (Abstract #4128)  

Brd. 32A Analysis of D7S486 in primary gastric cancer and evaluation of TESTIN as a candidate tumor suppressor gene. (Abstract #4129)  
J. Xia, D. Weng, H. Ma, Y. Chen, W. Huang, K. Pan

Brd. 32B Dynamic changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. (Abstract #4130)  
P. Cen, F. Banki, L. Cheng, L. R. Kaiser, K. Khalil, X. L. Du, R. J. Amato

Brd. 32C Identification of three potential biomarkers in early resectable hepatocellular carcinoma. (Abstract #4131)  

Brd. 33A Clinical outcomes and survival in patients with hepatocellular carcinoma and HIV infection. (Abstract #4132)  
M. Berretta, E. Garlassi, P. Ventura, B. Cacopardo, A. Lleshi, S. Cocchi, G. Guaraldi, A. Pietrangelo, U. Tirelli

Brd. 33B Analysis of biomarker expression (ki67, EGFR, HER2, NFKB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. (Abstract #4133)  

Brd. 33C A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer. (Abstract #4134)  
M. Aglietta, C. Barone, M. Muliello, C. Bagalà, D. Ferraro, K. D. Fly, B. Huang, F. Leone

Brd. 34A Clinical outcome of local recurrence cases after endoscopic mucosal resection (EMR) for Japanese Classification stage 0 esophageal cancer. (Abstract #4135)  
T. Yoshii, S. Ohkawa

Brd. 34B A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC). (Abstract #4136)  

Brd. 34C Final results from ARQ 197–114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC). (Abstract #4137)  
Brd. 35A  The utility of PET/CT in the treatment management of gastroesophageal cancer (GEC): Impact on staging and treatment decisions. (Abstract #4138)
W. Shan, C. K. Kollmannsberger, D. Wilson, A. Briede, C. D. Blanke, H. J. Lim

Brd. 35B  Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC). (Abstract #4139)

Brd. 35C  Use of serum VEGF (SVEGF) levels to predict outcome of esophageal cancer (EC) patients undergoing preoperative chemoradiation (CRT). (Abstract #4140)
F. De Vita

Brd. 35D  Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma. (Abstract #4141)
A. Nicolini, A. Sangiovanni, M. Iavarone, L. Martinetti, M. A. Manini, S. Crespi, C. Della Corte, S. Vavassori, M. Colombo

Brd. 35E  Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study. (Abstract #4142)
M. Dalla Chiesa, R. Poli, G. Tomasello, S. Lazzarelli, S. Buti, M. Brighenti, F. Negri, A. Curti, A. Azzani, R. Passalacqua

Brd. 35F  Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. (Abstract #4143)

Brd. 35G  Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy. (Abstract #4144)

Brd. 35H  A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. (Abstract #4145)

Brd. 36A  Upregulation of multidrug resistance-associated protein 4 in the early stage of vascular invasion of hepatocellular carcinoma. (Abstract #4146)
K. Higuchi, T. Terada, M. Fukudo, K. Ogasawara, T. Katsura, E. Hatano, I. Ikai, K. Inui

Brd. 36B  A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum. (Abstract #4147)

Brd. 36C  Prediction of prognosis in hepatocellular carcinoma based on a gene signature from highly tumorigenic liver cancer cells. (Abstract #4148)
X. Yang, J. Fan, Y. Xu, J. Zhou, B. Yu

Brd. 36D  Phase I and II studies of intravenous Rexin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer. (Abstract #4149)

Brd. 36E  Phase II study of FOLFIRI chemotherapy as first-line treatment for elderly patients (pts) with advanced gastric cancer (AGC). (Abstract #4150)
Y. Becouarn, C. Bellera, R. Brunet, J. Legoux, L. Cany, J. Dauba, D. Smith, D. Auby, C. Mertens, M. Fonck
Sunday, June 6, 2010

Brd. 36F Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP). (Abstract #4151)

Brd. 36G Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors. (Abstract #4152)

Brd. 36H Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC). (Abstract #4153)
Y. Z. Patt, A. D. Baron, V. A. Parks, A. Small, M. Roach, S. Lee, F. Lee

Brd. 37A Maruyama index (MI) and outcomes of gastric cancer resection. (Abstract #4154)

Brd. 37B A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC). (Abstract #4155)

Brd. 37C Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric cancer undergoing a potentially curative resection. (Abstract #4156)

Brd. 37D Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. (Abstract #4157)
R. Lin, N. Fan, L. Chen, J. Liu

Brd. 37E Role of MT1-MMP and Kras in invasive pancreatic tumors with pronounced fibrosis. (Abstract #4158)
S. B. Krantz, S. Dangi-Garimella, M. A. Shields, P. J. Grippo, D. J. Bentrem, H. G. Munshi

Brd. 37F Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. (Abstract #4159)

Brd. 37G Analysis of four human PlGF isoforms and of VEGFR-1 in esophageal carcinoma. (Abstract #4160)
A. Schultze, M. Bubenheim, E. Yekebas, A. Erbersdobler, U. Reichelt, J. R. Izbicki, K. Pantel, C. Bokemeyer, W. M. Fiedler, S. Loges, Otten, Jasmin; Riethdorf, Sabine

Brd. 37H A phase II/III study of photodynamic therapy (PDT) using HPPH for the treatment of Barrett’s and precancerous lesions of the esophagus. (Abstract #4161)
H. R. Nava, S. S. Allamaneni, M. T. Cooper, T. Dougherty, G. E. Wilding, B. W. Henderson

Brd. 38A Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin. (Abstract #4162)
A. B. Farris, R. Dhanasekaran, N. Dursun, I. Coban, E. B. McIntosh, V. Adsay, H. S. Kim

Brd. 21G A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). (Abstract #4163)
2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Pediatric Oncology
Location: S Hall A2
Tracks(s): Pediatric Oncology

Brd. 43A  Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors. (Abstract #9543)
L. Mascarenhas, S. Armenian, J. L. Harrington, H. Mahmoud, R. Sposto, M. H. Malogolowkin

Brd. 43B  A phase I trial of continuous hyperthermic peritoneal perfusion using cisplatin in pediatric patients with carcinomatosis. (Abstract #9544)
A. A. Hayes-Jordan, H. L. Green, P. M. Anderson, L. Xiao, K. Hunt, P. F. Mansfield

Brd. 43C  Pilot study of the novel chemotherapy regimen of topotecan, ifosfamide, and carboplatin (TIC) in children with refractory/recurrent solid tumors. (Abstract #9545)
A. Lee, C. Handler, L. Harrison, W. V. Shen, L. Gates, R. J. Wells, J. E. Wolff, J. H. Garvin, D. Yamashiro, M. S. Cairo

Brd. 43D  Dose-finding study by continuous reassessment method (CRM) for topotecan (TT) in combination with ifosfamide (IF) as a second-line therapy for pediatric solid cancer: Preliminary report of phase I/II study. (Abstract #9546)

Brd. 43E  An investigator-initiated registration-directed phase I/II clinical trial of irinotecan hydrochloride for refractory pediatric solid tumors. (Abstract #9547)
A. Makimoto, H. Mugishima, T. Taga, Y. Ishida, Y. Nagatoshi, K. Ida, M. Kumagai, T. Kimura, Y. Ohashi, M. Kaneko

Brd. 43F  Simulations of cilengitide PK profiles in pediatric population by means of allometric scaling: Reliability and support to BSA-based dose adjustment strategy. (Abstract #9548)
M. Zuehlsdorf, M. Campioni, U. Forssmann, A. Munafo, A. Kovar

Brd. 43G  Intensity-modulated radiation therapy for pediatric head and neck rhabdomyosarcoma: French preliminary results. (Abstract #9549)
J. Leseur, V. Bernier, J. Habrand, A. Laprie, M. Mahe, S. Supiot, G. Truc, E. Le Prisè, L. Claude, C. Carrie

Brd. 43H  Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma. (Abstract #9550)

Brd. 44A  Late side effects of neoadjuvant chemotherapy in patients treated for osteosarcoma and Ewing’s sarcoma: An Italian Sarcoma Group study. (Abstract #9551)
A. Longhi, C. Ferrari, A. Tamburini, M. Berta, F. Fagioli, G. Bacci, M. Mercuri, S. Ferrari

Brd. 44B  Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children’s Oncology Group (COG) study. (Abstract #9552)
P. Leavey, J. L. Glade Bender, L. Mascarenhas, L. Granowetter, M. Anderson, M. D. Krailo, R. G. Gorlick, N. Marina

Brd. 44C  Long-term results of expandable endoprosthesis replacement in children with malignant bone tumors. (Abstract #9553)
W. Woźniak, I. Ługowska, A. Szymborska

Sunday, June 6, 2010

277
Sunday, June 6, 2010

Brd. 44D Long-term neurocognitive outcomes in adult survivors of childhood medulloblastoma. (Abstract #9554)

Brd. 44E Premature deaths and severe morbidity in 192 long-term survivors of pediatric optic pathway tumors (OPT): A 50-year study. (Abstract #9555)

Brd. 44F Medulloblastoma histological variants as the most powerful prognostic indicator: A 10-year mono-institutional experience. (Abstract #9556)
M. Massimino, L. Gandola, V. Biassoni, P. Collini, B. Pollo, F. Giangaspero

Brd. 44H Improved collaboration and clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA program. (Abstract #9558)
P. H. Shaw

Brd. 45A Survival by race among children with extracranial solid malignancies. (Abstract #9559)
K. Johnson, R. Aplenc, R. Bagatell

Brd. 45B Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of ASCO oncologists. (Abstract #9560)
M. Kigin, F. J. Hlubocky, K. Wroblewski, C. Daugherty, T. O. Henderson

Brd. 45C Allogeneic stem cell transplantation from HLA identical donor in high-risk sarcoma (Abstract #9561)
F. Fagioli

Brd. 45D Reduced intensity conditioning regimen and allogeneic stem cell transplantation from related or unrelated HLA identical donor in high-risk neuroblastoma. (Abstract #9562)
A. Prete

Brd. 45E Tandem stem cell transplantation as consolidation therapy for high-risk neuroblastoma: The Children’s Healthcare of Atlanta experience. (Abstract #9563)
M. Qayed, K. Y. Chiang, A. E. Haight, B. A. George, R. Ricketts, A. Alazraki, A. Tahvildari, N. Esiashvili, H. M. Katzenstein

Brd. 45F STAT3 as a molecular target in pediatric T-cell leukemia. (Abstract #9564)
J. Ding, A. Batista, A. Turk, S. Rodriguez-Rodriguez, L. Wang, C. Mumaw, N. Carlesso, A. A. Cardoso

Brd. 45G Activity of the heat shock protein 90 (HSP90) inhibitor, SNX-2112, in pediatric cancer cell lines. (Abstract #9565)
D. C. Chinn, W. S. Holland, J. M. Yoon, T. Zwerdling, P. C. Mack

Brd. 45H Effect of bortezomib on ER stress and killing of cisplatin-resistant U2OS osteosarcoma cell line. (Abstract #9566)
W. Zhao, M. Callaghan, A. Fribley, Y. Ravindranath, Z. J. Wang

Brd. 46A Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. (Abstract #9567)

Brd. 46B GD2 expression in tumorspheres from neuroblastoma cell lines and in tumor-initiating cells derived from patient samples. (Abstract #9568)
A. M. Hammill, P. Wang, L. M. Hansford, D. Kaplan, T. P. Cripe

Brd. 46C Effect of all-trans retinoic acid on proliferation of human rhabdomyosarcoma and remission in an in vivo mouse xenograft model. (Abstract #9569)
R. H. Saab

Brd. 46E Plasma fractionated total metanephrines for biochemical diagnosis of neuroblastoma. (Abstract #9571)
L. Crosazzo Franscini, E. Grouzmann, M. Faouz, M. Beck Popovic
Brd. 46F  A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B) and high-risk (Group C) mature B-NHL: A Children’s Oncology Group report. (Abstract #9572)
S. Goldman, J. C. Lynch, L. Harrison, M. S. Cairo

Brd. 46G  High-dose methotrexate in the treatment of acute lymphoblastic leukemia: Toxicity profile and comparison of tolerability between two dosage schedules. (Abstract #9573)
A. R. Warrier, R. Rejiv, D. Biswajit, S. G. Ramanan, T. G. Sagar

Brd. 46H  T-cell lymphoblastic lymphoma in children and adolescents: The experience of the Israel Society of Pediatric Hematology Oncology. (Abstract #9574)

Brd. 47A  Risk-based outcome of childhood AML: Experience of National Guard Hospital, Jeddah, Saudi Arabia. (Abstract #9575)
W. A. Jastaniah, T. M. Khattab, S. K. Felimban

Brd. 47B  High frequency of Gilbert’s syndrome in ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): Implications for etiology. (Abstract #9576)

Brd. 47C  Clostridium difficile infection among children with cancer. (Abstract #9577)
E. Tai, L. C. Richardson, J. Townsend, E. Howard, C. McDonald

Brd. 47D  Iterative anesthesia for radiation therapy in pediatric oncology: Safety of a procedure using propofol alone. (Abstract #9578)

Brd. 47E  Diagnosis of invasive fungal infections by RQ-PCR assay in pediatric acute leukemia induction. (Abstract #9579)
S. Mandhaniya, S. Iqbal, S. K. Sharawat, I. Xess, S. Bakhshi

Brd. 47F  Clinical pharmacokinetics (PK) and safety of high-dose (HD) methotrexate (MTX) during induction therapy of pediatric patients younger than 3 years of age with primary brain tumors. (Abstract #9580)

Brd. 47G  Criteria defining the duration of chemoreduction with focal treatment in retinoblastoma: A retrospective analysis. (Abstract #9581)
M. Beck Popovic, H. Abouzeid, M. Gaillard, M. Faouzi, A. Pica, A. Balmer, F. Munier
General Poster Session

Sarcoma

2:00 PM - 6:00 PM
Location: S Hall A2
Tracks (s): Sarcoma

**Brd. 48A** Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST. (Abstract #10034)

**Brd. 48B** Combination of targeted therapy (imatinib) with immunotherapy (peginterferon α-2b) to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST). (Abstract #10035)

**Brd. 48C** Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma. (Abstract #10036)

**Brd. 48D** Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. (Abstract #10037)

**Brd. 48E** Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. (Abstract #10038^)

**Brd. 48F** Identification of oncogenic events in gastrointestinal stromal tumors (GISTs) by combined gene expression and copy number analysis. (Abstract #10039)
M. Nannini, M. A. Pantaleo, A. Astolfi, A. Maleddu, M. C. Heinrich, C. L. Corless, M. di Battista, F. Catena, D. Santini, G. Biasco

**Brd. 48G** Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study. (Abstract #10040)

**Brd. 48H** Radiofrequency ablation of lung metastases arising from sarcoma. (Abstract #10041)
J. Palussiere, A. Italiano, A. Avril, E. Descat, N. Bin Bui

**Brd. 49A** Improvement in the survival for adult soft tissue sarcoma with adjuvant anthracycline chemotherapy combination: A meta-analysis and metaregression. (Abstract #10042)
S. L. Afonso, L. A. Ramos, G. A. Viani, E. Stefano, V. Afonso

**Brd. 49B** BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors. (Abstract #10043)

**Brd. 49C** Use of a genome-wide single nucleotide polymorphism array-based chromosomal analysis to evaluate uniparental disomy (UPD) in gastrointestinal stromal tumors (GIST). (Abstract #10044)
N. Lourenço, J. Emile, S. Brahimi, J. Bachet, F. Jardin, J. Tran van Nhieu, J. Coindre, C. Penna

Brd. 49E  Novel reconstruction using tumor-containing autologous bone grafts frozen in liquid nitrogen. (Abstract #10046)

Brd. 49F  Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM). (Abstract #10047)
B. Nguyen, F. Grabelbus, M. Hoiczky, G. Taeger, M. H. Schuler, S. Bauer

Brd. 49G  Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. (Abstract #10048)
P. Hohenberger, S. Bauer, V. Gruenwald, J. T. Hartmann, E. Jaeger, O. G. Ottmann, C. Hosius, C. May, A. Pustowka, P. Reichardt

Brd. 49H  Targeting CHK1 pathway to induce cytotoxic response to histone deactylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and primary tumor xenografts. (Abstract #10049)
D. R. Reed, W. Brazelle, J. Gemmer, S. Altik

Brd. 50A  CSPG4 and B7-H3 as prognostic biomarkers in chordoma. (Abstract #10050)
A. Schoenfeld, G. P. Nielsen, F. Hornicek, Z. Duan, S. Ferrone, J. H. Schwab

Brd. 50B  Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. (Abstract #10051)
P. Biron, P. A. Cassier, E. Fumagalli, A. Blesius, M. Debic-Rychter, A. Adenis, J. Verweij, P. Hohenberger, J. Blay, P. G. Casali, EORTC Soft Tissue and Bone Sarcoma Group

Brd. 50C  Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients. (Abstract #10052)

Brd. 50D  Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumor (GIST). (Abstract #10053)
O. Oladeji, E. Wardelmann, U. Ronellenfitsch, D. Pink, P. Reichardt, P. Ströbel, P. Hohenberger

Brd. 50E  Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib. (Abstract #10054)

Brd. 50F  Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A French Sarcoma Group (FSG) retrospective review. (Abstract #10055)
P. Duffaud, P. A. Cassier, A. Adenis, O. Bouche, M. Rios Sr., O. Collard, E. Bompas, S. Chabaud, J. Blay, A. Le Cesne

Brd. 50G  Surgery of residual disease of myxoid liposarcoma (MLS) patients responding to trabectedin. (Abstract #10056)

Brd. 50H  Quality of randomized controlled trials reporting in the treatment of sarcomas. (Abstract #10057)
M. Toulmonde, C. Bellera, S. Mathoulin-Pelissier, N. Bin Bui, A. Italiano
Brd. 51A  Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS). (Abstract #10058)

Brd. 51B  Sunitinib (SU)-related hypertension in a randomized placebo (P)-controlled trial of GIST patients (pts). (Abstract #10059)
M. Ewer, T. M. Suter, D. J. Lenihan, L. Niculescu, A. Breazna, R. J. Motzer, G. D. Demetri

Brd. 51C  A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-α or -β; (PDGFR-α/ PDGFR-β): An Italian Sarcoma Group study. (Abstract #10060)
G. Grignani, E. Palmerini, S. Stacchiotti, A. Boglione, V. Ferraresi, S. Frustaci, A. Comandone, P. G. Casali, S. Ferrari, M. Aglietta

Brd. 51D  Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment. (Abstract #10061)

Brd. 51E  Quality of life (QoL) in osteosarcoma: First results of the presurgery treatment period of EURAMOS-1 (NCT00134030). (Abstract #10062)
A. Wiener, R. Nagarajan, L. Hjorth, M. Jenney, P. De Vos, M. L. Bernstein, M. D. Krailo, M. R. Sydes, G. Calaminus, for the EURAMOS-1 Study Group

Brd. 51F  High-dose photon-beam radiation therapy in chordoma: A single-institution retrospective analysis. (Abstract #10063)
C. Sangalli, S. Stacchiotti, A. Gronchi, P. G. Casali, E. Pignoli, P. Pittoni, E. Palassini, P. Olmi

Brd. 51G  Impact of imatinib plus best supportive care in imatinib- and sunitinib-exposed patients with refractory advanced gastrointestinal stromal tumor. (Abstract #10064)
A. Sawaki, T. Kanda, Y. Komatsu, T. Nishida

Brd. 51H  Metronomic oral cyclophosphamide (CPM) and prednisolone in elderly patients (pts) with inoperable or metastatic soft tissue sarcoma (STS). (Abstract #10065)

Brd. 52A  PAX3/7-FOXO1 fusions by fluorescent in situ hybridization (FISH) using an adult rhabdomyosarcoma tissue microarray. (Abstract #10066)
S. N. Dumont, A. J. Lazar, A. J. Bridge, J. C. Trent

Brd. 52B  Cutaneous angiosarcoma of the head and neck. (Abstract #10067)
P. K. Pandalai, J. L. Hornick, Q. Wang, J. A. Morgan, S. George, E. H. Baldini, P. M. Devlin, C. P. Raut

Brd. 52C  Quality of surgical margins and local recurrence in primary extremity soft tissue sarcoma (STS). (Abstract #10068)
S. Bonvalot, A. Dunant, C. le Pechoux, P. Terrier, F. Rimareix, B. Boulet, L. Medjoub, A. Cioffi, J. Domont, A. Le Cesne

Brd. 52D  Immunohistochemical study and fluorescent in situ hybridization analysis of JAZF1 in 67 cases of endometrial stromal tumors collected in a tissue microarray. (Abstract #10069)
J. Duclos, A. Valenti, G. Malouf, F. Drusch, N. Auger, P. Vielh, G. Vassal, P. Duvillard, P. Pautier

Brd. 52E  Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study. (Abstract #10070)
Brd. 52F  Absence of correlation between the molecular subtype of COL1A1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans: Analysis of 35 novel cases and review of 137 cases from the literature. (Abstract #10071)

Brd. 52G  Nonstandard dosing in gastrointestinal stromal tumors: A registry observation. (Abstract #10072)
P. W. Pisters, M. von Mehren, E. Stealey, L. A. Sirulnik, J. C. Trent

Brd. 52H  Imaging-guided core needle biopsies (CNB) compared to surgical biopsies (SB) for soft tissue tumors: A cost-effectiveness analysis. (Abstract #10073)
S. Taieb, Y. Robin, M. Morel, F. Watelle, L. Vanseymortier, N. Penel

Brd. 53A  First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study. (Abstract #10074)

Brd. 53B  First report of outcomes with neoadjuvant chemoradiotherapy (NCR) using weekly intravenous (IV) cisplatin with radiation (NCWR) for treatment of stage II and III extremity soft tissue sarcoma (STS). (Abstract #10075)

Brd. 53F  Antitumor activity of pemetrexed (Pem) in second-line advanced/metastatic osteosarcomas: A multicenter phase II study. (Abstract #10076)
N. Bin Bui, G. Egerer, S. Ferrari, A. Comandone, A. Cioffi, H. Rassam, A. Michel, S. Ameryckx, S. Weitckus, F. Duffaud

Brd. 54A  Effect of adjuvant radiotherapy on survival in localized limb or trunk wall well-differentiated liposarcoma (WDLPS). (Abstract #10079)
A. Duret, E. Stoeckle, S. Bonvalot, A. Italiano, S. Piperno-Neumann, G. Kantor, C. le Pechoux, L. Guillou, J. Coindre, J. Blay

Brd. 54B  Efficacy of neoadjuvant doxorubicin and ifosfamide (AI) in myxoid/round cell liposarcoma (MRCL): The M. D. Anderson Cancer Center experience (MDACC). (Abstract #10080)

Brd. 54F  Assessment of early response to imatinib 800 mg after 400 mg progression by 18 f-fluorodeoxyglucose positron emission tomography in patients with metastatic gastrointestinal stromal tumor. (Abstract #10081)

Brd. 54G  Effect of radiation therapy on survival of patients with surgically resected retroperitoneal sarcoma: A population-based matched pair study. (Abstract #10082)
A. Choi, J. Barnholtz-Sloan, J. Kim

Brd. 54H  Sunitinib as the second-line therapy for advanced GISTs after failure of imatinib in Korean patients. (Abstract #10083)
Sunday, June 6, 2010

Brd. 55A  Gastrointestinal stromal tumors (GISTs) and other cancers: Cambridge GIST Study Group experience. (Abstract #10084)
V. R. Bulusu, N. Carroll, S. Pursglove, V. Save, R. Hardwick

Brd. 55B  Impact of subspecialty, clinical volume, and years of practice in selection of treatment sequencing in the management of localized extremity soft tissue sarcoma. (Abstract #10085)

Brd. 55C  Pattern of growth of retroperitoneal sarcoma: Do they push or infiltrate adjacent organs? Analysis of a single institution series. (Abstract #10086)
C. E. Mussi, P. Bagnoli, M. Coladonato, A. Bertuzzi, S. Secondino, A. Santoro, P. Colombo, P. Navarria, E. Morenghi, V. Quagliuolo

Brd. 55D  Neoadjuvant, adjuvant, and palliative treatment with imatinib in patients with gastrointestinal stromal tumors. (Abstract #10087)

Brd. 55E  Long-term results of primary re-excision after unplanned resection of a soft tissue sarcoma of the extremities and trunk. (Abstract #10088)
M. Peiper, A. Rehders, E. Boelke, W. Budach, C. Poremba, W. Knoefel

Brd. 55F  Effect of histone deacetylase inhibitor (HDACi) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. (Abstract #10089)

Brd. 55G  Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S). (Abstract #10090)

Brd. 55H  Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948). (Abstract #10091)

Brd. 56A  The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST—Second annual summary. (Abstract #10092)

Brd. 56B  Extraskeletal osteosarcoma: Clinicopathologic features and results of multimodal management. (Abstract #10093)
N. Fabbri, A. Tiwari, M. Umer, D. Vanel, M. Alberghini, P. Ruggieri, S. Ferrari, P. Picci, M. Mercuri

Brd. 56C  Analysis of prognostic factors of pediatric-type sarcomas in adult patients. (Abstract #10094)
H. Ahn, J. Um, J. Lee, W. Kim, D. Lim, J. Park

Brd. 56D  Radiological tissue changes and pathological response in localized high-grade soft tissue sarcomas (STS) as predictors of outcome after neoadjuvant treatment with chemoradiotherapy (CRT). (Abstract #10095)

Brd. 56E  Clear cell sarcoma (CCR): Clinical behavior and response to chemotherapy. (Abstract #10096)
S. Stacchiotti, E. Palassini, T. Negri, M. Orsenigo, R. Bertulli, C. Morosi, S. Pilotti, M. Fiore, A. Gronchi, P. G. Casali
Brd. 56F  A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO. (Abstract #10097)
J. Bay, A. Le Cesne, A. Cioffi, N. Penel, F. Duffaud, D. Cupissol, S. Piperno-Neumann, C. Cropet, L. Bouclier, I. Ray-Coquard

Brd. 56G  Systemic therapy in clear cell sarcoma. (Abstract #10098)
Sunday, June 6, 2010

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Predictors of Response to Preoperative Therapy: Where Are We?
Location: N Hall B1
CME credit: 1.5
Track(s): Breast Cancer

William Fraser Symmans, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center

Antonio C. Wolff, MD—Co-Chair
The Johns Hopkins University

Discussion
4:30 PM Gabriel N. Hortobagyi, MD
University of Texas M. D. Anderson Cancer Center
Preoperative Therapy in Operable Breast Cancer: How, When, and Why?

4:45 PM Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006–03). (Abstract #500)
E. Alba, L. Calvo, J. Albanell, J. De la Haba, J. Chacon, A. Arcusa Lanza, P. Sanchez Rovira, A. Plazaola, J. Lopez Garcia-Asenjo, A. Lluch, on behalf of GEICAM

5:00 PM Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. (Abstract #501)

5:15 PM Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC). (Abstract #502)
M. Martin, A. Romero, J. Lopez Garcia-Asenjo, M. C. Cheang, B. Oliva, J. Garcia Saenz, X. He, T. Caldes, E. Diaz-Rubio, C. M. Perou

5:30 PM Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivities to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. (Abstract #LBA503)
H. R. Bonnefoi, J. Bogaerts, M. Piccart, L. Mauriac, P. Fumoleau, J. Jassem, V. Becette, D. A. Cameron, J. Bergh, R. Iggo, on behalf of the EORTC, SweBCG, SAKK, and ACCOG Investigators

Discussion
5:45 PM Mitchell Dowsett, PhD (Abstracts #500–LBA503)
Royal Marsden Hospital
4:45 PM - 6:00 PM
SPECIAL SESSION

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
Location: S100a
CME credit: 1.25
Track(s): Special Session; Geriatric Oncology

Harvey Jay Cohen, MD
Duke University Medical Center
Geriatric Oncology: Where Have We Been? Where Are We Going?
Sunday, June 6, 2010

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How?
Location: S404
CME credit: 1.25
Track(s): Gastrointestinal (Colorectal) Cancer; Geriatric Oncology

Richard M. Goldberg, MD—Chair
University of North Carolina
Elderly and/or Frail Patients with Colorectal Cancer: A Clinician’s Approach

Martine Extermann, MD
H. Lee Moffitt Cancer Center & Research Institute
Age and Frailty: More Than Two Sides of the Same Coin?

Daniel J. Sargent, PhD
Mayo Clinic
Age, Frailty, and Chemotherapy: Data, More Data, and More Confusion

Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia
Location: E354a
CME credit: 1.25
Track(s): Leukemia, Myelodysplasia, and Transplantation

Guillermo Garcia-Manero, MD—Chair
University of Texas M. D. Anderson Cancer Center
Prognostic Models in MDS

David Steensma, MD
Dana-Farber Cancer Institute
Beyond Supportive Care in MDS: Growth Factors—Epigenetic Therapies, Immunomodulators, and Novel Chemotherapeutic Agents

Farhad Ravandi Kashani, MD
University of Texas M. D. Anderson Cancer Center
Acute Leukemia in the Elderly: Who Should Be Treated and How?

New Technology in Cancer Immune Therapy
Location: E353
CME credit: 1.25
Track(s): Tumor Biology; Developmental Therapeutics

Michel Sadelain, MD, PhD—Chair
Memorial Sloan-Kettering Cancer Center
Chimeric Immunoreceptor Engineered T-cells

Zelig Eshhar, PhD
Weizmann Institute of Science
T-cell Engineering for Adoptive Immunotherapy

Leisha A. Emens, MD, PhD
The Johns Hopkins University
Combinatorial Immunotherapy
Nonmelanoma Skin Cancers: New Insights, New Directions
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Melanoma/Skin Cancers

Paul Nghiem, MD, PhD—Chair
University of Washington
Merkel Cell Carcinoma: New Biologic Insights and Management Strategies

Juergen C. Becker, MD, PhD
University of Wuerzburg
Nonmelanoma Skin Cancer in the Immunosuppressed Patient

Jean Y. Tang, MD, PhD
Stanford University
Molecular Pathways In Basal Cell Carcinoma and Clinical Trials

Physical Activity in Cancer Populations: What’s New?
Location: E354b
CME credit: 1.25
Track(s): Patient and Survivor Care; Breast Cancer; Gastrointestinal (Colorectal) Cancer

Jennifer A. Ligibel, MD—Chair
Dana-Farber Cancer Institute
Physical Activity and Cancer: Overview and Implications for Survivorship

Kerry S. Courneya, PhD
University of Alberta
Randomized Trials of Exercise in Cancer Patients: Health-related Fitness and Patient-reported Outcomes

Kathryn Schmitz, PhD, MPH
University of Pennsylvania
Exercise Testing and Prescription for Cancer Survivors: Guidelines from the American College of Sports Medicine

Stem Cells in Neuro-oncology
Location: S100b
CME credit: 1.25
Track(s): Central Nervous System Tumors; Tumor Biology

Richard Gilbertson, MD, PhD—Chair
St. Jude Children’s Research Hospital
Stem Cells in Neuro-oncology: Overview

Charles D. Stiles, PhD
Dana-Farber Cancer Institute
Central Nervous System Stem Cells as Therapeutic Targets

Evan Snyder, MD, PhD
Burnham Institute for Medical Research
Using Stem Cells to Treat Brain Tumors
Sunday, June 6, 2010

The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?
Location: E Hall D1
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Cancer Genetics; Cancer Prevention/Epidemiology

Johanna C. Bendell, MD—Chair
Sarah Cannon Research Institute
Understanding the Evolution in Epidemiology of Esophagogastric Cancer

Jason L. Hornick, MD, PhD
Brigham and Women’s Hospital
The Molecular Continuum of Barrett’s Esophagus to Esophagogastric Cancer

Janusz Jankowski, PsyD
Digestive Diseases Center
Using the Newest Molecular Markers in Prognosis and Risk Stratification
4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION

Cutaneous B-cell Lymphoma (M08)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders

Lynn D. Wilson, MD, MPH
Yale University

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management (C10)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Health Services Research; Patient and Survivor Care

Scott Michael Gilbert, MD, MS—Chair
University of Florida
The Incidental Renal Mass: Evaluation and Management in the Cancer Patient

J. Stuart Wolf Jr., MD
University of Michigan
The Incidental Adrenal Mass: Evaluation and Management in the Cancer Patient

David E. Ost, MD
University of Texas M. D. Anderson Cancer Center
The Incidental Pulmonary Nodule: Evaluation and Management in the Cancer Patient
Monday, June 7, 2010

7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY

Highlights of the Day II including Partners in Progress Award
Location: E Hall D1
CME credit: 1.5
Track(s): Special Session; General Oncology

Kim Allyson Margolin, MD—Co-Chair
Seattle Cancer Care Alliance
Douglas W. Blayney, MD—Co-Chair
University of Michigan

7:30 AM
Ellen V. Sigal, PhD—Partners in Progress Award Recipient
Friends of Cancer Research

7:40 AM
Nicholas J. Vogelzang, MD
Nevada Cancer Institute
Genitourinary (Prostate) Cancer

7:55 AM
Howard S. Hochster, MD
New York University
Gastrointestinal (Colorectal) Cancer

8:10 AM
Claire F. Verschraegen, MD
University of New Mexico
Gynecologic Cancer

8:25 AM
Jean-Luc Harousseau, MD
Rene Gauducheau Cancer Center
Myeloma

8:40 AM
Scott Michael Lippman, MD
University of Texas M. D. Anderson Cancer Center
Cancer Prevention/Epidemiology
8:00 AM - 9:15 AM
SPECIAL SESSION

Cancer Survivors: A Challenge to Health Care Systems Worldwide
Location: S100b
CME credit: 1.25
Track(s): Special Session; Health Services Research; International

Eliezer Robinson, MD—Chair
Israel Cancer Association
The Needs of Cancer Survivors

Douglas W. Blayney, MD
University of Michigan
ASCO’s Efforts to Promote Survivorship Care

Eva Grunfeld, MD, PhD
University of Toronto
Follow-up and Other Health Care Needs of Cancer Survivors: How Are Different Health Care Systems Meeting the Challenge?

Sophie D. Fossa, MD
The Norwegian Radium Hospital
Life-threatening Long-term Effects after Cancer: Who Needs What Follow-up?

Lawrence N. Shulman, MD
Dana-Farber Cancer Institute
Challenges and Opportunities in Developing a Cancer Survivorship Program in the Context of Current Trends in Oncology Care
Monday, June 7, 2010

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold
Location: S100a
CME credit: 1.25
Track(s): Gastrointestinal (Colorectal) Cancer; Tumor Biology

Al Bowen Benson III, MD—Chair
Northwestern University
Overview of Adjuvant Clinical Trials in Stage II Colon Cancer: Results, Challenges, and Confusion

Sabine Tejpar, MD, PhD
UZ Gasthuisberg-Katholieke University Leuven
Prognostic and Predictive Molecular Biomarkers in Stage II Colon Cancer: Current Evidence and Future Perspective

Neal J. Meropol, MD
University Hospitals Case Medical Center
Biomarker-driven Treatment Decisions in Stage II Colon Cancer: Making Sense of What We Know

Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer
Location: N Hall B1
CME credit: 1.25
Track(s): Breast Cancer

Anthony Howell, MD—Chair
Christie Hospital NHS Trust
Is It Ok Not to Give Chemotherapy in Node-positive Breast Cancer?

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Tailoring Adjuvant Therapy for HER2-negative Breast Cancer

Ana M. Gonzalez-Angulo, MD, MSc
University of Texas M. D. Anderson Cancer Center
Small HER2-positive Tumors: When to Add Anti-HER2 Therapy?

Disparities in Cancer Care
Location: S404
CME credit: 1.25
Track(s): Health Services Research; Geriatric Oncology; International

Lisa A. Newman, MD, MPH—Chair
University of Michigan
Evolving U.S. Population Demographics and Implications for Disparities in Cancer Care

Beverly Moy, MD, MPH
Massachusetts General Hospital
Complex Etiologies and Strategies for Reducing Disparities in Cancer Care

Michael Silbermann, DMD, PhD
Middle East Cancer Consortium
Cancer Care in Different Contexts: Domestic and International Perspectives
Health Disparities in Lung Cancer: Race, Sex, and Genes
Location: E Hall D2
CME credit: 1.25
Track(s): Lung Cancer; Health Services Research; Tumor Biology

Alex A. Adjei, MD, PhD—Chair
Roswell Park Cancer Institute
Molecular Epidemiology of Lung Cancer: Ancestry Matters

Patrick C. Ma, MD, MSc
Case Western Reserve University
Molecular Genetic Variations between Human Populations

Nithya Ramnath, MD
University of Michigan
Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer

Impact of Health Literacy on Health Care, Decision Making, and Consent
Location: E353
CME credit: 1.25
Track(s): Patient and Survivor Care; Clinical Trials; Health Services Research

Terry C. Davis, PhD—Chair
Louisiana State University Medical Center
Impact of Limited Health Literacy: Assessing Literacy and Overcoming Barriers to Limited Literacy in Delivering Health Care

Cathy A. Coyne, PhD
West Virginia University
Overcoming Literacy Issues in Obtaining Informed Consent

Angela Fagerlin, PhD
University of Michigan
Decision Making in Breast and Prostate Cancer

Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia
Location: E354a
CME credit: 1.25
Track(s): Leukemia, Myelodysplasia, and Transplantation

Susan Mary O’Brien, MD—Chair
University of Texas M. D. Anderson Cancer Center
Evolving Therapies for CLL

Sami N. Malek, MD
University of Michigan
Prognostic Markers in CLL: Do They Matter?

Clive Zent, MD
Mayo Clinic
CLL in the Elderly: How Should It Be Treated?
Monday, June 7, 2010

The Biology and Treatment of Wilms Tumor
Location: S504  
CME credit: 1.25  
Track(s): Pediatric Oncology; Tumor Biology

Jeffrey Dome, MD—Chair  
Children’s National Medical Center  
Wilms Tumor: Unsettled Questions and Controversies

Nazneen Rahman, PhD, FRCP  
The Royal Marsden Institute of Cancer Research  
New Developments in Wilms Tumor Genetics

Elizabeth Perlman, MD  
Northwestern University  
Gene Expression Arrays: What Have They Taught Us about Wilms Tumor?

Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?  
Location: E354b  
CME credit: 1.25  
Track(s): Genitourinary Cancer; Patient and Survivor Care

Christian K. Kollmannsberger, MD—Chair  
British Columbia Cancer Agency  
Management Options for Early-stage Seminoma and Nonseminoma

David Peter Wood, MD  
University of Michigan  
Is RPLND Still Relevant?

George J. Bosl, MD  
Memorial Sloan-Kettering Cancer Center  
Toxicity and Survivorship in Testicular Cancer Survivors: Should It Modify What I Do?

Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?  
Location: S406 (Vista Room)  
CME credit: 1.25  
Track(s): Sarcoma; Pediatric Oncology

Lee J. Helman, MD—Chair  
National Institutes of Health/National Cancer Institute  
IGF1R Targeting of Translocation-associated Sarcomas

Marc Ladanyi, MD  
Memorial Sloan-Kettering Cancer Center  
Target Genes of Chimeric Transcription Factors in Pediatric Sarcomas: A Source of Potential Therapeutic Targets

Jeffrey Toretsky, MD  
Georgetown University  
Targeting Protein Products of Sarcoma-specific Translocations with Small Molecules
8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Contract Negotiation for Your First Job (M09)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Professional Development

Jamie H. Von Roenn, MD
Northwestern University

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY

The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease (C11)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Genitourinary Cancer; Patient and Survivor Care

Steven Campbell, MD, PhD—Chair
Cleveland Clinic
Diagnosis and Management of the Renal Mass

Przemyslaw Twardowski, MD
City of Hope
Management of Non-clear Cell Histology

Tim Eisen, PhD, FRCP
University of Cambridge/Cancer Research UK
Optimal Management of Toxicities Related to Targeted Agents
Monday, June 7, 2010

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Paths for Clinical Development of PI3K Inhibition
Location: E Arie Crown Theater
CME credit: 1.5
Track(s): Developmental Therapeutics

A. Dimitrios Colevas, MD—Co-Chair
Stanford University
Pasi A. Janne, MD, PhD—Co-Chair
Dana-Farber Cancer Institute

Discussion
8:00 AM Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center

8:15 AM A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. (Abstract #3003)

8:30 AM A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. (Abstract #3004)

8:45 AM First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. (Abstract #3005)

Discussion
9:00 AM Carlos L. Arteaga, MD (Abstracts #3003–3005)
Vanderbilt University Medical Center

Next Steps in Clinical Development of PI3K Inhibitors?
8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION

Melanoma/Skin Cancers
Display Time: 8:00 AM - 12:00 PM
Display Location: S403
Discussion Time: 11:00 AM - 12:00 PM
Discussion Location: S406 (Vista Room)
CME credit: 1
Track(s): Melanoma/Skin Cancers

Ravi K. Amaravadi, MD—Co-Chair
University of Pennsylvania
Gregory A. Daniels, MD, PhD—Co-Chair
University of California, San Diego Moores Cancer Center

Discussion
11:00 AM  Julie R. Lange, MD (Abstracts #8513–8517)
The Johns Hopkins University School of Medicine

Discussion
11:15 AM  David F. McDermott, MD (Abstracts #8518–8522)
Beth Israel Deaconess Medical Center

Discussion
11:30 AM  Henry B. Koon, MD (Abstracts #8523–8526)
Ireland Cancer Center/University Hospital

Discussion
11:45 AM  Anna C. Pavlick, MD (Abstracts #8527–8532)
New York University Cancer Institute

Brd. 1  Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as an independent prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. (Abstract #8513)

Brd. 2  Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients. (Abstract #8514)
C. A. Voit, A. C. Van Akkooi, G. Schaefer-Hesterberg, A. Schoengen, W. Sterry, A. M. Eggermont

Brd. 3  Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes? (Abstract #8515)
N. Wasif, R. J. Gray, B. A. Pockaj

Brd. 4  Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAOMOUS study. (Abstract #8516)

Brd. 5  Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008. (Abstract #8517)

Brd. 6  Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. (Abstract #8518)
L. Decoster, B. Neyns, I. Vande Broek, E. Anckaert, D. De Clerck, J. De Mey, F. Majois, J. Baurain, H. Denys, J. De Greve
Monday, June 7, 2010

Brd. 7  A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). (Abstract #8519)^
R. D. Carvajal, M. K. Wong, J. A. Thompson, M. S. Gordon, K. D. Lewis, A. C. Pavlick, J. D. Wolchok, F. E. Fox, J. D. Schwartz, A. Y. Bedikian

Brd. 8  Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma. (Abstract #8520)

Brd. 9  First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). (Abstract #8521)

Brd. 10  Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma. (Abstract #8522)
R. Mouawad, J. Spano, R. Conforti, S. Vignot, T. de La Motte Rouge, D. Khayat

Brd. 11  Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. (Abstract #8523)

Brd. 12  Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. (Abstract #8524)

Brd. 13  Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. (Abstract #8525)

Brd. 14  Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (Abstract #8526)

Brd. 15  A phase II study of imatinib for advanced melanoma patients with KIT aberrations. (Abstract #8527)
J. Guo, L. Si, Y. Kong, X. W. Xu, K. T. Flaherty, C. L. Corless, Y. Y. Zhu, L. Li, H. F. Li

Brd. 16  Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). (Abstract #8528)
L. G. Feun, M. You, C. Wu, M. Wangpaichitr, M. T. Kuo, A. Marini, A. Jungbluth, N. Savaraj

Brd. 17  Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. (Abstract #8529)

Brd. 18  Phase II study of vorinostat in patients with advanced melanoma. (Abstract #8530)

Brd. 19  Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma. (Abstract #8531)

Brd. 20  A phase I/II trial of DTIC and dasatinib in metastatic melanoma. (Abstract #8532)
8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy
Location: S Hall A2
Tracks(s): Developmental Therapeutics

Brd. 1A  A phase I study of CD40 agonist monoclonal antibody (CP-870, 893) with gemcitabine in pancreatic cancer. (Abstract #2539)

Brd. 1B  Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. (Abstract #2540)
D. S. Hong, B. S. Koetz, R. Kurzrock, N. N. Senzer, W. Hanekom, A. Naing, J. J. Wheiler, J. Mink, M. Ren, J. J. Nemunaitis

Brd. 1C  A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. (Abstract #2541)
D. D. Von Hoff, P. LoRusso, R. Tibes, G. Shapiro, G. J. Weiss, J. A. Ware, J. Fredrickson, K. E. Mazina, G. G. Levy, A. J. Wagner

Brd. 1D  Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines. (Abstract #2542)


Brd. 1F  Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells. (Abstract #2544)

Brd. 1G  Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI #8057). (Abstract #2545)

Brd. 1H  A phase I/II study of intravenous Rexin-G and Reximmune-C for cancer immunotherapy: The GeneVieve protocol. (Abstract #2546)

Brd. 2A  Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. (Abstract #2547)

Brd. 2B  Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. (Abstract #2548)

Brd. 2C  New approach for assessment of potential ethnic differences in parallel phase I/II studies in the United States and Asia. (Abstract #2549)
Monday, June 7, 2010

Brd. 2D  Overall survival (OS) analysis of a phase I trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). (Abstract #2550)  
R. A. Madan, M. Mohibbash, P. M. Arlen, M. Vergati, S. M. Steinberg, K. Y. Tsang, W. L. Dahut, J. Schlom, J. L. Gulley

Brd. 2E  The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome—New analysis of a pivotal phase II/III study. (Abstract #2551)  
M. G. Ott, H. Lindhofer, R. G. Linke, M. Hennig, H. Martinius, A. Klein, D. Seimetz

Brd. 2F  A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. (Abstract #2552)  

Brd. 2G  Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies. (Abstract #2553)  
H. Xu, D. Yin, K. J. Pierce, S. M. Shreeve, B. Duncan, A. Bello

Brd. 2H  Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors. (Abstract #2554)  

Brd. 3A  CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes. (Abstract #2555)  
A. Yang, R. F. Kendle, B. A. Ginsberg, R. Roman, A. I. Heine, E. Pogoriler, J. D. Yuan, J. D. Wolchok

Brd. 3B  ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases. (Abstract #2556)  

Brd. 3C  Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors. (Abstract #2557)  
J. Wilmink, M. J. Deenen, H. Klümper, R. Sparidans, J. Beijnen, J. H. Schellens, D. Richel

Brd. 3D  A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential. (Abstract #2558)  

Brd. 3E  NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. (Abstract #2559)  

Brd. 3F  A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors. (Abstract #2560)  
M. S. Gordon, R. Just, L. S. Rosen, A. Dorr

Brd. 3G  Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors. (Abstract #2561)  
C. Massard, C. A. Gomez-Roca, R. Bahleda, B. Nguyen, V. D’hondt, T. Besse-Hammer, A. Awada, J. Soria
Brd. 3H  A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma). (Abstract #2562)


Brd. 4A  A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors. (Abstract #2563)


Brd. 4B  Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors. (Abstract #2564)

A. C. Fan, J. Dermody, C. Kong, N. Zhang, A. D. Colevas, D. W. Felsher

Brd. 4C  Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations. (Abstract #2565)


Brd. 4D  Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial. (Abstract #2566)


Brd. 4E  Effect of TGF-β1 expressed on tumor-derived exosomes on survival and function of regulatory T cells. (Abstract #2567)

H. Onishi, J. Wada, H. Suzuki, A. Yasamaki, S. Nagai, T. Morisaki, M. Katano

Brd. 4F  Factors of interindividual hematopoietic toxicity of carboplatin. (Abstract #2568)


S. Lu, Y. Xu

Brd. 4H  A phase I study of ARRY-520 in solid tumors. (Abstract #2570)


Brd. 5A  A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). (Abstract #2571)


Brd. 5B  Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors. (Abstract #2572)


Brd. 5C  Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BITE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. (Abstract #2573)


Brd. 5D  Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression. (Abstract #2574)

D. I. Healey, P. S. Carlson, B. Huang, M. A. Marshall
Brd. 5E Early disease progression in a phase I study of bortezomib (B), cetuximab (C), and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma of the head and neck (SCCHN). (Abstract #2575)

Brd. 5F Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer. (Abstract #2576)

Brd. 5G Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin. (Abstract #2577)

Brd. 5H Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade. (Abstract #2578)
L. Fong, S. Kwek, V. Dao, R. Roy, Y. Hou, J. Simko, E. J. Small

Brd. 6A Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase II/II study. (Abstract #2579)

Brd. 6B Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. (Abstract #2580)

Brd. 6C Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy. (Abstract #2581)

Brd. 6D Eribulin mesylate pharmacokinetics in patients with hepatic impairment. (Abstract #2582)

Brd. 6E PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. (Abstract #2583)

Brd. 6F Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies. (Abstract #2584)

Brd. 6G Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma. (Abstract #2585)

Brd. 6H Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC). (Abstract #2586)
T. C. Gray, E. Siegel, R. Govindarajan
Brd. 7A Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC). (Abstract #2587)

Brd. 7B Improving patient selection for oncology phase I trials: Predictors of 90-day mortality and overall survival. (Abstract #2588)

Brd. 7C Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. (Abstract #2589)

Brd. 7D Phase I/II study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma. (Abstract #2590)
D. A. Reardon, Y. Fu, H. C. Thurm, on behalf of the Phase I Study Group

Brd. 7E A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies. (Abstract #2591)

Brd. 7F A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #2592)
A. Chatterjee, J. Biswas, A. K. Chatterjee, S. Bhattacharya, B. P. Mukhopadhyay, A. Chakraborty, S. Das, R. S. Bhakta

Brd. 7G Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors. (Abstract #2593)
M. Gilabert, B. Esterni, F. Bertucci, P. Viens, A. Goncalves

Brd. 7H Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. (Abstract #2594)

Brd. 8A Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies. (Abstract #2595)
E. Bustinza-Linares, G. S. Falchook, S. Fu, A. Naing, D. S. Hong, W. Hu, S. L. Moulder, J. J. Wheler, A. Sood, R. Kurzrock

Brd. 8B Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. (Abstract #2596)

Brd. 8C Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor. (Abstract #2597)

Brd. 8D Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). (Abstract #2598)

Brd. 8E A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. (Abstract #2599)
Monday, June 7, 2010

**Brd. 8F** Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy. (Abstract #2600)
D. Kim, S. Kim-Schulze, G. Deraffele, J. Schlom, H. Kaufman

**Brd. 8G** A comparison of the Cockcroft-Gault (CG) and the modification of diet in renal disease (MDRD) equations for estimating renal function and guiding dose adjustment of oncology-related drugs. (Abstract #2601)
J. A. Grillo, S. Abraham, A. Khandelwal, Q. Liu, B. Booth, N. A. Rahman

**Brd. 8H** A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors. (Abstract #2602)

**Brd. 8A** Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN). (Abstract #2603)

**Brd. 8B** Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. (Abstract #2604)

**Brd. 8C** A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas. (Abstract #2605)

**Brd. 8D** Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment. (Abstract #2606)

**Brd. 8E** Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle. (Abstract #2607)

**Brd. 8F** Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results. (Abstract #2608)

**Brd. 8G** Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. (Abstract #2609)
M. A. Marshall, A. Ribas, B. Huang

**Brd. 8H** Phase I trial of dasatinib (D) and lapatinib (L). (Abstract #2610)
C. Erlichman, M. E. Menefee, D. W. Northfelt, R. Qin, J. M. Reid, M. Oursler, R. Marks, P. Haluska, J. R. Molina, K. Koch

**Brd. 10A** Trabedersen (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data. (Abstract #2611)

**Brd. 10B** Phase I, dose-escalation study of BIIIB022 (anti-IGF-1R antibody) in advanced solid tumors. (Abstract #2612)
A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. (Abstract #2613)

Monday, June 7, 2010

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Developmental Therapeutics—Experimental Therapeutics
Location: S Hall A2
Tracks(s): Developmental Therapeutics

**Brd. 10D**
Phase I study of PF-03446962, a fully human mab against ALK 1, a TGFβ receptor involved in tumor angiogenesis. (Abstract #3034)

**Brd. 10E**
Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. (Abstract #3035)

**Brd. 10F**
French, multicentric, prospective study of dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of antiangiogenic treatments in 400 patients. (Abstract #3036)

**Brd. 10G**
Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. (Abstract #3037*)

**Brd. 10H**
Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer. (Abstract #3038)

**Brd. 11A**
Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). (Abstract #3039)

**Brd. 11B**
Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies. (Abstract #3040)

**Brd. 11F**
Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer. (Abstract #3041)

**Brd. 11G**
Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. (Abstract #3042)
J. Gollob, J. R. Infante, G. Shapiro, P. LoRusso, B. J. Dezube, J. Heymach, J. Cehelsky, R. Faizone, A. Vaishnaw, H. A. Burris III

**Brd. 11H**
Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. (Abstract #3043)

**Brd. 12A**
Proposal of a new population pharmacokinetics (PK) model of sorafenib and rationale for a three-daily schedule. (Abstract #3044)
Brd. 12B  Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. (Abstract #3045)

Brd. 12F  A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors. (Abstract #3046)

Brd. 12G  Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors. (Abstract #3047)

Brd. 12H  Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). (Abstract #3048)
B. Suttle, H. A. Ball, M. Molimard, D. Rajagopalan, R. S. Swann, R. G. Amado, L. Pandite

Brd. 13A  Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib: A novel molecular imaging study. (Abstract #3049)

Brd. 13B  Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI. (Abstract #3050)

Brd. 13C  Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T). (Abstract #3051)

Brd. 13D  Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI)-induced macrocytosis. (Abstract #3052)

Brd. 13E  Extended linifanib therapy in patients with advanced solid tumors in a phase I trial. (Abstract #3053)
B. C. Goh, C. Wong, J. Qian, E. McKeegan, J. L. Ricker, D. M. Carlson, R. A. Soo

Brd. 13F  A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation. (Abstract #3054)

Brd. 13G  Phase II trial of dose-escalated sorafenib in advanced solid tumors. (Abstract #3055)

Brd. 13H  Association of VEGF feedback production in bevacizumab therapy with systemic response. (Abstract #3056)
P. Starlinger, T. Maier, D. Schauer, C. Nemeth, L. Alidzanovic, B. Gruenberger, T. Gruenberger, C. Brostjan

Brd. 14A  A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. (Abstract #3057)
Monday, June 7, 2010

(Abstract #3058)  
D. S. Thompson, A. Patnaik, J. C. Bendell, K. Papadopoulos, J. R. Infante,  
R. A. Mastico, D. Johnson, A. Qin, J. J. O’Leary, A. W. Tolcher

Brd. 14C  A phase I study of two different schedules of nab-paclitaxel (Nab-p) with  
ascending doses of vandetanib (V) in patients (pts) with advanced solid  
tumors.  (Abstract #3059)  
A. B. El-Khoueiry, S. Iqbal, H. Lenz, L. Roman, B. J. Gitlitz, D. Yang, S. Cole,  
J. Shriki, C. Hughlett, A. Garcia

Brd. 14D  Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in  
combination with letrozole for first-line treatment of patients with  
ER-positive, HER2-negative breast cancer.  (Abstract #3060)  
D. J. Slamon, S. A. Hurvitz, S. Applebaum, J. A. Glaspy, M. K. Allison,  
B. A. DiCarlo, R. D. Courtney, S. T. Kim, S. Randolph, R. S. Finn

Brd. 14E  Final analysis of a phase I single dose-escalation study of the novel  
polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.  
(Abstract #3061)  
T. Gil, P. Schöffski, A. Awada, H. Durnez, S. Bartholomeus, J. Selleslach,  
M. Tatton, H. Fritsch, P. Glomb, G. M. Munzert

Brd. 14F  Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736  
(PF-736), a selective inhibitor of CHK1 kinase.  (Abstract #3062)  
N. Brega, G. A. McArthur, C. Britten, S. G. Wong, E. Wang, K. D. Wilner,  
A. Blasina, G. K. Schwartz, J. Gallo, A. N. Tse

Brd. 14G  Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination  
gemcitabine in advanced solid tumors.  (Abstract #3063)  
R. Bahleda, A. Spreatico, J. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri,  
M. A. Pacciarini, B. Laffranchi, M. Reni

Brd. 14H  A phase I dose-escalation study of SCH 900776, a selective inhibitor of  
checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in  
subjects with advanced solid tumors.  (Abstract #3064)  
A. Daud, G. M. Springett, D. S. Mendelson, P. N. Munster, J. W. Goldman,  
J. R. Strosberg, G. Kato, T. Nesheiwat, R. Isaacs, L. S. Rosen

Brd. 15A  Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with  
prolonged schedules of administration.  (Abstract #3065)  
S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri,  
M. A. Pacciarini, R. Alzani, L. Gianni

Brd. 15B  Phase I study of danusertib (D) in combination with bevacizumab (B) in solid  
tumors.  (Abstract #3066)  
P. J. Rosen, A. W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa,  
M. G. Jannuzzo, S. Comis, K. Papadopoulos

Brd. 15C  A phase I pharmacological and pharmacodynamic study of MK-1775, a  
Wee1 tyrosine kinase inhibitor, in monotherapy and combination with  
gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.  
(Abstract #3067)  
S. Leijen, J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, T. Demuth,  
J. Viscusi, J. D. Cheng, Y. Xu, A. M. Oza

Brd. 15D  Safety and clinical activity of the histone deacetylase inhibitor givinostat in  
combination with mecloretamine in relapsed/refractory Hodgkin lymphoma  
(HL).  (Abstract #3068)  
C. Carlo-Stella, A. Guidetti, S. Viviani, V. Bonfante, A. Marchiano, B. Gatti,  
C. D’Urzo, M. A. Di Nicola, P. Corradini, A. M. Gianni

Brd. 15E  Phase I pharmacokinetic and pharmacodynamic study of the heat shock  
protein 90 inhibitor AT13387 in patients with refractory solid tumors.  
(Abstract #3069)  
G. Shapiro, E. L. Kwak, B. J. Dezube, D. P. Lawrence, J. M. Cleary, S. Lewis,  
M. Squires, V. Lock, J. F. Lyons, M. Yule
Brd. 15F A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. (Abstract #3070)

Brd. 15G First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. (Abstract #3071)

Brd. 15H Phase I dose-finding study of BN80927 as an intravenous infusion every 21 days in patients with advanced malignant solid tumors. (Abstract #3072)
T. Lesimple, F. Bertheault-Cvitkovic, P. Delavault, G. Prevost, V. Fohanno

Brd. 16A Emergence of oral targeted agents in early clinical development: Experience at M. D. Anderson Cancer Center (MDACC) Clinical and Translational Research Center (CTRC). (Abstract #3073)
K. S. Culotta, R. Kurzrock, M. Persic, S. Tahir, J. Morgan, C. Gourley, N. S. Stuart, S. M. Crawford, G. J. Rustin

Brd. 16B Application of multinomial (MN) phase II designs in trials of targeted agents. (Abstract #3074)
R. Jamal, R. A. Goodwin, D. Tu, W. Walsh, E. A. Eisenhauer

Brd. 16C Novel strategy to identify drugs that delay relapse. (Abstract #3075)

Brd. 16D Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. (Abstract #3076)

Brd. 16E Phase I trial of OGX-427, a 2′methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. (Abstract #3077)

Brd. 16F A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. (Abstract #3078)

Brd. 16G A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s lymphoma. (Abstract #3079)
S. Dolly, A. J. Wagner, J. C. Bendell, Y. Yan, J. A. Ware, K. E. Mazina, S. N. Holden, M. K. Derynck, J. S. De Bono, H. A. Burris III

Brd. 16H A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN). (Abstract #3080)
E. M. Karapanagiotou, J. D. Chester, H. S. Pandha, G. M. Gill, M. C. Coffey, K. Mettinger, K. J. Harrington


Brd. 17B A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle. (Abstract #3082)
Monday, June 7, 2010

Brd. 17C A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors. (Abstract #3083)

Brd. 17D Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study. (Abstract #3084)
R. Dreicer, D. B. Agus, G. R. MacVicar, J. Wang, D. MacLean, W. M. Sladler

Brd. 17E A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. (Abstract #3085)

Brd. 17F Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603). (Abstract #3086)

Brd. 17G First-in-human study evaluating safety and pharmacokinetics of endoxifen, a potent estrogen-receptor antagonist for breast cancer. (Abstract #3087)
A. Ahmad, S. Shahabuddin, S. Sheikh, P. Kale, M. K, R. C. Rane, I. Ahmad

Brd. 17H A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer. (Abstract #3088)

Brd. 18A Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isof orm inhibitor of PI3 kinase. (Abstract #3089)
A. Jimeno, R. S. Herbst, G. S. Falchook, W. A. Messersmith, S. Hecker, S. Peterson, D. F. Hausman, R. Kurzrock, S. G. Eckhardt, D. S. Hong

Brd. 18B Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression. (Abstract #3090)

Brd. 18C Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response. (Abstract #3091)

Brd. 18D Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program. (Abstract #3092)

Brd. 18E Sensitive detection of gamma-H2AX induction as a pharmacodynamic marker for profiling patients with cancer treated with topotecan. (Abstract #3093)
D. W. Davis, D. Mittelman, G. Copper, Y. Zhang, S. Sukumaran, W. Yutzy, J. J. Ji

Brd. 18F Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU). (Abstract #3094)

Brd. 18G Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors. (Abstract #3095)
X. Wang, S. Syed, E. Masson, I. B. Walters, A. Roy
Brd. 18H  Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer.  
(Abstract #3096)  

Brd. 19A  Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.  
(Abstract #3097)  

Brd. 19B  Pharmacogenetic factors predicting the need for a higher dose of imatinib.  
(Abstract #3098)  
H. Klumpen, K. Eechoute, M. S. Hertzberg, A. A. Schwarer, D. Goldstein, T. P. Hughes, C. Liddle, R. Mathijssen, J. H. Schellens, H. Gurney

Brd. 19C  DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine.  
(Abstract #3099)  

Brd. 19D  Relationship of HLA-DQA1*0201 and lapatinib-induced hepatotoxicity in women with advanced breast cancer.  
(Abstract #3100)  
C. F. Spraggs, L. R. Budde, L. P. Briley, N. Bing, A. J. Preston, V. E. Mooser, L. R. Cardon, S. H. Stein

Brd. 19E  The contribution of UGT1A and ABCB1 to irinotecan-induced toxicity: A prospective pharmacogenetic study of patients with metastatic colorectal cancer.  
(Abstract #3101)  
E. Levesque, A. Bélanger, F. Couture, D. J. Jonker, L. Villeneuve, M. Harvey, C. Guillemette

Brd. 19F  Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.  
(Abstract #3102)  
S. P. Chawla, J. Tabernero, H. L. Kindler, E. G. Chiorean, P. LoRusso, M. Hsu, V. Haddad, B. A. Bach, J. Baselga

(Abstract #3103)  
K. Kelly, J. J. Hwang, G. Shapiro, S. Mani, M. M. Cotreau, M. Credi, M. Al-Adhami, P. Bhargava

Brd. 19H  Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.  
(Abstract #3104)  
J. Desai, B. J. Solomon, I. D. Davis, L. R. Lipton, R. Hicks, A. M. Scott, J. Park, P. L. Clemens, T. A. Gestone, F. G. Finckenstein

Brd. 20A  A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.  
(Abstract #3105)  

Brd. 20B  Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265–101).  
(Abstract #3106)  

Brd. 20C  Evaluation of serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib.  
(Abstract #3107)  
Y. Pei, S. Wei, B. Yao, X. Ma, Y. Yang, L. Yuan, Q. Li, P. Ji, S. Hu, L. Ji

Brd. 20D  A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265–102).  
(Abstract #3108)  
The Trials in Progress Poster Session is a new Annual Meeting session designed to facilitate awareness of open, ongoing clinical trials. This session will encourage discussions of new clinical research and the exchange of ideas on clinical trial design. There will be no presentation of trial results. Abstracts being presented during the poster session are listed below.

**Breast Cancer—Local-Regional and Adjuvant Therapy**

**Brd. 20E**  Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. (Abstract #TPS100)

J. C. Sachdev, L. E. Kronish, S. West, L. Schwartzberg, M. Jahanzeb

**Brd. 20F**  Feasibility of an exercise program for aromatase inhibitor-related arthralgia (AIRA) in breast cancer survivors. (Abstract #TPS101)

J. Katz, D. C. Savior, P. Gilman

**Brd. 20G**  A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer. (Abstract #TPS102)


**Brd. 20H**  TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. (Abstract #TPS103)


**Brd. 21A**  ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophosphamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast. (Abstract #TPS104) G. Von Minckwitz

**Brd. 21B**  A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study). (Abstract #TPS105)


**Brd. 21C**  WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1. (Abstract #TPS106^)


**Brd. 21D**  A phase II clinical trial of four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel given concurrently with pazopanib as neoadjuvant therapy followed by postoperative pazopanib for women with locally advanced breast cancer (LABC): A phase II trial of the NSABP foundation research group (FB-6/VEG110264). (Abstract #TPS107)

Brd. 21E A randomized, pharmacologic intervention study evaluating the effect of the angiotensin II-receptor blocker candesartan versus placebo to prevent trastuzumab-associated cardiotoxicity in women with early breast cancer. (Abstract #TPS108)
R. Altena, A. H. Boekhout, on behalf of the Candy Study Co-Investigators

Brd. 21F Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer. (Abstract #TPS109)

Brd. 21G Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. (Abstract #TPS110)
W. M. Sikov, C. M. Perou, M. Golshen, D. Collyar, D. A. Berry, O. M. Hahn, B. Singh, C. Hudis, E. P. Winer, Cancer and Leukemia Group B, North American Intergroup

Brd. 21H A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). (Abstract #TPS111)

Brd. 22A SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with previously untreated primary breast cancer (BC). (Abstract #TPS112)
S. Loibl, German Breast Group

Brd. 22B MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. (Abstract #TPS113)

Brd. 22C Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial. (Abstract #TPS114)

Brd. 22D A new resource to accelerate translational breast cancer research: The Love/Avon Army of Women. (Abstract #TPS115)
S. M. Love

Brd. 22E LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial. (Abstract #TPS116)
D. A. Cameron, S. Marreaud, K. Zaman, A. Bodmer, J. Pierga, E. Brain, C. Veyret, J. M. Bartlett, J. Bogaerts, H. R. Bonnefoi

Brd. 22F Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of approved hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall. (Abstract #TPS117)
N. Borys, F. Muggia, W. Simonich, S. A. Lewis

Brd. 22G A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1–4, N1–2, M0) at initial diagnosis: ACOSOG Z1071. (Abstract #TPS118)

Brd. 22H A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC). (Abstract #TPS119)
Monday, June 7, 2010

Breast Cancer—Metastatic

Brd. 23A A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801. (Abstract #TPS120)

H. L. Gomez, S. P. Neciosup, Y. Neron do Nascimento, G. Ismael, C. H. Barrios

Brd. 23B Suppression of bone turnover following treatment with zoledronic acid in patients with metastatic breast cancer: Duration of effect—The SuBDuE study. (Abstract #TPS121)

C. E. Simmons, E. Amir, E. Lee, S. Hogeveen, R. A. Dent, P. J. Goodwin, M. Clemons

Brd. 23C Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. (Abstract #TPS122)


Brd. 23D Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine for the treatment of meningeal metastases (NM) in HER2-positive breast cancer patients. (Abstract #TPS123)

J. Bischoff

Brd. 23E Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC). (Abstract #TPS124)


Brd. 23F Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC). (Abstract #TPS125)

J. D. Hainsworth, D. A. Yardley, H. A. Burris

Brd. 23G Metronomic chemotherapy with cyclophosphamide and celecoxib in breast cancer patients progressing after standard chemotherapy: Phase I/II trial. (Abstract #TPS126)

V. R. Rozados, A. Rossa, C. M. Alasino, H. A. Perroud, F. N. Queralt, S. M. Pezzotto, O. G. Scharovsky

Brd. 23H Randomized phase II study of metronomic chemotherapy (MC) plus aromatase inhibitor (AI) versus MC alone in postmenopausal hormone receptor-positive, metastatic breast cancer (MBC), with correlative circulating endothelial cell (CEC), circulating endothelial progenitor cell (CEP), VEGF, and VEGFR levels. (Abstract #TPS127)

N. Wong, K. Hui, F. Sun, Y. Yap, R. C. Ng, J. W. Chia, L. Ngo, S. Lo

Brd. 24A A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC). (Abstract #TPS128)


Brd. 24B N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. (Abstract #TPS129)


Brd. 24C Gene signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC). (Abstract #TPS130)

Brd. 24D  Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). (Abstract #TPS131)
L. J. Goldstein, S. M. Stemmer, B. Schmalfeldt, N. Gottschalk, F. Cardoso, H. Dushkin, C. Mala, N. Uebler, P. Bevan, N. Harbeck

Brd. 24E  TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). (Abstract #TPS132)

Brd. 24F  Three parallel randomized phase II trials of dasatinib plus hormone therapy (HT) in advanced ER+ breast cancer (ER+ ABC). (Abstract #TPS133)

Brd. 24G  A phase II comparative study of metformin plus first-line chemotherapy (CT) versus CT alone in HER2-negative, insulin-resistant (IR), nondiabetic metastatic breast cancer (MBC). (Abstract #TPS134)

Brd. 24H  A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC). (Abstract #TPS135)

Brd. 25A  A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients. (Abstract #TPS136)

Brd. 25B  Comparison of zoledronic acid retention in bone of multiple myeloma and breast cancer patients: Consequences for efficacy? (Abstract #TPS137)

Brd. 25F  Evaluation of toll-like receptor (TLR)-7 agonist imiquimod applied topically to breast cancer chest wall recurrences or skin metastases. (Abstract #TPS138)
S. Adams, Z. Dewan, T. Meng, J. D. Goldberg, A. Tiersten, N. Bhardwaj, S. Formenti, S. Demaria

Cancer Prevention/Epidemiology

Brd. 25G  Utilization of 5HTT-gene polymorphism as a prognostic indicator in cancer. (Abstract #TPS139)
N. M. Awad, M. Farouk, H. Elshafei, S. Ghobashy, M. Elbordiny, A. A. Elsaid, A. Omar

Brd. 25H  Fish oil, green tea, and prostate cancer prevention. (Abstract #TPS140)

Brd. 26A  A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer. (Abstract #TPS141)

Brd. 26B  Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. (Abstract #TPS142)

Brd. 26F  Sulforaphane supplementation in women newly diagnosed with DCIS: A biomarker study. (Abstract #TPS143)
Central Nervous System Tumors

Brd. 26G Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients. (Abstract #TPS144)

Brd. 26H Phase II trial of chemotherapy with temozolomide in combination with topotecan for central nervous system (CNS) metastases of solid tumors. (Abstract #TPS145)
P. Z. New, J. Jac

Brd. 27A Phase I study of bendamustine and fractionated stereotactic radiotherapy (FSRT) in patients with one to three brain metastases from solid malignancies. (Abstract #TPS146)
J. C. Grecula, M. Ammirati, K. L. Kendra, M. Phelps, R. Cavaliere, B. McCracken-Bussa, J. Radawski, L. Wei, E. Mrozek, N. A. Mayr

Brd. 27B A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas. (Abstract #TPS147)

Brd. 27C Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with one to three newly diagnosed brain metastases. (Abstract #TPS148)

Brd. 27E A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. (Abstract #TPS150)
P. Chinnaiyan, S. Chowdhary, S. Brem, M. Yu, R. Murtagh, A. Rojiani, Y. Tsai, E. Pan

Brd. 27F Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study. (Abstract #TPS151)
L. B. Nabors, K. Fink, D. A. Reardon, G. J. Lesser, J. Trusheim, S. N. Raval, C. Hicking, M. Picard, T. Mikkelsen

Brd. 27G Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). (Abstract #TPS152)

Brd. 27H An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging and molecular markers during bevacizumab/irinotecan therapy for recurrent malignant glioma. (Abstract #TPS153)
M. Hutterer, M. Nowosielski, T. Gotwald, D. Putzer, D. Waitz, H. Maier, A. Muigg, H. Kostron, G. Stockhammer

Brd. 28A Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma. (Abstract #TPS154)

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Brd. 28B Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). (Abstract #TPS155)
Brd. 28C  Catumaxomab observational study to investigate efficacy and safety profile in clinical practice. (Abstract #TPS156)
V. Kunzmann, R. G. Linke, P. Ruf, H. Lindhofer, M. Hennig, M. M. Essing

Brd. 28D  Phase I trial of CCL21 gene modified dendritic cells in non-small cell lung cancer. (Abstract #TPS157)

Brd. 28E  New approaches in dendritic cell vaccination design and efficacy tests for patients with advanced ovarian cancer: Prospects for a phase I clinical study. (Abstract #TPS158)
M. Imhof

Brd. 28F  An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors. (Abstract #TPS159)
M. Beeram, S. C. Novick, A. Qureshi, A. Patnaik, K. Papadopoulos, A. W. Tolcher

Brd. 28G  Dose-escalation phase I study of NKTR-105, a novel pegylated form of docetaxel. (Abstract #TPS160)
E. Calvo, U. Hoch, D. J. Maslyar, A. W. Tolcher

Brd. 28H  Treating HIV+/H11545 patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patients on ART. (Abstract #TPS161)

Brd. 29A  Use of a human ribonuclease variant, QBI-139, for the treatment of cancer. (Abstract #TPS162)
L. E. Strong, J. A. Kink, B. Mei, M. N. Shahran, R. T. Raines

Brd. 29B  Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors. (Abstract #TPS163)

Brd. 29C  A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden. (Abstract #TPS164)
P. N. Mainwaring, J. Lickliter, M. P. Brown, M. Millward, D. J. Chaplin, Z. Goldberg

Brd. 30A  Attempt to improve the safety of development studies with a new design for phase I combination trials of targeted therapies: The PARASOL trial. (Abstract #TPS165)
S. Negrier, D. Pérol, J. Soria, S. Chabaud, S. Metzger, B. Escudier

Brd. 30B  Phase I trial of everolimus and gemcitabine for patients with solid tumors refractory to standard therapy and for a cohort of patients with cholangiocarcinoma/gallbladder cancer. (Abstract #TPS166)


Brd. 31A  Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors. (Abstract #TPS168)
Monday, June 7, 2010

Brd. 31B A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. (Abstract #TPS169)
C. S. Denlinger, M. Beeram, A. W. Tolcher, L. J. Goldstein, W. J. Slichenmyer, J. Murray, C. McDonagh, K. Andreas, V. M. Moyo

Brd. 31C SORAVE trial: Phase I sorafenib and everolimus in solid tumors. (Abstract #TPS170)

Brd. 32A A randomized, open-label phase IIb study of maintenance therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. (Abstract #TPS171)
H. J. Gray, A. A. Secord, M. L. Anderson, G. DelPriere, N. E. Tchabo, J. S. Berek

Brd. 32B Multiple tumor associated peptide vaccination as consolidation treatment in women affected by breast and ovarian cancer. (Abstract #TPS172)

Brd. 32C A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer. (Abstract #TPS173)

Brd. 33A A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund’s adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission. (Abstract #TPS174)

Brd. 33B Endogenous heat-shock protein vaccines for metastatic melanoma. (Abstract #TPS175)

Developmental Therapeutics—Experimental Therapeutics

Brd. 33C Investigation of pathways regulating early antiangiogenic response to bevacizumab given prior to neoadjuvant breast cancer chemotherapy. (Abstract #TPS176)

Brd. 34A A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. (Abstract #TPS177)
A. F. Eichler, H. A. Shih, L. V. Sequist, P. Y. Wen, R. K. Jain, A. G. Sorensen, T. Batchelor

Brd. 34B Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). (Abstract #TPS178^)

Brd. 34C Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma. (Abstract #TPS179)

Brd. 35A A phase Ia study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with advanced solid tumors. (Abstract #TPS180)

320
Brd. 35B Combination of vorinostat with whole-brain radiotherapy in the treatment of brain metastases. (Abstract #TPS181)
Y. R. Lawrence, R. M. Pfeffer, M. Werner-Wasik, H. Choy, A. Dicker

Brd. 35C Correlation between FLT-PET and Ki-67 change in breast cancer during neoadjuvant chemotherapy (Abstract #TPS182)
S. C. Blackman, R. A. Railkar, R. Fox, L. George, R. Iannone, D. A. Bergstrom, P. D. Mozley

Brd. 35D APR-246, a new class anticancer compound in phase I/IIa clinical trials. (Abstract #TPS183)
C. Liljebris, N. Mohell, E. Olaisson, T. Uhlin, K. G. Wiman, S. Lehmann

Brd. 35E Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study. (Abstract #TPS184)
S. Wroblewski, W. Shi, P. Mudd Jr., M. Aivado

Brd. 35F An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary. (Abstract #TPS185)

Brd. 35G A randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328, an anti-IL-6) in patients with multicentric Castleman’s disease. (Abstract #TPS186)
J. Vermeulen, M. Qi, J. B. Herring, J. Flisak, H. M. Prince, J. Rossi, M. J. Cornfeld, F. Van Rhee

Brd. 35H A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM). (Abstract #TPS187)

Brd. 36A An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors. (Abstract #TPS188)

Gastrointestinal (Colorectal) Cancer
Brd. 36B PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS. (Abstract #TPS189)
L. S. Schwartzberg, V. J. Wagner

Brd. 36C Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type KRAS colorectal cancer with metastases confined to liver. (Abstract #TPS190)

Brd. 36D A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT). (Abstract #TPS191)

Brd. 36E FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer. (Abstract #TPS192)
R. G. Gray, D. Morton, G. Brown, D. R. Ferry, L. Magill, P. Quirke, M. T. Seymour, B. Warren, on behalf of the FOxTROT Collaborative Group
Monday, June 7, 2010

Brd. 36G  Phase I/II personalized therapy trial for metastatic colorectal cancer using functional pathway mapping: Stratification to imatinib therapy. (Abstract #TPS194)

Brd. 36H  SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors. (Abstract #TPS195)
A. L. Cohn, K. Krishnan, J. R. Hecht

Brd. 37A  Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study. (Abstract #TPS196)

Brd. 37B  Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver. (Abstract #TPS197)
R. Murthy, A. Mahvash, R. Avritscher, W. Erwin, B. Chasen, C. Eng

Brd. 37C  Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial. (Abstract #TPS198)

Brd. 37D  The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS199)

Gastrointestinal (Noncolorectal) Cancer

Brd. 37E  Perioperative chemotherapy plus bevacizumab with early salvage therapy based on PET response in patients with locally advanced resectable gastric/GEJ cancer. (Abstract #TPS200)

Brd. 37F  Phase I study of sunitinib with irinotecan/5-fluourouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. (Abstract #TPS201)
N. I. Khushalani, G. J. Fetterly, R. V. Iyer, A. Litwin, W. Brady, M. Brady, M. Javle

Brd. 37H  Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma. (Abstract #TPS203)

Brd. 38A  A phase II trial of combined treatment of endoscopic mucosal resection (EMR) and chemoradiotherapy (CRT) for clinical stage I esophageal squamous cell carcinoma (ESCC): Japan Clinical Oncology Group study JCOG0508. (Abstract #TPS204)
T. Tsuchida, M. Muto, K. Minashi, H. Ono, Y. Morita, R. Ishihara, I. Toshiro, H. Kawai, N. Boku, H. Fukuda

Brd. 38B  Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071). (Abstract #TPS205)
A. Roth, M. H. Moehler, M. Mauer, A. Schad, M. Karrasch, M. Praet, M. L. Lim, A. Das-Gupta, M. P. Lutz

Brd. 38C  Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC). (Abstract #TPS206)
Brd. 38D  Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. (Abstract #TPS207)  
F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu, The Western Cooperative Gastrointestinal Oncology Group of China

Brd. 38E  DRAFT: RAMSETE trial of everolimus (RAD001) in the treatment of silent (nonfunctioning) advanced neuroendocrine tumors. (Abstract #TPS208)  
B. Wiedemann, S. Caglio, L. Decroix, C. May, K. E. Oberg

Brd. 38F  A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060). (Abstract #TPS209)  

Brd. 38G  Gefitinib in the adjuvant treatment of hepatocellular carcinoma: A pilot study by the Singapore hepatocellular carcinoma consortium. (Abstract #TPS210)  
G. Lopes, C. K. Ho, K. H. Liau, A. Chung, P. Cheow, A. Y. Chang, Singapore Hepatocellular Carcinoma Consortium

Brd. 38H  Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT). (Abstract #TPS211)  

Brd. 39A  A phase I trial of escalating doses of the anti-IGF-1R monoclonal antibody (mAb) cixutumumab (IMC-A12) and sorafenib for treatment of advanced hepatocellular carcinoma (HCC). (Abstract #TPS212)  

Brd. 39B  A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC). (Abstract #TPS213)  

Brd. 39F  Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. (Abstract #TPS214)  

Brd. 39G  ARQ 197–215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). (Abstract #TPS215)  

Brd. 39H  Dose-escalating study of yttrium 90 microspheres with capecitabine for intrahepatic cholangiocarcinoma or metastatic disease to the liver. (Abstract #TPS216)  
R. M. Hickey, M. F. Mulcahy, R. Lewandowski, R. Salem

Brd. 40A  Combined biological treatment and chemotherapy for patients with inoperable cholangiocarcinoma. (Abstract #TPS217)  

Brd. 40B  ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers. (Abstract #TPS218)  
J. W. Valle, J. A. Bridgewater, M. Roughton, C. Dive, S. Hughes, H. S. Wasan

Brd. 40F  The antiproliferative effect of pasireotide LAR alone and in combination with everolimus (RAD001) in patients with progressive medullary thyroid cancer (MTC): A single-center, open-label, phase II, proof-of-concept study. (Abstract #TPS219)  
A. Faggiano, A. Colao
MONDAY
Monday, June 7, 2010

Brd. 40G  Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. (Abstract #TPS220)

Brd. 40H  A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC). (Abstract #TPS221)

Brd. 41A  A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. (Abstract #TPS222)
S. Mukherjee, C. Hurt, G. Griffiths, T. Crosby, J. Staffurth, S. Bridges, J. A. Bridgewater, A. Mcdonald, S. Falk, T. S. Maughan, scaloptmg

Brd. 41B  SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. (Abstract #TPS223)

Brd. 41C  APRiCoT-P: A phase II randomized placebo controlled study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib and gemcitabine in pancreatic cancer patients. (Abstract #TPS224)

Brd. 41D  CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluourouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase II trial. (Abstract #TPS225)
J. Stieler, U. Pelzer, M. Sinn, B. Dörken, H. Oettle, H. Riess

Brd. 41E  A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations. (Abstract #TPS226)

Genitourinary Cancer

Brd. 41F  Novel early stopping rule uses early progression rather than lack of response as rapid assessment for futility. (Abstract #TPS227)
Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, S. M. Cohen, H. Tuttle, G. R. Hudes

Brd. 41G  A randomized phase II study of a novel antigen-presenting cell-targeted hCG-β vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer. (Abstract #TPS228)
D. A. Bradley, M. Morse, T. Keler, J. A. Green, T. A. Davis, B. A. Inman

Brd. 41H  Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. (Abstract #TPS229)

Brd. 42A  Pilot study of external hyperthermia and intravesical mitomycin-C to treat recurrent bladder cancer after failed standard therapy. (Abstract #TPS230)
Z. Vujaskovic, O. I. Craciunescu, P. Stauffer, M. Carroll, L. Lan, M. Dewhirst, B. A. Inman
Brd. 42B  A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. (Abstract #TPS231)
S. S. Sridhar, C. M. Canil, S. D. Mukherjee, E. Winquist, C. Elser, A. Eisen, A. Chung, Y. Ko

Brd. 42C  First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). (Abstract #TPS232)
J. J. Knox, A. C. Kay, E. Schiff, N. Hollaender, N. Rouyrre, A. Ravaud, R. J. Motzer

Brd. 42D  Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC). (Abstract #TPS233)
B. Tannir, S. Hardikar

Brd. 42E  Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma. (Abstract #TPS234)
S. Caglio, K. Slimane, C. May, B. Escudier

Brd. 42F  Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). (Abstract #TPS235)
E. Jonasch, A. Bair, Y. Chen, B. I. Rini

Brd. 42G  Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001. (Abstract #TPS236)
L. C. Harshman, A. McMillan, S. Srinivas

Brd. 42H  A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC). (Abstract #TPS237)
B. J. Escudier, D. Celli, J. E. Gschwend, T. Powles, C. N. Sternberg, R. Hodge, M. Lau, M. Neary, F. Mehmud, T. Eisen

Brd. 43A  Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear renal cell carcinoma. (Abstract #TPS238)
A. Ravaud, E. Bajetta, A. C. Kay, D. Pelov, N. Hollaender, N. Rouyrre, J. A. Thompson

Brd. 43B  Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. (Abstract #TPS239)

Brd. 43C  A phase II trial of docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced and metastatic carcinoma of the penis (CRUK/09/001). (Abstract #TPS240)
A. K. Bahl, S. Nicholson, J. Barber, E. Hall

Brd. 43D  A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC). (Abstract #TPS241)
R. Z. Szmulewitz, E. M. Posadas, B. Manchen, W. M. Stadler

Brd. 43E  Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC). (Abstract #TPS242)

Brd. 43F  Phase I/II study of sorafenib concurrent with androgen deprivation and radiotherapy in treatment of intermediate- and high-risk localized prostate cancer. (Abstract #TPS243)
S. Talwar, S. M. Cohen, N. A. Romas, R. D. Ennis
Monday, June 7, 2010

Brd. 43G Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients. (Abstract #TPS244)  
G. Gibney, A. Elfiky, C. J. Holmes, A. Burns, E. Rowen, J. A. McDonough, R. Lampert, C. Gross, W. K. Kelly

Brd. 43H First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. (Abstract #TPS245)  
P. Kantoff, D. P. Petrylak, M. Pomerantz, R. J. Israel, W. C. Olson, T. Ramakrishna, S. Morris

Brd. 44A A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). (Abstract #TPS246)  
U. Emmenegger, S. S. Sridhar, C. M. Booth, R. Kerbel, S. R. Berry, Y. Ko

Brd. 44B Phase I dose-escalation study of docetaxel/prednisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC). (Abstract #TPS247)  

Brd. 44C A randomized phase II trial of 177Lu radiolabeled monoclonal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy. (Abstract #TPS248)  

Brd. 44D Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. (Abstract #TPS249)  
A. J. Armstrong, G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, M. Garcia-Blando

Brd. 44E Phase II study of preoperative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: A platform for radiosensitizer development. (Abstract #TPS250)  
M. Garzotto, A. Hung, T. M. Beer, P. E. Farris

Brd. 44F Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial. (Abstract #TPS251)  

Gynecologic Cancer

Brd. 44G Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer. (Abstract #TPS252)  

Brd. 44H Phase I/II trial of reovirus serotype 3–Dearing strain in patients with recurrent ovarian cancer. (Abstract #TPS253)  

Brd. 45A Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild type: An ongoing, nonrandomized, multicenter, phase II trial. (Abstract #TPS254)  
Brd. 45B  A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. (Abstract #TPS255)

Brd. 45C  Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer. (Abstract #TPS256)

Brd. 45D  A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. (Abstract #TPS257)
J. D. Hainsworth, T. M. Numnum, G. G. Rao

Brd. 45E  Phase II study of clinical activity of pegaspargase in women with relapsed or refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer. (Abstract #TPS258)
G. Kim, J. Squires, M. Yu, A. Walker, N. D. Houston, L. Otten, E. C. Kohn

Brd. 45F  Enrolling a rare patient population: Establishing proof of concept for FP-1039, an FGF “trap,” in endometrial cancer patients with the S252W FGFR2 mutation. (Abstract #TPS260)
H. N. Keer, T. C. Harding, W. M. Kavanaugh

Brd. 45G  Randomized phase II trial of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. (Abstract #TPS257)
J. D. Hainsworth, T. M. Numnum, G. G. Rao

Head and Neck Cancer

Brd. 46A  A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract #TPS262)

Brd. 46B  Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone. (Abstract #TPS263)
M. S. Brose, A. B. Troxel, R. Mamtani

Brd. 46C  Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract #TPS264)

Brd. 46D  Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial). (Abstract #TPS265*)

Brd. 46E  A phase I/II study of erlotinib in combination with chemoradiation in patients with surgically resected locally advanced squamous head and neck cancer (HNSCC). (Abstract #TPS266)
Monday, June 7, 2010

Brd. 46F  VortigERN: Variation of radiotherapy target volume definition, dose to organs at risk (OAR), and clinical target volumes using anatomic (CT) versus combined anatomic and molecular imaging (PET-CT): Intensity-modulated radiotherapy delivered using a tomotherapy hi art machine. (Abstract #TPS267)

Brd. 46G  Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib (GORTEC-GETTEC CARISSA trial): Implications for sensitivity to gefitinib. (Abstract #TPS268)

Brd. 46H  Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical phase II trial and correlation to retinoid and peroxisome proliferator-activated receptor gamma receptors expression. (Abstract #TPS269)
L. P. De Oliveira, B. Haugen, M. Kane, A. Jimeno, J. Klopper

Brd. 47A  Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: An ongoing pilot, randomized, sham-controlled trial. (Abstract #TPS270)

Brd. 47B  Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable adenoid cystic carcinoma of the head and neck. (Abstract #TPS271)
A. P. Kotsakis, W. E. Gooding, A. Arigiris

Brd. 47C  A pilot study comparing a patient-centered symptom-reporting follow-up program to standard care in patients who have completed the acute phase of treatment for early breast cancer. (Abstract #TPS272)

D. R. Close

Brd. 47E  Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (Abstract #TPS274)

Brd. 47F  CPX-351: A randomized phase llb study first-relapse patients younger than age 65. (Abstract #TPS275)
J. E. Kolitz, J. E. Cortes, K. Paulsen, A. C. Louie

Brd. 47G  A phase llb study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML). (Abstract #TPS276)

Brd. 47H  The OPAL study: A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia. (Abstract #TPS277)
J. E. Cortes, E. J. Feldman, K. W. Yee, M. J. Toal, A. Richardson, A. Charman, N. Flores, The OPAL Investigators
Brd. 48A  A phase IIa pharmacokinetic and efficacy study of amonafide (AS1413) in combination with cytarabine in patients with acute myeloid leukemia. (Abstract #TPS278)
A. S. Lundberg, S. L. Allen, AS1413–101 Investigator Group

Brd. 48B  A multicenter dose-finding randomized controlled phase IIb study of the aptamer AS1411 in patients with primary refractory or relapsed AML. (Abstract #TPS279)
R. K. Stuart, A. Wei, I. D. Lewis, E. Estey, F. Erlandsson, G. J. Schiller

Brd. 48C  An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients. (Abstract #TPS280)

Brd. 48D  Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph+) leukemias resistant or intolerant to imatinib. (Abstract #TPS281)
J. A. Rosenberg, D. Derreumaux, L. Gore, P. Kearns, A. Baruchel, T. Barrett, M. Zwaan

Brd. 48E  A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). (Abstract #TPS282)

Brd. 48F  A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis. (Abstract #TPS283)

Lung Cancer—Local Regional and Adjuvant Therapy

Brd. 48G  Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer. (Abstract #TPS284)

Brd. 48H  A multi-institutional feasibility study of induction pemetrexed (Pem) plus cisplatin (Cis) followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation (RT) for malignant pleural mesothelioma (MPM): Japan Mesothelioma Research Center (JMRC) 001001 trial. (Abstract #TPS285)

Brd. 49A  A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer. (Abstract #TPS286)
R. H. Decker, S. N. Gettinger, L. D. Wilson

Brd. 49B  Trial of poor performance status patients (ToPPS): A randomized phase II trial of pemetrexed versus pemetrexed/bevacizumab versus pemetrexed/carboplatin/bevacizumab in patients with stage IIIb/IV non-small cell lung cancer and ECOG performance status 2. (Abstract #TPS287)
D. R. Spigel, R. Lilienbaum, J. D. Hainsworth

Brd. 49C  Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter phase II study. (Abstract #TPS288)
Monday, June 7, 2010

**Lung Cancer—Metastatic**

**Brd. 49D** Peripheral non-small cell lung cancer treated in stereotactic conditions: A prospective medico-economic French study. (Abstract #TPS289)
L. Claude, B. Prevost, P. Boisselier, F. Gassa, C. Carrie, S. Dussart

**Brd. 49E** Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology. (Abstract #TPS290)
R. Zinner, S. Saxman, G. Peng, W. F. Ortuzar

**Brd. 49F** Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. (Abstract #TPS291)

**Brd. 49G** Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. (Abstract #TPS292)

**Brd. 49H** Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC. (Abstract #TPS293)
K. M. Kerr, D. A. Fennell, R. N. Shah, M. Kumar, G. Skailes, V. A. Potter, S. Moore, P. Maxwell, M. Das, M. Nicolson

**Lymphoma and Plasma Cell Disorders**

**Brd. 50A** Phase II trial evaluating addition of fulvestrant to erlotinib in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who are stable on erlotinib and exhibit immunohistochemical (IHC) or PCR positivity for estrogen or progesterone receptor (PR). (Abstract #TPS294)
L. Bazhenova, R. Quintana, R. H. Hastings, K. Messer

**Brd. 50B** Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). (Abstract #TPS295)

**Brd. 50C** Randomized phase II study of human anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody (MC-3G3) with paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #TPS296)

**Brd. 50D** A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. (Abstract #TPS297)

**Brd. 50E** ENGAGE-501: Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin’s lymphoma (HL). (Abstract #TPS298)
A. Younes, P. J. Rosen, F. J. Hernandez-Illizalturri, G. Bociek, Y. L. Kasamon, A. Copeland, G. T. Lee

**Brd. 50F** An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL). (Abstract #TPS299)
P. B. Johnston, L. T. Lewis, J. W. Rogerio
Brd. 50G A pilot study of sorafenib examining biomarkers in refractory or relapsed T-cell lymphoma patients. (Abstract #TPS300)
F. Lansigan, M. Komarovskaya, S. Seropian, D. Cooper, F. M. Foss

Brd. 50H Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies. (Abstract #TPS301)

Brd. 51A A phase II trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic lymphoma. (Abstract #TPS302)
C. Rudin, R. J. Johnson, B. Pottinger, P. Smith, O. A. Adedayo

Brd. 51B A randomized, open-label, multicenter phase II study of bortezomib with fludarabine in comparison to rituximab with fludarabine in follicular lymphoma subjects previously treated with rituximab. (Abstract #TPS303)
P. Theocharous, O. Shpilberg, Y. A. Elsayed

Brd. 51C RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL). (Abstract #TPS304)

Brd. 51D Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. (Abstract #TPS305)
J. R. Westin, F. Chu, M. Foglietta, R. Rotem-Yehudar, S. S. Neelapu

Brd. 51E A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. (Abstract #TPS306)

Brd. 51F Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ) and dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts). (Abstract #TPS307)

Brd. 51G PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed BTZ-refractory multiple myeloma (MM). (Abstract #TPS308)

Melanoma/Skin Cancers

Brd. 51H A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma. (Abstract #TPS309)

Brd. 52A Treatment of melanoma with wild-type p53 (wtp53) and detectable S100B using pentamidine: A phase II trial with correlative biomarker endpoints. (Abstract #TPS310)

Brd. 52B Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase II/II study. (Abstract #TPS311)
L. Ridolfi, L. Fiammenghi, M. Petrini, A. Granato, V. Ancarani, E. Pancisi, M. Guidoboni, A. Riccobon, P. A. Ascierto, R. Ridolfi

Brd. 52C A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). (Abstract #TPS312)
K. Kalinsky, S. J. Lee, D. P. Lawrence, J. M. Kirkwood
Monday, June 7, 2010

**Brd. 52D** LPS-activated dendritic cell vaccine in combination with immunomodulatory dose of cytoxan in patients with stage IV melanoma: Phase I/IIa clinical trial. (Abstract #TPS313)

**Brd. 52E** An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTS) with metastatic malignant melanoma (MMM). (Abstract #TPS314)
E. Hersh, M. Millward, I. Elias, J. Iglesias

**Patient and Survivor Care**

**Brd. 52F** Randomized phase II study of gabapentin alone versus gabapentin plus tramadol for the management of oxaliplatin-induced peripheral neuropathy. (Abstract #TPS315)
H. Shim, J. Yoon, J. Hwang, W. Bae, S. Cho, I. Chung

**Brd. 52G** Evaluation of a Web-based cognitive rehabilitation program for cancer survivors with self-reported cognitive impairment. (Abstract #TPS316)
V. J. Bray, H. M. Dhillon, J. L. Vardy

**Brd. 52H** ICORG 07–11: A phase II trial evaluating the efficacy of a radiobiological based re-irradiation strategy for patients with malignant spinal cord compression. (Abstract #TPS317)

**Brd. 53A** The effect of dexamethasone on symptom burden in patients with advanced cancer. (Abstract #TPS318)
S. Yennurajalingam, J. L. Palmer, J. M. Reuben, E. Bruera

**Brd. 53B** A randomized placebo-controlled trial of melatonin for poor appetite in advanced cancer patients. (Abstract #TPS319)
E. Del Fabbro, S. Dalal, R. Dev, E. Bruera

**Brd. 53F** A randomized, controlled trial of parenteral hydration in patients with advanced cancer. (Abstract #TPS320)

**Brd. 53G** A randomized, double-blind, controlled trial of methylphenidate for fatigue in patients with advanced cancer. (Abstract #TPS321)

**Brd. 53H** Phase II randomized study of compound Chinese herbal extract LC09 for external treatment of hand-foot syndrome induced by anticancer therapy. (Abstract #TPS322)
L. Jia

**Brd. 54A** Feasibility of a comprehensive lifestyle modification program during and for one year after completing cancer treatment in breast and prostate cancer patients in a large urban health center. (Abstract #TPS323)

**Brd. 54B** A randomized comparison of oral methadone as a “first-switch” opioid versus opioid switching between sustained-release morphine and oxycodone for oncology outpatients with pain management problems. (Abstract #TPS324)
A. F. Elsayem, K. T. Bain, J. L. Palmer, J. Bearden, M. Fisch

**Brd. 54F** Design of an ongoing randomized study on the long-term safety and efficacy of darbepoetin alfa (DA) administered 500 mcg every three weeks (Q3W) to non-small cell lung cancer (NSCLC) patients (pts) with anemia concomitant with chemotherapy (ACC). (Abstract #TPS325)
P. Gascon, D. H. Henry, A. Fleishman, J. E. Borenstein
Brd. 54G  A phase III randomized, double-blind, placebo-controlled study of pegfilgrastim in first-line colorectal cancer patients receiving bevacizumab and either FOLFOX or FOLFIRI. (Abstract #TPS326)
T. Pinter, J. Decaestecker, L. Choi, M. Mo, S. Whittaker, T. A. Rado, L. B. Holt

Pediatric Oncology
Brd. 54H  A phase I study of clofarabine and liposomal daunorubicin in childhood and adolescent acute myeloid leukemia. (Abstract #TPS327)
N. J. Graham, P. J. Johnson, M. Cummins, R. Keenan, B. Gibson, I. Hawley, P. Kearns

Brd. 55A  Randomized phase II study of two cross-over sequences comprising vinorelbine/cyclophosphamide and temozolomide/etoposide in outpatient setting for relapsed or refractory solid tumors in children and young adults. (Abstract #TPS328)
M. Saito, H. Kawamoto, A. Ogawa, A. Makimoto

Brd. 55B  A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma. (Abstract #TPS329)

Brd. 55C  A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). (Abstract #TPS330)

Sarcoma
Brd. 55D  Viscum album fermentatum Pini versus oral etoposide as adjuvant treatment in osteosarcoma patients after second relapse. (Abstract #TPS331)
A. Longhi, S. Ferrari, E. Mariani

Brd. 55E  Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). (Abstract #TPS332^)

Brd. 55F  Phase I and II trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with soft tissue sarcoma of the extremity. (Abstract #TPS333)

Brd. 55G  An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide. (Abstract #TPS334)
S. P. Chawla, A. P. Staddon, C. Messam, A. M. Graham, Y. M. Mostafa Kamel

Brd. 55H  Sorafenib (S) with preoperative chemoradiotherapy for extremity soft tissue sarcomas (STS) and evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). (Abstract #TPS335)

Tumor Biology
Brd. 56A  Phase 0 microdose trial to identify chemo-resistance in lung and bladder cancer. (Abstract #TPS336)
Monday, June 7, 2010

**Brd. 56B** Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer. (Abstract #TPS337)

**Brd. 56C** MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors. (Abstract #TPS338)
M. Hewish, C. Saffery, Y. Barbachano, A. Wotherspoon, G. Brown, S. A. Martin, C. J. Lord, I. Chau, A. Ashworth, D. Cunningham

**Brd. 56D** Phase Ib trial of lapatinib oxaliplatin and capecitabine in early HER2-overexpressing esophagogastric cancer. (Abstract #TPS339)

**Brd. 56E** Molecular prognostic and predictive markers in gynecologic cancers: The translational 1 (T-1) study of the Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) Group. (Abstract #TPS340)
A. Mosconi, L. Crino, V. Ludovini, G. Scambia, G. Ferrandina, E. Breda, R. Sabbatini, C. Caserta, V. De Angelis, S. Pignata

**Brd. 56F** DCIS neoadjuvant therapy: Targeting the autophagy pathway in malignant precursor cells. (Abstract #TPS341)

**Brd. 56G** Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. (Abstract #TPS342)
A. Goldkorn, T. Xu, B. Lu, A. Williams, L. M. Fink, C. M. Tangen, P. Twardowski, Y. Tai, D. I. Quinn, R. Cote, Southwest Oncology Group (SWOG) Genitourinary Committee

**Brd. 56H** Autophagy as a therapeutic target in cancer treatment. (Abstract #TPS343)
V. Karantza, R. A. Moss, J. M. Mehnert, M. N. Stein, E. Poplin, B. Saraiya, J. Aisner, A. R. Tan, E. White, R. S. DiPaola
8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Genitourinary (Prostate) Cancer
Display Time: 8:00 AM - 12:00 PM
Display Location: E450a
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E Hall D2
CME credit: 1
Track(s): Genitourinary Cancer

Andrea Lynne Harzstark, MD—Co-Chair
University of California, San Francisco
Daniel W. Lin, MD—Co-Chair
University of Washington

Discussion
12:00 PM Johann Sebastian De Bono, MD, PhD (Abstracts #4544–4549)
Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
Biomarkers of Response in Prostate Cancer

Discussion
12:15 PM Robert Dreicer, MD (Abstracts #4550–4552)
Cleveland Clinic Taussig Cancer Institute
Can Immunotherapy Be Personalized?

Discussion
12:25 PM Celestia S. Higano, MD (Abstracts #4553–4557)
University of Washington
Novel Therapies and Response Predictors for CRPC

Discussion
12:40 PM Matthew Raymond Smith, MD, PhD (Abstracts #4558–4560)
Massachusetts General Hospital
The Impact of ADT on Bone and Brain

Discussion
12:50 PM Joel B. Nelson, MD (Abstracts #4561–4565)
University of Pittsburgh
Risk Identification, Chemoprevention, Surveillance, and Neoadjuvant Therapy in Early Prostate Cancer

Brd. 1 A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis. (Abstract #4544)

Brd. 2 Bone scan “flare” in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. (Abstract #4545)

Brd. 3 Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. (Abstract #4546)
Monday, June 7, 2010

Brd. 4 Use of “intracrine androgen signaling signature” to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). (Abstract #4547) E. Efthathiou, S. Tu, A. Aparicio, A. Hoang, S. Wen, P. Troncoso, L. A. Smith, N. Chieffo, A. Molina, C. Logothetis

Brd. 5 Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity. (Abstract #4548) T. M. Beer, B. L. Rademacher, H. Geng, J. Pittsenbarger, M. Garzotto, P. Nelson, C. S. Higano, D. Z. Qian

Brd. 6 The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials. (Abstract #4549) E. S. Antonarakis, J. Lin, D. Keizman, M. A. Carducci, M. A. Eisenberger


Brd. 9 Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. (Abstract #4552) F. P. Stewart, C. P. dela Rosa, N. A. Sheikh, D. G. McNeel, M. W. Frohlich, D. L. Urdal, N. M. Provost


Brd. 11 Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts). (Abstract #4554) D. Keizman, V. J. Sinibaldi, M. A. Carducci, S. R. Denmeade, C. G. Drake, R. Pili, E. S. Antonarakis, S. Hudock, M. Zahurak, M. A. Eisenberger

Brd. 12 Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. (Abstract #4555) M. T. Fleming, M. A. Kolodziej, S. Awasthi, T. E. Hutson, D. Martinic, G. Sonpavde, Y. Wang, K. A. Boehm, L. Asmar, T. M. Beer

Brd. 13 ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (Abstract #4556) M. N. Stein, Y. Chen, G. R. Hudes, M. A. Carducci, W. Tan, R. S. DiPaola


Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States. (Abstract #4559)

The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer. (Abstract #4560)

The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study. (Abstract #4561)
D. G. Bostwick, D. J. Tindall, C. A. Pettaway, T. L. Tammela, C. Teloken, T. H. Wilson, R. S. Castro

Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study. (Abstract #4562)
O. W. Brawley, G. L. Andriole, C. Teloken, M. C. Somerville, R. P. Gagnier

Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). (Abstract #4563)
D. Reding, C. McCarty, T. Riley, T. Hickey, W. G. Hocking

Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer. (Abstract #4564)

Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. (Abstract #4565)
Monday, June 7, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Lung Cancer—Metastatic
Display Time: 8:00 AM - 12:00 PM
Display Location: E450b
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E Hall D1
CME credit: 1
Track(s): Lung Cancer

Shirish M. Gadgeel, MD—Co-Chair
Karmanos Cancer Institute/Wayne State University
Taofeek Kunle Owonikoko, MD—Co-Chair
Winship Cancer Institute of Emory University

Discussion
12:00 PM  Michael J. Kelley, MD (Abstracts #7512–7517)
Duke University Medical Center
Biomarkers

Discussion
12:15 PM  Karen L. Reckamp, MD, MS (Abstracts #7518–7524)
City of Hope
New Approaches in EGFR Targeted Therapy

Discussion
12:30 PM  Silvia Novello, MD, PhD (Abstracts #7525–7529)
University of Turin
Antiangiogenic Agents

Discussion
12:45 PM  Suresh S. Ramalingam, MD (Abstracts #7530–7535)
Winship Cancer Institute of Emory University
New Agents

Brd. 1  Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer. (Abstract #7512)

Brd. 2  Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy. (Abstract #7513)
D. R. Gandara, P. P. Grimminger, P. C. Mack, P. V. Danenberg, P. Lara Jr., K. D. Danenberg

Brd. 3  Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. (Abstract #7514)

Brd. 5  Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. (Abstract #7516)

Brd. 6  Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retasipimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC). (Abstract #7517)
Brd. 7 A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). (Abstract #7518)
R. M. Gaafar, V. Surmont, G. Scaglioni, R. Van Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, J. P. Van Meerbeeck

Brd. 8 Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. (Abstract #7519)

Brd. 9 Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). (Abstract #7520)
G. R. Oxnard, G. J. Riely, M. H. Arcila, M. G. Kris, W. Pao, M. Ladanyi, V. A. Miller

Brd. 10 A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). (Abstract #7521^)

Brd. 11 Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504). (Abstract #7522)

Brd. 12 Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). (Abstract #LBA7523)

Brd. 13 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7524)

Brd. 14 Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHIR). (Abstract #7525)

Brd. 15 Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (Abstract #7526)
F. F. Kabbinavar, V. A. Miller, B. E. Johnson, P. G. O’Connor, C. Soh, ATLAS Investigators

Brd. 16 A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC). (Abstract #7527)
B. Han, Q. Xiu, Y. Luo, C. Bai, S. Guo, W. Liu, Z. Zhuang, Y. Zhang, J. Zhou, X. Jin

Brd. 17 Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7528)
Monday, June 7, 2010

Brd. 19 Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). (Abstract #7530)

Brd. 20 Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #7531)

Brd. 22 Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC). (Abstract #7533)

Brd. 23 A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC). (Abstract #7534)

Brd. 24 Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). (Abstract #7535)
C. S. Karapetis, P. R. Clingan, N. B. Leighl, B. Durbin-Johnson, V. O’Neill, D. R. Spigel
9:30 AM - 10:45 AM
EDUCATION SESSION

Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Genitourinary Cancer; Geriatric Oncology; Patient and Survivor Care

**David I. Quinn, PhD, FRACP, MBBS—Chair**
University of Southern California
Review of Standard and Emerging Therapies for Localized and Advanced Urothelial Cancer

**Jonathan E. Rosenberg, MD**
Dana-Farber Cancer Institute
Personalizing Therapy for Urothelial Cancer: Clinical and Molecular Biomarkers

**Ralph deVere White, PhD**
University of California, Davis
How to Overcome Barriers to the Adoption of Neoadjuvant Therapy for Locally Advanced Urothelial Cancer
Breast Cancer—Local-Regional and Adjuvant Therapy

Seema Ahsan Khan, MD, FACS, MPH—Co-Chair
Northwestern Memorial Hospital
Rita Nanda, MD—Co-Chair
The University of Chicago

9:30 AM ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. (Abstract #CRA504)

9:45 AM Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (Abstract #LBA505)

10:00 AM ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node. (Abstract #CRA506)

10:15 AM Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. (Abstract #507)
K. S. Hughes, L. A. Schnaper, C. Cirrincione, D. A. Berry, B. McCormick, H. B. Muss, B. Shank, C. Hudis, E. P. Winer, B. L. Smith, CALGB, ECOG, RTOG

Discussion

10:30 AM William C. Wood, MD (Abstracts #CRA504–507)
Emory University

10:45 AM Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. (Abstract #508)

11:00 AM Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (Abstract #509)

11:15 AM Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. (Abstract #510)

MONDAY

Monday, June 7, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

CME credit: 3
Track(s): Breast Cancer
Discussion
11:30 AM  Angelo Di Leo, MD, PhD (Abstracts #508–510)
Sandro Pitigliani Medical Oncology Unit

11:45 AM  Potential biologic causes of the racial survival disparity in adjuvant trials of
ER-positive breast cancer. (Abstract #511)
K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, D. F. Hayes, for The Breast
Cancer Intergroup of North America

12:00 PM  Impact of body mass index (BMI) on endocrine therapy in premenopausal
breast cancer patients: An analysis of the ABCSG-12 trial. (Abstract #512)
G. Pfeiler, R. Königsberg, C. F. Singer, M. Seifert, P. C. Dubsky, H. Samonigg,
V. Bjelic-Radisic, R. Greil, C. Marth, M. Gnant

Discussion
12:15 PM  Pamela Jean Goodwin, MD (Abstracts #511–512)
Mount Sinai Hospital
Monday, June 7, 2010

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Health Services Research
Location: S404
CME credit: 3
Track(s): Health Services Research

Elena B. Elkin, PhD—Co-Chair
Memorial Sloan-Kettering Cancer Center
Sarah T. Hawley, MD, PhD—Co-Chair
University of Michigan Health Systems

9:30 AM  Changes over time in quality of psychosocial care: Results from the Quality Oncology Practice Initiative (QOPI). (Abstract #6000)
          P. B. Jacobsen, P. Kadlubek

9:45 AM   Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone—A study of NCI-CTEP-sponsored clinical trials. (Abstract #6001)
          S. K. Cheng, M. S. Dietrich, S. Finnigan, D. M. Dilts

10:00 AM  Assessment of performance measures for patients with the myelodysplastic syndrome (MDS) in the United States. (Abstract #6002)
          G. A. Abel, B. A. Neville, J. C. Weeks, R. M. Stone

Discussion
10:15 AM  Steven J. Katz, MD (Abstracts #6000–6002)
          University of Michigan
Implementing Performance Measures to Improve Patient Care

10:30 AM  Comparison of SEER registry data to patient self-report. (Abstract #6003)

10:45 AM  State-wide application of breast and colon cancer quality measures (QMs) using linked claims and registry data. (Abstract #6004)
          S. B. Edge, K. Mallin, B. E. Palis, A. Stewart, L. N. Newcomer, D. E. Walczak,
          J. Singer, J. Barron, W. J. Blumenthal, B. L. Warther

11:00 AM  Comorbidity severity and long-term mortality in men with early-stage prostate cancer. (Abstract #6005)
          T. J. Daskivich, N. Sadetsky, S. H. Kaplan, S. Greenfield, M. S. Litwin

11:15 AM  Development of a performance status prediction model for use in administrative data analyses. (Abstract #6006)
          A. J. Davidoff, I. H. Zuckerman, N. B. Pandya, F. Hendrick, X. Ke, A. Hurria,
          S. M. Lichtman, A. Hussain, M. J. Edelman

Discussion
11:30 AM  To be determined

11:45 AM  Adoption of CT-based simulation and outcomes following radiation for stage III non-small cell lung cancer. (Abstract #6007)
          A. B. Chen, B. A. Neville, D. Schrag

12:00 PM  Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC). (Abstract #6008)
          J. Y. Lai, A. V. Tinker, W. Y. Cheung

Discussion
12:15 PM  Joseph Lipscomb, PhD (Abstract #6008)
          Emory University
Diffusion of Therapeutic and Preventive Innovations
9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Leukemia, Myelodysplasia, and Transplantation
Location: E354b
CME credit: 3
Track(s): Leukemia, Myelodysplasia, and Transplantation

Jessica K. Altman, MD—Co-Chair
Northwestern University
William G. Blum, MD—Co-Chair
The Ohio State University

9:30 AM Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study. (Abstract #LBA6500)

9:45 AM Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. (Abstract #6501)

10:00 AM Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). (Abstract #6502)
J. E. Cortes, H. Kantarjian, T. Brümmendorf, H. J. Khoury, D. Kim, A. Turkina, A. Volkert, J. Wang, S. Arkin, C. Gambacorti-Passerini

Discussion
10:15 AM
Michael J. Mauro, MD (Abstracts #LBA6500–6502)
Oregon Health and Science University
Chronic Phase CML: Beyond Imatinib?

10:30 AM Time-dependent decision analysis: Stable disease in azacitidine (AZA) treated patients (pts) with higher-risk MDS. (Abstract #6503)

10:45 AM A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS). (Abstract #6504)
E. Jabbour, H. Kantarjian, G. Garcia-Manero, F. Ravandi Kashani, G. Borthakur, Z. Estrov, V. Gandhi, A. Byrd, M. Kawai, S. Faderl

11:00 AM Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and npm status except npm
11545
/flt3(ITD)-. (Abstract #6505)

Discussion
11:15 AM
Jeffrey E. Lancet, MD (Abstracts #6503–6505)
H. Lee Moffitt Cancer Center & Research Institute
High-risk MDS and AML in Elderly Patients: Are We Making Progress?

11:30 AM Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). (Abstract #6506)
D. A. Thomas, S. M. O’Brien, S. Faderl, F. Ravandi Kashani, W. G. Wierda, M. Andreeff, R. S. Garris, R. E. Champlin, J. E. Cortes, H. Kantarjian
Monday, June 7, 2010

11:45 AM  Phase II study of vincristine sulfate liposomes injection in adult patients with refractory or relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). (Abstract #6507)

Discussion
12:00 PM  To be determined

12:15 PM  A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. (Abstract #6508)
9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Pediatric Oncology II
Location: S504
CME credit: 3
Track(s): Pediatric Oncology

Gregory T. Armstrong, MD, MSCE—Co-Chair
St. Jude Children's Research Hospital
Tara O. Henderson, MD, MPH—Co-Chair
The University of Chicago

9:30 AM Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children’s Oncology Group study. (Abstract #9512)

9:45 AM Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91–01 randomized trial. (Abstract #9513)
S. E. Lipshultz, S. R. Lipsitz, T. L. Miller, D. S. Neuberg, S. E. Dahlberg, S. D. Colan, L. B. Silverman, L. L. Cushman, J. M. Henkel, S. E. Sallan, The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium

10:00 AM Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor study. (Abstract #9514)

Discussion
10:15 AM Melissa M. Hudson, MD (Abstracts #9512–9514)
St. Jude Children's Research Hospital
Cardiac Status in Survivors of Pediatric Cancer

10:30 AM Childhood cancer: Do females experience more acute toxicities than males? A Report from the Children’s Oncology Group (Abstract #9515)
K. A. Meeske, L. Ji, A. Butturini, D. R. Freyer, P. S. Gaynon, K. Ruccione, R. Spooto, N. L. Seibel, S. E. Siegel

10:45 AM MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. (Abstract #9516)

11:00 AM Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children’s Oncology Group (COG) study. (Abstract #9517)

11:15 AM Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database. (Abstract #9518)
W. B. London, K. K. Matthay, P. F. Ambros, T. Monclair, A. D. Pearson, S. L. Cohn, V. Castel

Discussion
11:30 AM Andrew Pearson, MD, FRCP (Abstracts #9515–9518)
The Institute of Cancer Research
Prognostic Variables in Neuroblastoma
Monday, June 7, 2010

11:45 AM  Multiple subsequent neoplasms in the Childhood Cancer Survivor Study (CCSS) cohort. (Abstract #9519)

12:00 PM  Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9520)

Discussion
12:15 PM  Flora E. Van Leeuwen, PhD (Abstracts #9519–9520)
The Netherlands Cancer Institute
9:45 AM - 11:00 AM
SPECIAL SESSION

ASCO–American Cancer Society Award and Lecture
Location: S100b
CME credit: 1.25
Track(s): Special Session

Joseph V. Simone, MD
University of Florida Shands Cancer Center
Promoting Excellence in Cancer Care
Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient
Location: E353
CME credit: 1.25
Track(s): Patient and Survivor Care; Ethics; Professional Development

Francis J. Keefe, PhD—Chair
Duke University Medical Center
Partner-based Interventions to Enhance Coping and Pain Management and to Reduce Distress in Individuals with Cancer

Barbara Given, PhD, RN, FAAN
Michigan State University
Family and Caregiver Needs over the Course of the Cancer

Wendy Demark-Wahnefried, MD
University of Texas M. D. Anderson Cancer Center
Capitalizing on the Mother-Daughter Bond to Promote Primary and Tertiary Prevention

Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction?
Location: E Hall D2
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Clinical Trials; Head and Neck Cancer

Peter C. Enzinger, MD—Chair
Dana-Farber Cancer Institute
(Neo)adjuvant Chemotherapy in the Management of Localized Esophagogastric Carcinoma

Mohan Suntharalingam, MD
University of Maryland Medical Center
Neoadjuvant Chemoradiation in the Management of Localized Esophagogastric Carcinoma

Cliff P. Connery, MD
Beth Israel Cancer Center
Implications for Surgery Following Chemotherapy or Chemoradiation

Seminal Advances in Lung Cancer Research 2010: Translational and Clinical
Location: E Hall D1
CME credit: 1.25
Track(s): Lung Cancer

Jeffrey Crawford, MD—Chair
Duke University Medical Center
Perspectives on Recent Advances in Lung Cancer

Ravi Salgia, MD, PhD
The University of Chicago
Translational Advances in Lung Cancer

Ramaswamy Govindan, MD
Washington University School of Medicine
Clinical Advances in Lung Cancer
9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor (M10)-TICKETED SESSION
Location: E451b
CME credit: 1.25
Track(s): Professional Development; Clinical Trials; Developmental Therapeutics

Evanthia Galanis, MD
Mayo Clinic

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY

Treatment of Barrett’s Esophagus to Prevent Esophageal Cancer (C12)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Cancer Prevention/Epidemiology; Gastrointestinal (Noncolorectal) Cancer

Brian J. Reid, MD, PhD—Chair
Fred Hutchinson Cancer Research Center
*Risk Stratification, Chemoprevention, and Early Detection in Barrett’s Esophagus*

Hiran C. Fernando, MD, MBBS
Boston University School of Medicine
*Esophageal Resection for High-grade Dysplasia and Superficial Cancer*

Kenneth K. Wang, MD
Mayo Clinic
*Multimodality Approaches for Endoscopic Ablation of Barrett’s Esophagus*
9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Novel Therapies and Approaches for Management of Gynecologic Cancers
Location: E Arie Crown Theater
CME credit: 1.5
Track(s): Gynecologic Cancer

Robert L. Coleman, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Ronald J. Buckanovich, MD—Co-Chair
University of Michigan

9:45 AM Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. (Abstract #5000)

Discussion
10:00 AM George Coukos, MD, PhD (Abstract #5000)
University of Pennsylvania, Perelman Center for Advanced Medicine
Anti-angiogenic Options in Ovarian Cancer

10:15 AM Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. (Abstract #5001)

Discussion
10:30 AM Alan Hilary Calvert, MD (Abstract #5001)
Cancer Research Unit
Targeting the Folate Receptor in Ovarian Cancer

10:45 AM Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer. (Abstract #5002)

Discussion
11:00 AM Hani Gabra, PhD, FRCP (Abstract #5002)
Imperial College, London
Mechanisms of Resistance in Ovarian Cancer
9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Promising Targeted Therapies for Head and Neck Cancer
Location: E354a
CME credit: 1.5
Track(s): Head and Neck Cancer

Bonnie S. Glisson, MD—Chair
University of Texas M. D. Anderson Cancer Center

9:45 AM  Phase II study of fitigumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008–02. (Abstract #5500)
S. Schmitz, M. Kaminsky-Forrett, S. Henry, S. Zanetta, L. Geoffrois, E. Bompas, A. Moxhon, J. Guigay, J. H. Machiels

Discussion
10:00 AM  Bonnie S. Glisson, MD (Abstract #5500)
University of Texas M. D. Anderson Cancer Center

10:15 AM  BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. (Abstract #5501)

Discussion
10:30 AM  Lisa F. Licitra, MD (Abstract #5501)
Istituto Nazionale Tumori

10:45 AM  Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. (Abstract #5502)

Discussion
11:00 AM  Manisha H. Shah, MD (Abstract #5502)
The Ohio State University
Monday, June 7, 2010

9:45 AM - 11:30 AM
EDUCATION SESSION

Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the National Cancer Institute’s Clinical Trials and Translational Research Advisory Committee
Location: S100a
CME credit: 1.75
Track(s): Clinical Trials; Health Services Research; Special Session

James H. Doroshow, MD—Chair
National Cancer Institute
Streamlining the Extramural Clinical Trials System

David M. Dilts, PhD, MBA
Oregon Health & Science University
Obstacles to Clinical Trial Development and Implementation

John Mendelsohn, MD
University of Texas M. D. Anderson Cancer Center
Recommendations by the IOM on Reinvigorating Cooperative Group Clinical Trials

Richard L. Schilsky, MD
The University of Chicago
The Role of Cooperative Groups in Comparative Effectiveness Research

11:30 AM - 12:45 PM
SPECIAL SESSION

The Hospital/Physician Relationship: Tensions Arising
Location: E354a
CME credit: 1.25
Track(s): Practice Management and Information Technology; Special Session

Barbara L. McAneny, MD—Chair
New Mexico Oncology Hematology Consultants, Ltd.
Where We Have Been, Where We Are: The Life of a Practice and the Pros and Cons of Intersecting with the Hospital

Michael L. Blau, JD
Foley & Lardner LLP
Options for Practice and for Hospitals: How to Balance For-profit and Nonprofit Entities?

Lowell E. Schnipper, MD
Beth Israel Deaconess Medical Center
Why We Must Cooperate: An Integrated Health Care Delivery Model Is Important—Cost and Quality and Survival

Hoangmai Pham, MD, MPH
The Johns Hopkins University
11:30 AM - 12:45 PM
EDUCATION SESSIONS

Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the “New Bad News”
Location: E353
CME credit: 1.25
Track(s): Professional Development; Health Services Research; Practice Management and Information Technology

Lidia Schapira, MD—Chair
Massachusetts General Hospital
Communication about Cost of Cancer Care

Deborah Schrag, MD
Dana-Farber Cancer Institute
Communicating the Costs and Benefits of Medical Interventions

Anthony Back, MD
Seattle Cancer Care Alliance
Inside the Patient-Physician Encounter: Communication and Value

---

Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials
Location: S100b
CME credit: 1.25
Track(s): Ethics; Clinical Trials; Developmental Therapeutics

Jeffrey M. Peppercorn, MD, MPH—Chair
Duke University Medical Center
The Ethical Framework: Can We Pursue Mandatory Research Biopsy under Select Circumstances?

Eric P. Winer, MD
Dana-Farber Cancer Institute
What Can We Learn? The Scientific Justification for Consideration of Mandatory Research Biopsy within Some Clinical Trials

Michael Katz
Eastern Cooperative Oncology Group, Patient Advisory Board
Are We Asking Too Much? Ethical Concerns over Mandatory Research Biopsy: Concerns over Coercion

---

Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Genitourinary Cancer; General Oncology; Geriatric Oncology; Patient and Survivor Care

Michael J. Morris, MD—Chair
Memorial Sloan-Kettering Cancer Center
Phase III Trial Results and the Impact on Standard of Care and Trial Design

Kim N. Chi, MD
British Columbia Cancer Agency
Second-line Treatment after Docetaxel

Evan Y. Yu, MD
University of Washington
Bone-directed Therapy for Prostate Cancer: Present Standards and Potential New Options
Monday, June 7, 2010

11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY

Management of Less Common Head and Neck Cancers (C16)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Head and Neck Cancer; Melanoma/Skin Cancers

David J. Adelstein, MD—Chair
Cleveland Clinic Taussig Cancer Institute
Salivary Gland Cancer

Quynh-thu Le, MD
Stanford University
Nasopharyngeal Carcinoma

Carol Rossier Bradford, MD
University of Michigan
Cutaneous Melanoma of the Head and Neck

12:00 PM - 1:00 PM
SPECIAL SESSION

ASCO Annual Business Meeting including ASCO Statesman Awards (ASCO Members Only)
Location: Hyatt McCormick Place Regency Ballroom
Track(s): Special Session
1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Sarcoma
Location: S406 (Vista Room)
CME credit: 3
Track(s): Sarcoma

Mark Agulnik, MD—Co-Chair
Northwestern University
Richard Riedel, MD—Co-Chair
Duke University Medical Center

1:00 PM Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): Results of a phase II SARC study. (Abstract #10000)

1:15 PM AMG 479 in relapsed or refractory Ewing’s family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. (Abstract #10001)

1:30 PM Combination mTOR/IGF-IR inhibition: Phase I trial of everolimus and CP-751,871 in patients (pts) with advanced sarcomas and other solid tumors. (Abstract #10002)
R. H. Quek, J. A. Morgan, G. Shapiro, J. E. Butrynski, Q. Wang, T. Huftalen, N. Jederlinic, A. J. Wagner, G. D. Demetri, S. George

Discussion
1:45 PM To be determined

2:00 PM Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS). (Abstract #10003)
A. Gronchi, S. Frustaci, M. Mercuri, J. Martin Broto, A. Lopez-Pousa, L. Mariani, P. Verderio, V. Quagliuolo, P. G. Casali, P. Picci

2:15 PM A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). (Abstract #10004)

2:30 PM Identification of selective inhibitors of dedifferentiated liposarcoma cells by high-throughput screening (HTS). (Abstract #10005)
C. V. Angeles, B. Laxa, D. Shum, P. DeCarolis, R. Gobble, E. Brill, S. Ugras, R. O’Connor, H. Djaballah, S. Singer
Monday, June 7, 2010

Discussion
2:45 PM Andrew J. Wagner, MD, PhD (Abstracts #10003–10005) Dana-Farber Cancer Institute

3:00 PM Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. (Abstract #10006)

3:15 PM In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors. (Abstract #10007)

3:30 PM Succinate dehydrogenase in KIT/PDGFRA wild-type gastrointestinal stromal tumors. (Abstract #10008)
K. A. Janeway, S. Kim, M. Lodish, V. Nose, P. Dahia, P. Rustin, G. D. Demetri, J. A. Fletcher, L. J. Helman, C. A. Stratakis, Consortium for Pediatric and Wildtype GIST Research (CPGR)

Discussion
3:45 PM Robert D. Marsh, MD (Abstracts #10006–10008) Kellogg Cancer Center, Northshore University Health System
1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Genitourinary Cancer
Location: S Hall A2
Tracks(s): Genitourinary Cancer

Brd. 1A The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience. (Abstract #4566)

Brd. 1B Impact of dose density of adjuvant chemotherapy for locally advanced urothelial cancer. (Abstract #4567)

Brd. 1C Concentration-depth profiles of mitomycin-C in the human bladder wall after passive diffusion, thermochemotherapy, and electromotive drug administration. (Abstract #4568)

Brd. 1D Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. (Abstract #4569)
D. Raghavan, C. M. Tangen, C. Moinpour, C. Gotay, K. S. Albain, S. Louie, H. Lenz, D. I. Quinn, M. Hussain, I. Thompson, Southwest Oncology Group

Brd. 1E The impact of a bladder cancer diagnosis on smoking behavior: An opportunity to improve care. (Abstract #4570)
J. C. Bassett, J. L. Gore, A. C. Chi, L. Kwan, K. Chamie, C. Saigal

Brd. 1F Evaluation of African American ethnicity and socioeconomic status as prognostic factors for overall survival in bladder cancer. (Abstract #4571)
F. Jiang, A. Ziogas, J. A. Zell, S. I. Ou

Brd. 1G Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder. (Abstract #4572)
H. M. Khaled, F. Abu-Taleb, A. Zekri, R. Haggag

Brd. 1H Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). (Abstract #4573)
M. D. Galsky, G. Sonpavde, B. A. Hellerstedt, S. A. McKenney, T. E. Hutson, M. A. Rauch, Y. Wang, K. A. Boehm, L. Asmar

Brd. 2AGemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). (Abstract #4574)
S. Krege, H. Rexer, F. vom Dorp, P. Albers, P. De Geeter, T. Klotz, AUO

Brd. 2BValidation of a trimodality treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome. (Abstract #4575)
F. Krause, O. Ott, L. Haeberle, B. Wullich

Brd. 2CCorrelation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. (Abstract #4576)

Brd. 2DComparison of HER2 amplification in primary tumors and lymph node metastases of urinary bladder cancer. (Abstract #4577)
A. Fleischmann, R. Seiler, D. Rotzer, G. N. Thalmann

Brd. 2EInfluence of age and socioeconomic status (SES) on testicular cancer (TC) specific mortality: A population-based study of 27,948 patients. (Abstract #4578)
S. D. Fossa, L. B. Travis, L. Chen, M. Cvancarova
Monday, June 7, 2010

Brd. 2F  Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy. (Abstract #4579)

Brd. 2G  Management of testicular neoplasms in France and compliance with national guidelines. (Abstract #4580)
S. Culine, S. Hoppe, C. Hennequin, M. Saves, N. Mottet, FRANCIM network

Brd. 2H  2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial. (Abstract #4581)

Brd. 3A  Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study. (Abstract #4582)

Brd. 3B  Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT). (Abstract #4583)

Brd. 3C  Impact of delayed orchiectomy (OE) on overall survival (OS) in patients (pts) with metastatic germ cell tumors (mGCT). (Abstract #4584)

Brd. 3D  Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin +/- paclitaxel. (Abstract #4585)

Brd. 3E  Residual tumor resection in patients with germ cell tumors (GCT): Use of IGCCCG risk group and tumor volume to predict additional vascular procedures. (Abstract #4586)
C. Winter, C. Bingoeel, R. Witthuhn, P. De Geeter, P. Albers

Brd. 3F  Paclitaxel plus BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis: A phase II study. (Abstract #4587)
A. Tryakin, M. Fedyanin, U. Sergeev, I. Pokataev, B. Ahmedov, T. Zakharova, A. Mitin, I. Fainstein, A. Garin, S. Tjulandin

Brd. 3G  A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. (Abstract #4588)
A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, W. L. Williams, R. Jain, T. G. Chew, C. A. Nicolette, R. A. Figlin, AGS-003–006 Study Group

Brd. 3H  Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC). (Abstract #4589)
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, L. Ridolfi, C. Porta, R. Miceli, N. Zilembo, E. Bajetta, on behalf of ITMO Study Group

Brd. 4A  A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). (Abstract #4590)

Brd. 4C Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma (mRCC) receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. (Abstract #4592)
P. Karakiewicz, M. Sun, V. Sneller, B. Escudier

Brd. 4D Use of the UCLA Integrated Staging System (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma. (Abstract #4593)

Brd. 4E TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). (Abstract #4594)

Brd. 4F Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial. (Abstract #4595)

A. B. Hauber, A. F. Mohamed, F. R. Johnson, M. Neary

Brd. 4H Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN-α): Analysis of the pivotal randomized trial. (Abstract #4597)

Brd. 5A Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT) and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts). (Abstract #4598)
D. W. Shek, M. Brown, C. Pan, P. Lara Jr.

Brd. 5B Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT). (Abstract #4599)

Brd. 5C Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group. (Abstract #4600)

Brd. 5D A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. (Abstract #4601)
N. A. Ilias-Khan, A. Y. Khakoo, N. M. Tannir

Brd. 5E Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials. (Abstract #4602)
F. A. Schutz, Y. Je, G. R. Azzi, T. K. Choueiri

Brd. 5F The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. (Abstract #4603)
T. Powles, I. Kayani, C. U. Blank, S. Chowdhury, S. Horenblas, N. Sarwar, P. D. Nathan, E. Boleti, J. B. Haanen, A. Bex
Brd. 5G  Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. (Abstract #4604)
E. R. Plimack, E. Jonasch, B. N. Bekele, W. Qiao, C. S. Ng, N. M. Tannir

Brd. 5H  Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies. (Abstract #4605)

Brd. 6A  Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. (Abstract #4606)

Brd. 6B  Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue. (Abstract #4607)
A. Bex, E. Jonasch, F. Vyθ-Dreese, C. de Hoog, T. Dellemijn, A. W. Griffioen

Brd. 6C  Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4608)

Brd. 6D  Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients. (Abstract #4609)
G. R. Azzi, F. A. Schutz, Y. Je, T. K. Choueiri

Brd. 6E  Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC). (Abstract #4610)

Brd. 6F  An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients. (Abstract #4611)
R. Casciano, E. Malangone, S. Sherman, J. Baladi, A. C. Kay, D. Kim, C. A. Garay, N. Hollaender, J. Wang

Brd. 6G  Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. (Abstract #4612)
G. H. Mickisch, B. Schwander, B. J. Escudier, J. Bellmunt, J. P. Maroto, C. Porta, S. Walzer, M. Nuijten

Brd. 6H  Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). (Abstract #4613)

Brd. 7A  Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal cell carcinoma (RCC) treated for 12 to 42 months (mos). (Abstract #4614)

Brd. 7B  Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG). (Abstract #4615)
R. Passalacqua, S. Buti, M. Brighenti, L. Rivoltini, C. Castelli, C. Camisaschi, C. Simonelli, G. Lo Re, R. Mattioli, S. Lazzarelli

Brd. 7C  Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis. (Abstract #4616)
X. Su, V. Ranpura, S. Wu
Brd. 7D  Effect of GSK-3 inhibition in vitro and in vivo on antitumor effect of sorafenib in renal cell carcinoma (RCC). (Abstract #4617)
H. Kawazoe, V. Bilim, K. Yuuki, S. Naito, A. Muto, Y. Tomita

Brd. 7E  Detection of circulating tumor cells in patients with renal cell carcinoma compared with a control group. (Abstract #4618)

Brd. 7F  Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy. (Abstract #4619)

Brd. 7G  The effect of sunitinib on immune parameters and hematopoietic stem cell markers in patients with untreated clear cell renal cancer. (Abstract #4620)

Brd. 7H  Fibroblast growth factor pathway in renal cell carcinoma. (Abstract #4621)
I. Tsimafeyeu, L. Demidov, H. Ta, E. Stepanova, N. Wynn

Brd. 8A  Expression of enhancer of zeste homolog 2 in renal cell carcinoma and relationship to downregulation of micro RNA-101. (Abstract #4622)

Brd. 8B  Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. (Abstract #4623)

Brd. 8C  Renal cell carcinoma in octogenarians: Comprehensive analysis using the SEER database. (Abstract #4624)
N. J. Hellenthal, M. H. Hayn, H. L. Kim, W. Underwood III, T. Schwaab

Brd. 8D  Single-fraction radiosurgery for treatment of spinal and cerebral metastases from renal cell carcinoma under systemic tyrosine kinase inhibition. (Abstract #4625)
M. D. Staehler, N. Haseke, P. Nuhn, C. Nordhaus, C. G. Stief, B. Wowra, A. Muacevic

Brd. 8E  Metastatic renal cell carcinoma (mRCC): Relationship between initial non-renal RECIST-target metastases hypoxia, change after 1 month of sunitinib, and therapeutic response: An 18F-MISO PET-CT study. (Abstract #4626)
F. Hugonnert, L. Fournier, S. Oudard, Hypoxia in Renal Cancer (HYRC) Multicentric Group

Brd. 8F  Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma. (Abstract #4627)
M. Schmidinger, M. Bojic, U. Vogl, W. Lamm, C. Zielinski

Brd. 8G  Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alpha-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial. (Abstract #4628)
S. Bracarda, V. Ludovini, C. Porta, C. Boni, A. Santoro, D. Gasparro, E. Cortesi, V. De Angelis, M. Sisani, L. Crinò, GOIRC Group

Brd. 8H  Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib. (Abstract #4629)
Brd. 9A Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). (Abstract #4630)

Brd. 9B Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). (Abstract #4631)
A. J. Armstrong, D. J. George, S. Halabi

Brd. 9C A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. (Abstract #4632)

Brd. 9D Treatment of intermediate- or high-risk prostate cancer by dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B): Early results of a prospective comparative trial. (Abstract #4633)

Brd. 9E Phase II/III trial of combined hormonal therapy and hypofractionated accelerated radiotherapy with concomitant intensity-modulated boost for high-risk prostate cancer: Toxicity analysis. (Abstract #4634)

Brd. 9F Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. (Abstract #4635)

Brd. 9G A sensitive exosome-based biosignature for the diagnosis of prostate cancer. (Abstract #4636)
C. Kuslich, T. L. Pawlowski, T. Deng, T. Tinder, J. Kim, J. Kimbrough, D. Spetzler

Brd. 9H Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. (Abstract #4637)

Brd. 10A Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer. (Abstract #4638)

Brd. 10B Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC). (Abstract #4639)
M. Nakabayashi, W. K. Oh, L. Werner, W. Xie, M. M. Regan, T. J. McKearn, P. Kantoff, M. Pomerantz

Brd. 10C Serum-free circulating DNA as a biomarker of prostate cancer diagnosis. (Abstract #4640)
E. Gordian, K. Ramachandran, I. M. Reis, M. Manoharan, M. S. Soloway, R. Singal

Brd. 10D Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD). (Abstract #4641)
V. J. Sinibaldi, D. Keizman, M. A. Carducci, S. R. Denmeade, P. Huang, M. A. Eisenberger
Brd. 10F  Effect of tissue ischemia on prostatic androgen levels. (Abstract #4643)
M. C. Risk, E. A. Mostaghel, B. March, A. M. Matsumoto, P. Nelson,
R. B. Montgomery, D. W. Lin

Brd. 10G  Prognostic value of metastasis pattern for morbidity in prostate cancer measured by quantitative bone scintigraphy. (Abstract #4644)
M. Hoejgaard, B. Zerahn, K. Avogdilan, B. Kristensen, K. J. Mikines

Brd. 10H  Performance of expressed prostatic secretion assays in prediction of surgical pathology outcomes in patients undergoing radical prostatectomy. (Abstract #4645)
C. M. Whelan, J. P. Clark, T. G. Wilson, D. Y. Josephson, M. H. Kawachi,
L. E. Crocito, D. D. Smith, S. S. Smith

Brd. 11A  Correlation of epigenetic silencing of SOCS3 with a subset of prostate cancer with aggressive behavior. (Abstract #4646)
F. Pierconti, M. Martini, T. Cenci, F. Pinto, P. Bassi, L. Larocca

Brd. 11B  Prostate cancer metastasis, the noncanonical Wnt pathway, and the transcription factor PITX2. (Abstract #4647)
I. Vela, C. Morrissey, E. Corey, R. Vessella, S. Chen, G. Strutton, C. Nelson,
J. Clements, D. Nicol, E. M. Gardiner

Brd. 11F  PCA3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. (Abstract #4648)
K. Okihara, A. Ochiai, Z. Fros, T. Miki

Brd. 11G  Neuroendocrine carcinoma in conjunction with Gleason score 8-10 prostate cancer: Clinical implications for patients treated with radiotherapy. (Abstract #4649)
D. J. Krauss, M. Amin, S. Hayek, H. Ye, L. L. Kestin, F. Vicini, A. Martinez

Brd. 11H  Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer. (Abstract #4650)
P. Yip, J. Kench, K. Rasiah, R. Benito, C. Lee, S. Henshall, R. Sutherland,
L. Horvath

Brd. 12A  Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy. (Abstract #4651)
M. J. Donovan, F. Khan, G. Fernandez, V. Bayer-Zubek, P. C. Albertsen

Brd. 12B  Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer. (Abstract #4652)

Brd. 12F  Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial. (Abstract #4653)
M. R. Smith, R. J. Cook, J. B. Nelson

Brd. 12G  Prostate cancer in men under the age of 50: A comparison of race and outcomes. (Abstract #4654)
P. M. Parker, K. R. Rice, Y. Chen, D. G. McLeod, S. A. Brassell

Brd. 12H  Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare. (Abstract #4655)
M. Grabner, E. Onukwugha, C. D. Mullins, B. S. Seal, A. Hussain

Brd. 13A  A population-based study of cardiovascular (CV) mortality among patients with prostate cancer (PCa) treated with radical external beam radiation therapy (EBRT) with and without adjuvant androgen deprivation therapy (ADT) at a provincial cancer agency. (Abstract #4656)
J. O. Kim, M. Vaid, S. Tyldeles, R. Woods, T. Pickles

Brd. 13B  A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. (Abstract #4657)
J. L. Gulley, W. D. Stein, J. Schlim, R. A. Madan, W. L. Dahut, W. D. Figg,
Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare. (Abstract #4658)
E. Onukwugha, M. Grabner, C. D. Mullins, B. S. Seal, A. Hussain

Characteristics of men with abnormal prostate-specific antigen (PSA) who had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). (Abstract #4659)
W. G. Hocking, C. McCarty, T. Riley, T. Hickey, J. K. Burmester, D. Reding

Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostate cancer (CRPC). (Abstract #4660)

A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes. (Abstract #4661)

A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa). (Abstract #4662)

Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel. (Abstract #4663)
V. Tzelepi, E. Efstathiou, P. Troncoso, C. A. Pettaway, A. Hoang, C. Logothetis, L. C. Pagliaro

Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety. (Abstract #4664)

Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC). (Abstract #4665)
F. Dayyani, G. E. Gallick, J. T. Thompson, G. C. Trudel, C. Logothetis, J. C. Araujo

Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07). (Abstract #4666)
R. Catheromas, C. Rothermundt, R. von Moos, D. C. Betticher, R. C. Winterhalder, C. Droege, D. Siciliano, D. R. Berthold, M. Pless, S. Gillessen

Phase I trial of fractionated-dose 177Lu-lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). (Abstract #4667)

Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome. (Abstract #4668)

Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC). (Abstract #4669)

The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study. (Abstract #4670)

Brd. 15A Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC). (Abstract #4672) D. Bianchini.

Brd. 15B Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. (Abstract #4673) N. D. Shore, J. W. Moul, E. Crawford, T. Olesen, B. Persson


Brd. 15E Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy. (Abstract #4676) M. K. Brawer, M. R. Smith, S. B. Malkowicz, M. L. Hancock, R. A. Morton, M. S. Steiner

Brd. 15F Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) +/- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747. (Abstract #4677) E. Porfiri, S. I. Collins, D. Barton, L. Billingham, D. McLaren, G. G. Nixon, J. M. Russell, C. Parker, J. Wylie, N. D. James, Trapeze Phase II

Brd. 15G Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials. (Abstract #4678) S. Nilsson, C. Parker, I. Haugen, A. Lokna, A. Aksnes, B. Bolstad, G. O’Bryan-Tear, O. S. Brueland

Brd. 15H Analysis of the cost-effectiveness of zoledronic acid for the prevention of skeletal-related events in patients with prostate cancer and bone metastases: A comparison across four European countries. (Abstract #4679) M. Botteman, F. Logman, S. Kaura


Brd. 16C Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC). (Abstract #4682) C. W. Reuter, V. Gruenwald, P. Ivanyi, M. A. Morgan, M. Fenner, A. Ganser
Monday, June 7, 2010

Brd. 16D  Phase II trial of non pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study. (Abstract #4683)

Brd. 16E  Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. (Abstract #4684)

Brd. 16F  Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy +/- docetaxel: An analysis of final safety results. (Abstract #4685)
S. Oudard, I. Latorzeff, P. Beuzeboc, A. Caty, E. Sevin, R. Delva, F. Rolland, L. Mourey, F. Priou, S. Culin

Brd. 16G  Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. (Abstract #4686)
S. Niraula, I. Tannock, G. R. Pond, R. De Wit, M. A. Eisenberger, A. M. Joshua

Brd. 16H  Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer. (Abstract #4687)
D. R. Shepard, A. Weil, J. A. Garcia, R. Dreicer, D. Raghavan

Brd. 17A  A phase I study of combined docetaxel and repeated high activity rhenium-186-HEDP in castration resistant prostate cancer metastatic to bone (the TAXIUM trial). (Abstract #4688)
J. M. van Dodewaard-de Jong, H. Bloemendal, J. M. de Klerk, B. P. van Bezooijen, M. J. de Haas, R. H. Wilson, J. M. O’Sullivan

Brd. 17B  Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4689)

Brd. 17C  Correcting overall survival (OS) effect for the impact of cross-over via rank preserving structural failure time (RPSFT) model: Case of mRCC RECORD-1 trial of everolimus (EVE). (Abstract #4690)
1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Health Services Research
Location: S Hall A2
Tracks(s): Health Services Research

Brd. 18A Effect of computerized physician order entry (CPOE) on chemotherapy prescribing error. (Abstract #6034)
R. Stein, S. Cheesman, D. Blake, N. Saini, T. Cave, G. Pang, B. Bagnall, J. Bradley

Brd. 18B RCT of community-based patient assistance to improve breast cancer care. (Abstract #6035)
N. Bickell, R. Franco, K. Fei, H. Leventhal

Brd. 18C Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population. (Abstract #6036)

Brd. 18D Cost-effectiveness of lapatinib plus capecitabine (LAP+C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ+C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the U.K. National Health Service (NHS) perspective. (Abstract #6037)
O. Sofrygin, T. E. Delea, P. Tappenden, J. Karnon, D. Browning, M. Amonkar, K. Lykopoulous, D. A. Cameron

Brd. 18E Impact of medicaid-enrollment status/timing on stage at diagnosis among male cancer patients. (Abstract #6038)

Brd. 18F Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites. (Abstract #6039)

Brd. 18G Barriers to treatment in patients with locally advanced breast cancer. (Abstract #6040)

Brd. 18H Physician’s perspectives and racial disparity in the surgical treatment of early lung cancer. (Abstract #6041)
P. R. Walker, S. Cykert

Brd. 19A Cost-effectiveness of adding information about common risk alleles to current decision models for breast cancer chemoprevention. (Abstract #6042)
T. Dinh, L. Green, P. Alperin, D. Hinds, B. Walser

Brd. 19B Initial use of newer agents for advanced non-small cell lung cancer: Evidence from the National Cancer Institute Patterns of Care study. (Abstract #6043)
B. L. Goulart, S. D. Ramsey

Brd. 19C Analysis of the cause of discordance between two radiologists on the assessment of radiographic response and progression for subjects enrolled in breast cancer clinical trials employing blinded independent central review. (Abstract #6044)
K. Borradaile, R. Ford, J. M. O’Neal, K. Byrne
Monday, June 7, 2010

Brd. 19D Communication of the essential elements of informed consent (IC) for research: A RIAS analysis of phase I clinical trial encounters. (Abstract #6045)

Brd. 19E The impact of routine pathology review on treatment for node-negative breast cancer. (Abstract #6046)
H. F. Kennecke, C. Speers, K. A. Gelmon, I. Olivotto, M. Hayes

Brd. 19F Characterization of prostate cancer treatment information quality obtained through Yahoo, Google, and Bing search engines. (Abstract #6047)
D. Landau, J. Hajdenberg

Brd. 19G Costs of absenteeism and short-term disability associated with breast cancer to U.S. employers. (Abstract #6048)
S. D. Sullivan, A. Z. Fu, M. Jhaveri, N. P. Christiansen

Brd. 19H Changes in chemotherapy uptake and wait times in early-stage non-small cell lung cancer (NSCLC). (Abstract #6049)
S. L. Gray, J. Bu, N. Saint-Jacques, D. Rayson, T. Younis

Brd. 20A Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements. (Abstract #6050)
P. K. Cheema, S. Gavura, B. Godman, L. Yeung, M. E. Trudeau

Brd. 20B Medical oncologists and quality of life of women treated for breast cancer. (Abstract #6051)
C. R. Friese, T. M. Pini, P. Abrahamse, S. T. Hawley, S. J. Katz

Brd. 20C Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. (Abstract #6052)
D. J. Stewart, R. Kurzrock, S. Whitney

Brd. 20D Practice standardization in the staging and treatment of colon cancer at Intermountain Healthcare. (Abstract #6053)
J. R. Whisenant, T. Belnap, B. D. Rowley, K. Alleman, K. G. Rowe, C. Jones, W. T. Sause

Brd. 20E Impact of cancer on the quality of life and health status of patients and their family members. (Abstract #6054)
Y. T. Shih, I. Pan

Brd. 20F Health care cost of breast cancer: A claims data analysis. (Abstract #6055)
A. Z. Fu, M. Jhaveri, S. D. Sullivan, N. P. Christiansen

Brd. 20G Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer Registry among patients with lung cancer. (Abstract #6056)

Brd. 20H Unmet psychosocial needs among cancer patients at the National Cancer Centre Singapore (NCCS). (Abstract #6057)
R. C. Ng, H. Verkooijen, L. L. Ooi, W. Koh

Brd. 21A Accuracy of cancer information on the Internet: A comparison of a Wiki with a professionally maintained database. (Abstract #6058)
M. S. Rajagopalan, V. Khanna, M. Stott, Y. Leiter, T. N. Showalter, A. Dicker, Y. R. Lawrence

Brd. 21B Quality of published studies supporting off-label and accelerated approval oncology indications. (Abstract #6059)
K. R. Carson, Y. Chia, J. Sekhar, R. R. Coeytaux, J. L. Wheeler, C. L. Bennett, A. P. Abermethy

Brd. 21C Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. (Abstract #6060)
M. Jackson, A. Brandt, A. Gutierrez-Barrera, F. Meric-Bernstam, J. K. Litton, K. H. Lu, G. N. Hortobagyi, B. Arun
Brd. 21D The impact of breast care nurses on early-stage breast cancer patients’ perception of quality of care: The results of a multilevel regression analysis. (Abstract #6061)
C. Kowalski, S. Diener, P. Steffen, R. Wuerstlein, N. Harbeck, H. Pfaff

Brd. 21E Consenting factors in clinical cancer research: Observations from a cancer center tissue repository. (Abstract #6062)

Brd. 21F Changing rates of organ-preservation therapy over time for head and neck cancer: A SEER-Medicare analysis. (Abstract #6063)
D. J. Sher, B. A. Neville, R. B. Tishler, D. Schrag

Brd. 21G Social, biological, and tumor characteristics of 139 African American (AA) women with newly diagnosed breast cancer in Chicago. (Abstract #6064)
S. J. Gehlert, B. N. Polite, T. A. Grushko, T. Cipriano, S. Charoenthammaraksa, Z. Franklin, S. D. Conzen, M. McClintock, O. I. Olopade

Brd. 21H FDA accelerated approval of anticancer agents. (Abstract #6065)

Brd. 22A Protocol performance metrics and resource utilization of phase II investigator-initiated trials. (Abstract #6066)
H. Durivage, K. D. Bridges, J. Sauers, M. Wellons, L. Baker

Brd. 22B Factors influencing use of genetic tests in clinical practice among U.S. oncologists. (Abstract #6067)
J. M. Peppercom, E. P. Hamilton, L. Beskow, I. Lipkus, P. K. Marcom, G. H. Lyman

Brd. 22C Treatment delays in non-small cell lung cancer (NSCLC) and their prognostic implications. (Abstract #6068)
R. Diaconescu, C. Lafond, L. Choiniere, C. Sirois, B. Laliberte, M. Doyon, R. Whittom

Brd. 22D Nature and outcome of clinical trials conducted by the Eastern Cooperative Group (ECOG) from 1977 to 2006. (Abstract #6069)

Brd. 22E Factors contributing to delays in breast cancer management. (Abstract #6070)
E. Barlow, S. Verma, F. Kanji, S. Hopkins, L. Paquet

Brd. 22F Impact of Medicare’s July 2007 erythropoiesis-stimulating agent (ESA) national coverage determination (NCD) on transfusion use in chemotherapy-treated cancer patients. (Abstract #6071)

Brd. 22G Influence of patient beliefs and patient knowledge on adherence to hormone treatment for breast cancer. (Abstract #6072)
K. P. Joseph, R. Franco, K. Fei, N. Bickell

Brd. 22H Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors. (Abstract #6073)

Brd. 23A Predictors of BRCA-positive parents’ disclosure of cancer risk and risk reduction options to offspring. (Abstract #6074)

Brd. 23B The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel. (Abstract #6075)

Brd. 23C Follow-up of abnormal Pap smear results: A population-based study. (Abstract #6076)
R. Kupets, L. F. Paszat

Monday, June 7, 2010
Brd. 23D  NCI Cancer Trials Support Unit at year 10. (Abstract #6077)  
S. E. Riordan, M. F. Hering, J. R. Hopkins, R. Lambersky, D. M. Marinucci,  
K. E. Martier, M. M. Mooney, A. Nelson, R. Rajaram, J. S. Abrams

Brd. 23E  Retrospective health care claims database analysis of direct medical costs of  
newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the  
United States. (Abstract #6078)  
A. S. Poklepovic, A. Sanyal, E. Moyneur, S. Meyers, V. Barghout

Brd. 23F  Using administrative data to describe adherence to colon cancer follow-up  
testing in Manitoba, Canada. (Abstract #6079)  
J. J. Sisler, B. Seo, A. Katz, E. Shu

Brd. 23G  Information technology (IT) and chemotherapy (CT) prescribing errors.  
(Abstract #6080)  
M. Aita, O. Belvedere, F. De Pauli, L. Deroma, L. Gurrieri, J. Menis, V. Merlo,  
F. Puglisi, L. Zanier, G. Fasola

Brd. 23H  Strategies to increase access to quality genetic testing services: Case study  
of BRCA1/2 testing. (Abstract #6081)  
B. Kim, T. G. Bentley, S. S. Olmsted, S. Wooding, E. Eiseman, M. T. Scheuner

Brd. 24A  Synergy made simple: What does it mean and how valid are claims for  
synergy between antitumor agents? (Abstract #6082)  
A. Ocana, C. Yeung, I. Tannock

Brd. 24B  Treatment patterns by oncologists and urologists for castration-resistant  
prostate cancer (CRPC). (Abstract #6083)  
B. Alemayehu, N. M. Engel-Nitz, F. E. Nathan

Brd. 24C  Analysis of cancer clinical trials in the United States with comparison of  
National Institute of Health (NIH) and pharmaceutical industry (PHARMA)-  
sponsored studies. (Abstract #6084)  
K. R. Oettel, N. R. Ruther, M. A. Mathiasson, J. K. Keller, J. E. Schroeder, R. S. Go

Brd. 24D  Rural-urban disparity in cancer screening among elder Medicare  
beneficiaries: Does rurality matter? (Abstract #6085)  
L. Fan, S. G. Mohile, K. Noyes

Brd. 24E  Small world networks and treatment discovery process in cancer. (Abstract  
#6086)  
A. Tsalatsanis, I. Hozo, B. Djulbegovic

Brd. 24F  Baseline MUGA scans for patients with early-stage breast cancer receiving  
adjuvant chemotherapy. (Abstract #6087)  
A. S. Jeyakumar, J. Dipenta, S. L. Snow, D. Rayson, K. Thompson, C. Theriault,  
T. Younis

Brd. 24G  Neutropenic risk, use of colony-stimulating factors, and impact on the  
relative dose intensity of administered chemotherapy. (Abstract #6088)  
W. B. Webb, Y. Wu, H. Head, S. Singh, G. H. Lyman

Brd. 24H  A prospective evaluation of the patients’ knowledge about their  
chemotherapy treatment (CT) before the first course. (Abstract #6089)  
N. Kohen, E. L. Morgenfeld, C. Garcia Gerardi, M. Nacul, C. Coronel Lezcano,  
E. Rivarola, E. Gil Deza, N. Gercovich, F. G. Gercovich

Brd. 25A  Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC)  
treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two  
large U.S. health care claims databases. (Abstract #6090)  
S. M. Keefe, E. Moyneur, S. Meyers, V. Barghout, K. T. Flaherty

Brd. 25B  Pattern of aromatase inhibitor use in males. (Abstract #6091)  
M. Subar, C. J. Kuntz, S. Lust

Brd. 25F  Concomitant medication (CM) use in phase I and II cancer clinical trials  
(CCT): Effects on trial eligibility and potential interactions with study  
medications. (Abstract #6092)  
M. Benjamin, K. K. Curtis, R. Tribes, R. K. Ramanathan, D. D. Von Hoff, K. Wright,  
G. S. Jameson, M. J. Borad
Brd. 25G Evaluation of multidisciplinary (MultiD) care in thoracic oncology. (Abstract #6093)
G. L. Phelps, O. O. Bankole, S. Sarwar, J. J. McFarlane, R. U. Osarogiagbon

B. Zuckerman, J. Corrigan

Brd. 26A Adherence to cardiovascular (CV) medications after myocardial infarction (MI) in cancer survivors (CS). (Abstract #6095)
S. Setoguchi, M. L. McBride, R. Levin, W. Y. Cheung

Brd. 26B Quality and consistency in breast cancer clinical guidelines internationally: Are we globally consistent? (Abstract #6096)
C. E. Simmons, S. Hogeveen, J. Nichols, S. Trudeau-Tavara, M. Quan

Brd. 26F The relationship between service quality measures and patient willingness to recommend at a national oncology provider network: The Cancer Treatment Centers of America experience. (Abstract #6097)
D. Gupta, M. Rodeghier, J. F. Grutsch, A. Roberts, C. G. Lis

Brd. 26G Patients’ views on delayed diagnosis in cancer. (Abstract #6098)

Brd. 26H Optimal chemotherapy utilization rate in cancer care: Setting an evidence-based benchmark for quality improvement. (Abstract #6099)
W. L. Ng, S. Jacob, G. Delaney, M. Barton

Brd. 27A Patients’ willingness to be informed on cancer clinical trials. (Abstract #6100)
I. Pauprote, E. Manach, M. Duprayy, N. Tammavong, N. Bachouche, A. Hommais

Brd. 27B Utility of routine cardiac ejection fraction (EF) measurement prior to anthracycline-based chemotherapy (ABC) in patients with diffuse large b-cell lymphoma (DLBCL). (Abstract #6101)
A. L. Conrad, V. L. McHugh, J. D. Gundrum, R. S. Go

Brd. 27C Treatment strategies for low-risk febrile neutropenia in adult cancer patients: A cost-utility analysis. (Abstract #6102)
O. Teuffel, E. Amir, L. Sung, S. M. Alibhai

Brd. 27D What are physician and patient factors important for proper follow-up of high-grade Pap smear abnormalities? (Abstract #6103)
L. F. Paszat, R. Kupets

Brd. 27E The shortage of medical oncologists and low chemotherapy utilization in Australia. (Abstract #6104)
B. Koczwara, M. Barton, P. L. Blinman, S. Crossing, P. S. Grimison, E. T. Walpole, N. Wong, K. Francis

Brd. 27F Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention. (Abstract #6105)

Brd. 27G Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. (Abstract #6106)
M. A. Neubauer, J. L. Espirito, M. Clayton, D. A. Patt, US Oncology Pathways Task Force

Brd. 27H Association of black race and outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC): Results from a U.S. local oncology practice. (Abstract #6107)
Monday, June 7, 2010

Brd. 28A  Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT). (Abstract #6108)

Brd. 28B  Relationship between neuroendocrine tumor-related symptoms and PROMIS health-related quality-of-life scores. (Abstract #6109)
J. L. Beaumont, Z. Liu, S. Choi, J. C. Yao, A. T. Phan, D. Cella

Brd. 28C  The value of concurrent symptoms in predicting clinical outcomes in lung cancer survivors. (Abstract #6110)

Brd. 28D  Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors. (Abstract #6111)

Brd. 28E  Estimating minimally important differences (MID) for the worst pain rating of the brief pain inventory (BPI)-short form (SF). (Abstract #6112)
S. D. Mathias, R. D. Crosby, Y. Qian, K. Chung

Brd. 28F  The long-term impact of surgical complications after resection of stage I non-small cell lung cancer: A population-based survival analysis. (Abstract #6113)
N. M. Rueth, H. M. Parsons, S. S. Groth, E. B. Habermann, B. A. Virnig, T. M. Tuttle, R. S. Andrade, M. Maddaus, J. D’Cunha

Brd. 28G  Cancer recurrence and survival in patients with early-stage triple-negative breast cancer in a U.S. local oncology practice. (Abstract #6114)

Brd. 28H  Evaluation of the state of health of patients with localized prostate cancer (cT1-cT2) compared to the normal population. (Abstract #6115)
M. J. Mathers, S. Roth, M. Gerken, M. Klinkhammer-Schalke, F. Hofstädtter, A. Heidenreich, T. Klotz

Brd. 28I  Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings. (Abstract #6116)
A. I. Leal, W. F. Barra, D. F. Saragiotto, E. D. Saad, P. M. Hoff

Brd. 28J  The role of acculturation in end-of-life outcomes for Latino advanced cancer patients. (Abstract #6117)

Brd. 29A  Neuroendocrine tumor disease state and PROMIS health-related quality of life scores. (Abstract #6118)
D. Cella, J. L. Beaumont, Z. Liu, A. T. Phan, S. Choi, J. C. Yao

Brd. 29B  Racial disparities in stage II prostate cancer outcomes in the Veterans Affairs hospital system. (Abstract #6119)

Brd. 30A  A prospective paired survey of oncologist and patient attitudes toward therapeutic cancer clinical trial (CT) enrollment in a diverse academic health center patient population. (Abstract #6120)
M. Ray, D. M. Smith, O. I. Olupade, B. N. Polite

Brd. 30B  Impact of response shift in longitudinal postoperative quality of life (QoL) analysis among breast cancer (BC) patients: A randomized multicenter cohort study. (Abstract #6121)
F. Bonnetain, T. Conroy, M. Velten, D. Jolly, M. Mercier, S. Cauzeret, J. Cuisenier, O. Graesslin, M. Gauthier, F. Guillemin, Plateforme de Recherche Clinique Qualité de Vie et Cancer

Brd. 30C  Adequacy of data provision and analysis in oncology phase III trials over the past 5 years. (Abstract #6122)
H. K. Gan, B. You, G. R. Pond, E. X. Chen
Brd. 31B The National Lung Cancer Audit in the United Kingdom: Results after 4 years. (Abstract #6123)
P. Beckett, I. Woolhouse, R. Stanley, M. D. Peake

Brd. 31C Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials. (Abstract #6124)
M. Di Maio, A. Morabito, S. Barbera, V. Gebbia, B. Daniele, A. Ceribelli, F. Garrozza, A. Rossi, S. Signoriello, C. Gridelli

Brd. 32A Relationship between survival and lymph node assessment from a population-based study of colorectal cancer patients. (Abstract #6125)

Brd. 32B Comparison between the causes of rejection to participate (RP) and screening failures (SF) in oncology clinical trials (OCT). (Abstract #6126)
L. E. Fein, A. Romera, M. C. Micheri, M. I. Diaz, R. A. Sala

Brd. 32C Outcomes from placebo/best supportive care-controlled trials (PBSCT) in the era of molecular targeted therapy: A meta-analysis. (Abstract #6127)
M. C. Miranda, A. B. Fede, N. Magalhaes, N. Fraile, V. Ayres, M. B. Santos, S. Gonzaga, K. Brunetti, A. Del Giglio, R. Riechelmann

Brd. 33A Is the informed consent (IC) to treatment truly “informed”? The use of a comprehension check tool (CCT). (Abstract #6128)
R. Biamonte, S. Turano, C. Mastroianni, V. Liguori, R. De Simone, S. Conforti, G. Gaadlela-Calderola, A. Piattelli, M. Iuvaro, S. Palazzo

Brd. 33B Assuring continuous quality improvement using outcomes data: A potential role for cancer registries. (Abstract #6129)
R. O. Dillman, S. E. McClure

Brd. 33C Evaluation of hormone receptor and benefit from adjuvant chemotherapy in breast cancer patients with intermediate- and high-risk disease. (Abstract #6130)

Brd. 34A Second-line pancreatic cancer therapy: Patterns of care and survival. (Abstract #6131)
S. N. Hoang, J. R. Hoverman, B. Turnwald, US Oncology Pathways Task Force

Brd. 34B Effect of race and comorbidities on patterns of bevacizumab toxicity: A single-institution experience. (Abstract #6132)
M. Raza, S. Raza, Z. Latif, J. C. Sachdev

Brd. 34C Symptom burden in chronic myeloid leukemia (CML). (Abstract #6133)
L. A. Williams, P. Ault, C. S. Cleeland, R. J. Reynolds, N. A. Shah, P. K. Shah, J. E. Cortes

Brd. 35A Correlation of 5-year survival and cure in NSCLC: An analysis of delayed cancer deaths in long-term survivors of NSCLC. (Abstract #6134)
M. O. Hubbard, P. Fu, J. L. Worthington, A. Dowlati, P. A. Linden

Brd. 35B Impact of neoadjuvant chemotherapy on breast reconstruction. (Abstract #6135)

Brd. 35C Can patient-reported kidney cancer–specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma? (Abstract #6136)

Brd. 35D Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting. (Abstract #6137)
Monday, June 7, 2010

Brd. 35E Capturing breast cancer patients’ experience beyond disease progression: Implementation of a patient-reported outcome (PRO) substudy in the VIRGO Metastatic Breast Cancer Observational Cohort study. (Abstract #6138)

Brd. 35F Retrospective application of Nottingham Prognostic Index (NPI) and Adjuvant! Online tool in newly diagnosed patients with early breast cancer in mid-western Ireland. (Abstract #6139)
K. I. Quintyne, B. Woulfe, R. K. Gupta

Brd. 35G Cost and outcome of vascular resections during pancreaticoduodenectomy. (Abstract #6140)
G. Bullock, M. J. Ott, T. Belnap, J. R. Whisenant

Brd. 35H Technologic advancements and error rates in radiation therapy (RT) delivery. (Abstract #6141)
D. N. Margalit, K. Heckman, Y. Chen, P. J. Catalano, T. Vivenzio, K. Nissen, P. Mauch, A. K. Ng

Brd. 36A Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service. (Abstract #6142)

Brd. 36B Novel uses of coded data in clinical trials. (Abstract #6143)

Brd. 36C Factors influencing the career decisions of United States hematology oncology fellows training at NCI- and NCCN-designated cancer centers. (Abstract #6144)
L. Horn, E. Koehler, Y. Shyr, J. Gilbert, D. H. Johnson

Brd. 36D Continuity of care for cancer patients at the end of life (EoL). (Abstract #6145)
R. Bascioni, B. Esperide, D. Iacopini, F. Basirat, F. Rastelli, L. Acito, R. Bisonni, L. Giustini, F. Giorgi

Brd. 36E Care delivery barriers to personalized medicine in breast cancer. (Abstract #6146)

Brd. 36F Hepatitis B screening prior to chemotherapy: A survey of practitioners’ knowledge, beliefs, and screening practices. (Abstract #6147)
R. Lee, C. M. Bell, L. K. Hicks

Brd. 36G The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB). (Abstract #6148)

Brd. 36H Prescribing and safety issues of oral molecular therapies and chemotherapies in Australian haematology oncology practice. (Abstract #6149)
M. J. Dooley, M. A. Larizza, S. G. Poole, C. Carrington

Brd. 37A Comparison of hospital costs versus DRG reimbursement for treatment of febrile neutropenia during adjuvant CTX for primary breast cancer. (Abstract #6150)

Brd. 37B Development and testing of multiple versions of a radiation oncology treatment planning workflow application in the era of HIPAA. (Abstract #6151)
Brd. 37C  Evaluating clinical trials: What exactly do medical oncologists know and use? (Abstract #6152)
K. R. Hoffman

Brd. 37D  Quantitative aspects of failure mode and effects analysis (FMEA) scoring in a prospective safety study of a large academic radiation oncology department. (Abstract #6153)
S. A. Terezakis, L. Myers, R. Bell, A. Souranis, D. Y. Song, R. C. Zellars, T. L. DeWeese, E. C. Ford

Brd. 37E  The 2008 National Comprehensive Cancer Network (NCCN) Research Benchmarking Survey (RBS): Clinical trials (CTs) operations in the academic center. (Abstract #6154)

Brd. 37F  Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (Abstract #6155)

Brd. 37G  ERCC, TS, RRM1, EGFR, and KRAS biomarker integration into a community-based medical oncology practice. (Abstract #6156)
S. K. Reddy

Brd. 37H  Fellowship characteristics associated with fellows’ interest in pursuing clinical research: A National Comprehensive Cancer Network (NCCN) survey. (Abstract #6157)
J. M. Hinkel, J. L. Vandergrift, E. M. Lepisto, K. A. Minogue, F. M. Stewart

Brd. 38A  Physicians’ nonverbal behaviors: Oncology patients perspective. (Abstract #6158)
H. V. Naina, S. Harris
Monday, June 7, 2010

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Patient and Survivor Care
Location: S Hall A2
Tracks(s): Patient and Survivor Care

Brd. 39A Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. (Abstract #9042)

Brd. 39B Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial. (Abstract #9043)

Brd. 39F Contraception after breast cancer: Results of a survey among French gynecologists. (Abstract #9044)

Brd. 39G Treatment with antidepressant and anti-anxiety medications after breast cancer diagnosis in a large HMO. (Abstract #9045)
V. P. Quinn, C. C. Avila, J. E. Schottinger, A. H. Fisher, R. Haque

Brd. 40A Influence of fatigue after breast cancer adjuvant therapy on health care utilization and perceived needs. (Abstract #9047)
K. Webber, D. Goldstein, B. K. Bennett, F. M. Boyle, P. L. De Souza, N. Wilicken, M. Friedlander, A. R. Lloyd

Brd. 40B Satisfaction with physician–patient discussions on fertility and sexual health among young women with cancer. (Abstract #9048)
M. M. Scanlon, A. H. Blaes, M. A. Geller, N. S. Majhail, T. C. Haddad

Brd. 40F Utility of pre-chemotherapy echocardiographical assessment of cardiac abnormalities. (Abstract #9049)
N. V. Karanth, A. Roy, M. Joseph, C. Depasquale, C. S. Karapetis, B. Koczwarra


Brd. 40H Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC). (Abstract #9051)
V. J. Seery, B. M. McGree, M. Lee, D. F. McDermott, D. C. Cho

Brd. 41A Impact of the change in service name from “palliative” to “supportive” care on patient referral at a comprehensive cancer center. (Abstract #9052)
S. Dalal, S. L. Palla, R. Chacko, L. Nguyen, N. A. Fadul, Z. Li, E. Bruera

Brd. 41B Pathophysiological role of hormones and cytokines in cancer cachexia. (Abstract #9053)
H. Park, H. Kim, J. Kwon, J. Yun, S. Lee, S. Bae, C. Kim, N. Lee, D. Hong

Brd. 41C The cancer survivor survey: Using Web-based technology to assess cancer survivor challenges. (Abstract #9054)
Brd. 41D Vanderbilt Head and Neck Symptom Survey Version 2.0 (VHNSS 2.0): A tool for the study of long-term oral health consequences of therapy for head and neck cancer (HNC). (Abstract #9055)
E. Cooperstein, J. B. Epstein, B. A. Murphy, M. S. Dietrich, J. Gilbert

Brd. 41E Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). (Abstract #9056)

Brd. 41F Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). (Abstract #9057)
R. J. Gralla, B. L. Rapoport, K. Jordan, J. C. Street, A. Carides

Brd. 41G The impact of bone health on endocrine treatment strategy in older adults with early-stage, hormone receptor–positive breast cancer. (Abstract #9058)
S. K. Pal, A. Hurria, L. Wong, A. Naeim

Brd. 41H Expectations of benefit and symptom burdens among advanced cancer patients (ACP) and spousal caregivers during the course of phase I trials. (Abstract #9059)
F. J. Hlubocky, T. G. Sher, K. Wroblewski, E. Luzar, M. J. Ratain, C. Daugherty

Brd. 42A Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing. (Abstract #9060)

Brd. 42B Predicting cisplatin-induced ototoxicity in testicular germ cell cancer. (Abstract #9061)

Brd. 42C Timing of palliative care referral and symptom burden in phase I cancer patients: A retrospective cohort study. (Abstract #9062)

Brd. 42D Evaluation of axillary node dissection on measures of upper-extremity disability and overall quality of life after breast cancer surgery. (Abstract #9063)
S. A. McLaughlin, A. S. Parker, N. N. Diehl, M. Arnold, J. H. Nguyen, E. A. Perez

Brd. 42E Mini-Cog: A brief screening tool for cognitive impairment in older cancer patients. (Abstract #9064)
M. S. Thein, I. S. Browner, C. Klein, M. Binner, G. R. Shapiro

Brd. 42F Changes in symptoms and inpatient mortality among advanced cancer patients admitted to a palliative care unit in a comprehensive cancer center. (Abstract #9065)
M. Mori, H. A. Parsons, M. De la Cruz, A. F. Elsayem, S. L. Palla, J. Liu, Z. Li, J. L. Palmer, E. Bruera, N. A. Fadul

Brd. 42G Retrospective mortality comparisons of cancer patients with sepsis syndromes. (Abstract #9066)
D. Joyce, V. Holly, R. Dukes, E. Trueblood

Brd. 42H Cancer care on a continuum: Maintaining fertility after diagnosis and treatment. (Abstract #9067)
J. M. Knopman, J. A. Grifo, P. A. Labella, N. Noyes

Brd. 43A Use of thermal sensation as a biomarker of response to palliative radiotherapy for cancer-induced bone pain. (Abstract #9068)
Brd. 43B An evaluation of health literacy (HL) in a consecutive sample of patients (pts) with cancer (ca) of the head and neck (H+N) region. (Abstract #9069)  

Brd. 43C Innovative quality initiative measurement using Web-based drug dispensing technology with interactive physician queries to evaluate bisphosphonate use across community oncology practices nationwide. (Abstract #9070)  

Brd. 43D The associations between spirituality (S), religiosity (R), and spiritual pain (SP) in advanced cancer patients (AdCa). (Abstract #9071)  
M. O. Delgado-Guay, D. Hui, H. A. Parsons, M. De la Cruz, K. B. Govan, L. Arciniega, S. Thorney, J. L. Palmer, E. Bruera

Brd. 43E The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash with cetuximab in cancer patients: A meta-analysis. (Abstract #9072)  
Y. Balagula, S. Wu, X. Su, S. W. Dusza, M. E. Lacouture

Brd. 43F Use of unnecessary medications by terminally ill cancer patients. (Abstract #9073)  

Brd. 43G Polypharmacy in elderly cancer patients. (Abstract #9074)  
T. L. Jorgensen, J. Hallas, J. Herrstedt

Brd. 43H The association between clinical, sociodemographic, and logistic-administrative factors and adherence to completing health-related quality-of-life questionnaires. (Abstract #9075)  
J. Vercauteren, J. Maringwa, C. Coens, C. Quinten, C. Gotay, J. Ringash, M. King, D. Osoba, H. Flechtner, A. Bottomley, on behalf of the EORTC

Brd. 44A Evaluation of variants of the rs1934951 locus of CYP2C8 and bisphosphonate-related osteonecrosis of the jaw in castrate-resistant prostate cancer (CRPC) patients. (Abstract #9076)  

Brd. 44B An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus ≥10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA). (Abstract #9077)  

Brd. 44C Interpretation of do-not-resuscitate (DNR) orders among oncology health care professionals and the potential for these orders to influence care for medical issues unrelated to resuscitation. (Abstract #9078)  
C. R. Lund, R. Samant

Brd. 44D How accurate is clinician reporting of chemotherapy side effects? A prospective study comparing clinician with patient-reported symptoms. (Abstract #9079)  

Brd. 44E The effect of palliative care consultations on the end-of-life care in the Veteran’s cancer population. (Abstract #9080)  
W. Gonsalves, T. Tashi, I. Aldoss, M. Kalaiah, N. Didwaniya, S. Stenoien, C. Eberle, A. Ganti, S. Subbiah, P. T. Silberstein

Brd. 44F Validation of first speech-specific questionnaire for English-speaking head and neck cancer (HNC) patients. (Abstract #9081)  
R. Kazi, R. C. Dwivedi, S. St. Rose, J. W. Roe, C. Nutting, P. H. Rhys-Evans, K. J. Harrington

Brd. 44G Differences in lung cancer clinical trial accrual between a public and university medical oncology clinic. (Abstract #9082)  
**Brd. 44H** Barriers to symptom management in oncology. (Abstract #9083)
B. R. Ferrell, M. Koczywas, T. Borneman, B. F. Piper, G. Uman

**Brd. 45A** Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose. (Abstract #9084)
M. K. Bamat, R. Tremmel, J. D. O'Neil, R. von Borstel

**Brd. 45B** Differences between old (70–80 years) and very old (80+ years) cancer patients: Results from the IN-GHO registry. (Abstract #9085)
F. Honecker, U. Wedding, K. Rettig, S. Huschens, C. Bokemeyer, on behalf of the IN-GHO Advisory Board

**Brd. 45C** Depression and EGFR mutation status in stage IV non-small cell lung cancer. (Abstract #9086)
W. F. Pirl, J. Greer, H. Bemis, R. S. Heist, E. Gallagher, L. V. Sequist, J. A. Engelman, L. Traeger, I. T. Lennes, J. S. Temel

**Brd. 45D** Polypharmacy and functional status in older patients with breast, colon, and lung cancers. (Abstract #9087)
G. K. Prithviraj, R. Bagai, S. M. Koroukian, N. A. Berger, C. Owusu

**Brd. 45E** Reactivation of chronic hepatitis B virus in cancer patients receiving immunosuppression: The case for screening. (Abstract #9088)
R. B. Mendelsohn, S. Nagula, Y. Taur, M. Kamboj, K. Sepkowitz, A. D. Zelenetz, E. Ludwig

**Brd. 45F** Osteopenia in survivors of childhood cancer. (Abstract #9089)

**Brd. 45G** Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care. (Abstract #9090)
E. Grunfeld, M. N. Levine, J. Julian, A. Folkes, G. R. Pond, E. Maunsell, FUP2 Trial Investigators

**Brd. 45H** The use of complementary and alternative medicine in patients seen in phase I clinical trials program. (Abstract #9091)

**Brd. 46A** Late toxicity and quality of life in oral cavity and oropharyngeal cancer survivors treated with chemoradiotherapy. (Abstract #9092)
M. Oliveira, A. Luis, E. Carvalho, S. Esteves, I. Sargento, M. Ferreira, A. Moreira, J. Oliveira

**Brd. 46B** What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development. (Abstract #9093)
H. Raftopoulos, R. J. Gralla, P. J. Holien, B. J. Davis, J. A. Petersen, J. L. Horigan

**Brd. 46C** Long-term safety, tolerability, and acceptability of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain. (Abstract #9094)

**Brd. 46D** Randomized trial of combined treatment versus usual care plus antidepressant in depressed oncologic patients: One-year follow-up. (Abstract #9095)
A. Palao Tarrero, C. Bayón Perez, G. Torres Sancho, A. Hospital Moreno, B. Castelo Fernandez, J. Barriuso, B. Rodriguez Vega

**Brd. 46E** The prognostic role of quality-of-life assessment in lung cancer. (Abstract #9096)
D. P. Braun, D. Gupta, J. F. Grutsch, E. D. Staren

**Brd. 46F** Predictors of high symptom severity in caregivers of underserved minority cancer patients. (Abstract #9097)
Monday, June 7, 2010

Brd. 46G Correlates and mediators of worry about breast cancer recurrence. (Abstract #9098)

Brd. 46H Role of yoga in modulating fatigue, sleep disturbances, salivary cortisol, and immune measures in breast cancer survivors: A randomized controlled trial. (Abstract #9099)
R. M. Raghavendra, B. S. Ajai Kumar, H. S. Vadiraja, S. Patil, R. B. Diwakar, P. Sashidhara, R. Nagaratha

Brd. 47A A randomized trial of weekly high-dose calcitriol and weight-bearing exercise for cancer treatment–induced bone loss (CTIBL) and bone metabolism in ER+ breast cancer (BC) patients. (Abstract #9100)

Brd. 47B Longitudinal prospective assessment of sleep disturbance in breast cancer. (Abstract #9101)

Brd. 47C Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02). (Abstract #9102)

Brd. 47D The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. (Abstract #9103)
J. R. Westin, F. B. Hagemeister, M. A. Thompson, V. D. Cataldo, B. B. Toth, P. Sanjorjo, S. Bourgeois, C. Jimenez, W. A. Murphy, L. W. Kwak, M. D. Anderson Department of Lymphoma/Myeloma

Brd. 47E Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. (Abstract #9104)

Brd. 47F Geriatric assessment in 347 elderly cancer patients: Study of geriatric factors modifying the cancer treatment plan. (Abstract #9105)
P. Caillet, E. Paillaud, J. Vouriot, M. Berle, N. Reinald, S. Bastuji-Garin, S. Culine

B. E. Kiely, Y. Soon, M. H. Tattersall, M. Stockler

Brd. 47H Assessing the clinical significance of real-time quality of life (QOL) data in cancer patients treated with radiation therapy. (Abstract #9107)
M. Y. Halyard, A. Tan, M. D. Callister, J. B. Ashman, S. A. Vora, W. Wong, S. E. Child, P. J. Atherton, J. A. Sloan

Brd. 48A Pilot trial of decision aids for patients with advanced breast, lung, colorectal, or prostate cancer. (Abstract #9108)

Brd. 48B National survey of U.S. oncologists’ knowledge, attitudes, and practice patterns regarding herb and supplement use by cancer patients. (Abstract #9109)
R. T. Lee, L. Cohen, O. I. Olopade, F. C. Curn

Brd. 48C Patient surveillance following curative-intent treatment for breast carcinoma: Current practice patterns. (Abstract #9110)

Brd. 48D Perspectives on the financial burden of cancer care: Concurrent surveys of patients (Pts), caregivers (CGs), and oncology social workers (OSWs). (Abstract #9111)
M. Eichholz, J. Pevar, T. Bernthal
Brd. 48E  Cancer treatment impact on cognitive functioning and quality of life in lung cancer survivors. (Abstract #9112)
S. Kohli, P. J. Novotny, J. A. Sloan, J. C. Buckner, P. D. Brown, P. Yang

Brd. 48F  A phase II clinical study of interleukin-11 mutein to treat patients with chemotherapy-induced thrombocytopenia. (Abstract #9113)
Y. Jung, S. Ho, S. Yu, S. Wu, Y. Zhang, L. Xu, Y. Dai, Y. Teng, S. Ma, S. Song

Brd. 48G  Can the short screening test Vulnerable Elders Survey 13 (VES-13) substitute for the time-consuming comprehensive geriatric assessment (CGA) to identify vulnerable/frail elderly breast cancer patients? (Abstract #9114)

Brd. 48H  A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer. (Abstract #9115)
W. R. Simons, Y. Choe, A. Powers, C. McQueen

Brd. 49A  A report on the development and validation of first-ever perceptual speech evaluation tool for head and neck cancer (HNC) patients. (Abstract #9116)
R. C. Dwivedi, S. St. Rose, C. Nutting, P. H. Rhys-Evans, K. J. Harrington, R. Kazi

Brd. 49B  Adolescent and young adult use of Internet-based cancer survivorship care plans. (Abstract #9117)

Brd. 49C  Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG’s SOAPP study). (Abstract #9118)

Brd. 49D  Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005. (Abstract #9119)

Brd. 49E  A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). (Abstract #9120)

Brd. 49F  Prechemotherapy hepatitis B virus (HBV) screening in medical oncology patients: A national survey. (Abstract #9121)
F. L. Day, E. Link, K. Thursky, D. Rischin

Brd. 49G  Pregnancy and survival after primary breast carcinoma in young women: A meta-analysis of healthy mother effect studies. (Abstract #9122)
D. Mauri, A. Valachis, L. Tsai, K. Tsaiis, N. P. Polyzos, L. L. Pesce

Brd. 49H  Patients’ self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403). (Abstract #9123)

Brd. 50A  Out-of-pocket (OOP) spending burden for Medicare beneficiaries with cancer. (Abstract #9124)
X. Ke, F. Hendrick, T. Shaffer, A. J. Davidoff

Brd. 50B  Development of the lymphedema symptoms intensity and distress survey arm. (Abstract #9125)
S. H. Ridner, M. S. Dietrich

Brd. 50D  Chemotherapy-induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT3-RA anti-emetic regimens. (Abstract #9127)
H. T. Hatoum, S. Lin, D. Buchner, D. Cox
Monday, June 7, 2010

Brd. 50E The development and implementation of an institution-based communication skills training program for oncologists. (Abstract #9128)
P. A. Bialer, T. Gilewski, D. Kissane, T. Levin, M. N. Dickler, B. J. Park, C. Bylund

Brd. 50F Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: A phase I study. (Abstract #9129)

Brd. 50G Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib. (Abstract #9130)

Brd. 50H Quality of life (QOL) and cognitive performance among irradiated brain cancer patients. (Abstract #9131)

Brd. 51A The impact of pharmacotherapy on depression and quality of life in patients undergoing a bone marrow transplant (BMT). (Abstract #9132)
P. B. Mumby, C. Garcia, R. Trivedi-Purohit, R. Gourvitz, K. Rychlik, T. Rodriguez, S. E. Smith, A. A. Toor, M. Rao, P. J. Stiff, BMT Program

Brd. 51B Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. (Abstract #9133)

Brd. 51C Prevalence of memory problems that limit daily functioning in adult cancer patients: A national representative sample of the U.S. population. (Abstract #9134)

Brd. 51D Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1. (Abstract #9135)

Brd. 51E Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis. (Abstract #9136)
A. F. Sher, S. Wu

Brd. 51F Prevalence of lymphedema and upper-limb impairments after axillary lymph node dissection or sentinel lymph node dissection in breast cancer: A two-year follow-up study. (Abstract #9137)
A. Sagen, R. Kåresen, M. J. Hjermstad, M. Risberg, Oslo University Hospital

Brd. 51G Effect of timing of information on exercise on exercise behavior during cancer treatment: A URCC CCOP protocol. (Abstract #9138)

Brd. 51H Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB. (Abstract #9139)

Brd. 52A Testosterone levels and quality of life (QoL) in male patients with hormone-independent cancers (HIC). (Abstract #9140)
S. B. Fleishman, H. Khan, M. J. Guarino, M. Suhail, R. A. Strebel, P. Homel, V. Rosenwald, T. Mirzoyev, T. F. Wozniak, K. Suppiah

Brd. 52B Overall survival in randomized controlled trials of chemotherapy (CT) with or without GCSF support: A systematic review. (Abstract #9141)
G. H. Lyman, D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff, N. M. Kuderer, J. Crawford
Brd. 52C Disparities in receipt of supportive/palliative care services among women with breast cancer. (Abstract #9142)
M. T. Halpern, D. J. Holden, A. Larsen

Brd. 52D Post-traumatic stress in patients with acute leukemia. (Abstract #9143)

Brd. 52E Potential plasma biomarkers predicting radiation dermatitis in breast cancer patients. (Abstract #9144)
J. L. Ryan, A. P. Pentland, C. E. Heckler, G. R. Morrow

Brd. 52F The impact of symptom clusters on survival in patients with advanced cancer. (Abstract #9145)
A. Aktas, L. A. Rybicki, D. Walsh

Brd. 52G Use of health-related quality of life and clinical data as prognostic tools for survival prediction in a subgroup of metastatic cancer patients. (Abstract #9146)
C. Quinten, F. Martinelli, J. Vercauteren, E. Greimel, M. J. Taphoorn, C. S. Cleeland, J. Weis, J. Schmucker-Von Koch, A. Bottomley, on behalf of the EORTC

Brd. 52H Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia. (Abstract #9147)
M. S. Steiner, K. G. Barnette, M. L. Hancock, S. T. Dodson, D. Rodriguez, R. A. Morton

Brd. 53A Effect of gabapentin on anxiety among 306 breast cancer patients: A URCC CCOP study. (Abstract #9148)

Brd. 53B Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. (Abstract #9149)
C. M. Walko, R. E. Aubert, N. M. La-Beck, G. Hawk, V. Herrera, H. Kourlas, R. S. Epstein, H. L. McLeod

Brd. 54A Randomized phase II trial of carboplatin (C) and gemcitabine (G) with or without dexamethasone (Dex) in patients (pts) with stage IV non-small cell lung cancer (NSCLC). (Abstract #9150)
J. J. Rinehart, S. M. Arnold, G. H. Kloeker, A. Lim, M. A. Zaydan, S. Slone, J. Croley, E. Kvale

Brd. 54B Effect of oral magnesium on hot flashes in breast cancer survivors. (Abstract #9151)
H. Park, T. J. Smith, G. L. Parker, P. Dodson, C. Boardman, M. M. Morris

Brd. 55A PROCHE: A program to monitor side effects among patients treated in a medical oncology outpatient unit. (Abstract #9152)

Brd. 55B Cardioprotective effect of telmisartan in cancer patients treated with telmisartan. (Abstract #9153)

Brd. 55C Venothromboembolism (VTE) in patients (pts) with acute myelogenous leukemia (AML). (Abstract #9154)

Brd. 55D Pharmacokinetic study of pegylated liposomal doxorubicin (PLD) in patients over 70: Association with increasing age and cutaneous toxicity. (Abstract #9155)
A. Bononi, M. Gusella, I. Modena, C. Bolzonella, C. Barile, G. Crepaldi, D. Menon, L. Stievano, S. Tos, F. Pasini
Monday, June 7, 2010

Brd. 55E Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors. (Abstract #9156)

Brd. 55F Bone mineral density in childhood cancer survivors (CCS). (Abstract #9157)

Brd. 55G Venous thrombosis associated with central venous catheter in cancer patients with surgical chest port (S) or venography-guided arm port insertion (R): A randomized controlled study. (Abstract #9158)

Brd. 55H Coping strategies in young women with breast cancer. (Abstract #9159)

Brd. 56A A practical program for measuring the quality of ambulatory oncology care in the United States: The Quality Oncology Practice Initiative. (Abstract #9160)

Brd. 56B Chemotherapy-associated cardiotoxicity: Timeline of left ventricular function recovery on standard heart failure regimen. (Abstract #9161)
J. K. Steiner, V. L. Beggs, G. N. Schwartz, A. T. Kono

Brd. 56C Biochemical correlates of fatigue in patients at a comprehensive cancer center. (Abstract #9162)
A. A. Bharne, P. Mills, W. Bardwell, M. White, K. Messer, L. Bazhenova

Brd. 56D Supplemental oxygen for relief of dyspnea in hospice patients. (Abstract #9163)
L. A. Joque, J. S. Kaur, R. A. Vierkant

Brd. 56E Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial. (Abstract #9164)

Brd. 56F An analysis of prognostic factors of comprehensive geriatric assessment (CGA) and development of a clinical scoring system in elderly Asian cancer patients. (Abstract #9165)
R. Kanesvaran, H. Li, K. Koo, D. Poon

Brd. 56G Use of a pharmacist/nurse model for the delivery of supportive care in adult oncology clinics at the University of North Carolina Hospital. (Abstract #9166)
S. A. Bernard, J. Valgus, S. Jarr, M. Rice, R. Schwartz
1:15 PM - 2:30 PM
SPECIAL SESSION

ASCO/European CanCer Organisation Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Special Session; Lung Cancer

Michael Baumann, MD—Co-Chair
University Hospital Carl Gustav Carus, TU Dresden
Introduction: The Need for Personalized Medicine in Locally Advanced NSCLC

Douglas W. Blayney, MD—Co-Chair
University of Michigan
Summary: The Future of Personalized Medicine

David Paul Carbone, MD, PhD
Vanderbilt University Medical Center
Tumor Biology and Its Impact on Decision Making (Assay Technology)

Michael Brada, MD
Institute of Cancer Research and Royal Marsden NHS Trust
Multidisciplinary Localized Therapy: Innovative Developments in Multidisciplinary Treatments of NSCLC

Jean-Charles Soria, MD, PhD
Gustave Roussy Institute
Systemic Therapy: What Lies Ahead?
Monday, June 7, 2010

1:15 PM - 2:30 PM
EDUCATION SESSIONS

Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice?
Location: N Hall B1
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Developmental Therapeutics

David Linehan, MD—Chair
Washington University School of Medicine
Surgical Approach in Resectable and Borderline Resectable Pancreatic Cancer

Gauri R. Varadhachary, MD
University of Texas M. D. Anderson Cancer Center
The Role of Neoadjuvant versus Adjuvant Chemotherapy in Pancreatic Cancer: What Does the Data Tell Us?

Theodore Steven Lawrence, MD, PhD
University of Michigan
Role of Radiation in Locally Advanced Pancreatic Cancer

Complications of Myeloma and Myeloma Therapies
Location: E354a
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care

Todd M. Zimmerman, MD—Chair
The University of Chicago
Prophylaxis of Venous Thromboembolic Disease Associated with Immunomodulatory Agents

Paul Gerard Guy Richardson, MD
Dana-Farber Cancer Institute
Prevention and Management of Treatment-induced Peripheral Neuropathy

G. David Roodman, MD, PhD
University of Pittsburgh
Myeloma Bone Disease: What’s New?

Controversies in the Management of Metastatic Breast Cancer
Location: E Hall D1
CME credit: 1.25
Track(s): Breast Cancer; Professional Development

Cliff Hudis, MD—Chair
Memorial Sloan-Kettering Cancer Center
Integration and Sequence of Systemic Options: How to Translate Clinical Trial Results into Routine Practice?

Jonas Bergh, MD, PhD
Karolinska University Hospital
Biological Evolution of Breast Cancer: Should a Metastasis Be Rebiopsed?

Michael J. Hassett, MD, MPH
Dana-Farber Cancer Institute
Should Cost Be a Consideration in the Management of Metastatic Breast Cancer?
Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce
Location: E353
CME credit: 1.25
Track(s): Professional Development; Ethics

Timothy Jerome Moynihan, MD—Chair
Mayo Clinic
Can We Teach Professionalism?

Robert Martensen, MD, PhD
National Institutes of Health
Medical Professionalism in Historical Perspective

David H. Johnson, MD
Vanderbilt Ingram Cancer Center
Professionalism and the Oncologist: How Professionalism Impacts Practice

Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions
Location: E Hall D2
CME credit: 1.25
Track(s): Genitourinary Cancer; Geriatric Oncology; Patient and Survivor Care

William K. Oh, MD—Chair
Mount Sinai School of Medicine
Exploiting the Endocrine Axis in Prostate Cancer: What Are the New Targets?

Mary-Ellen Taplin, MD
Dana-Farber Cancer Institute
Recent Advances in Endocrine Therapy for Prostate Cancer: New Agents, New Options

Peter Nelson, MD
Fred Hutchinson Cancer Research Center
Where Is Endocrine Therapy Going in the Next Five Years?

Imunoconjugates as Cancer Therapeutics
Location: S100b
CME credit: 1.25
Track(s): Developmental Therapeutics; Lymphoma and Plasma Cell Disorders; Tumor Biology

Andrew Antony Raubitschek, MD—Chair
City of Hope
The History and Evolution of Immunoconjugate Treatment as Anticancer Therapy

Raffit Hassan, MD
National Cancer Institute
The Present State of Trials Using Immunoconjugates Targeting Solid Tumors and New Strategies Emerging from the Lab

Paul A. Hamlin, MD
Memorial Sloan-Kettering Cancer Center
The Present State of Trials Using Immunoconjugates Targeting Lymphoma and Heme Malignancies and New Strategies Emerging from the Lab
Monday, June 7, 2010

NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting
Location: S404  
CME credit: 1.25  
Track(s): Clinical Trials; Practice Management and Information Technology; Professional Developmental

Mark Krasna, MD—Chair  
St. Joseph Medical Center  
Multidisciplinary Cancer Care as the Paradigm for Prospective Case Management and Clinical Trial Accrual in the Community Setting

John E. Niederhuber, MD  
National Cancer Institute  
The Vision of the NCCCP and Its Potential Impact on Community Cancer Care in the Future

Nicholas J. Petrelli, MD  
Helen F. Graham Cancer Center  
Disparities and Community Outreach in the NCCCP

Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma
Location: S504  
CME credit: 1.25  
Track(s): Pediatric Oncology; Lymphoma and Plasma Cell Disorders

Cindy L. Schwartz, MD—Chair  
Brown Medical School  
Optimizing Chemotherapy: Response and Biology

Louis S. Constine, MD  
James P. Wilmot Cancer Center  
RT or not RT: That Is the Question!

Stephan Voss, MD, PhD  
Children’s Hospital Boston  
Functional Imaging and Hodgkin Lymphoma

The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment
Location: E354b  
CME credit: 1.25  
Track(s): Leukemia, Myelodysplasia, and Transplantation

Olatoyosi Odenike, MD—Chair  
University of Chicago  
Epigenetic and Other Rational Therapeutic Approaches in MPD

Catriona Jamieson, MD, PhD  
University of California, San Diego  
JAK 2 and Related Mutations in Myeloid Neoplasms: Biology and Therapeutic Implications

Guido Marcucci, MD  
The Ohio State University Medical Center  
MicroRNA in AML and CLL: What Does It Mean?
1:15 PM - 2:30 PM
CLINICAL PROBLEMS IN ONCOLOGY

Nonglial and Heritable Central Nervous System Tumors (C14)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Central Nervous System Tumors

Marc C. Chamberlain, MD—Chair
University of Washington
Adult Meningioma: The Evolving Role for Oncologists

Patrick Y. Wen, MD
Dana-Farber Cancer Institute
Neurofibromatosis Type 2

Michael Prados, MD
University of California, San Francisco
Adult Medulloblastoma
Monday, June 7, 2010

1:15 PM - 2:45 PM  
CLINICAL SCIENCE SYMPOSIUM

Unraveling the Cancer Genome: Clinical Implications of Next-generation Technologies  
Location: S100a  
CME credit: 1.5  
Track(s): Tumor Biology

Anil Potti, MD—Chair  
Duke University Medical Center

1:15 PM  Massive parallel sequencing of an African-American basal-like breast cancer: Comparison of primary tumor, metastasis, and xenograft. (Abstract #10500)  
E. Mardis, L. Ding, S. Li, D. E. Larson, K. Chen, J. Wallis, J. Hoog, K. Deshryver, R. Wilson, M. J. Ellis

1:30 PM  Characterization of the microRNAome in a patient with acute myeloid leukemia. (Abstract #10501)  

Discussion  
1:45 PM  Samuel Aparicio, BM, BCh, PhD, MRCPath (Abstracts #10500–10501)  
British Columbia Cancer Agency

2:00 PM  Detection of phosphoinositide-3-kinase, catalytic, and alpha polypeptide (PIK3CA) mutations in matched tissue and plasma samples from patients with metastatic breast cancer. (Abstract #10502)  
P. Angenendt, K. David, H. Juhl, F. Diehl

2:15 PM  Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry. (Abstract #10503)  
C. Beadling, M. C. Heinrich, K. Schuff, B. J. Druker, C. L. Corless

Discussion  
2:30 PM  Matthew James Ellis, PhD, MB, BCh (Abstracts #10502–10503)  
Siteman Cancer Center, Washington University
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Breast Cancer—Local-Regional and Adjuvant Therapy
Display Time: 2:00 PM - 6:00 PM
Display Location: S403
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: N Hall B1
CME credit: 1
Track(s): Breast Cancer

Stephen K. L. Chia, MD—Co-Chair
British Columbia Cancer Agency
Lisa Yee, MD—Co-Chair
The Ohio State University

Discussion
5:00 PM Seema Ahsan Khan, MD, FACS, MPH (Abstracts #LBA513–LBA517)
Northwestern Memorial Hospital

Discussion
5:15 PM Antonio C. Wolff, MD (Abstracts #518–522)
The Johns Hopkins University

Discussion
5:30 PM Claudine Isaacs, MD (Abstracts #523–528)
Lombardi Comprehensive Cancer Center

Discussion
5:45 PM Carlos Caldas, MD (Abstracts #530–535)
Cambridge University

Brd. 1 ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. (Abstract #LBA513)

Brd. 2 Impact of multifocal/multicentric versus unifocal breast cancer on local recurrence. (Abstract #514)

Brd. 3 Determination of clear margin in breast-conserving surgery: Is 1 mm needed? (Abstract #515)

Brd. 5 Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow-up. (Abstract #LBA517)
M. Baum, D. J. Joseph, J. S. Tobias, F. K. Wenz, M. R. Keshtgar, M. Alvarado, M. Balsara, W. Eiermann, N. R. Williams, J. S. Vaidya, on behalf of the TARGIT Trialists’ Group

Brd. 6 Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. (Abstract #518)

Brd. 7 Final results of a meta-analysis testing HER2 and topoisomerase IIa genes as predictors of incremental benefit from anthracyclines in breast cancer. (Abstract #519)
Monday, June 7, 2010

Brd. 8 Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women. (Abstract #520)
P. Bedard, R. Salgado, S. K. Singhal, V. Durbecq, M. Ignatiadis, B. Haibe-Kains, M. Piccart, C. Sotiriou, S. Loi

Brd. 9 Clinically relevant gene signatures in triple-negative and basal-like breast cancer. (Abstract #521)

Brd. 10 Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy. (Abstract #522)
S. Loi, B. Haibe-Kains, D. N. Brown, J. Metallo, L. X. Huan, C. Desmedt, L. Pusztai, M. Piccart, F. J. Esteva, C. Sotiriou

Brd. 11 First results from the Patient’s Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC). (Abstract #523)

Brd. 12 Early discontinuation of tamoxifen and aromatase inhibitors (Als) by postmenopausal women with early-stage breast cancer. (Abstract #524)
J. A. Charlson, T. Hedin, R. Sparapani, C. Guo, A. Nattinger

Brd. 14 Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors. (Abstract #526)
J. Mao, I. Su, R. Feng, K. Desai, M. Horn, D. Chan, A. DeMichele

Brd. 16 Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. (Abstract #528)
L. Del Mastro, L. Boni, A. Michelotti, T. Gamucci, N. Olmeo, M. Giordano, S. Gori, O. Garrone, C. Bighin, M. Venturini, GIM group

Brd. 18 Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). (Abstract #530)

Brd. 19 Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC). (Abstract #531)

Brd. 21 Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. (Abstract #533)
Brd. 22  Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8. (Abstract #534)

Brd. 23  Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study. (Abstract #535)
Monday, June 7, 2010

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Cancer Prevention/Epidemiology
Display Time: 2:00 PM - 6:00 PM
Display Location: E450b
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E451b
CME credit: 1
Track(s): Cancer Prevention/Epidemiology

Kala Visvanathan, MD, MHS—Co-Chair
The Johns Hopkins University
Marie Wood, MD—Co-Chair
University of Vermont

Discussion
5:00 PM  Judy Ellen Garber, MD, MPH (Abstracts #1509–1514)
Dana-Farber Cancer Institute

Discussion
5:15 PM  Barnett S. Kramer, MD, MPH (Abstracts #1515–1520)
National Institutes of Health

Discussion
5:30 PM  Dean Brenner, MD (Abstracts #1521–1524)
University of Michigan Medical Center

Discussion
5:45 PM  To be determined

Brd. 1  Impact of early detection strategies on cancer mortality in germline TP53 mutation carriers in Li-Fraumeni syndrome. (Abstract #1509)
A. Villani, U. Tabori, J. D. Schiffman, A. Shlien, H. Druker, A. Novokmet, J. L. Finlay, D. Malkin

Brd. 2  PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics, onco-phenotype, and molecular analysis. (Abstract #1510)
M. M. Patnaik, S. Khambatta, S. I. Robinson, R. L. Richardson, M. P. Goetz

Brd. 3  Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer. (Abstract #1511)
F. Fostira, M. Tsitlaidou, H. Gogas, M. Pertesi, D. Yannoukakos, E. Bournakis, V. Karavassilis, P. Skarlos, I. Konstantopoulou, G. Fountzilas

Brd. 4  Primary fallopian tube lesions in BRCA mutation carriers undergoing risk-reducing surgery. (Abstract #1512)
F. Dao, G. Han, K. J. Park, G. J. Gardner, N. D. Kauff, R. R. Barakat, R. A. Soslow, D. A. Levine, Memorial Sloan-Kettering Cancer Center

Brd. 5  Noncancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. (Abstract #1513)

Brd. 6  Characterization of new Ashkenazi Jewish founder mutations in MSH6 causing Lynch syndrome. (Abstract #1514)

Brd. 7  What size of tumors should we detect as early-stage lung cancers in CT screening? Stage-size relationship in long-term repeated screening over 15 years. (Abstract #1515)
N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, M. Kusumoto, T. Tsuchida, H. Nishiya, N. Moriyama
Brd. 8 Assessment of overdiagnosis in CT screening for lung cancer. (Abstract #1516)

Brd. 9 Prospective evaluation of whole-body cancer screening with multiple modalities including FDG-PET: Results from annual screening for 5 years in 1,197 healthy volunteers. (Abstract #1517)

Brd. 10 Optically guided surgical approach and the outcome of early-stage oral cancers. (Abstract #1518)

Brd. 12 Effect of screening on the detection of good and poor prognosis breast cancers. (Abstract #1520)

Brd. 13 Phase II randomized placebo-controlled double-blind chemoprevention trial of fruit/vegetable concentrates on intermediate biomarkers in head/neck cancer. (Abstract #1521)
E. G. Shaw, L. D. Case, J. D. Browne, J. Gilbert, J. Metzner-Sidurski, E. Franzmann, B. Frizzell, C. Schneider, V. Thomas, J. J. Hu

Brd. 14 Effect of successful weight loss program on biomarkers for breast cancer in postmenopausal high-risk women. (Abstract #1522)

Brd. 15 Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas. (Abstract #1523)

Brd. 16 Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT). (Abstract #1524)
S. R. Land, N. Christian, W. M. Cronin, D. Wickerham, J. P. Costantino, P. A. Ganz

Brd. 17 Race and colon cancer: Unanswered questions. (Abstract #1525)

Brd. 18 Investigation of ethnic differences in the prevalence of chromosomal number aberrations of luminal and triple-negative breast cancers associated with risk of recurrence. (Abstract #1526)

Brd. 19 Celecoxib and aromatase activity in breast cancer: Results from a prospective randomized preoperative trial. (Abstract #1527)

Brd. 20 Evaluation of the potential clinical utility of risk models incorporating genomic risk information. (Abstract #1528)

Brd. 21 Integration of specific copy number imbalances and prediction models of early-stage breast cancer recurrence. (Abstract #1529)
Monday, June 7, 2010

Brd. 22  Nicotinic acetylcholine receptor polymorphism, smoking history, and tobacco-related cancer in the general population. (Abstract #1530)  D. Kaur-Knudsen, S. E. Bojesen, A. Tybjærg-Hansen, B. G. Nordestgaard


2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Leukemia, Myelodysplasia, and Transplantation
Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E354a
CME credit: 1
Track(s): Leukemia, Myelodysplasia, and Transplantation

Lucy A. Godley, MD, PhD—Co-Chair
The University of Chicago
Rami S. Komrokji, MD—Co-Chair
H. Lee Moffitt Cancer Center & Research Institute

Discussion
5:00 PM  Mier Wetzler, MD (Abstracts #6509–6514)
Roswell Park Cancer Institute
Optimizing TKI Therapy in Advanced CML

Discussion
5:15 PM  John C. Byrd, MD (Abstracts #6515–6523)
The Ohio State University
Advances in the Therapy of Chronic Lymphoid Leukemias

Discussion
5:30 PM  Harry Paul Erba, MD, PhD (Abstracts #6524–6528)
University of Michigan Health Systems
Novel Therapeutic Strategies in MDS and AML

Discussion
5:45 PM  Jane Liesveld, MD (Abstracts #6529–6532)
University of Rochester
Can Management of High-risk AML Be Optimized?

Brd. 1  Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. (Abstract #6509)

Brd. 2  Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. (Abstract #6510)
F. J. Giles, H. Kantarjian, P. D. le Coutre, M. Baccarani, R. E. Blakesley, N. J. Gallagher, K. Gillis, R. A. Larson, O. G. Ottmann

Brd. 3  Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies. (Abstract #6511)

Brd. 4  Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. (Abstract #6512)
N. P. Shah, J. E. Cortes, C. A. Schiffer, P. le Coutre, E. Bahceci, A. Lambert, G. Saglio

Brd. 5  Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib. (Abstract #6513)
Monday, June 7, 2010

Brd. 6 Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML). (Abstract #6514)

Brd. 7 Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. (Abstract #6515)
G. Rosti, F. Castagnetti, F. Palandri, A. Poerio, S. Soverini, M. Breccia, F. Pane, G. Martinelli, M. Baccarani, G. Saglio

Brd. 8 Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #6516)

Brd. 9 Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV. (Abstract #6517)
R. Hehlmann, M. Lauseker, S. Jung-Munkwitz, J. E. Schubert, C. Haferlach, S. W. Krause, A. Gratwohl, J. Hasford, A. Hochhaus, S. Sausselle, the German CML Study Group

Brd. 10 Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients. (Abstract #6518)

Brd. 11 Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). (Abstract #6519)

Brd. 12 Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL). (Abstract #6520)

Brd. 13 Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS). (Abstract #6521)

Brd. 14 Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL). (Abstract #6522)

Brd. 15 Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia. (Abstract #6523)
R. J. Kreitman, M. S. Tallman, S. E. Coutre, T. Robak, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, J. T. McDevitt, I. Pastan

Brd. 16 Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL). (Abstract #6524)
Brd. 17  Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules. (Abstract #6525)

Brd. 18  Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. (Abstract #6526)

Brd. 19  Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). (Abstract #6527)
F. Ravandi Kashani, J. Jorgensen, S. Faderl, J. Issa, J. Autry, G. Garcia-Manero, G. Borthakur, X. Huang, J. E. Cortes, H. Kantarjian

Brd. 20  A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. (Abstract #6528)

Brd. 21  Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). (Abstract #6529)
T. M. Kadia, F. Ravandi Kashani, S. M. O'Brien, J. E. Cortes, E. Jabbour, G. Borthakur, S. Faderl, S. Pierce, M. Brandt, H. Kantarjian

Brd. 22  Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients. (Abstract #6530)
C. Gardin, R. Itzykson, S. Thépot, C. Recher, A. Marfaing, O. Beyne-Rauzy, S. Boehrer, F. Dreyfus, P. Fenaux, H. Dombret, for the GFM and ALFA Groups

Brd. 23  Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. (Abstract #6531)
M. R. Baer, S. L. George, B. L. Sanford, R. M. Stone, G. Marcucci, R. J. Mayer, R. A. Larson

Brd. 24  Treatment of acute myeloid leukemia (AML) in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT). (Abstract #6532)
Monday, June 7, 2010

3:00 PM - 4:15 PM
EDUCATION SESSIONS

Acute Leukemia: Integration of Novel Diagnostic and Therapeutic Measures
Location: E354a
CME credit: 1.25
Track(s): Leukemia, Myelodysplasia, and Transplantation

Richard F. Schlenk, MD—Chair
University of Ulm
Molecular/Cytogenetic Prognostication in AML and Its Impact on Treatment

Ivana Gojo, MD
University of Maryland
Upfront and Salvage Therapy in AML: What’s New?

Anjali S. Advani, MD
Cleveland Clinic
An Update on Treatment of Adult ALL

Caring for the Child with Brain Cancer
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Central Nervous System Tumors; Health Services Research

Stewart Goldman, MD—Chair
Children’s Memorial Hospital
Relapsed Pediatric Central Nervous System Tumors in 2010: Strategies and New Agents

Amar J. Gajjar, MD
St. Jude Children’s Research Hospital
High-dose Chemotherapy for Malignant Brain Tumors: What Have We Learned in the Past Two Decades and What Does the Future Hold for This Therapy?

Thomas E. Merchant, DO, PhD
St. Jude Children’s Research Hospital
Understanding Late Effects of Irradiation and Measures to Reduce Dose to Normal Tissue

Integrated Considerations in the Management of the Patient with Advanced Ovarian Cancer
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Gynecologic Cancer

Elise C. Kohn, MD—Chair
National Cancer Institute
The Promise and Toxicity of Novel Targeted Therapies in Ovarian Cancer: Hope or Hype?

Andreas Du Bois, MD, PhD
HSK, Dr. Horst Schmidt Klinik
Balancing Biologic Behavior with Surgical Therapy

Michael Friedlander, MD, PhD
The University of New South Wales
Does Palliative Chemotherapy Palliate? Assessment of Symptom Benefit in Recurrent Ovarian Cancer
Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness
Location: S404
CME credit: 1.25
Track(s): Lung Cancer; General Oncology

Tom Stinchcombe, MD—Chair
University of North Carolina
Maintenance Therapy for Advanced NSCLC Is Not Standard of Care

Tracey L. Evans, MD
University of Pennsylvania
Maintenance Therapy for Advanced NSCLC Is Standard of Care

Scott Ramsey, MD, PhD
Fred Hutchinson Cancer Research Center
Cost Effectiveness in Lung Cancer Trials and Treatment

Navigating Conflicts of Interest in Medicine and Research: Proper Interactions with Industry in a Time of Increasing Scrutiny
Location: S100b
CME credit: 1.25
Track(s): Ethics

Richard M. Goldberg, MD—Chair
University of North Carolina
Conflicts of Interest: The Physician’s and ASCO’s Viewpoints

Bernard Lo, MD
University of California, San Francisco
Conflicts of Interest in Medicine: An Ethicist’s View of the Changing Landscape

Stephen M. Weiner, JD
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.
Conflicts of Interest: The Public Policy, the Science, and the Professional Standards

Physician Burnout: How to Survive and Stay Happy in Oncology
Location: E353
CME credit: 1.25
Track(s): Professional Development

Tait D. Shanafelt, MD—Chair
Mayo Clinic
Physician Burnout: What Is It? What Are the Consequences, and How Do We Recognize It in Ourselves or Our Colleagues?

Charles M. Balch, MD, FACS
The Johns Hopkins University
Recognizing Risk Factors for Physician Burnout and Developing Strategies to Intervene

Amanda Kracen, MS
Virginia Commonwealth University
Prevention of Physician Burnout
Monday, June 7, 2010

3:00 PM - 4:15 PM
CLINICAL PROBLEMS IN ONCOLOGY

Neuro-oncology for Medical Oncologists (C15)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Central Nervous System Tumors

Lisa Marie DeAngelis, MD—Chair
Memorial Sloan-Kettering Cancer Center
Neurology Perspective

Roger Stupp, MD
University of Lausanne Hospital
Medical Oncology Perspective
3:00 PM - 4:30 PM
CLINICAL SCIENCE SYMPOSIUM

Circulating Tumor Cells in Breast Cancer: Where Are We?
Location: N Hall B1
*CME credit: 1.5
Track(s): Breast Cancer

Suzanne D. Conzen, MD—Co-Chair
The University of Chicago
Minetta C. Liu, MD—Co-Chair
Georgetown University Hospital

Discussion
3:00 PM  John W. Park, MD
University of California, San Francisco

3:15 PM  Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. (Abstract #1000)
A. Giordano, M. Giuliano, L. Hsu, B. C. Handy, N. T. Ueno, E. Andreopoulou, R. H. Alvarez, V. Valero, G. N. Hortobagyi, M. Cristofanilli

3:30 PM  Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. (Abstract #1001)

3:45 PM  Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results. (Abstract #1002)

4:00 PM  Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict increased risk for relapse: The SUCCESS trial. (Abstract #1003)

Discussion
4:15 PM  Lyndsay Harris, MD (Abstracts #1000–1003)
Yale University
3:00 PM - 5:30 PM
ORAL ABSTRACT SESSION

Lung Cancer—Metastatic
Location: E Hall D2
CME credit: 2.5
Track(s): Lung Cancer

Nithya Ramnath, MD—Co-Chair
University of Michigan
Lecia Sequist, MD—Co-Chair
Massachusetts General Hospital

3:00 PM Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. (Abstract #7503)

3:15 PM TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. (Abstract #7504)
S. Lee, R. Rudd, I. Khan, S. Upadhyay, C. R. Lewanski, S. Falk, G. Skailes, R. Partridge, Y. Ngai, C. Boshoff

Discussion
3:30 PM Fadlo Raja Khuri, MD (Abstracts #7503–7505)
Winship Cancer Institute at Emory University
EGFR Inhibitors: Are We Done Yet?

3:45 PM Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7506)

4:00 PM Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. (Abstract #7507)

4:15 PM International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial. (Abstract #7508)
C. Gridelli, F. Ciardiello, R. Feld, C. A. Butts, V. Gebbia, G. Genestreti, A. G. Favaretto, R. Wierzbicki, C. Gallo, F. Perrone, on behalf of the TORCH Investigators

Discussion
4:30 PM Gregory Peter Kalemkerian, MD (Abstracts #7506–7508)
University of Michigan
Maintenance Therapy: Are We There Yet?

4:45 PM Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial. (Abstract #7509)
J. S. Temel, J. Greer, E. Gallagher, S. Admane, W. F. Pirl, V. Jackson, C. Dahlin, A. Muzikansky, J. Jacobsen, T. J. Lynch
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). (Abstract #LBA7511)

Discussion
Raffit Hassan, MD (Abstract #7509–LBA7511)
National Cancer Institute
Optimizing Care in Advanced Lung Cancer
3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Gastrointestinal (Noncolorectal) Cancer
Location: E Hall D1
CME credit: 3
Track(s): Gastrointestinal (Noncolorectal) Cancer

Theodore S. Hong, MD—Co-Chair
Massachusetts General Hospital
Alexandria T. Phan, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center

3:00 PM Effect of preoperative concurrent survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. (Abstract #4004)

3:15 PM Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. (Abstract #4005)

3:30 PM CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. (Abstract #4006)

3:45 PM AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). (Abstract #LBA4007)

Discussion
4:00 PM Charles Fuchs, MD (Abstracts #4004–LBA4007)
Dana-Farber Cancer Institute

4:15 PM Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. (Abstract #4008)
S. Qin, Y. Bai, S. Ye, J. Fan, H. Lim, J. Y. Cho, S. Thongprasert, Y. Chao, K. Rau, Y. Sun

4:30 PM Effect of IFN therapy and amino acid substitutions in the hepatitis C virus (HCV) core region on hepatocarcinogenesis in HCV-related cirrhotic patients. (Abstract #4009)

Discussion
4:45 PM Timothy Pawlik, MD, MPH (Abstracts #4008–4009)
The Johns Hopkins University

5:00 PM Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. (Abstract #4010)


Discussion

5:45 PM  Margaret A. Tempero, MD (Abstracts #4010–LBA4012) University of California, San Francisco
3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Head and Neck Cancer
Location: E354b
CME credit: 3
Track(s): Head and Neck Cancer

Søren M. Bentzen, MD—Co-Chair
University of Wisconsin
A. Dimitrios Colevas, MD—Co-Chair
Stanford University

3:00 PM  Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). (Abstract #5503)

3:15 PM  Phase II trial of sunitinib in medullary thyroid cancer (MTC). (Abstract #5504)

3:30 PM  Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5505)

3:45 PM  An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE). (Abstract #5506)
J. H. Machiels, S. Subramanian, A. Ruzsa, G. Repassy, I. Lifrenko, A. Flygare, P. Sorensen, E. Ehnrooth, O. Baadsgaard, P. M. Clement

Discussion
4:00 PM  A. Dimitrios Colevas, MD (Abstracts #5503–LBA5506)
Stanford University

4:15 PM  A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. (Abstract #5507)

4:30 PM  Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group. (Abstract #5508)

Discussion
4:45 PM  Søren M. Bentzen, MD (Abstracts #5507–5508)
University of Wisconsin

5:00 PM  Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. (Abstract #5509)
Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003. (Abstract #5510) M. L. Gillison, Q. Zhang, K. Ang, K. K. Fu, M. E. Hammond, R. Jordan, A. Trotti, S. Spencer, M. Rotman, C. H. Chung

PTEN as prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. (Abstract #5519) M. P. Sniertura, M. Jaworska, J. Mlynarczyk-Liszka, W. Piglowski, G. Wozniak, D. Lange, R. Suwinski

Discussion

Ezra E. W. Cohen, MD, FRCPC (Abstracts #5509, 5510, 5519) The University of Chicago
3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Tumor Biology
Location: S100a
CME credit: 3
Track(s): Tumor Biology

Robert Arthur Kratzke, MD—Co-Chair
University of Minnesota
Jorge Reis-Filho, MD, PhD—Co-Chair
Breakthrough Breast Cancer Research Centre

3:00 PM  Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors. (Abstract #10504)
S. D. Hsu, M. K. Kim, A. Foye, A. Silvestri, H. K. Lyerly, M. Morse, E. Petricoin III, P. G. Febbo

3:15 PM  Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. (Abstract #10505)
E. Schütz, J. Beck, W. M. Mitchell, H. B. Urnovitz

3:30 PM  Use of integrated genomic analysis to evaluate BRCA-associated protein 1 (BAP1) as a mutated gene in malignant pleural mesothelioma (MPM). (Abstract #10506)

3:45 PM  Characterizing the clinical relevance of epithelial-mesenchymal transition (EMT) in human tumors. (Abstract #10507)
K. A. Higgins, K. S. Walters, A. Potti

Discussion
4:00 PM  David N. Hayes, MD (Abstracts #10504–10507)
University of North Carolina

4:15 PM  Pre-existence of invasive cells in breast ductal carcinoma in situ. (Abstract #10508)

4:30 PM  Relationship of breast cancer stem cells (CSCs) and chronic O2/glucose deprivation (C-OGD). (Abstract #10509)
M. Quintela-Fandino, E. Arpaia, R. Cairns, H. Blaser, M. W. Tusche, R. Colomer, A. Rufini, A. Wakeham, T. W. Mak

Discussion
4:45 PM  Sridhar Ramaswamy, MD (Abstracts #10508–10509)
Massachusetts General Hospital

5:00 PM  Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. (Abstract #10510)

5:15 PM  PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. (Abstract #10511)

5:30 PM  Protein signal pathway mapping of human breast cancer from I-SPY: Correlations with response and genomic subtyping. (Abstract #10512)

Discussion
5:45 PM  James M. Ford, MD (Abstracts #10510–10512)
Stanford University Medical Center
4:45 PM - 6:00 PM
SPECIAL SESSION

From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation—An ASCO/American Association for Cancer Research Joint Session
Location: S404
CME credit: 1.25
Track(s): Special Session; Cancer Genetics

Douglas W. Blayney, MD—Co-Chair
University of Michigan
Welcome and Introduction

Tyler Jacks, PhD—Co-Chair
Massachusetts Institute of Technology Center for Cancer Research
Conclusion

Stephen B. Gruber, MD, PhD
University of Michigan
Next-generation Sequencing and Clinical Applications

Jeffrey M. Trent, PhD
TGen/VARI
System Medicine in Cancer Therapeutics

A. John Iafrate, MD, PhD
Massachusetts General Hospital
Challenges in Clinical Tumor Genotyping Applications
Monday, June 7, 2010

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Biology and Treatment of Breast Cancer in Survivors of Pediatric Cancer
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Breast Cancer

Tara O. Henderson, MD, MPH—Chair
The University of Chicago
Overview of Breast Cancer Incidence in Pediatric Cancer Survivors with a Focus on Education and Screening

Gail E. Tomlinson, MD, PhD
University of Texas Health Science Center at San Antonio
Update on the Genetics of Pediatric Survivors Who Develop Breast Cancer and Tumor Biology

Melanie R. Palomares, MD
City of Hope National Medical Center
Use of Tamoxifen in Hodgkin’s Patients for the Prevention of Breast Cancer

Decision-making Capacity: When Should Oncologists Honor Refusals of Treatment by Individuals with Diminished Capacity?
Location: S100b
CME credit: 1.25
Track(s): Ethics; Geriatric Oncology; Pediatric Oncology

Rebecca D. Pentz, PhD—Chair
Winship Cancer Institute at Emory University
Cancer Patients with Diminished Capacity: Ethical Dilemmas and Strategies for Resolving Them

Scott Y. Kim, MD, PhD
University of Michigan
Overview of Criteria for and Methods of Determining Capacity

Steven Joffe, MD, MPH
Dana-Farber Cancer Institute
Lessons from Pediatrics

Oral Chemotherapy: A Hard Pill to Swallow
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Developmental Therapeutics; Health Services Research; Patient and Survivor Care

Merrill J. Egorin, MD—Chair
University of Pittsburgh Cancer Institute
General Issues Relevant to Oral Chemotherapy and Patient Health Care Literacy

Jan Hendrik Beumer, PhD, PharmD
University of Pittsburgh
Drug-Drug and Food-Drug Interactions Relevant to Oral Chemotherapy Agents

Ann H. Partridge, MD
Dana-Farber Cancer Institute
Adherence and Persistence (Or Lack Thereof) with Oral Agents: The Scope of the Problem—What the Data Say
4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY

Advances in Hereditary Pancreatic Cancer (C13)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Cancer Genetics; Gastrointestinal (Noncolorectal) Cancer

Teresa Brentnall, MD—Chair
University of Washington
Pancreatic Cancer Screening

Ralph Hruban, MD
The Johns Hopkins University
Genetics of Hereditary Pancreatic Cancer

Sean J. Mulvihill, MD
University of Utah
Surgical Management and Hereditary Pancreatic Cancer

6:30 PM - 9:00 PM
SPECIAL SESSION

Answers to Cancer: Annual Meeting Public Forum
Location: Sheraton Chicago Hotel & Towers, Chicago Ballroom 10
CME credit: 0
Track(s): Special Session
Tuesday, June 8, 2010

7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY

Highlights of the Day III
Location: E Hall D1
CME credit: 1.5
Track(s): Special Session; General Oncology

Kathy Miller, MD—Chair
Indiana University

7:30 AM
Kathy Miller, MD
Indiana University
Breast Cancer—Local-Regional and Adjuvant Therapy

7:45 AM
Charles M. Rudin, MD, PhD
The Johns Hopkins University
Lung Cancer—Metastatic

8:00 AM
Gary K. Schwartz, MD
Memorial Sloan-Kettering Cancer Center
Sarcoma

8:15 AM
Charles D. Blanke, MD
University of British Columbia/British Columbia Cancer Agency
Gastrointestinal (Noncolorectal) Cancer

8:30 AM
Everett E. Vokes, MD
The University of Chicago
Head and Neck Cancer

8:45 AM
To be determined
Leukemia, Myelodysplasia, and Transplantation
8:00 AM - 9:15 AM
EDUCATION SESSIONS

Building Bridges for Successful Breast Cancer Survivorship Care
Location: E354a
CME credit: 1.25
Track(s): Breast Cancer; Geriatric Oncology; Patient and Survivor Care

Claire Frances Snyder, PhD—Chair
The Johns Hopkins University School of Medicine
Coordination of Care in Breast Cancer Survivors: An Overview

Sharon Hermes Giordano, MD
University of Texas M. D. Anderson Cancer Center
Impact of Comorbid Conditions on Breast Cancer Survivorship

Larissa Nekhlyudov, MD, MPH
Harvard Medical School
Information and Training Needs of Primary Care Providers to Promote Quality Care for Breast Cancer Survivors

Eva Grunfeld, MD, D.Phil
University of Toronto
Communication Strategies, Models, and Tools for Partnerships between Primary Care and Oncology Care to Provide Quality Breast Cancer Survivorship Care

Comparative Effectiveness Research in Oncology: Opportunities and Challenges
Location: S404
CME credit: 1.25
Track(s): Health Services Research; Patient and Survivor Care

Neal J. Meropol, MD—Chair
University Hospitals Case Medical Center
Comparative Effectiveness Research to Address Uncertainties in Oncology Practice

Gary H. Lyman, MD, MPH
Duke Comprehensive Cancer Center
Comparative Effectiveness Research: What Is It and Why Is It Important?

Jerome Seidenfeld, PhD
American Society of Clinical Oncology
Methods of Comparative Effectiveness Research in Oncology

Developing Drugs in Special Populations: Organ Dysfunction Studies
Location: E354b
CME credit: 1.25
Track(s): Developmental Therapeutics; Clinical Trials; Gastrointestinal (Noncolorectal) Cancer

Daniel Mulkerin, MD—Chair
University of Wisconsin
Renal Dysfunction Studies

Ghassan K. Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
Liver Dysfunction Studies

Shiew-Mei Huang, PhD
U.S. Food and Drug Administration
Regulatory Considerations for Organ Dysfunction Studies
Tuesday, June 8, 2010

Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment
Location: E353
CME credit: 1.25
Track(s): Lung Cancer; General Oncology

Harvey I. Pass, MD—Chair
New York University School of Medicine
Lobectomies for Small or Noninvasive Lung Cancers: Going, Going, Gone?

Scott Shofer, MD, PhD
Duke University Medical Center
Nonsurgical Staging of the Mediastinum

Andrea Bezjak, MD
Princess Margaret Hospital
Outcome of Early-stage NSCLC Treated with SBRT

Localized Prostate Cancer: Reducing Mortality and Burden of Therapy
Location: E Arie Crown Theater
CME credit: 1.25
Track(s): Genitourinary Cancer; Geriatric Oncology; Health Services Research

Andrew J. Stephenson, MD—Chair
Cleveland Clinic
Everything You Need to Know about Prostate Cancer Screening

David C. Miller, MD
University of Michigan
Elevated PSA: Biopsy or Chemoprevention?

Laurence Klotz, MD, FRCSC
Stony Brook University Cancer Center
What Is “Active Surveillance” and What Is Its Role in Management Today?

Omics: Toward Personalizing Care
Location: S100a
CME credit: 1.25
Track(s): Tumor Biology

Dimitrios Spentzos, MD—Chair
Beth Israel Deaconess Medical Center
From High-throughput Transcriptomics to Personalized Cancer Care

Kate Nathanson, MD, FACP
University of Pennsylvania
The Genomics and Genetics of Melanoma

Gordon B. Mills, MD
University of Texas M. D. Anderson Cancer Center
Proteomics Pathway Analysis for Tumor Classification and Therapy (Focus on Breast and Ovary)
Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice
Location: S100b
CME credit: 1.25
Track(s): Clinical Trials; Developmental Therapeutics

Christopher M. Booth, MD—Chair
Queen’s University
Translating Clinical Trial Results into Societal Benefit: The Role of Population-based Outcome Studies

Carlos Cordon-Cardo, MD, PhD
Columbia University
Use of Molecular Markers as Surrogate Endpoints in Clinical Trials

Mary W. Redman, PhD
Fred Hutchinson Cancer Research Center
Design of Clinical Trials to Achieve Meaningful Results
Tuesday, June 8, 2010

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY

Debates in Adjuvant Therapy: Chemotherapy versus Observation for Node-negative Non-small Cell Lung Cancer and Radiotherapy versus Observation for Node-positive Non-small Cell Lung Cancer (C17)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Lung Cancer

Heather A. Wakelee, MD—Chair
Stanford University
Neoadjuvant versus Adjuvant Chemotherapy for Early-stage Non-small Cell Lung Cancer: Does Pre versus Post Really Matter?

Katherine Pisters, MD
University of Texas M. D. Anderson Cancer Center
Is There a Role for Adjuvant Chemotherapy for Node-negative Non-small Cell Lung Cancer?

Christopher Ryan Kelsey, MD
Duke University Medical Center
When Should One Consider Adjuvant Radiotherapy for Resected Non-small Cell Lung Cancer?
Gastrointestinal (Colorectal) Cancer
Display Time: 8:00 AM - 12:00 PM
Display Location: S403
Discussion Time: 11:00 AM - 12:00 PM
Discussion Location: S406 (Vista Room)
CME credit: 1
Track(s): Gastrointestinal (Colorectal) Cancer

Richard Herrmann, MD—Co-Chair
University Hospital
John S. Kauh, MD—Co-Chair
Winship Cancer Institute at Emory University

Discussion
11:00 AM  Bruce D. Minsky, MD (Abstracts #3509–3512)
The University of Chicago

Discussion
11:15 AM  Patrick Johnston, MD, PhD (Abstracts #3513–3519)
Queen’s University Belfast

Discussion
11:30 AM  To be determined

Discussion
11:45 AM  Wells A. Messersmith, MD (Abstracts #3525–3535)
University of Colorado

Brd. 1  A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).
(Abstract #3509)

Brd. 2  Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial. (Abstract #3510)

Brd. 3  Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. (Abstract #3511)

Brd. 4  Identification of localized rectal cancer (RC) patients (pts) who may not require preoperative (preop) chemoradiation (CRT). (Abstract #3512)

Brd. 5  Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. (Abstract #3513)

Brd. 6  Genome-wide association study for germline prognostic markers in colorectal cancer. (Abstract #3514)
Tuesday, June 8, 2010

Brd. 7 Metachronous colorectal cancer in mismatch repair gene mutation carriers: The advantage of more extensive surgery. (Abstract #3515)  
S. Parry, A. Win, F. Macrae, B. Parry, N. M. Lindor, S. Gallinger, J. L. Hopper, M. A. Jenkins, Colon Cancer Family Registry

Brd. 8 Use of a combination of prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. (Abstract #3516)  

Brd. 9 Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. (Abstract #3517)  
G. Hutchins, K. Southward, K. Handley, L. Magill, C. Beaumont, S. Richman, M. T. Seymour, D. J. Kerr, R. G. Gray, P. Quirke, for the QUASAR Collaborative Group

Brd. 10 Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC). (Abstract #3518)  

Brd. 11 DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials. (Abstract #3519)  

Brd. 12 Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials. (Abstract #3520)  
C. D. Blanke, B. M. Bot, D. M. Thomas, A. Bleyer, C. Kohne, M. T. Seymour, A. De Gramont, R. M. Goldberg, D. J. Sargent, LIVESTRONG Young Adult Alliance (LSYAA)

Brd. 13 Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS). (Abstract #3521)  

Brd. 14 FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. (Abstract #3522)  
C. Tournigand, T. Andre, J. Bachet, L. Teixeira, C. Boni, P. R. Clingan, T. Hickish, J. Tabernero, A. De Gramont, for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators and GERCOR

Brd. 15 Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset. (Abstract #3523)  
D. J. Sargent, G. A. Yothers, E. Green, C. D. Blanke, M. J. O’Connell, R. Labianca, A. Bleyer, A. De Gramont, D. M. Thomas, A joint project of the LIVESTRONG Young Adult Alliance and the ACCENT Collaborative Group

Brd. 16 Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. (Abstract #3524)  
Brd. 17  Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial. (Abstract #3525)

Brd. 18  A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. (Abstract #3527)

Brd. 19  Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (Abstract #3528^)
J. Douillard, J. Cassidy, J. Jassem, F. Rivera, I. Kocáková, W. Rogowski, J. R. Canon, E. P. Yanez, F. Xu, J. L. Gansert

Brd. 20  Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). (Abstract #3529^)

Brd. 21  Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). (Abstract #3530)

Brd. 22  Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC). (Abstract #3531)

Brd. 23  A randomized phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results. (Abstract #3532)

Brd. 24  DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer. (Abstract #3533)

Brd. 25  Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC). (Abstract #3535)
I. Altomare, K. B. Russell, H. E. Uronis, M. Morse, S. D. Hsu, Y. Zafar, J. C. Bendell, A. Starodub, W. Honeycutt, H. Hurwitz
Tuesday, June 8, 2010

8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION

Patient and Survivor Care
Display Time: 8:00 AM - 12:00 PM
Display Location: E450a
Discussion Time: 11:00 AM - 12:00 PM
Discussion Location: E353
CME credit: 1
Track(s): Patient and Survivor Care

Amy Pickar Abernethy, MD—Co-Chair
Duke University Medical Center
Janet Lee Abraham, MD—Co-Chair
Dana-Farber Cancer Institute

Discussion
11:00 AM Michael Fisch, MD, MPH (Abstracts #9017–9022)
University of Texas M. D. Anderson Cancer Center

Discussion
11:15 AM Vered Stearns, MD (Abstracts #9023–9028)
The Johns Hopkins University

Discussion
11:30 AM Charles L. Loprinzi, MD (Abstracts #9029–9034)
Mayo Clinic

Discussion
11:45 AM Frederick J. Meyers, MD (Abstracts #9035–9041)
University of California, Davis

Brd. 1 Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. (Abstract #9017)

Brd. 2 Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). (Abstract #9018)
P. J. Atherton, K. N. Burger, C. L. Loprinzi, R. C. Miller, A. Jatoi, J. A. Sloan

Brd. 3 CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. (Abstract #9019)

Brd. 4 Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial. (Abstract #9020)
R. M. Navari, S. E. Gray, A. C. Kerr

Brd. 5 Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. (Abstract #9021^)
S. M. Grunberg, D. T. Chua, A. Maru, S. DeVandry, J. A. Boice, J. Hardwick, A. Taylor, A. Carides, F. Roila, J. Herrstedt, PN017 Study Group

Brd. 6 To be determined

Brd. 7 A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. (Abstract #9023)
L. Bordelreau, O. Jugovic, M. Ennis, K. I. Pritchard, D. Warr, R. Haq, C. L. Loprinzi, P. J. Goodwin

Brd. 8 A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. (Abstract #9024)
Tuesday, June 8, 2010

Brd. 9  Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients. (Abstract #9025)  Y. Cheng, M. Takagi, A. Milbourne, R. E. Champlin, N. T. Ueno

Brd. 10  Value of early referral to improve fertility preservation outcomes in women with breast cancer. (Abstract #9026)  K. Oktay, S. Lee, S. Ozkavukcu, E. Heytens, R. M. Alappat

Brd. 11  Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study. (Abstract #9027)  S. M. Alibhai, S. Marzouk, G. Naglie, I. Tannock, G. A. Tomlinson, N. Timilshina, D. Stewart, N. Fleshner, P. R. Warde, S. Duff Canning


Brd. 13  Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy. (Abstract #9029)  T. J. Smith, P. J. Coyne, P. Dodson, G. L. Parker, V. Ramakrishnan


Brd. 17  Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy. (Abstract #9033)  T. A. Giever, K. M. Adwan, Y. Cheng, E. L. Atallah


Brd. 20  Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors. (Abstract #9036)  R. Soffietti, R. P. Mueller, M. U. Abacioglu, S. Villa, F. Fauchon, B. Baumert, L. Fariselli, G. Tridello, M. Kocher, A. Bottomley

Tuesday, June 8, 2010

Brd. 22  Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy. (Abstract #9038)
        I. T. Lennes, J. S. Temel, C. Hoedt, P. J. Saylor, T. M. Ortiz, S. Admane, E. B. Lamont

Brd. 23  Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer. (Abstract #9039)

Brd. 24  Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer. (Abstract #9040)

Brd. 25  Symptom burden in cancer survivors 1 year after diagnosis: A report from the American Cancer Society’s studies of cancer survivors. (Abstract #9041)
        Q. Shi, T. Smith, J. D. Michonski, K. Stein, C. Kaw, C. S. Cleeland
8:00 AM - 12:00 PM
POSTER DISCUSSION SESSION

Sarcoma
Display Time: 8:00 AM - 12:00 PM
Display Location: S103
Discussion Time: 11:00 AM - 12:00 PM
Discussion Location: S100a
CME credit: 1
Track(s): Sarcoma

Mark Agulnik, MD—Co-Chair
Northwestern University
Anette Duensing, MD—Co-Chair
University of Pittsburgh School of Medicine

Discussion
11:00 AM  Ian Robert Judson, MD (Abstracts #10009–10014)
Cancer Research UK

Discussion
11:15 AM  Margaret von Mehren, MD (Abstracts #10015–10020)
Fox Chase Cancer Center

Discussion
11:30 AM  Rashmi Chugh, MD (Abstracts #10021–10026)
University of Michigan

Discussion
11:45 AM  James E. Butrynski, MD (Abstracts #10027–10033)
Dana-Farber Cancer Institute

Brd. 1  Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. (Abstract #10009)

Brd. 2  Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma. (Abstract #10010)

Brd. 3  Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. (Abstract #10011)

Brd. 4  Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). (Abstract #10012)

Brd. 5  Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF). (Abstract #10013)

Brd. 6  Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS). (Abstract #10014)
E. Palassini, S. Stacchiotti, T. Negri, S. Brich, A. Marrari, C. Morosi, F. Crippa, A. Gronchi, S. Pilotti, P. G. Casali

Brd. 7  Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. (Abstract #10015)
Tuesday, June 8, 2010

Brd. 8  Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib. (Abstract #10016)
        K. Kim, M. Ryu, C. Yoo, B. Ryoo, D. Choi, H. Chang, J. Lee, T. Kim, M. Beck, Y. Kang

Brd. 9  Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. (Abstract #10017^)

Brd. 10 Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors. (Abstract #10018)
        P. Rutkowski, E. Bylina, A. Wozniak, Z. Nowecki, C. Osuch, M. Matlok, W. Michej, A. Pienkowski, H. Joensuu, W. Ruka

Brd. 11 Correlation of the topography of Kit exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group. (Abstract #10019)

Brd. 12 Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. (Abstract #10020)
        G. Floris, R. Sciot, A. Wozniak, C. Deroose, P. Vermaelen, B. Dewaele, M. Debiec-Rychter, P. Schoffski

Brd. 13 Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. (Abstract #10021)

Brd. 14 Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. (Abstract #10022)

Brd. 15 A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas. (Abstract #10023)

Brd. 16 Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study. (Abstract #10024)
        X. Garcia del Muro, A. Lopez-Pousa, J. Martin Broto, R. Cubedo, L. Jimenez Colomo, O. Gallego, M. Provencio-Pullala

Brd. 17 Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. (Abstract #10025)

Brd. 18 A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS). (Abstract #10026)
Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study. (Abstract #10027)
B. L. Samuels, W. D. Tap, S. Patel, M. von Mehren, J. T. Hamm, P. E. Kaiser, S. Schuetze, J. Li, E. Bayever, G. D. Demetri

Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose. (Abstract #10028)

Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr). (Abstract #10029)

Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions. (Abstract #10030)

Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). (Abstract #10031)

Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment—A French Sarcoma Group study. (Abstract #10032)

Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (Abstract #10033)
A. Le Cesne, I. Ray-Coquard, N. Bin Bui, A. Adenis, M. Rios Sr., F. Duffaud, F. Bertucci, S. Chabaud, J. Emile, J. Blay
Tuesday, June 8, 2010

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Lung Cancer—Local-Regional and Adjuvant Therapy
Display Time: 8:00 AM - 12:00 PM
Display Location: E450b
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E354b
CME credit: 1
Track(s): Lung Cancer

Joseph Kamel Salama, MD—Co-Chair
The University of Chicago
Corey J. Langer, MD—Co-Chair
University of Pennsylvania

Discussion
12:00 PM  John Heymach, MD, PhD (Abstracts #7008–7013)
University of Texas M. D. Anderson Cancer Center
Biomarkers in Early-stage Non-small Cell Lung Cancer: Has the Future Arrived?

Discussion
12:15 PM  Jeffrey Bogart, MD (Abstracts #7014–7016)
SUNY Upstate Medical University
New Directions for Radiotherapy in Non-small Cell Lung Cancer

Discussion
12:30 PM  William Roy Smythe, MD (Abstracts #7017–7020)
Texas A&M University
Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma

Discussion
12:45 PM  Jessica S. Donington, MD (Abstracts #7021–7026)
New York University School of Medicine
Alternate Approaches to Advanced, Resectable Non-small Cell Lung Cancer

Brd. 1 Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. (Abstract #7008)

Brd. 2 Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma. (Abstract #7009)

Brd. 3 Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy. (Abstract #7010)
K. W. Wagner, Y. Ye, J. Lin, A. A. Vaporiaiyen, J. A. Roth, M. R. Spitz, X. Wu

Brd. 4 Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. (Abstract #7011)

Brd. 5 Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression. (Abstract #7012)
Y. Bellili, A. M. Burke, I. S. Chan, W. Mostertz, A. Potti

Brd. 6 KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424. (Abstract #7013)
Brd. 7 Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC). (Abstract #7014)

Brd. 8 A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative Lung Research Group. (Abstract #7015)

Brd. 9 Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations. (Abstract #7016)
R. H. Mak, E. Doran, A. Muzikansky, J. Kang, N. C. Choi, H. Willers, D. M. Jackman, L. V. Sequist

Brd. 10 Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. (Abstract #7017)

Brd. 11 Adoption of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes study. (Abstract #7018)
C. M. Booth, F. A. Shepherd, Y. Peng, G. E. Darling, G. Li, W. Kong, W. J. Mackillop

Brd. 12 A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result. (Abstract #7019)
H. Jie, Z. Xiangru, B. Han, Y. Liu, Q. Wang, S. Xu, Y. Sheng, Q. Li, S. Wu, C. Chen

Brd. 13 IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. (Abstract #7020)
G. Zalcman, J. Margery, A. Scherpereel, P. Astoul, I. Monnet, B. J. Milleron, L. M. Paulé, M. André, D. Moro-Sibilot, J. Mazieres, on behalf of IFCT

Brd. 14 Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). (Abstract #7021)

Brd. 15 The impact of stage migration on survival after resection in the UICC 7 TNM classification of lung cancer. (Abstract #7022)
J. P. Van Meerbeeck, K. Chansky, P. Goldstraw, IASLC Staging Committee

Brd. 16 Prognostic significance of the number of tumor (+) N2 nodes in N2 stage IIIA non-small cell lung cancer after curative resection. (Abstract #7023)
C. Yoo, S. Yoon, D. Lee, C. Suh, J. Lee, S. Park, D. Kim, Y. Kim, W. Kim, S. Kim

Brd. 17 RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC. (Abstract #7024)
Tuesday, June 8, 2010

Brd. 18  Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806).  (Abstract #7025)

Brd. 19  Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival for patients with marginally resectable SST. (Abstract #7026)
R. Komaki, X. Wei, P. Allen, J. A. Roth, S. Swisher, D. C. Rice, G. L. Walsh, F. V. Fossella, J. J. Erasmus, J. D. Cox
9:00 AM - 12:00 PM  
SPECIAL SESSION

Advancing Pain and Palliative Care Globally for Patients with Cancer  

Location: S504  
CME credit: 3  
Track(s): Special Session; International; Patient and Survivor Care

**Jamie H. Von Roenn, MD—Chair**  
Northwestern University

**David Hill, PhD**  
International Union Against Cancer  
*Global Access to Cancer Pain Initiative*

**Joe B. Harford, PhD**  
National Cancer Institute/National Institutes of Health  
*International Activities in Cancer and Palliative Care*

**James F. Cleary, MD**  
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center  
*International Drug Policy and Cancer Pain Control*

**Frank Douglas Ferris, MD**  
Institute for Palliative Medicine at San Diego Hospice  
*International Education Activities in Palliative Care*

**Eduardo Bruera, MD**  
University of Texas M. D. Anderson Cancer Center  
*Panel: Palliative Care and Cancer in the Future*

**Kathleen M. Foley, MD**  
Memorial Sloan-Kettering Cancer Center  
*Panel: Palliative Care and Cancer in the Future*

**Aziza T. Shad, MD**  
Georgetown University  
*Panel: Palliative Care and Cancer in the Future*
Tuesday, June 8, 2010

9:30 AM - 10:45 AM
EDUCATION SESSIONS

Closing the Loop: Evidence, Guidelines, Reporting, and Quality
Location: S100a
CME credit: 1.25
Track(s): Health Services Research; Patient and Survivor Care

Sandra L. Wong, MD, MS—Chair
University of Michigan Health Systems
Barriers to Quality Improvement Initiatives

Craig Earle, MD
Sunnybrook Health Science Center
Quality Reporting, Measurement, and Feedback

Gary H. Lyman, MD, MPH
Duke Comprehensive Cancer Center
Distilling Research and Evidence into Opportunities for Quality Improvement

Supportive Care for Patients with Non-small Cell Lung Cancer
Location: E353
CME credit: 1.25
Track(s): Lung Cancer; Central Nervous System Tumors; General Oncology; Patient and Survivor Care

Minesh P. Mehta, MD—Chair
University of Wisconsin
Management of Brain Metastases in Lung Cancer Patients

David J. Feller-Kopman, MD
The Johns Hopkins University
Management of Dyspnea and Pleural Effusion in Patients with Lung Cancer

Vera Hirsh, MD
McGill University Health Centre
Ancillary Therapy for Bone Metastases in the Age of Bisphosphonates
9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Breast Cancer—Metastatic
Location: E Hall D1
CME credit: 3
Track(s): Breast Cancer

Herve R. Bonnefoi, MD—Co-Chair
Bergonié Institute, Bordeaux University
Elizabeth Claire Dees, MD—Co-Chair
University of North Carolina Lineberger Comprehensive Cancer Center

9:30 AM A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. (Abstract #CRA1004)

Discussion
9:45 AM
Harold J. Burstein, MD, PhD (Abstract #CRA1004)
Dana-Farber Cancer Institute

10:00 AM Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). (Abstract #LBA1010)

10:15 AM Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). (Abstract #LBA1011)

Discussion
10:30 AM
Kimberly L. Blackwell, MD (Abstracts #LBA1010–LBA1011)
Duke University Medical Center

10:45 AM A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). (Abstract #1005)

11:00 AM Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). (Abstract #1006)

Discussion
11:15 AM
Hope S. Rugo, MD (Abstracts #1005–1006)
University of California, San Francisco

11:30 AM Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. (Abstract #1007)

11:45 AM Should liver metastases of breast cancer be biopsied to improve treatment choice? (Abstract #CRA1008)
Tuesday, June 8, 2010

12:00 PM  Discordance in hormone receptor status in breast cancer during tumor progression. (Abstract #1009)

Discussion
12:15 PM  Andrea L. Richardson, MD, PhD (Abstracts #1007–1009)
Brigham and Women’s Hospital
9:30 AM - 12:30 PM  
**ORAL ABSTRACT SESSION**

**Developmental Therapeutics—Clinical Pharmacology and Immunotherapy**

**Location:** E354a  
**CME credit:** 3  
**Track(s):** Developmental Therapeutics

**Tyler J. Curiel, MD—Chair**  
University of Texas Health Science Center at San Antonio

9:30 AM  
**Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.**  
(Abstract #2506)  
M. Sznol, J. D. Powderly, D. C. Smith, J. R. Brahmer, C. G. Drake, D. F. McDermott, D. P. Lawrence, J. D. Wolchok, S. L. Topalian, I. Lowy

9:45 AM  
**A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.**  
(Abstract #2507)  
P. W. Johnson, N. M. Steven, F. Chowdhury, J. Dobbyn, E. Hall, M. Ashton-Key, E. Hodges, C. H. Ottensmeier, A. Williams, M. Glennie

10:00 AM  
**Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).**  
(Abstract #2508)  

**Discussion**  
10:15 AM  
**Tyler J. Curiel, MD (Abstracts #2506–2508)**  
University of Texas Health Science Center at San Antonio

10:30 AM  
**Cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma.**  
(Abstract #2509)  

10:45 AM  
**Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematologic malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: A phase II study.**  
(Abstract #2510)  
S. Slavin

11:00 AM  
**Vaccination with DC/RCC fusions following cytoreductive nephrectomy.**  
(Abstract #2511)  

**Discussion**  
11:15 AM  
To be determined

11:30 AM  
**A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.**  
(Abstract #2512)  
G. S. Falchook, J. J. Wheler, A. Naing, D. S. Hong, S. L. Moulder, S. A. Piha-Paul, C. S. Ng, E. Jackson, R. Kurzrock

11:45 AM  
**First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3-ig (IMP321), a novel MHC class II agonist, on T-cell responses and antitumor activity.**  
(Abstract #2513)  
M. Gutierrez, C. Brignone, F. Mefti, F. Triebel

12:00 PM  
**Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.**  
(Abstract #2514)  

**Discussion**  
12:15 PM  
**Mark J. Ratain, MD (Abstracts #2512–2514)**  
The University of Chicago
9:30 AM A randomized phase III study comparing standard-dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). (Abstract #4512)
G. Daugaard, I. A. Skoneczna, N. Aass, R. De Wit, M. De Santis, H. Dumez, S. Marreaud, L. Collette, C. Bokemeyer, H. Schmoll

9:45 AM Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. (Abstract #4513)

Discussion
10:00 AM Derek Raghavan, MD, PhD (Abstracts #4512–4513)
Cleveland Clinic
Treatment Intensity and Outcome in Germ Cell Tumors

10:15 AM The high-dose aldesleukin (HD IL-2) SELECT trial in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4514)

10:30 AM A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS). (Abstract #4530)

10:45 AM Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. (Abstract #4516)

Discussion
11:00 AM Dror Michaelson, MD, PhD (Abstracts #4514, 4530, and 4516)
Massachusetts General Hospital
Metastatic Renal Cell Carcinoma: Which Way Forward?

11:15 AM Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). (Abstract #4517)
11:30 AM  Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. (Abstract #LBA4518)
  L. G. Paz-Ares, E. Solsona, E. Esteban, A. Saez, J. Gonzalez-Larriba, A. Anton, M. Hevia, F. de la Rosa, V. Guillem, J. Bellmunt

11:45 AM  Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. (Abstract #LBA4519)

Discussion
12:00 PM  Cora N. Sternberg, MD (Abstracts #4517–LBA4519)
San Camillo Forlanini Hospital

Is Systemic Therapy Impacting Progress in Urothelial Cancer?
Tuesday, June 8, 2010

9:45 AM - 11:00 AM
SPECIAL SESSION

Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO/Radiological Society of North America Joint Session
Location: S404
CME credit: 1.25
Track(s): Special Session; Practice Management and Information Technology

Richard Baron, MD, FACR—Co-Chair
The University of Chicago

Douglas W. Blayney, MD—Co-Chair
University of Michigan

Paul Chang, MD, FSIIIM
The University of Chicago
Imaging Informatics and How It Can Help Improve Quality of Care in Patients with Cancer

David M. Panicek, MD, FACR
Memorial Sloan-Kettering Cancer Center
Oncologic Imaging: Which Exam to Order and How to Integrate the Results?
9:45 AM - 11:00 AM
EDUCATION SESSIONS

Angiogenesis: Where Do We Go from Here?
Location: S100b
CME credit: 1.25
Track(s): Tumor Biology

Lee M. Ellis, MD, FACS—Chair
University of Texas M. D. Anderson Cancer Center
Targeting Tumor Angiogenesis: What Have Learned So Far?

George Coukos, MD
University of Pennsylvania Perelman Center for Advanced Medicine
Genomic Approaches for Vascular Target Identification in Solid Tumors

Robert S. Kerbel, PhD
Sunnybrook Health Sciences Centre
Contrasting Effects of VEGF Pathway-targeting Antibodies and TKIs on Microscopic versus Advanced Metastatic Disease

Even Patients with Liver Dysfunction Can Get Chemotherapy!
Location: E354b
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Developmental Therapeutics; Patient and Survivor Care

Melanie B. Thomas, MD—Chair
Hollings Cancer Center/Medical University of South Carolina
Management of Dosing and Side Effects of Specific Chemotherapeutic Agents

Lewis R. Roberts, PhD, MBChB
Mayo Clinic
Understanding Assessment of Liver Function and Viral Hepatitis for the Medical Oncologist

Timothy W. Synold, PharmD
City of Hope
Understanding the Importance of Hepatic Function and Dysfunction in Metabolism of Anticancer Agents Delivering Chemotherapy to the Patient with Liver Dysfunction
Tuesday, June 8, 2010

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY

The Best Treatment for Hepatic Metastases: What Is the Evidence? (C18)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Gastrointestinal (Colorectal) Cancer; Patient and Survivor Care

Christopher Willett, MD—Chair
Duke University Medical Center
The Incorporation of Conventional and Stereotactic Body Radiation Therapy into the Treatment of Hepatic Metastases

Heinz-Josef Lenz, MD
University of Southern California
Review of the Data Supporting Chemotherapy and Molecular Targeted Therapy in Management of Hepatic Metastases

Bryan M. Clary, MD
Duke University Medical Center
Evidence for Patient Benefit Using Surgical and/or Ablation for Hepatic Metastases

11:30 AM - 12:45 PM
EDUCATION SESSION

Management of the Elderly Patient with Cancer
Location: S100b
CME credit: 1.25
Track(s): Health Services Research; General Oncology; Geriatric Oncology; Patient and Survivor Care

Elizabeth B. Lamont, MD, MS—Chair
Harvard Medical School
Generalizability of Clinical Trials to the Elderly Patient

Cary P. Gross, MD
Yale University
Under-representation of Elderly Patients in Clinical Trials and Implications for Comparative Effectiveness Research

Arti Hurria, MD
City of Hope National Medical Center
Assessing Elderly Patients for Therapy
11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY

Hepatocellular Carcinoma: Is This Patient a Transplant, Resection, or Chemoembolization Candidate? (C19)-TICKETED SESSION
Location: E451a
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer

Lynt Johnson, MD, MBA—Chair
Lombardi Comprehensive Cancer Center
The Role of Liver Transplantation in Management of Hepatocellular Carcinoma

Riad Salem, MD, MBA
Northwestern University
The Role of Intrahepatic Interventions in Hepatocellular Carcinoma

Timothy Pawlik, MD, MPH
The Johns Hopkins University
The Role of Hepatic Resection in Management of Patients with Hepatocellular Carcinoma